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2ABSTRACT
The central effect of nicotine on cardiovascular regulation has been extensively studied. 
However, due to its unselective nature for nicotinic acetylcholine receptors (nAChR) the 
involvement of specific nAChRs at sites in the brain, in central nervous cardiovascular 
regulation remains unclear.  The effects of intracerebroventricular (i.c.v.) and 
intracistemal (i.e.) injections of the a7 selective agonist, PSAB-OFP, and the a4p2 
selective agonist, TC-2559, were investigated on blood pressure (BP), heart rate (HR) 
and renal sympathetic nerve activity (RSNA) compared with nicotine, in the 
anaesthetised rats.
PSAB-OFP and TC-2559 i.c.v. caused a delayed dose-related increase in BP and RSNA. 
When given i.e. the action was similar except the rise in BP was more immediate.  The 
possibility that the pressor response was partly due to the agonists causing the release of 
the vasoconstrictor vasopressin into the circulation was tested by repeating the i.c.v. and 
i.e. injections of the agonists in the presence of a selective vasopressin Via antagonist.  In 
the presence of V) antagonist (i.v.), PSAB-OFP and TC-2559 (i.c.v.) now induced no 
change in BP or RSNA; however i.e., the increase in BP and RSNA was delayed with 
TC-2559, while PSAB-OFP caused a decrease in BP and no change in RSNA.  The 
cardiovascular effects of i.c.v. PSAB-OFP and TC-2559 in the presence of V) receptor 
antagonist (i.c.v.) were also completely blocked.  PSAB-OFP and TC-2559 (i.e.) in rats 
pre-treated with V) antagonist (i.e.), no longer produced an increase in BP and RSNA. 
However, the delayed fall in BP caused by PSAB-OFP was potentiated.
Nicotine i.c.v. caused a dose-related increase in BP and renal sympathoinhibition; while 
i.e. the rise in BP was larger and now associated with a bradycardia.  In the presence of 
Vi antagonist (i.v.), nicotine’s (i.c.v.) cardiovascular effects were blocked; however 
nicotine i.e. caused a decrease in BP, RSNA and HR.  In the presence of V) antagonist 
(i.c.v.), nicotine caused no change in RSNA, but BP still increased.  In the presence of Vj 
antagonist (i.e.), nicotine i.e. induced a decrease in RSNA and HR, with no change in BP.
This study indicates that activation of a4p2 and a7 nAChRs in the hindbrain cause an 
increase in BP due to vasopressin release into the periphery, which is mediated by a 
central vasopressinergic pathway, possibly involving a pathway from the hindbrain to the 
PVN.  Interestingly, the renal sympathoexcitation was also prevented by blocking Via 
receptors in the periphery as well as in the brain.  A possible mechanism is discussed 
whereby vasopressin or its antagonist accesses the brain via the circumventricular organs 
and then indirectly influence the PVN, supra-medulla or supra-spinal vasopressin neurons 
influencing the renal sympathetic outflow.
Nicotine also causes an increase in BP by vasopressin release into the periphery, by 
acting on nAChR in the forebrain and the hindbrain.  Interestingly, the decrease in RSNA 
is still observed when in the presence of Vj antagonist, suggesting that the decrease in 
RSNA is partly mediated by an action of nicotine on nAChRs at sites in the hindbrain 
such as the NTS.
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21CHAPTER 1   GENERAL INTRODUCTION.
1.1.  Regulation of cardiovascular system.
The key function of the cardiovascular system is transport, most importantly, oxygen to 
all tissues and the removal of carbon.  The cardiovascular system is also involved in 
transporting nutrients from the sites that they are absorbed, or synthesised, to the tissue 
cells where they are used, as well as transporting hormones from endocrine organs, where 
they are produced, to target cells where they act.  Finally, the cardiovascular system is 
important in the transport of protective cells and substances to sites of tissue damage or 
infection, so allowing a defensive response and repair to be initiated.  In order for this to 
take place the transport medium required is blood and for the cardiovascular system to be 
in a state of homeostasis it depends upon the blood flow to all regions of the body being 
appropriate for the metabolic demands of each region, therefore the cardiovascular 
system is regulated by both peripheral and central structures, which are responsible for 
maintaining the internal environment of the body.  A number of factors are monitored by 
peripheral sensors which include blood pressure, cardiac output, blood volume and blood 
gas tensions, which when activated results in an appropriate compensatory response, 
leading to a number of complex feedback loops known as cardiovascular and respiratory 
reflexes.  The sensory receptors involved in the reflex feedback loops known to regulate 
the cardiovascular and respiration system are divided in to two, mechanoreceptors and 
chemoreceptors.  Mechanoreceptors are located in the aortic arch and carotid sinus 
(Figure 3a) and detect changes in blood vessel wall tension which is dependent on 
changes in arterial pressure (further explanation is given in section 1.1.3.1.). 
Mechanoreceptors have also been located in the atria and ventricles and in the endings of 
great veins (Spyer, 1990).  Chemoreceptors (section 1.1.3.2.) are located in the carotid 
body (Figure 3a), and also the ventral surface of the medulla, and are sensitive in 
particular to O2 and CO2 tensions, as well as the pH of arterial blood (see Daly, 1997).
22Overall these receptors relay information to central cardiovascular centres in the central 
nervous system (CNS) where they are integrated to cause the appropriate regulation of 
the heart and blood vessels, as well as the respiratory system.
1.1.1.  The autonomic nervous system
Regulation of the cardiovascular system by central cardiovascular centres requires axons 
between the CNS and the effector cells located on smooth and cardiac muscle, as well as 
glands and the gut.  This is termed the autonomic nervous system (ANS) and is divided 
into three parts known as; the sympathetic system, the parasympathetic system, and the 
enteric system.  Both the sympathetic and the parasympathetic have neuronal cell bodies 
located in both the CNS and peripheral nervous system (PNS), whereas the neurons of 
the enteric system are located exclusively in the walls of the gut (see Hardman J.G et al., 
2001; see Tortora & Grabowski, 2000).
The ANS pathways are made up of preganglionic and postganglionic neurones.  The 
arrangement of the ganglia is one way of differentiating between sympathetic and 
parasympathetic neurones of the ANS.  The sympathetic preganglionic cell bodies are 
located in the intermediolateral (IML) cell column of the spinal cord which leaves the 
CNS in segmental thoracic and lumbar roots (levels T1 to L2, see Figure 1) and forms a 
chain of sympathetic ganglia on either side of the spinal cord, known as the paravertebral 
ganglia.  The cell bodies of the postganglionic neurons are located close to those of the 
pre-ganglionic neurones, and at a distance from the target organs observed by long 
postganglionic fibres.  However, parasympathetic preganglionic neurones are located in 
the brainstem with axons travelling in the cranial nerves III, VII, XI and X, as well as the 
sacral region of the spinal cord (levels S2 - S4) (Figure 1).  Unlike the sympathetic 
ganglia, the parasympathetic ganglia are found near or in their target organs (see 
Hardman J.G et al., 2001; see Tortora & Grabowski, 2000).
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division is illustrated on both sides of the spinal outflow in order to demonstrate the full range of target structures 
innervated (modified from Rang et a l 1999)As you can observe in Figure 1, the sympathetic nerves are distributed widely throughout 
the body, innervating areas such as the heart and lungs via the superior cervical ganglia, 
as well as the stomach and lower intestine which are innervated via the celiac and inferior 
mesenteric ganglion respectively.  Sympathetic nerve fibres also innervate the smooth 
muscle of most blood vessels via the superior cervical ganglion.  In addition, Figure 1  
demonstrates the location of the parasympathetic neurones, which appears to have a 
restricted distribution.  For example, the Edinger-Westphal nucleus located in the 
midbrain innervates the eye via the III"1  cranial nerve.  The VIIth cranial nerve and the 
IXth nerve, located at the superior and inferior salivatory nucleus respectively, in the 
medulla innervate the lucrimal, nasal and parotid salivary glands.  The vagus nerve (Xth 
cranial nerve) innervates the heart, lungs and gut from the dorsal vagal nucleus (DVN) 
and nucleus ambiguus, which leaves the sacral plexus to innervate the colon, rectum, 
bladder and external genitalia via the pelvic splanchnic nerve.
Not only do sympathetic and parasympathetic differ in the location of their ganglia, they 
also vary in the neurotransmitter used.  In both sympathetic and parasympathetic 
divisions, the major neurotransmitter released between pre- and post-ganglionic neurons 
is acetylcholine, acting on nicotinic receptors.  In sympathetic neurones the major 
neurotransmitter between the postganglionic neurone and the target organs is 
noradrenaline acting on a and p adrenoceptors, although in some cases depending on 
species it can be acetylcholine acting on muscarinic receptors e.g. sweat glands.  While 
the postganglionic parasympathetic neuron release acetylcholine acting on muscarinic 
receptors (see Katzung B.G, 2001; see Rang et al., 1999; see Tortora & Grabowski,
2000).
251.1.2.  Brain areas involved in cardiovascular regulation.
1.1.2.1.  The nucleus tractus solitarius.
The nucleus tractus solitarius (NTS) is an elongated nucleus that extends throughout the 
dorsomedial part of the medulla oblongata from the level of the caudal edge of the facial 
motor nucleus to the cervical spinal cord.  The NTS is essentially involved in 
cardiovascular and respiratory regulation due to it being the principle site of termination 
of primary afferent fibres arising from cardiovascular receptors such as the arterial 
baroreceptors, chemoreceptors and lung stretch afferents, which provide essential 
information on the vascular system.  Therefore the neurons within the NTS are essential 
components of cardiovascular reflexes (see sections 1.1.3.1. -  1.1,3.2)(Spyer, 1990).
In addition to the primary afferents, the NTS receives innervation from all brain levels 
including the paraventricular nucleus (PVN) and lateral nuclei of the hypothalamus, 
amygdala, periaqueductal grey (PAG), area postrema (AP), raphe nuclei and A5 cell 
group.  Furthermore the NTS projects to various regions in the spinal cord, lower 
brainstem, midbrain and forebrain that are known to play an important role in 
cardiovascular control (Figure 2).  These regions include the IML cell column, the rostral 
and caudal ventrolateral medulla, the PVN and lateral hypothalamus, amygdala, PAG, 
raphe nuclei, parabrachial complex, AP, nucleus ambiguus and dorsal vagal nucleus 
(DVN), suggesting that the NTS has similar reciprocal connectivity (see Dampney,
1994).
Previous studies observing different areas of the brain innervating the NTS have shown 
that electrical stimulation of the PVN inhibits neurons in the NTS (Duan et al., 1999). 
Studies have shown that stimulation of the amygdala and AP results in excitation of 
neurons in the NTS (Cox et al., 1986; Hay & Bishop, 1991a; 1991b).
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27Chemical stimulation of the PAG leads to a pressor response and a increase in respiratory 
frequency, as well as a decrease in inspiratoiy and expiratory durations via neurones in 
the commissural subnucelus of the NTS (Huang et al., 2000).  Furthermore, stimulation 
of the parabrachial nucleus causes a bradycardia via neurones in the commissural NTS 
(Hamilton etai, 1981).
1.1.2.2.  The Rostral Ventrolateral Medulla.
The rostral ventrolateral medulla (RVLM) contains the sympathetic premotor neurones 
(Amendt et al., 1978) which send their axons to the sympathetic preganglionic neurons, 
found predominantly in the IML of the spinal cord.  The RVLM extends (in the rat) from 
1  to 2.5 mm rostral to the median rootlet of the XII nerve and 1.5 - 2 mm lateral to the 
midline (Benarroch et al., 1986).
The importance of the ventral surface of the brain stem in the regulation of the 
cardiovascular system (see Dampney, 1994) was demonstrated over a century ago. 
However, Guertzenstein & Silver, 1974 demonstrated in the cat that electrical bilateral 
lesions to small areas on the ventral surface known as the RVLM causes a profound falls 
in blood pressure similar to a C1   lesion.  This led to the view that this area was 
importance for the maintenance of blood pressure (see Dampney, 1994).
The RVLM is heavily innervated by the NTS (Ross et al., 1985), forming a major reflex 
pathway (Figure 2).  Furthermore, the RVLM is also innervated by the AP (Ross et al., 
1985; Shapiro & Miselis, 1985), which may relay information on circulating hormones to 
the RVLM, as well as major inputs from the PAG, the PVN and lateral hypothalamic 
area, which are though to be involved in reflex modulation and hypertension (Ross et al., 
1985).
281.1.2.3.  The Caudal Ventrolateral Medulla.
The caudal ventrolateral medulla (CVLM) is found between the nucleus ambiguus and 
lateral reticular nucleus (Figure 2) (see Dampney, 1994; see Sun, 1995)and was 
demonstrated to have an affect on cardiovascular function when application of nicotine to 
the ventral surface in the cat caused a decrease in blood pressure (Feldberg & 
Guertzenstein, 1976).
Additional studies have shown that electrolytic lesions or chemical inactivation, by the 
GABA receptor antagonist, muscimol, in the CVLM resulted in a rise in blood pressure, 
whereas electrical stimulation and chemical stimulation, by the excitatory amino acid 
glutamate, in the CVLM produced sympathoinhibition and a fall in blood pressure (Cravo 
et al., 1991; Gordon, 1987; Jeske et al., 1993).  The Al area of the CVLM has been 
proposed to be the location of the CVLM sympathoinhibitory neurons, as lesions cause 
an increase in blood pressure, whereas electrical or chemical stimulation of the CVLM 
area causes a depressor response (Ross et al., 1985), however more precise mapping of 
the depressor sites in the CVLM of the rat has indicated that the CVLM 
sympathoinhibitory neurons are located outside the Al cell group (see Dampney, 1994). 
Interestingly, it has been observed that there is an inhibitory GABAergic synapse from 
the sympathoinhibitory pathway in the CVLM depressor neurons to the RVLM 
sympathetic premotor neurons (Cravo et al., 1991).  It was suggested that it is by this 
pathway that activation of peripheral baroreceptors decrease or abolish the firing rate of 
RVLM sympathetic premotor neurons (Agarwal et al., 1990; Cravo et al., 1991; see 
Dampney, 1994; Gordon, 1987), therefore indicating that the CVLM elicits effects on the 
baroreflex by inhibiting neurons in the RVLM and causing sympathoinhibition and 
vasodepressor responses.
Originally it was believed that the NTS was the source of the GABAnergic input but 
studies have shown that the central baroreceptor pathway consists of a pathway from the 
NTS to the CVLM, probably by a glutamatergic projection, and then from CVLM to 
RVLM by a GABAergic input (Agarwal et al., 1990).  The involvement of NMD  A
29receptors in the CVLM was demonstrated by the use of selective NMDA receptor 
antagonists, which when applied to the CVLM abolished synaptically-mediated depressor 
responses caused by aortic nerve stimulation, indicating that neural transmission of aortic 
baroreceptor information in the CVLM is mediated by activation of NMDA receptors. 
The neurotransmitter released at the CVLM synapse may be an excitatory amino acid, 
possibly glutamate (Gordon, 1987).
1.1.2.4.  Nucleus Ambiguus & Dorsal Vagal Nucleus.
A key area in the regulation of the heart is the vagus (Xth) nerve, (see section 1.1.1). 
Location of cardiac vagal preganglionic neurones are in two main cell groups called the 
dorsal vagal nucleus (DVN) and the nucleus ambiguus (Bennett et al., 1981; Kalia & 
Mesulam, 1980; Nosaka et al., 1979; Stuesse, 1982).  Those with myelinated axons are 
found in the ambiguus and are the main neurones for control of the heart while the small 
group of unmyelinated axons do project from the DVN and only play a small role in the 
parasympathetic control of the heart (Figure 2),  These nuclei received input from other 
brain regions such as the parabrachial complex,  the PVN and the medullary reticular 
formation (Deuchars & Izzo, 2006; Hunt & Schmidt, 1978).
Studies of the nucleus ambiguus in the cat and rabbit have demonstrated that the low 
spontaneous firing rate produced by the cardiac vagal preganglionic neurones had a 
strong respiratory rhythm, firing during the post-inspiratory phase but was inhibited 
during the inspiration phase (Gilbey et al., 1984; Jordan et al., 1982; McAllen & Spyer, 
1978) and thus responsible for sinus arrhythmia.
301.1.2.5.  The hypothalamus
The hypothalamus has many autonomic and homeostatic roles.  The anteroventral third 
ventricular region participates in functions such as thermoregulation and drinking (Spyer, 
1994).  The PVN has diverse functions including secretion of releasing hormones, such 
as vasopressin, but also has various projections to cardiovascular areas (Spyer, 1994).  In 
addition, electrical and chemical stimulation of the PVN can increase or decrease blood 
pressure (Yang et al., 2001; Yang & Coote, 1998).  The lateral hypothalamic area has a 
sympathoexcitatory role, and stimulation causes hypertension and tachycardia (Coote et 
al., 1998).
In addition to the above, the dorsomedial hypothalamic nucleus (DMH) plays a key role 
in the cardiovascular response.  The classic defence response, such as a human subjected 
to a acute alerting stimulation, i.e. a loud noise, is characterised by a increase in blood 
pressure, heart rate and skeletal muscle blood flow, accompanied by vasoconstriction of 
renal and splanchnic vascular beds (Hilton, 1975).  This response increases cardiac output 
and redistributes blood towards skeletal muscle beds which is appropriate for an animal 
that may need to fight or flee from a threatening situation.
Electrical stimulation of a region in the hypothalamus referred to as the ‘defence area’ 
elicited a cardiovascular response very similar to that described above (Hilton, 1975). 
Furthermore, microinjection of either excitatory amino acid or GABA receptor antagonist 
in the DMH results in a cardiovascular response very similar to the defence reaction, as 
well as inhibition of DMH causing a decrease in pressor and tachycardia response to 
evoked stress in the conscious rat (DiMicco et al., 1996).
The DMH receives innervations from areas such as the amygdale and innervates areas 
such as the RVLM and the NTS (Fontes et al., 2001).  Innervation of the NTS and 
RVLM suggests why the stimulation of the hypothalamic ‘defence’ area modulates the 
baroreceptor reflex (Spyer, 1994) causing an increase in blood pressure but attenuating
31the reflex bradycardia, distributing the blood to required areas of the body in response to 
a threatening situation.
1.1.3.  Short term modulation of blood pressure
1.1.3.1.  The baroreflex.
As previously mentioned arterial baroreceptors are also known as mechanoreceptors and 
respond to the stretch of arterial vessel walls and are essential for maintaining blood 
pressure on a short term basis.
The arterial baroreceptors are located in two main areas known as the carotid sinus and 
the aortic arch (Figure 3a).  The carotid sinus is a portion of the carotid artery which 
supplies blood to the head and neck.  High in the neck, the common carotid arteries is 
divided into two smaller arteries, at this division the wall of the artery is thinner than 
usual and contains a large number of branching nerve endings.  These nerve endings are 
highly sensitive to stretch and upon a change in blood pressure, alter the stretch of the 
artery wall which stimulates a response.  In addition, another baroreceptor is located on 
the arch of the aorta and is termed the aortic arch, which is again sensitive to stretch of 
the artery wall (Spyer, 1990) (Figure 3a).
At normal blood pressure, baroreceptors afferents fire at tonic, pulse related rate, 
allowing reflex changes to occur if the afferent firing rate changes in either direction. 
Similarly, cardiac vagal afferents and sympathetic vasoconstrictor efferents fire at a tonic 
rate, allowing reflex increase or decrease to occur (Spyer, 1990).
An increase in blood pressure results in an increase in the firing rate of baroreceptors 
through stretch activation, the aortic nerve and carotid sinus baroreceptor afferents have
32been shown to project to the NTS (Donoghue et al, 1982; 1984; Spyer, 1990) and excite 
second-order neurons via a glutamatergic synapse.  NTS neurons conveying baroreceptor 
signals then project to and excite (again via a glutamatergic synapse) neurons within the 
CVLM.  The CVLM neurons project to and inhibit the sympathoexcitatory neurons in the 
RVLM via a GABAergic synapse (Agarwal et al, 1990; Dampney et al., 1982; Guyenet 
et al., 1987; Sun, 1995).  Therefore baroreflex sympathoinhibition involves switching off 
the tonic activity of the RVLM, and consequently ILM neurons, abolishment of this 
inhibitory synapse in the RVLM blocks the baroreflex demonstrating the pivotal role of 
this group of neurons in the baroreceptor reflex.  In addition, the NTS also innervates the 
nucleus ambiguus thus modulating heart rate via the vagus (Figure 3a).  Overall, when 
blood pressure is elevated, baroreceptors afferents increase their firing inhibiting 
sympathetic outflow to the heart, skeletal muscle, arterioles and increase the firing rate of 
cardiac vagal neurones, lowering heart rate.  This results in a drop in total peripheral 
resistance and cardiac output and helps return the blood pressure to near normal.
However, if blood pressure drops the reverse occurs, the firing rates of the carotid sinus 
and aortic arch baroreceptors decrease resulting in an increase in sympathetic tone due to 
disinhibition of the CVLM by the NTS, therefore the RVLM is not inhibited and 
increases sympathetic tone to the heart and blood vessels, as well as inhibiting the firing 
rate of the cardiac vagal preganglionic neurones.  Overall resulting in a increase in 
cardiac output (due to a increase in heart rate and stroke volume) and a increase in total 
peripheral resistance (blood vessel vasoconstriction) returning the blood pressure towards 
normal.
As previously noted (section 1.1.2.4) the baroreflex is able to be modulated under certain 
circumstances, for example respiration.  Studies have shown that the baroreflex 
bradycardia is subject to respiratory modulation (Haymet & McCloskey, 1975).  This is 
believed to occur at the level of the nucleus ambiguus, via the inhibition by inspiratoiy 
neurons.
33Figure 3A.  Diagram illustrating proposed pathways within the lower brainstem and 
spinal cord that are involved in regulation of arterial blood pressure by the 
baroreceptor and chemoreceptor reflex.  Pathways utilise 
neurotransmitters y-aminobutyric acid (GABA) or an excitatory amino 
acid (EAA).  The blue triangles indicate excitatory inputs and the red 
triangles inhibitory synapse inputs.  AMB, nucleus ambiguus; CVLM, 
caudal ventrolateral medulla; RVLM, rostral ventrolateral medulla; IML, 
intermediolateral cell column of the spinal cord; NTS, nucleus tractus 
solitarius; X, vagus nerve (modified from Dampney, 1994).
341.1.3.2.  The chemoreflex.
The primary function of the chemoreceptor reflex is to respond to changes in the oxygen 
tension in arterial blood.  Furthermore, chemoreceptors are also stimulated by excess 
carbon dioxide (CO2) and H+ in the blood.  The response to a decrease in oxygen is to 
stimulate breathing and to induce sympathetic vasoconstriction.  Arterial chemoreceptors 
are located in the carotid bodies, situated close to the bifurcation of the common carotid 
artery on either side of the neck and are served by the glassopharyngeal nerve, and the 
aortic bodies, situated close to the aortic arch and are served by the vagus nerve (ses 
Daly, 1997) (Figure 3a).
Chemoreceptor stimulation by cyanide (NaCN or KCN) causes hyperventilation, 
however due to the modulation of heart rate by respiration, the heart rate response was 
varied with a tachycardia, bradycardia and no change observed (Daly & Scott, 1958; 
1963).  Similar to the baroreflex, upon a decrease in oxygen in arterial blood, 
chemoreceptors activate cardiac vagal preganglionic neurones causing a bradycardia 
(Guyenet & Koshiya, 1995).  However, unlike the baroreflex, chemoreceptor input from 
the NTS is direct to the RVLM, via a glutamatergic synapse (Guyenet & Koshiya, 1995) 
(Figure 3a).
Overall, when there is a decrease in oxygen in the arterial blood, the chemoreceptors 
reflex increase breathing, via chemoreceptor afferents to the NTS and medulla and 
increase blood pressure due to a direct pathway from the NTS to the RVLM.  The 
increase in ventilation will tend to increase oxygen uptake into the blood, while the 
sympathetic vasoconstriction will tend to decrease oxygen consumption by the tissue, and 
thus conserve the available oxygen.  This stimulation also causes an altering response and 
this can interfere with the effects expect by the brainstem reflex pathway.
361.1.4.  Long term modulation.
Baroreflex and chemoreflex are short term modulators of arterial blood pressure, 
activated instantly by any blood pressure change and attempt to restore blood pressure 
rapidly to normal.  The major factor for long term modulation is blood volume.  Blood 
volume is a major determinant of arterial blood pressure because it influences in turn 
venous pressure, venous return, end-diastolic volume, stroke volume and cardiac output. 
Thus an increased blood volume increases arterial blood pressure.
1.1.4.1.  Sodium reabsorption
Sodium is a major extracellular solute, changes in total-body sodium results in similar 
changes in extracellular volume.  Since extracellular volume comprises plasma volume 
and intestinal volume, plasma volume is also significantly affected by total-body sodium. 
Plasma volume is an important determinant of the pressure in the veins, cardiac chambers 
and arteries, therefore low total-body sodium leads to low plasma volume, which leads to 
low cardiovascular pressure and vice versa.
Upon a decrease in total-body sodium, resulting in a decrease in blood pressure, a number 
of mechanisms occur to 1) increase sodium in the plasma; and 2) maintain a normal blood 
pressure.  A major mechanism in the decrease of total body sodium is the control of 
sodium reabsorption.  One of the key pathways is the renin-angiotensin system, with the 
rate limiting step being the rate of secretion of the protein renin, which needs to be 
stimulated to be released from juxtaglomerular cells of the kidneys into the blood(Reid,
1998).
Stimulation of the release of renin occurs by at least two distinct inputs to the 
juxtaglomerular cells; 1) the renal sympathetic nerves, and 2) intra-renal baroreceptors. 
The effect of the renal sympathetic nerve input makes sense since a reduction in body 
sodium and plasma volume lowers blood pressure, and via baroreceptors external to the
37kidneys, triggers an increase in sympathetic discharge to the juxtaglomerular cells, 
stimulating renin release.  The controlling of renin release by intra-renal baroreceptors is 
contained within the kidneys and requires no external neuroendocrine input.  The 
juxtaglomerular cells are located in the walls of the afferent arterioles and are themselves 
sensitive to the pressure within these arterioles, and so function as intra-renal 
baroreceptors.  When renal arterial pressure decreases, as would occur when extracellular 
volume is down, these cells secrete more renin.  Thus normally, the juxtaglomerular cells 
respond simultaneously to the combined effects of sympathetic input, triggered by 
baroreceptors external to the kidneys, and to their own pressure sensitivity (Reid, 1998).
The release of renin is involved in the renin-angiotensin system which ultimately leads to 
the synthesis and release of aldosterone, which controls the re-absorption of sodium. 
Renin acts as an enzyme to split off a small polypeptide, angiotensin I, from a large 
plasma protein, angiotensinogen, which is synthesized by the liver and is always present 
in the blood.  Angiotensin I then undergoes further cleavage to form angiotensin II.  This 
conversion is mediated by an enzyme called angiotensin converting enzyme (ACE), 
which again is always present in amounts adequate to convert all angiotensin I to 
angiotensin II.  Angiotensin II is a potent stimulator of aldosterone secretion and acts on 
the adrenal cortex, which controls the production and release of this hormone (Reid, 
1998XFigure3b).
Aldosterone stimulates sodium reabsorption by the cortical collecting ducts, controlling 
the reabsorption of the last remaining sodium by inducing the synthesis of proteins that 
function as sodium channels in the luminal membrane and proteins that constitute the 
sodium and potassium-ATPase pumps (Dolman & Edmonds, 1975; Halevy et al., 1986; 
Schultz, 1984).  Overall by the release of renin, which leads to the release of aldosterone, 
there is an increase in sodium reabsorption which increases the total-body sodium, and 
thereby plasma volume indicating that the renin-angiotensin system contributes to the 
control of arterial blood pressure.
Interestingly, this is not the only way in which the renin-angiotensin system influences 
blood pressure.  Angiotensin II is a potent vasoconstrictor of arterioles and this effect on
38peripheral resistance increases arterial blood pressure (Werner & Bohm, 2003) (Figure 
3b).  In addition, angiotensin II may also be having a central cardiovascular effect, 
inducing a sustained increase in renal sympathetic nerve activity and increasing arterial 
pressure.  Studies have shown that angiotensin II is able to act centrally by acting on 
areas of the rat brain that lack a blood brain barrier, known as the circumventricular 
organs (CVO), in particular the subfornical organ (SFO) and AP (Ferguson & Wall, 
1992).  A key central area that is believed to be affected by angiotensin II is the PVN. 
Activation of PVN neurons by inputs from the SFO has been observed to be modulated, 
in part by, angiotensin (ATj) receptors, as well as activation of this pathway increasing 
arterial blood pressure (Ferguson & Washburn, 1998).  The PVN is believed to be an 
important site mediating sustained increases in sympathetic activity in response to a 
variety of responses, such as stress, which is consistent with the PVN receiving inputs 
originating from higher centres and peripheral receptors, as well as the CVO (Badoer, 
2001; Blair et al., 1996; see Dampney, 1994).  Therefore, it is proposed that the PVN is 
activated by increasing levels of circulating angiotensin II, as well as additional stimuli, 
resulting in stimulation of the RVLM directly or indirectly increasing sympathetic output 
(Coote et al., 1998; Yang et al., 2001).
1.1.4.2.  Water reabsorption.
Upon a decrease in plasma volume, a increase in aldosterone secretion, via the renin- 
angiotensin system is observed, however there is also a mechanism involving the 
reabsorption of water which increase the plasma volume and therefore increases arterial 
blood pressure.  The decrease in plasma volume and hence arterial pressure triggers the 
release of vasopressin (also known as anti-diuretic hormone; section 1.10) from the 
posterior pituitary , via a neural input to the vasopressin-secreting cells from several 
baroreceptors in the cardiovascular system, possibly via the Al noradrenergic neurones 
(Blessing & Willoughby, 1985; Holmes et al., 2003).  Upon a decrease in firing from the 
baroreceptors due to a decrease in blood pressure that occurs when blood volume 
decreases, fewer impulses transmit from the baroreceptors, via afferent neurons to
39ascending pathways to the hypothalamus, resulting in an increase in vasopressin release 
evoking the retention of water and ultimately increasing plasma volume.  Hence an 
increase in blood pressure by an increase in plasma volume causes more firing by the 
baroreceptors resulting in a decrease in vasopressin secretion and increasing water 
excretion, therefore decreasing plasma volume.
Vasopressin releases into the periphery has a two-fold effect 1) by acting on Via receptors 
found on the smooth muscle of blood vessels, causing vasoconstriction inducing a 
increase in blood pressure, which maintains blood pressure due to the decrease in blood 
volume; and 2) acts on V2 receptors found on the kidneys, and induces the appearance of 
a population of vessels containing water channels on vasopressin-sensitive membranes of 
the kidney collecting tubules.  The insertion of the water channels give rise to the 
reabsorption of water, which increase plasma volume and blood pressure to normal limits 
(Holmes et al., 2003; Howl & Wheatley, 1995; Macfarlane et al., 1967).
1.2.  Nicotinic acetylcholine receptor structure.
1.2.1.  Structure.
Nicotinic ACh receptors (nAChR) belong to a superfamily of ligand gated ion channels, 
which include muscle and neuronal-type nicotinic ACh receptors, 5-hydroxytryptamine 
type 3 (5-HT3) receptors, y-aminobutyric acid type A (GABAa) and GAB  Ac receptors, 
glycine receptors and invertebrate glutamate receptors.  This superfamily are also known 
as Cys-loop receptors because all family subunits contain in their amino N-terminal, a 
pair of disulphide-bonded cysteines, which are separated by 13 residues (see Absalom et 
al., 2004; see Karlin, 2002).  Apart from structural homologies, fundamental differences 
exist within this superfamily of receptors, including ionic selectivity between cationic 
(nAChR and 5-HT3) and anionic (GABAa, GAB  Ac, glycine receptor and glutamate 
receptor) permeable channels (see Absalom et al., 2004; see Corringer et al., 2000).
40Figure 3B.  Flow diagram representing pathways by which decreased plasma volume 
leads, via the renin-angiotensin system and aldosterone, to increase 
sodium absorption and hence decrease sodium excretion.  Hence 
increasing plasma volume and returning arterial blood pressure to near 
normal.  NTS, nucleus tractus solitarius; RVLM, rostral ventrolateral 
medulla.
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42The study of nicotinic receptors has been made possible by the use of the electric organ 
of the electric ray Torpedo marmorata, and electrical eel, Electrophones, which contains 
an abundance of nicotinic synapses and receptors, the composition of which corresponds 
to the nicotinic receptors found at the neuromuscular junction (see Corringer et al., 2000; 
Miyazawa et al., 2003). Studies of nAChR on vertebrate neuromuscular junctions, 
Torpedo or electrical eel, have provided large amounts of information on peripheral 
nicotinic receptors which has lead to the identification of numerous neuronal nAChR in 
the mammalian central nervous system (see Sargent, 1993; see Schmitt, 2000). 
Additionally, these studies have demonstrated that neuromuscular and neuronal nAChR 
possess similar structural and functional properties.  Purification of neuromuscular 
nicotinic receptors, revealed a glycoprotein complex with a molecular weight of 
approximately 300 kDa.  Dissociation of the protein results in four different subtypes, 
termed al, pi, y and 8, according to their increasing molecular weight (see Itier & 
Bertrand, 2001).  Additional studies showed that the muscle nAChR is heteropentameric 
in structure and is composed of two al subunits and one of each of the three subunits, pi, 
y and 5 (Anand et al., 1991; see Lee, 2003; see Unwin, 2003).  It has been shown that in 
foetal muscle the receptor is composed of (al)2ply5 subunits, whereas, in the adult 
muscle nAChR, the composition is (al )2ple8 (Figure 4b)(see Karlin, 2002; see Kimura, 
1998; see Lee, 2003).
Neuronal nicotinic receptors vary when compared to muscle nAChRs, in that there are 
twelve known receptor subtypes, labelled a2-al0 and p2-p4.  The neuronal nAChR 
pentameric receptors can be expressed as either a homomeric assembly, comprised of 5 
subunits of a7-a9, or a heteromeric assembly, comprised of two or more distinct 
nAChRs.  In the latter, a2-a6 and alO subunits form functional complexes only when co­
expressed with a P subunit or with other a subunits (Figure 4b)(see Galzi & Changeux, 
1995; see Itier & Bertrand, 2001).  In both muscle and neuronal nicotinic receptors, the 
five membrane spanning subunits are arranged in a circular order (Figure 4a). At the 
oligmer centre is a pore that constitutes the ion conductance and gate, like a barrel staves 
around a central channel (Figure 4a)(Alexander et al., 2004; Cooper et al., 1991; see 
Galzi & Changeux, 1995; see Karlin, 2002; see Schmitt, 2000).
43The overall structure of the nicotinic receptor consists of a 5-subunit macromolecule with 
an overall length of 120 A, of which, 60 A is extracellular, 40 A transmembrane and 20 A 
intracellular.  The maximum width of the receptor is ~ 80 A (Figure 5)(see Lee, 2003).
All nAChR subunits exhibit significant homology in their amino acid sequence, as well 
as, similar distribution of hydrophilic and hydrophobic amino acids along their aligned 
sequence (see Galzi & Changeux, 1995; see Schmitt, 2000).  Overall it has been 
determined that each nAChR subunit contains four hydrophobic segments that form the 
transmembrane-spanning domains, termed M1-M4.  The four hydrophobic stretches 
compose the transmembrane part of the protein and some of them line the ion channel 
(Figure6b).  Figure 6a shows the other key structures on the nicotinic receptor; 1) a long 
N-terminal on the extracellular surface, which presents a glycosylation site and ligand 
binding domains, 2) a large intracellular domain between transmembrane spanning 
domain M3 and M4 presenting phosphorylation sites, and 3) a short C-terminal domain 
which originates from M4 (see Corringer et al., 2000; see Galzi & Changeux, 1995; see 
Itier & Bertrand, 2001; see Unwin, 2003).
1.2.2.  The N-terminal and ACh binding site.
The N-terminal of the nACh receptor contains the so-called Cys-loop, a characteristic 
feature of this superfamily, with the presence of the cysteine doublet believed to be 
involved in the ACh binding site.  The affinity-labelled residues are a pair of adjacent 
amino acids, a-Cysl92 and a-Cysl93, which form a highly unusual disulphide bond 
(Figure 6a), which is only found on the a-subunits, the other subunits also contain long 
N-terminals but without the cysteine loops (see Absalom et al., 2004; see Corringer et al.,
2000).
Studies of ACh binding sites have revealed that neighbouring subunits to the a subunit 
are also involved in the ACh binding, as heterologous expression of muscle al  subunits 
alone does not produce ACh-binding sites (see Karlin, 2002).  Muscle nicotinic receptors 
containing the subunit combination (al^plSy/e, have been shown to contain two binding
44sites each, one site located at the a5 interface and the other at the ay interface (Figure 6b) 
(see Lee, 2003).  Neuronal nAChRs exhibit differences in binding sites due to different 
subunit combinations when compared to muscle nAChRs (Figure 6b).  Heteromeric 
nicotinic receptors, which have the combination of (aMP)}, carry two binding sites 
situated between the a and p subunits, and homomeric receptors with the subunit 
confirmation of (a)s, have 5 binding sites situated between each a subunit ( see Schmitt,
2000).
The structure of the extracellular domain and in particular the ACh binding site, on the 
nicotinic receptor is a very difficult area to study.  Little was known about this region 
until the discovery of a homologous pentameric soluble protein, that efficiently binds 
ACh, called ACh-binding protein (AChBP) secreted by the glial cells of the snail, 
Lymnaea stagnalis (see Absalom et al., 2004; see Alexander et al., 2004; Brejc et al., 
2001).  The use of AChBP, allowed the first crystallisation of a protein that resembles the 
N-terminal ligand binding domain of the nAChR, the structure also showed the five 
identical subunits arranged in a cyclinder of 80 A in diameter with a central pore of ~ 20 
A (Dutertre & Lewis, 2004).  Studies using AChBP confirmed the existence of an 
interface between the a subunit and the adjacent subunit.  More importantly X-ray 
diffraction analyses of the AChBP indicated that six loops termed A-F where involved in 
the formation of the binding sites (Figure 7)(see Alexander et al., 2004; Dutertre &
Lewis, 2004).  The a-subunit is believed to contain three loops (A, B and C) and three 
loops from the adjacent subunits (y, 8 or e for the muscle and P for the neuronal nicotinic 
receptor) comprising D, E and F (see Arias, 2000; Brejc et al., 2001; see Itier & Bertrand,
2001).  Site-directed mutagenesis studies revealed the amino acids which contribute to 
the neurotransmitter binding area, with a decrease in affinity for agonists in a7 neuronal 
nicotinic, muscle and Torpedo receptors and therefore showed the functional importance 
in neurotransmitter binding for the loops A-F (Figure 7)(see Arias, 2000; see Galzi & 
Changeux, 1995; see Itier & Bertrand, 2001).  A large part of these data comes from 
experiments using the muscle-type receptor; however, sequence comparison indicates 
that residues in loop A-D are highly conserved in neuronal-type nAChR, while residues 
in loop E and F are not (Romanelli & Gualtieri, 2003).
45Overall, by the use of X-ray diffraction of the AChBP crystal structure and modelling of 
the three dimensional structure of the nAChR it has been demonstrated that the ACh 
binding site is located between two subunits, which form a ‘pocket’.  High resolution 
electron microscope techniques indicated that these ACh-binding sites are found at each a 
subunit.  Between the receptor sites and the outer borders the distance is approximately 
50 A apart and about 35 A above the surface membrane (Figure 5)(Corringer et al., 2000; 
see Lee, 2003; Valenzuela et al., 1994).  Ligands that move into the binding site of the 
nicotinic ACh receptor must penetrate down into the pocket to form appropriate chemical 
bridges and initiate the opening of the channel.  The ligand binding domains are each 
organised around two-sets of p-sheets, packed into a curled P-sandwich and joined 
through a disulphide bridge (Brejc et al., 2001), the encircling chains together create a 
long, ~ 20 A diameter, central vestibule (see Karlin, 2002 ; see Kimura, 1998).
46Figure 4 A.  Diagram representing the generic pentameric structure of nicotinic ACh receptor (nAChR).
47Figure 4B.  Diagramatic representation of the quaternary organisation of the muscle-type I, the heteromeric II, and the
homomeric, III, neuronal nAChRs.  The dark rings indicating the binding site for ACh.
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Figure 6 A.  Diagram of the receptor subunit structure demonstrating the general topology of all nAChRs:
the large hydrophobic N- terminal (with cysteine loop), the four hydrophobic transmembrane domains (M1-M4). 
The intracellular cytoplasmic loop and the short C-terminal.
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Figure 6B. (I) and (II) indicate the orientation of the four transmembrane domains in forming the nAChR subunits 
and how the M2 region of each subunit contributes to form the ion pore
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Residues identified by affinity labelling and site-direct mutagenesis are included in the primary site present on the a 
subunits and on the complementary site present on 8 or y subunit on muscle receptors or on a/p subunits for neuronal 
nAChR. Unlike muscle nAChRs, neuronal nAChRs only contain Loop A-E
521.2.3.  Channel pore.
The inner pore lining of nAChRs is made up of the transmembrane-spanning domain M2 
(Figure 6b).  Experiments performed to establish the hydrophilic and hydrophobic nature 
of the transmembrane spanning domains M1-M4 confirmed the division into lipid and 
water facing surfaces.  Transmembrane domains Ml, M3 and M4 residues have been 
observed facing the interior of the transmembrane since they can be labelled with 
lipophilic reagents; whereas experiments have shown that M2 can be labelled with water 
soluble compounds and is consistent with the findings that M2 makes minimal contact 
with the outer surface of the pentamer (Miyazawa et al., 2003).  The total length of the 
M2 helices, including the portion outside the membrane, which shape the conduction path 
are 40 A long and are observed to tilt towards the central axis until they reach the middle 
of the membrane, where they are slightly kinked (see Unwin, 2003).  The lumen of the 
pore has been observed to contain negatively charged groups, which influence the 
transport of cations when the pore opens, causing an increase in cation concentration 
while lowering concentration of anions. Upon closing of the nAChR pore, the M2 helices 
come together separately from the set of outer helices (Ml, M3 and M4).
The closed pore has been observed to have two special properties in the middle of the 
membrane.  Firstly, due to the small separation of the M2 helices and the presence of 
bulky hydrophobic side chains, the channel pore is maximally constricted in this region. 
Secondly, it is essentially symmetrical in this region, owing to equal side to side 
hydrophobic interactions between equivalent surfaces of homologous residues.  The
*yc i
contacts are at two levels; one involving leucine (at a-Leu  ) with the neighbouring 
alanine (or serine) side chains (at a-Ser  ) and the other phenylalanine (at a-Phe  ) 
with the neighbouring valine (or isoleucine) side chains (at a-Val 255).  Due to the 
symmetrical side to side interactions, the side chains on neighbouring helices are able to 
come together to make a tight hydrophobic restraint around the pore.  The tight 
hydrophobic restraint around the pore causes it to constrict to a diameter of ~ 6 A, which 
is too constricted for a sodium or potassium ion to pass through and therefore the 
hydrophobic restraint creates an energetic barrier to ion permeation across the lipid
53bilayer (Miyazawa et al., 2003).  There are no other types of barrier along the conduction 
path or possible protein occlusion that would block the flow of ions hence the 
hydrophobic barrier is identified as the gate of the nAChR pore.  The involvement of the 
hydrophobic chains as a pore barrier was firmly established when mutations of the 
leucine to serine or threonine, in any of the subunits, increased the sensitivity of the 
channel (Filatov & White, 1995; Labarca et al, 1995; Schaeppi, 1968), indicating that 
damage to the hydrophobic chains weakens the hydrophobic barrier and increases the 
relative stability of the open pore.
1.2.4.  Opening the channel pore.
By the use of AChBP, it is now possible to obtain a more detailed description of the 
conformational changes in the nicotinic receptor which allow the pore to open.
The ligand binding domain has been observed to be built around two sets of P-sheets 
packed into a curled p-sandwich and joined through a disulphide bridge (Brejc et al.,
2001).  Activation of the nicotinic receptor, by two molecules of ACh, has been shown to 
cause the pore to widen in the middle of the membrane (Unwin, 1995) which is evoked 
by a breakdown of the hydrophobic barrier and allows the ions to flow through the 
channel.  This is induced by a very simple mechanism.  First, binding of ACh to the 
ligand binding domain causes an allosteric change in the a-subunit, which brings about 
the rotation of the inner p-sheets.  Second, the rotations of the inner p-sheets are 
transmitted to the M2 helices via interaction between the pl/p2 loop and the end of M2. 
The rotational movement of the inner sheets of the a-subunits communicate through this 
connection and along the pore lining M2 helices to the hydrophobic barrier at the middle 
of the membrane.  Third, the twisting movement weakens the hydrophobic side to side 
interactions that hold the barrier together, which results in the helices collapsing back 
against the outer protein wall, making alternative hydrophobic interactions with the 
channel lining and allows the passage of ions through the channel (Miyazawa et al., 
2003;Unwin, 1995; see Unwin, 2003).
541.3.  Inhibition of nicotinic receptors.
There are currently three recognised mechanisms by which a compound can inhibit 
nicotinic receptors; competitive antagonists, non-competitive antagonists and channel 
blockers, all of which bind to different parts of the nAChR (Figure 8).
1.3.1.  Competitive Antagonists.
Competitive antagonists are defined as diverse ligands which compete for the neuronal 
and neuromuscular binding sites and inhibit channel opening (see Arias, 2000).  The most 
widely used competitive antagonist is the snake venom a-neurotoxin, a-bungarotoxin, 
which is obtained from the venom of the Taiwanese krait Bungarus multiunctus.  Other 
a-neurotoxins come from a family of toxins from the venoms of Elapidae snakes (which 
include cobras, kraits, mambas and coral snakes) and Hydrophidae (also known as sea 
snakes) (seeAlexander et al., 2004; see Arias, 2000).  Observations of the a-neurotoxin 
structure indicated a similar conformation between all a-neurotoxins.  They have been 
termed the ‘three-finger’ toxin family due to three adjacent loops or ‘fingers’ (I, II and 
III) that emerge from a hydrophobic core, which is cross-linked by four disulphide 
bridges (Figure 9)(see Tsetlin, 1999).  The a-neurotoxin family structure is essentially a 
flat ‘leaf-like’ molecule with a slight concavity (see Arias, 2000), containing practically 
no a-helical segments.  Instead its confirmation is determined by a triple-stranded p- 
structure formed by the two segments of the central loop II and by the fragment of loop 
III (see Tsetlin, 1999).  Interestingly a-bungarotoxin (a-BgT), unlike other a-neurotoxins, 
exists exclusively as a dimer, both in the crystal form and in solution, whereas, other a- 
neurotoxins are essentially monomeric.
Studies including electron paramagnetic resonance (EPR), chemical modification and 
site-directed mutagenesis, have demonstrated that amino acid residues located on the 
concave side of loops II and III are involved in specific neurotoxin binding to the 
nAChR. From these studies it was proposed that amino acid residue K27, which is found
55on the concave side of loop II (Figure 8 & 9), makes contact with the a subunit through 
receptor amino acid residue V188 -  D200 (on loop C) at the a5 and/or ay subunit interface, 
in the case of neuromuscular nAChRs, or between a/a for neuronal homomeric nAChRs 
or a/p for neuronal heteromeric nAChRs.  Other amino acid residues are also believed to 
be important in neurotoxin binding, which include R33 (Figure 9) (which is located in 
loop II) which has a strong energetic coupling for receptor amino acid residue aV188 (on 
loop C) and may stabilise the neurotoxin-nAChR complex (see Arias, 2000; Osaka et al.,
1999).  In a model investigating the interaction of the a-neurotoxins and nAChRs, it was 
proposed that 18% of the accessible surface of the free toxin is buried in the binding site. 
Loop II of the toxin appeared to be bound in the binding site cavity between adjacent 
subunits, with the rest of the toxin extended radially from the outside of the cylindrical 
pentamer, away from the axis (see Karlin, 2002).
In addition to a-neurotoxins, there is another family of peptide toxins which have been 
observed to be competitive antagonist for nAChRs.  This family are known as conotoxins 
(Ctx) (Janes, 2003).  The toxins come from the venom of marine snails of the genus 
Conus.  There are 3 different Ctx families which have been identified and observed to 
target nAChRs, of these three families a-Ctx is the largest (Dwoskin & Crooks, 2001).  a- 
Ctx can be further divided into structural families depending on the number of amino 
acids between the 2nd and 3rd cysteine residue and the 3rd and 4th cysteine residue (Millard 
et al., 2004; Nicke et al., 2004).  The a-Ctx subfamilies have four cysteine residues in the 
following conserved arrangement CCX3CX5C (which is termed the 03/5 subfamily), 
CCX4CX3C (the 04/3 subfamily) and CCX4CX7C (the a^n subfamily), where X represents 
the indicated number of amino acids between cysteine residues (see Arias & Blanton, 
2000; Millard et al., 2004).  Studies of a-Ctx subfamilies have indicated that a-Ctx are 
able to discriminate between muscle and neuronal nAChRs, with 03/5 Ctx (a-Ctx MI) 
found to be selective for muscle nAChRs, while 04/3 Ctx (a-Ctx Iml) and 04/7 Ctx (a-Ctx 
Mil) are selective for neuronal nAChRs (Dwoskin & Crooks, 2001; McIntosh et al.,
1999; Millard et al., 2004; Nicke et al., 2004).  Binding sites of a-Ctx to nAChRs, like 
those of other competitive antagonists, are located at the interface of a and non-a subunits 
(Dutertre & Lewis, 2004).  Three-dimensional visualisation of the binding sites has
56indicated that a-Ctx appear to bind mainly to loop C on the a-subunit, but also seem to 
bind to other parts of the receptor.
Similar to the a-neurotoxin binding to nAChRs, it was observed that specific amino acid 
residues found on loop I are energetically coupled with their corresponding pairs found 
on the a subunit, whereas amino acid residues on loop II interact with the non a subunit 
(see Arias & Blanton, 2000) stabilising the aCtx -  nAChR complex, and preventing ACh 
from binding and opening the nAChR.  Also, it is observed that binding of only one toxin 
molecule is sufficient to block receptor function (Dutertre & Lewis, 2004; Nicke et al., 
2004).
A well known antagonist for the muscle nAChR is d-tubocurarine (Chiara & Cohen, 
1997; Dwoskin & Crooks, 2001) which is isolated from the plant Chondodendron 
tomentosu and has also been observed to inhibit human neuronal nAChRs in Xenopus 
oocytes.  Studies such as photoaffinity labelling indicated that d-tubocurarine causes 
antagonism of the muscle nAChR by not only binding to the a subunit, but also the y and 
8 subunits, suggesting that each ACh binding site is at an interface between the two 
subunits (Pedersen & Cohen, 1990; Sullivan & Cohen, 2000), which correlates with the 
results obtained for a-neurotoxins and a-Ctx binding to the muscle and neuronal 
nAChRs.
1.3.2.  Positive and negative allosteric modulators.
Studies into the effects of agonists and competitive antagonists have shown that they bind 
to the same binding site as the neurotransmitter ACh.  Such studies have also indicated 
the involvement of a variety of compounds which are able to modulate the function of 
neuronal and neuromuscular nAChRs.  These compounds, which include physostigmine, 
steroids and calcium channel blockers, can activate or block nAChRs, but do not bind to 
the classical ACh site but to a number of structurally distinct allosteric sites which are in 
turn insensitive to ACh (Hogg et al., 2005).
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Figure 8. Diagram of the nAChR showing the ion channel, the ACh binding site and different allosteric sites positioned on 
the nAChR.  Allosteric sites include the non-competitive activator site (NCA); non-competitive negative 
allosteric site (NCB); binding sites for Ca2+ and steroid and phosphorylation sites (P)
58Figure 9.  A diagram of the structure of the a-neurotoxin Naja mossambica
mossambica (NmmI), which is shown with mutated side chains on 
loop II. The concave face of the toxin is facing the viewer. Taken 
from Osaka et al., 1999.
591.3.2.1.  Positive allosteric modulators.
As the name implies positive modulators, or allosterically potentiating ligands (APL), 
enhance channel opening (induced by ACh and nicotinic agonists), as well as enhancing 
ion conductance and decreasing receptor desensitisation (Pereira et al., 1993; see 
Romanelli & Gualtieri, 2003).  APL compounds including cholinesterase inhibitors, 
physostigmine and galanthamine (Hogg et al., 2005; Iorga et al., 2005) and the alkaloid, 
codeine, have been observed to be agonists with low efficacy at low doses and open 
channel blockers at high doses (Iorga et al., 2005).  Studies showed that APL compounds 
potentiated ACh and nicotine-induced activation as well as caused an increase in cation 
flux in muscle and Torpedo nACh receptors, even in the presence of competitive 
antagonists such as a-BgT.  This finding indicates that APL’s are interacting with the 
nAChR at different sites to ACh and competitive antagonists (see Arias, 1997; Pereira et 
al., 1993; see Romanelli & Gualtieri, 2003; Storch et al., 1995).  The binding site for the 
APL has been difficult to determine, although (-) physostigmine labelling indicated 
binding and labelling at amino acid sequence 109-151 of the a subunit, more precisely 
at Lys125 on the N-terminal domain of the a-subunit.  By hydrophobicity profile studies, 
the binding site was located in an amphipathic domain at the extracellular region of the 
nAChR which is not part of the ACh binding site(Figure 8)(see Arias, 1997; see 
Romanelli & Gualtieri, 2003).  Interestingly the residues around Lys 125 are conserved in 
most a subunits but are absent in non-a subunits.
1.3.2.2.  Negative allosteric modulators.
These are referred to as non-competitive antagonists (NCA) and in contrast to agonists, 
competitive antagonists and APL compounds, binding of NCAs inhibit ion channel 
function either by blocking the ion pore by a steric mechanism (in which the compound 
enters into the open channel lumen, binds and plugs it like a cork in a bottleneck) or by an 
allosteric mechanism (whereby the NCA binds to a specific site not located in the channel 
lumen; Figure 7)(see Arias, 1997).  NCAs make up a diverse range of compounds
60including the neuroleptic chlorpromazine, the hallucinogen phencyclidine (PCP), local 
anaesthetics, ethanol, barbiturates and nicotinic antagonists hexamethonium and 
mecamylamine, which exert their blocking action on ion channel without changing 
maximal agonist binding (Blanton et al., 2000b; Giraudat et al., 1986; see Romanelli & 
Gualtieri, 2003; Ziebell et al., 2004).  In studies trying to determine the binding sites of 
NCAs it was shown that there are two binding sites at which NCAs have different 
affinities for, which differ from competitive binding sites.  One site binds NCAs with a 
high affinity and is thus termed ‘high affinity NCA sites’, whereas, the second site binds 
NCAs with low affinity and as such is labelled ‘low affinity NCA site’.  Interestingly, 
upon binding of one molecule of high affinity another interaction of a second similar 
ligand does not occur (for example, binding of a local anaesthetic NCA will inhibit the 
interaction of PCP), this is termed mutually exclusive action.  Studies using 
photolabelling and photocrosslinking, to determine if the high affinity binding site 
existed, demonstrated that one NCA molecule is able to block the channel activity and is 
in contact with the five subunits of the nAChR (Giraudat et al., 1986; Ziebell et al.,
2004).  Analyses of the NCA-nAChR complex indicated that the homologous residues of 
serine (Ser) from the transmembrane-spanning domain M2 of each subunit were the 
preferred targets of several NCAs.  Labelling with the NCA chlorpromazine showed that 
Ser residues a248, 5262, (3254 and y257 were labelled, whereas, the NCA lipophilic cation 
TPMP+ (triphenylmethylphosphonium) labelled Ser residues at position a248, 8262 and p254 
(Giraudat et al., 1986).  The serine ring is part of a series of rings which span the ion 
channel from the extracellular to the intracellular channel portion in the order; valine 
ring, leucine ring, serine ring and threonine ring, and form an uncharged locus.  The 
importance of this serine ring in NCA binding to the ion channel was demonstrated using 
site directed mutagenesis, in combination with patch-clamp techniques.  Mutagenesis 
affected the pharmacological activity of QX-222 (which is a local anaesthetic) when a 
Ser-rich domain was mutated causing the NCA-nAChR bound state to be significantly 
shorter and affected the binding affinity (see Arias, 1997; Changeux & Edelstein, 2001; 
Giraudat et al., 1986; Hogg et al., 2005; Osaka et al., 1999).  Mutation of the serine ring 
also affected the binding of other NCA’s such as PCP, barbiturates and lipophilic 
substances such as TID (3-(3-iodophenyl)-3-trifluoromethyl-3H-diazirine) (Blanton etal., 
2000b).  The importance of the serine ring, with respect to NCA binding, was indicated
61when mutation of aSer  (not found on the serine ring) produced no change in channel 
conductance.  Mutations other than on the M2 (e.g. Cyt418 on aM4) caused no alteration 
in PCP non-competitive inhibition (see Arias, 1997).  NCA inhibition of ion channels is 
greatly facilitated by agonist activation of the receptor causing opening of the channel 
and allowing the NCA to move in and block the ion conductance by simple steric 
hindrance.  The hypothesis that one molecule of NCA binds and blocks the ion channel 
was proven by computational modelling which showed the NCA fitted into the channel 
on a parallel axis within a crevice formed by two adjacent nAChR subunits.  The low 
affinity binding sites which bind NCA ligands (>100 pM) are believed to be situated at 
the interface between the receptor protein and the lipid membrane (Figure 8)(Hogg et al.,
2005).  Binding of NCA ligands to the multiple sites present on each receptor (10-20 
sites) causes acceleration in desensitisation of the receptor-ion channel, resulting in 
receptor inhibition (Nagata et al., 1996).  Studies observing the effect of the NCA, 
ethanol, on nAChR function indicated that ethanol was able to reduce mean open time of 
channels in cultured PC 12, as well as, inhibiting ACh-induced currents of al nAChR in 
Xenopus oocytes, without affecting the affinity of ACh for the receptor (Nagata et al., 
1996).
1.4.  Neuronal nAChR discovery
The first discovery of neuronal nAChR subunits was recorded by Nef et al. (1986) and 
Boulter et al. (1986) who identified the chick al subunit and the rat a3 subunit, 
respectively.  This was accomplished by the use of muscle-type nAChR antibodies (Abs), 
which although specific for muscle nAChRs, were believed to be potentially useful in 
identifying neuronal nAChR subunits, since both proteins are encoded for by the same 
homologous genes (see Deneris et al., 1991; see McGehee & Role, 1995; see Sargent, 
1993).  By the use of monoclonal antibodies (mAb) mAb35, which were raised against 
nicotinic receptors from the electric organ of the electric ray and the electrical eel, and 
mAb210, which were raised against nicotinic receptors from bovine muscle, the question 
of whether neuronal nAChRs exist was examined (Whiting & Lindstrom, 1986).  It was
62observed that mAb35 bound and purified a neuronal nAChR from the chick brain which 
was observed to bind with a high affinity to [3H]-nicotine but not [125I]-aBgT (Whiting & 
Lindstrom, 1987; Whiting et al., 1987b).  Interestingly, mAb35 binding indicated two 
subunits which had a molecular weight (Mr) of48/49 kDa and 59 kDa.
Since this approach was successful, other mAbs were raised against the chicken brain for 
immunoprecipitation experiments, including mAb270 and mAb284. mAb270 labelled all 
the proteins labelled by mAb35, plus some additional proteins which included purifying a 
subunit with a Mr of 75 kDa, which was also observed to be labelled by mAb284 
(Whiting & Lindstrom, 1987; Whiting et al., 1987b).  From these studies it was suggested 
that neuronal nAChRs only have two different subunits, unlike neuromuscular nAChR 
which have four different subunits (Whiting & Lindstrom, 1986).  All of these mAb’s 
bound to nAChRs that were observed to have a high affinity for [3H]-nicotine (Whiting & 
Lindstrom, 1986), for example, mAb270 depleted over 90% of nicotine binding sites, 
whilst, mAb35 was observed to remove around 50% of [3H]-nicotine binding sites 
(Whiting et al., 1987b).  These mAb’s which were raised against nAChRs in the chicken 
brain were also able to detect nAChRs in the rat brain.  Monoclonal Ab270 purified a 
receptor containing two subunits with a Mr of 51 kDa and 79 kDa.  Originally the 
subunits were labelled by Whiting as a and P (Whiting et al., 1987a; 1987b; 1991a; 
Whiting & Lindstrom, 1986; 1987), depending on their increasing molecular weight. 
These subunits corresponded with the ACh binding subunits, identified by [3H]-MBTA 
labelling, (Whiting et al., 1987a; 1987b) located on the larger subunits (see Sargent,
1993).  Whiting et al. (1987) suggested that, by the use of mAb, there are two neuronal 
nAChRs, found in the chicken brain which have identical a subunits but different p 
subunits and can be composed of a(n=2-3)p(n=2-3) (Whiting et al., 1987b).
As well as immunoprecipitation studies looking into nAChR subtypes, experiments using 
recombinant technology to identify and clone genes (cDNA) of the nAChR in the brain 
were also performed.  Using the gene encoding the a subunit in the chicken muscle 
nAChR, three neuronal nAChR subunits were discovered, which were very similar in 
structure, in that they all contained adjacent cysteine residues at positions 192 and 193 
within the ACh binding site (see McGehee & Role, 1995; Nef et al., 1988; see Sargent,
631993).  The three nAChR subunits were termed a2, a3 and a4 which contradicted 
Whiting’s nomenclature as the 75 kDa band produced by mAb270 and mAb284 had an 
N-terminal amino acid sequence which corresponded to the a4 subunit (Nef et al., 1988; 
Whiting et al., 1991b).  This was also the case with the 49 kDa band produced by 
mAb270 which was termed an a subunit by Whiting but was shown to correspond with 
the N-terminal amino acid sequence of the avian p2 subunit identified by cDNA (Nef et 
al., 1988; see Sargent, 1993; Schoepfer et al., 1988).  The classifications of the nAChR 
were changed from Whiting’s original nomenclature to correspond to the cDNA 
nomenclature, in which subunits containing the cysteine 192/193 pair are referred to as a 
subunits and those without the cysteine pair where referred to as P subunits.
Using both the immunoprecipitation and the cDNA probe methods, a wide range of 
neuronal nAChR subunits were discovered in the chicken and rat which range from a2-a7 
and p2-p4 (Anand & Lindstrom, 1990; Balestra et al., 2000; Boulter et al., 1987; 
Couturier et al., 1990b; Keyser et al., 1993; see Lukas et al., 1999; Nef et al., 1988; see 
Sargent, 1993;Wada etal., 1988;Whiting etal., 1987a; 1991a).  Human neuronal nAChR 
subunit clones have also been produced with subunits ranging from a2-al0 and p2-p4 
(Anand & Lindstrom, 1990; Changeux & Edelstein, 1998; Chini et al., 1992; Elliott et 
al., 1996; Le & Changeux, 1995; see Sargent, 1993).  The neuronal nAChR subtypes 
purified from neuronal tissue had a sedimentation coefficient of 10-1 IS (Whiting & 
Lindstrom, 1986; 1987; Whiting et al., 1987b), which corresponds to a molecular weight 
of approximately 300 MDa, and suggests a pentameric subunit arrangement in 
comparison with the muscle nAChR (Anand et al., 1991; Cooper et al., 1991; Whiting et 
al., 1991a).
It has been previously discussed that mAb270 precipitated nAChRs which consisted of 
a4 and P2 subunits and that mAb270 caused removal of over 90% of [3H]-nicotine 
binding, which suggested that a4p2 nAChRs may account for a majority of the high 
affinity [3H]-nicotine binding (Whiting & Lindstrom, 1986).  On the other hand, it has 
been shown that nicotinic antagonist a-BgT binds with high affinity to areas of the brain 
that are distinct from high [3H]-nicotine affinity areas (Clarke et al., 1985; Perry et al., 
1992;  Rubboli etal., 1994a;  Spurden et al., 1997).  These a-BgT binding sites were
64shown to be mostly a7 nAChR subunits and are found in many areas of the mammalian 
CNS (Keyser et al., 1993).  This demonstrated that at least two classes of nAChR are 
expressed in the nervous system; however molecular biology studies of cloned nAChR 
subunits have indicated that a very large number of nAChR subtypes are theoretically 
possible.
1.5.  Expression of neuronal nAChRs
Studies using Xenopus oocytes and human embryonic kidney (HEK) cells have examined 
the expression of neuronal nAChRs.  These studies have indicated that neuronal nAChRs 
fall into two categories depending on the formation of subunits in the functional receptor. 
These receptors are termed heteromeric nAChRs, which are made up of two or more 
different neuronal nAChR subunits, and homomeric nACh receptors, which are made up 
of five of the same subunit.  Possible combinations of nAChR subunits forming 
functional nicotinic receptors are shown in table 1.
1.5.1.  Heteromeric neuronal nAChR
The expression of neuronal nAChRs was observed first in the Xenopus oocytes when 
Wada et al. (1988) injected messenger RNA (mRNA) encoding the cDNA for a2, a3, a4 
and P2 subunits.  It was observed that these subunits injected alone into the cell would 
not produce a functional ion channel but when a2 and p2 mRNA where added together a 
response to ACh was observed, which was blocked by the nicotinic antagonist d- 
tubocurarine (Wada et al., 1988).  Additional experiments have also shown that when a2- 
4 and P2 or P4 are expressed in pairs, the functional receptors which are produced have 
different pharmacological and physiological profiles; these include a2p2, a2p4, a3p2, 
a3p4, a4p2 and a4p4 (Anand et al., 1991; Couturier et al., 1990b; Luetje & Patrick,
1991; Nef et al., 1988; Vibat et al., 1995; Wada et al., 1988; Wang et al., 1996).  Later 
studies were done with cell lines such as HEK-293, M10 cells and SH-SY5Y
65Nicotinic receptor subtype Subunits involved
Nicotinic ACh receptor 
subunit compositions
Muscle-type al,p i,y , 5,8 al,P l,y,5
al,pl,e,y
Neuronal type (o-BgT- a2 -  a6, p2 - p4 a2p2
insensitive) o2P4
a3p2
a3p4
a4p2
a4p4
a6p2
a6p4
a2a5p2
a3a5p2
a3a5p4
a3a6p2
a3a6p4
a3p3p4
a4a5p2
a5a6p2
a6p3p4
a3a5p2p4
a3a6p3p4
a4a5a6p2
a4p2p3p4
Neuronal type (o-BgT- a7 -  alO a7
sensitive) a8
a9
a7p2
a7p3
a7a8
a9al0
a5a7p2
a5a7p4
Table 1.  The composition and assembly of muscle-type and neuronal-type nicotinic 
ACh receptors. Taken from (see Millar, 2003).
66neuroblastoma cells injected with chick, rat and human mRNA coding for neuronal 
nAChR subtypes a2-4, 02 and 04, which showed stable expression when applied in pairs, 
especially a402 and a302, but produced no functional channel when the subunits were 
injected into the cell alone (Chavez-Noriega et al, 1997; 2000; Gopalakrishnan et al, 
1996; Perry et al, 2002; Sabey et al, 1999; Warpman et al, 1998; Whiteaker et al,
1998; Whiting et al, 1991a; Yeh et al, 2001).  These observations indicate that this 
group of subunits can only form heteromeric receptors.
Functional studies on these neuronal nAChRs have indicated that both the a and 0 
subunits contribute to the sensitivity of the neuronal nAChR to agonists and antagonists, 
channel opening times and pharmacological and functional profiles (de Fiebre et al,
1995; Luetje & Patrick, 1991; Papke etal, 1997; Sabey etal, 1999; Sharpies etal,
2000; Warpman et al, 1998; Warpman & Nordberg, 1995).  As shown in Tables 2 -5 , 
when the receptor is comprised of different neuronal nAChR subunits then the EC50, K* 
and order of potency of different agonists and antagonists are different (Chavez-Noriega 
et al., 1997; 2000; see Court JA et al, 1994; de Fiebre et al, 1995; Papke et al, 1997; 
Sharpies et al, 2000; Warpman et al, 1998).  For example a202 was 5 fold more 
sensitive to nicotine than to ACh, while a302 was 17-fold less sensitive to nicotine than 
to ACh (Table 2 and 3XLuetje & Patrick, 1991).  Differences in antagonist affinity is also 
effected by varying composition of the neuronal nAChR, for example, Dh0E was 
observed to have a high affinity for a402 and a202 but not for a304, a204 and al (Tables 
2,4b and 5b)(Chavez-Noriega et al, 1997; 2000).
Other differences include desensitization rate, upregulation, channel conductance and 
average channel opening times (Alkondon & Albuquerque, 1993; Gopalakrishnan et al, 
1996; see McGehee & Role, 1995; Peng et al, 1994; see Sargent, 1993; Warpman et al, 
1998; Whiting et al, 1991a; Zwart et al, 1994).  Although it has been demonstrated that 
a and 0 subunits both affect the function of the nAChR, it has been suggested that the 0 
subunit has the major influence in the receptor.  This was suggested when it was observed 
that a2-4 bound with 02, had 14-100 fold less sensitivity to cytisine than to ACh, 
whereas, a2-4 bound to 04 were 3-17 fold more sensitive to cytisine that to ACh (Luetje 
& Patrick, 1991).  It was also observed that a402 and a302 had veiy different affinity to
67agonist and antagonist when compared to a4(54 and a3p4 (Tables 2-5) (Chavez-Noriega 
et al., 1997; Luetje & Patrick, 1991; Papke et al., 1997; Stetzer et al., 1996; Wheeler et 
al., 1993).
Apart from neuronal nAChRs a2-4, p2 and (34, neuronal nAChR subunits a5 and a6 have 
also been cloned.  Unlike the other a subunits that are able to form functional receptors 
alone, or with a (3  subunit, a5 and a6 subunits have been shown to be unable to form 
functional ion channels when they are injected into a cell alone or with any p subunit. 
However they are able to bind with functional nACh receptors such as a3p2 and a4p4 
and form functional receptors such as a3p2a5 and a4p4a6 (Anand et al., 1991; Couturier 
et al., 1990b; Evans et al., 2003; Wang et al., 1996).  In the case of the a5 subunit, when 
it is bound to a3p2 to form a3p2a5, there is an increase in affinity for nicotine from 50% 
for <x3P2 receptors, to 100% on a3p2a5 receptors (Wang et al., 1996).  It was shown that 
both a3p2 and a3p2a5 receptors when expressed in Xenopus oocytes, had a 
sedimentation size of 11S, which is in accordance with the size reported for the native a3 
containing receptors in human neuroblastoma cell lines (Wang et al., 1996).  Thus, 
a3p2a5 is approximately the same size as all nACh receptors and suggests that it is 
composed of a five subunit nAChR (Chini et al., 1992; Wang et al., 1996).  Heteromeric 
a4p4a6 receptors were observed to be expressed in HEK-293 cells and have a high 
affinity for epibatidine, which was similar to a4p4.  It was also demonstrated that a4p4a6 
was sensitive to inhibition by a-conotoxin Mil, whereas, a4p4 was insensitive (Evans et 
al., 2003), indicating differences in the two neuronal nAChRs and providing a useful 
starting block for determining the pharmacological profile of the wild type a6 containing 
nAChR.
The most extensively studied heteromeric nAChR is a4p2, which was shown to be the 
cause of high nicotine binding in the rat and human cell lines and tissue (Table 4 -5 ) 
(Vibat et al., 1995; Warpman & Nordberg, 1995).  It was shown that this neuronal 
nAChR not only has a pentameric structure, but is comprised of two a4 nAChR subunits 
and three p nAChR subunits (Anand et al., 1991), which is the general nomenclature of 
heteromeric neuronal nAChRs.
68Agonists
Human EC50 (pM) Rat  EC50 (pM) Chick  EC50 
(pM)
a4p2 a3p2 a3p4 a7 a4p2 a3p2 a3p4 al a4p2
Nicotine 3.5 -5.5 6.8 -7.7 80.3 113.3 0.3-14 28 47 0.35-0.84
ACh 44-100 28 - 443 203.1 180 -322 3-270 30-65 207 274-316
Cytisine 2 - 38.2 67.1-72 0.9 71.4 0.031-1.23
DMPP 2.5-18 6.7-55.9 18.67 30.9 0.073
Epibatidine
0.017-
0.043
0.19 0.016 0.1 0.1 1
ABT-418 10.6 6 119 188 155
TC-2559 0.18 >100 >30 >100
GTS-21 109 81
Table 2.  Showing the functional potency of nicotinic agonists for neuronal nAChR in human and rat transfected cells.
69Neuronal
nACh
receptor
[3H] -  nicotine
Kd  n  
,  .«  Bmax 
(nM)
[3H] -  epibatidine
Kd  n   .  ...  Bmax 
(nM)
[3H] -  cytisine
Kd  D  ,  ...  Bmax 
(nM)
[125I] -  aBgT
Kd  „ ,  ...  Bmax 
(nM)
Order of potency
a4p2 [0.4 A  ]  [544 A   ] 0.033 A   1564 A
0.21 A   1359 A  
[0.12 A ]  [383 A ]
TC-2559 ~ Epib > Cyt ~ DMPP = Nic 
> ABT-418 > ACh (1)
Epib > Cyt ~ Nic ~ DMPP > ACh (2)
a3p2 5.4*
0.12*
0.15 ~  1564 A  
0.007 A
Epib > DMPP ~ Nic > Cyt > ACh (1) 
DMPP ~ Cyt ~ Nic > ACh (3)
a3p4 4.9*
Epib > Cyt = DMPP > Nic > ACh (1) 
DMPP > Cyt ~ Nic > ACh (3)
a7 0.71 A   973 A  
[0.48°]  [3.42°]
DMPP > Cyt > GTS-21   ~ Nic > ACh 
(1)
DMPP > Cyt ~ Nic « ACh (3)
Table 3.  Showing the binding of nicotinic agonists for neuronal nAChR in human and rat transfected cells, including the order of 
potency of agonists for neuronal nAChRs.
Bmax values as fmol/mg of protein
* = expressed in Xenopus oocytes  0 = expressed in GH4C1  cells  (1) = Taken from EC50 in Table 2.
A  = expressed in HEK-293 cells  [ ] = Rat nAChRs observed  (2) = Taken from (Chavez-Noriega et al., 2000)
~ = expressed in SH-SY5Y  (3) = Taken from (Chavez-Noriega et al., 1997)
Abbreviations: Epib -  Epibatidine, Nic -  Nicotine, Cyt -  Cytisine, ACh -  Acetylcholine
70Agonists
Human Ki (nM) Rat Ki (nM) Chick Ki (nM)
ot4p2 a3 a3p2 a3p4 a7 a4p2 a7 a4p2 a7
Nicotine 1.05 e* 1610b*
0.43 e‘ 
4.1 a
400 b" 
820-900b"
3.9 d o °
rj f j  d < X )
ACh 2.66 e* 19.3 a~ 35.4 a~ 9910b* 6200-8900b"
Cytisine 0.43 e* 16.5 a~ 13.1 a~ 270 d* 3883 b*
3.3 
1.7d'
1800-2300b A
0 .14 3 0 0  
3.3 d a0
DMPP 10.71e* 14.7 a~ 16.3 a~ 160-670b A 9.4 d o D
Epibatidine 0.07 e* 0.035 d” 0.59d* 20.6b* 0.061 d* 0.018d'
(+)
Anatoxin-a
0.55 e* 63.3 b’ 4.2d*
ABT-418 7.89 e* J   d o O
UB-165 0.44 d*
Carbachol 68 e* 21500 b* 9300- 
13000 b A
360 acc
(-) Lobeline 1.92 e* 13100 b‘
Table 4a.  Showing the binding affinity of nicotinic agonists for neuronal nAChR in human, rat and chick transfected cells.
71Antagonists
Human Ki (nM) Rat Ki (nM) Chick Ki (nM)
a4p2 a7 a4p2 a7 a4p2 a7
DhpE 60.1 e* 57900 b’ 22 e* 270 d o °
a-BgT 4729e* 0.48b* 0.23-0.95 *
MLA 3205 e* 10.3 b‘ 3.1-3.9b A 1600 d Q 0
Mec >10000e*
>100000
b* >1000 d o °
Table 4b.  Showing the binding affinity of antagonists for human, rat and chick transfected cells.
a = [3H] - nicotine  * = HEK-293 cells
= [  I] - aBgT  # = Xenopus oocytes expression
c = [3H] -  MLA  oo = Ml 0 cells
d = [3H] -  epibatidine  A  = GH4C1  cells
e = [3H] - cytisine  ~ = SH-SY5Y cells
f = [3H] - MCC
Abbreviations: ACh -  Acetylcholine, DMPP -  Dimethylphenylpiperazinium , DhpE -  Dihydro-p-ethroydine, a-BgT -  a-Bungarotoxin, 
MLA -  Methyllcaconitine, Mec -  Mecamylamine.
72Agonists
Human Ki (nM) Rat Ki (nM) Chick Ki (nM)
a4p2 a7 a4p2 a7 a4p2 a7
Nicotine 8-16a 1700 b
0.6-15 8  
3-10 d 
0.6-3.5e
400-14000b 
450-6100c
2.4-6.7 8 
38 d
ACh 14.5 e 4000-7600 b 57 d
Cytisine 0.8-1.6 a
0.56 d 
0.12-1.88 
0.16-0.46e
1400-2800 b 0.14-1.2“
2.7 d
DMPP 6500a
8.7-408  
8.2 e 250 b 40 d
Epibatidine
0.02-0.06 d 
0.04e 
0.021 8
230-233 b 
170c
0.046 d
+
Anatoxin-a
1.25 a 
1.27 d
1840-2040 b
707 c
ABT-418 46 8
UB-165 0.27 8 2760-2790 b
TC-2559 5 8
Table 5a.  Showing the binding affinity of agonists for human, rat and chick
tissue.
8 = [3H] - nicotine 
b= [125I]-oBgT 
c = [3H] - MLA 
d = [3H] - epibatidine 
e = [3H] - cytisine
Abbreviations: ACh -  Acetylcholine, DMPP - Dimethylphenylpiperazinium
73Antagonists
Human Ki (nM) Rat Ki (nM) Chick Ki(nM)
a4p2 a7 a4p2 a7 a4p2 a7
DhpE 1900 8
13-13.98  
14.5-15.5 d 
14.8e
2500 b
a-BgT >10,000 8 0.35-1.1 b 
1.78-7 c
0.73 b
MLA 1560-37008 1-7.9 b 
0.98-2.3 c
37008 5.4 b
Mec >20,000 c
Table 5b.  Showing the binding affinity of antagonists for human, rat and
chick tissue.
a = [3H] - nicotine 
b = [,25I] - oBgT 
c = [3H] - MLA 
d = [3H] - epibatidine 
e = [3H] - cytisine
Abbreviations: DhpE -  Dihydro-p-ethroydine, a-BgT -  a-Bungarotoxin, MLA - 
Methyllcaconitine, Mec - Mecamylamine
74Observations from expression studies suggested that heteromeric receptors have an 
important role in calcium signalling.  Firstly, it has been seen in HEK-293 cells injected 
with rat a3, 04, a4 and 02 mRNA, that heteromeric receptors are not only permeable to 
cations such as Na+, but also to Ca2+ (Sabey et al., 1999; Stetzer et al., 1996).  Secondly, 
extracellular calcium affects the heteromeric receptors which was demonstrated when 
increases in extracellular calcium increased a402 nAChR’s response to nicotine, whereas, 
a decrease in extracellular calcium decreased nicotine’s response (Sabey et al., 1999).
1.5.2.  Homomeric receptors
Contrary to heteromeric receptors, which form functioning neuronal nicotinic AChRs by 
two or more different subunits, homomeric receptors are composed of a single type of 
subunit which form a functional pentameric structure and can be composed of either a7, 
a8 or a9 neuronal nAChR subunits (Couturier et al., 1990a; Gerzanich et al., 1994; 
Seguela et al., 1993).  Although, observed to be similar in size to the heterologous 
nAChRs, the homomeric neuronal nAChR’s have different pharmacological and 
physiological profiles (Table 2-5).  Chick and rat homomeric neuronal nAChRs have 
been expressed in Xenopus oocytes and it has been shown that a7 is sensitive to nicotine, 
with an order of potency of nicotine > cytisine > DMPP > ACh for the rat and chick 
neuronal nAChR.  In contrast the order of potency for human al neuronal nAChR in 
Xenopus oocytes was observed to be DMPP > cytisine > nicotine > ACh (Table 2 and 4) 
(Chavez-Noriega et al., 1997; Gerzanich et al., 1994; Seguela et al., 1993).  The order of 
potency observed for chick a8 neuronal nAChR’s expressed in Xenopus oocytes was 
shown to be nicotine ~ cytisine > ACh > DMPP, indicating similarities between al and 
a8 neuronal nAChRs.  However, there are also differences, such as a8 has a higher 
sensitivity to agonists than al.  In addition, it has been shown that there are also 
similarities between al and a8 homomeric receptors expressed in Xenopus oocytes 
compared with the native al and a8 neuronal nAChRs (Gerzanich et al., 1994), for 
example, radioligand binding of al nAChR in HEK-293 cells noted the agonists affinity 
for al was nicotine > cytisine > ACh, which is observed to be veiy similar to al
75expressed in Xenopus oocytes (Table 4) (Gopalaknshnan et al., 1995; Zhao et al., 2003). 
Rat pituitary clonal cell lines, GH4C1, expressed a7 nAChR stably and had 
pharmacological and functional properties similar to a-BgT nAChRs in rat brain (Quik et 
al., 1996).  The homomeric receptors, especially al, are observed to be blocked by 
nanomolar concentrations of a-BgT.  Therefore the high affinity of al nAChRs for a- 
BgT suggested that a7 subunits may play a major role in determining the properties of the 
rat brain a-BgT binding studies (Tables 2 -5 ) (Gerzanich et al., 1994; Gopalakrishnan et 
al., 1995; Quik et al., 1996; see Sargent, 1993; Seguela et al., 1993; Zhao et al., 2003).
Interestingly, similar to heteromeric neuronal nAChRs, homomeric nAChRs have been 
shown to not only be permeable to cations such as Na+ but also to Ca2+ (Gerzanich et al., 
1994; Gopalakrishnan et al., 1995; Seguela et al., 1993).  Calcium ions have also been 
shown to have an effect on al and a8 nAChRs, whereby it was observed that 
extracellular Ca  positively regulates al and a8 nAChR channel opening, since human 
al nAChR responses to nicotine were suppressed when there was a reduction in external 
Ca2+ (Gopalakrishnan et al., 1995; Zhao et al., 2003).  Although it has been stated that 
homomeric subunits can not co-assemble with any other subunit, it is now believed that 
in some cases co-assembly occurs.  This arose from the suggestion that al nAChRs, 
found in rat hippocampal interneurons, were shown to have properties unlike those seen 
in homomeric al nAChRs, for example, these native al containing receptors desensitize 
more slowly and have a smaller single channel conductance.  It was shown that al and P2 
subunits can co-assemble and form functional heteromeric nAChRs with functional and 
pharmacological properties different from those of homomeric al channels (Khiroug et 
al., 2002).
761.6.  Distribution of neuronal nAChR
1.6.1.  Autoradiography techniques
By the use of methods which included radioligand binding, in situ hybridisation and 
immunohistochemistry, using subunit specific antibodies, the locations of neuronal 
nAChRs were determined.  The first method used for isolating nAChRs was radioligand 
binding in autopsy tissue homogenates, or for greater anatomical detail, autoradiography 
of tissue sections (Wada et al., 1989).  The first compounds used in the autoradiography 
technique were [3H]-nicotine, as this has been demonstrated to bind with high affinity to 
cell lines expressing neuronal nAChRs (Table 4 & 5), and [125I]-a-bungarotoxin ([l25I]- 
aBgT) which was shown to block nicotinic cholinergic transmission and bind to rat brain 
membranes with high affinity (Table 4 & 5) (Clarke et al., 1985; Hunt & Schmidt, 1978; 
Morley et al., 1977; Segal et al., 1978).  As well as these nicotinic compounds, [3H]-ACh 
(in the presence of atropine) was also used (Table 6 & 7) (Adem et al., 1987; Perry et al., 
1992).  Interestingly, it was observed that there were two distinct patterns of distribution 
for the [3H]-nicotine and [125I]-aBgT binding, with little overlapping, whereas [3H]- 
nicotine and [3H]-ACh binding were almost identical (Clarke et al., 1985), indicating that 
[3H]-nicotine and [3H]-ACh probably labelled the same neuronal nAChRs (Table 6 & 7).
In the rat brain, [3H]-nicotine binding was observed in high density in the thalamus as 
well as the hippocampus and cerebral cortex (Clarke et al., 1984; 1985; Hunt & Schmidt, 
1978; Morley et al., 1977; Oswald & Freeman, 1981).  These high density binding sites 
in the rat brain correlate with autoradiography studies in the human brain, which showed 
high [3H]-nicotine binding sites in the subiculum, presubiculum and entorhinal cortex 
areas of the hippocampus (see Court JA et al., 2000; Perry et al., 1992; Rubboli et al., 
1994a) and within the thalamus, in areas such as the lateral dorsal, median and lateral 
geniculate and anterior nuclei (Rubboli et al., 1994a; Spurden et al., 1997).  Other areas 
of high [3H]-nicotine binding in the human brain were observed in the basal ganglia
77which included the putamen and caudate (Table 6 & 7) (Adem et al., 1989; see Court JA 
et al., 2000; Rubboli et al., 1994a).
Studies looking into [125I]-aBgT binding in the human brain showed that the areas high in 
nicotine binding were observed to have low [125I]-aBgT binding especially in the basal 
ganglia, hippocampus areas and an overall low binding in the thalamus (Clarke et al., 
1984; see Court JA et al., 2000; Rubboli et al., 1994a; Spurden et al., 1997) apart from in 
the reticular thalamic nuclei which showed very high [125I]-aBgT binding (Breese et al., 
1997; Spurden et al., 1997).  High density binding of radioligand [125I]-aBgT in the 
human brain was observed in the hypothalamus in areas such as the paraventricular 
nucleus (PVN), supraoptic nucleus (SON) and mammillary bodies (Table 6).  Similar 
binding was also shown by autoradiography performed on the rat brain (Breese et al., 
1997; Clarke etal., 1985; Hunt & Schmidt, 1978).
Overall, autoradiography studies using the two radioligand compounds [3H]-nicotine and
1  25 [  I]-aBgT indicated that there are at least two different neuronal nACh receptors present 
in the human and rodent brain.  These receptors were referred to as a-BgT insensitive 
nAChRs, which were observed to be selective for the nicotine agonist but not the a-BgT 
antagonist, and a-BgT sensitive nAChRs which has a low selectivity for nicotine but 
were selective for a-BgT.  Although this categorised the nAChRs and indicated where 
they are located in the brain, information regarding nACh receptor composition was still 
unclear, which was due to unavailable subtype selective ligands.
As a result of extensive research into nAChR composition, function and binding affinity, 
agonists were discovered that are selective to certain nAChR subtypes, for example, [3H]- 
cytisine was shown to label a3, a4 and P4 subunits, whilst [3H]-epibatidine labelled a3, 
a4 and a7 nAChR subunits (Marutle et al., 1998; Rubboli et al., 1994a; Rubboli et al., 
1994b; Spurden et al., 1997).  By the use of partially selective ligands, it was observed by 
autoradiography that there is an overall high binding of cytisine and epibatidine in the 
thalamus, with moderate binding in the basal ganglia (Marutle et al., 1998; Rubboli et al., 
1994a; Sihver et al., 1998) and varied results with the binding in the cerebral cortex 
(Table 7) (Sihver etal., 1998; 1999).
78Brain Region [125I]-aBgT binding [3H]- Nicotine binding
Cerebral Cortex
- Frontal Cortex + 4-+
- Occipital Cortex ± / + + /+++
- Parietal Cortex ± ++
- Temporal Cortex + + /++
- Cingulate Cortex + /+++ +++
- Insular Cortex ±/ + + /++
- Neocortex + /++
Limbic Areas
-Hippocampus
- Overall + /++
- Pyramidal layer CA1 + /++ ++
- CA2 & CA3 + /++ ±/ +
- Mol layer of dentate gyrus +
- Granular layer of dentate + /++ ±
- Presubiculum - +++
- Subiculum + +++
- Entorhinal Cortex +++
- Dentate gyrus ++ ++ / +++
- Amygdala ++
Basal Ganglia
- Putamen -/ + ++ / +++
- Caudate -/ + ++ / +++
- Claustrum ++
Thalamus
- Overall -/ + +++
- Midline n + +++
- Anterior n ± ++
- Dorsal medial n ±
- Ventral lateral n ± ++
- Reticular n. ++ + /++
79HvDOthalamus
+ +  / + + +
- PVN.
-SON.
“ M— r
- Mammillary bodies
“ i t
- Substantia nigra
- /  +
-  parscompacta
Midbrain
- Superior colliculus + + +
- Inferior colliculus + + +
- Raphe + + + + + +
- Reticular formation + +
Cerebellum
- Overall - / ±
- Molecular layer + +
- Granular layer ++ +
- Deep cerebellum n. ++
Hindbrain &  Medulla
- Medulla overall +
- Inferior olive complex +
- Parabrachial n. ++ +
Table 6.  Comparing the expression of [3H]-nicotine and [125I]-a-
Bungarotoxin radioligand binding in the human brain.
Symbols indicate:
- = Not Detected
± = Very Weak Signal
+ = Weak Signal
++ = Moderate Signal
+++ = High Signal
80Brain Region
[3H]- Nicotine 
binding
[3H]- ACh 
binding
[3H]- Epib 
binding
[3H]- Cyt 
binding
Cerebral Cortex
- Frontal Cortex ++ + /+++ ++
- Occipital Cortex + /+++ + /+++ + /++
- Parietal Cortex ++ ++ ++
- Temporal Cortex + /++ + /+++ +
- Cingulate Cortex +++ ++ +
- Insular Cortex + /++ +
- Neocortex
- All layers + /++
Limbic Areas
- Hippocampus
- Overall + /++ + + /++
- Pyramidal layer CA1 ++
- CA2 & CA3 ± / + ±
- Dentate granular layer ± ±
- Presubiculum +++ ++
- Subiculum +++ ++
- Entorhinal Cortex +++ ++
- Dentate gyrus ++ / H — 1 — I -
Basal Ganglia
- Globus Pallidus +
- Putamen ++ / +++ ++ ++ ++
- Caudate ++ / +++ ++ ++ / +++ + /++
- Claustrum ++
Thalamus
- Overall +++ +++ +++ ++
- Pulvinar n. +
- Lateral dorsal +++
- Medial geniculate +++
- Lateral geniculate +++
- Anterior n ++
- Lateral posterior n. +++ ++
- Ventral anterior n. ++
- Ventral lateral n. ++
- Ventroposteromedial n. ++
- Ventroposterolateral n. + /++ ++
81- Reticulum n.
- Centromedial n.
- Dorsomedial n.
- Reticular hotspots
- Subthalamic n.
+ /++ 
+ /++
+++
+
++
+++
HvDothalamus
- Overall
++
Substantia nigra
- Overall
- Pars compacta
- Pars reticulate
+++
++/+++
++
Midbrain
- Raphe n.
- Periaqueductal grey 
matter
- Locus coeruleus
+++
++
+++
Cerebellum
- Overall
- Molecular layer
- Granular layer
++
+++
++
Striatum +++
White matter -
Table 7.  Comparing the expression of [3H]-nicotine, [3H]-ACh, [3H]-
epibatidine (Epib) and [3H]-cytisine (Cyt) radioligand binding in 
the human brain.
Symbols indicate:
- = Not Detected
± = Very Weak Signal
+ = Weak Signal
++ = Moderate Signal
+++ = High Signal
82It was demonstrated that there was similar distribution of [3H]-nicotine, [3H]-cytisine and 
[3H]-epibatidme in the cerebral cortex, indicating that they are all binding to a similar 
receptor; however, the levels of binding were shown to be different.  Similar binding of 
all three was observed in the parietal cortex, with nicotine and epibatidine having high 
binding sites in laminar layers I, III and IV, although nicotine was also observed to have 
high binding in laminar VI, unlike epibatidine.  Cytisine had moderate binding 
throughout laminar I to VI.  High binding in the frontal cortex was indicated with 
nicotine and epibatidine compared with moderate to low binding with cytisine.  In 
laminar III of the frontal cortex both nicotine and epibatidine were shown to have high 
binding and similarities in binding density at all other layers (Table 7).  This similarity in 
site and binding density indicate they are binding to the same receptor, most likely the a4 
nAChR.  However, differences in binding densities in certain areas of the cerebral cortex, 
indicate that there may also be another high affinity nACh receptor involved, most 
possibly the a3 nAChR (Sihver et al., 1998; 1999).
Overall, it was demonstrated that at least two classes of neuronal nAChR are present in 
the human brain which are distinguishable by their affinities for [3H]-nicotine, [3H]-ACh, 
[3H]-epibatidine and [125I]-aBgT.
1.6.2.  Neuronal nAChR subunit distribution
Although autoradiography is accurate it is unable to specifically state what nAChR 
subtypes are present in the human brain.  By the use of molecular genetics, the primary 
structure of nAChR subunits expressed in the brain which combine to form nAChRs were 
discovered and it was noted that different genes make up the individual subunits making 
what is known today as an nAChR gene family (Rubboli et al, 1994b; Wada et al.,
1989).  Originally, the genes encoding rat neuronal nAChR subtypes were identified and 
genes encoding for a2-9 and 02-4 were discovered (Breese et al, 1997; Rubboli et al., 
1994b; Shioda et al., 1997a; Wada et al., 1989; Whiting et al., 1991a) and by 2003, 
twelve nAChR subunit genes had been identified (a2-10, 02-4) (Graham et al., 2003).  It
83was shown that mRNA encoding certain nAChR subunits, injected into Xenopus oocytes 
formed functional neuronal nAChRs such as a4p2 and a2f2 (Wada et al., 1989; Whiting 
et al., 1991a).  In situ hybridisation enabled the various subunit mRNAs required to make 
nAChRs, to be identified in both the rat and human brain.  Table 8 shows the distribution 
of a3, a4 and p2 mRNA subunits in the rat brain.  There was high density of mRNA in 
the thalamus for all three of the subunits, interestingly, it was observed that the a4 and P2 
subunit seem to have very similar densities in most of the CNS including the 
hippocampus, cerebral cortex, especially laminar II and V, and thalamus, indicating that 
these two subunits could bind and form functional nAChRs (Nakayama et al., 1995; 
Wada etal., 1989).  In situ hybridisation and RT-PCR enabled studies into the expression 
of a4, a3, P2 and a7 nAChR subunits in the human brain (Table 8 & 10) (Dursun et al., 
1994; Guan etal., 2002; Hellstrom-Lindahl etal., 1999; Rubboli etal., 1994b; Schroder 
et al., 1995; Wada et al., 1989; Whiting et al., 1991a).  It was shown that a4 mRNA was 
found throughout the cerebral cortex especially in the frontal and temporal cortex 
(Hellstrom-Lindahl et al., 1999; Wevers et al., 1994), whereas, a3 is found in high 
amounts in the frontal and parietal cortex, with moderate mRNA density in the temporal 
cortex (Hellstrom-Lindahl et al., 1999).  This correlates with the high nicotine and 
epibatidine binding demonstrated by autoradiography and indicates that the a4 nAChR 
subunit is a predominant subunit in the cerebral cortex.  The mRNA data for a3 also 
correlate with the nicotine and epibatidine high density binding in different areas of the 
brain shown by autoradiography (Sihver et al., 1998; 1999; Wevers et al., 1994). 
Surprisingly, high density a7 nAChR subunit mRNA was detected in the cerebral cortex
1  7S
which contradicts the autoradiography studies which showed very little [  I]-aBgT 
binding in all regions of the cerebral cortex (Breese et al., 1997; Hunt & Schmidt, 1978; 
Utsugisawa et al., 1999).  This may be due to several factors, such as age and disease, 
causing varying levels of [125I]-aBgT binding sites (Agulhon et al., 1999;Hellstrom- 
Lindahl et al., 1998) but it is important to note, that mRNA expression studies localise 
the mRNA encoding the receptor and not the receptor protein, which might move from 
the site and form a receptor in another area (Wada et al., 1989).  Studies observing al 
mRNA expression were recorded in the hippocampus, particularly in the pyramidal layers 
CA1 to CA3, entorhinal cortex and subiculum (Table 9 & 10) (Agulhon et al., 1999; 
Breese et al., 1997; Rubboli et al., 1994a).
84Using immunohistochemistry and RT-PCR, it was shown that the a7 nAChR are present 
in pyramidal layers CA1/CA3 as well as in the subiculum of the hippocampus in the 
human and rat brain (Dominguez del et al, 1994; Graham et al., 2003). 
Immunohistochemistry studies in the hippocampus have also shown that low protein 
expression is seen in the pyramidal layer, CA1, for a4 and 02 subunits with low to high 
expression observed in CA2 to CA4.  Although moderate expression of a3 protein 
subunit is observed in CA1/2, there is a low to high expression in CA3/4.  Both a4 and a3 
protein expression is observed in the subiculum, although the expression is not as dense 
as with the a7 nAChR subunit (Table 8-10) (Graham et al, 2003).  Low mRNA 
expression for the al subunits is seen in the overall thalamus, apart from moderate 
expression in the reticular thalamic nucleus, which was also shown to have high [125I]- 
aBgT binding (Breese et al, 1997).  Interestingly, it was shown that there was high al 
mRNA expression in the thalamus in a 25 week old human brain.  However, other studies 
have shown less expression in older brains, indicating that loss of mRNA may occur with 
age (Agulhon et al, 1999; Schroder et al, 2001; Wade & Timiras, 1980).  Other mRNA 
subunits that are expressed in the thalamus are a3 and 02 and are expressed in different 
intensities at the thalamus.  a3 was shown to have moderate to high expression in the 
ventroposterolateral nucleus, lateroposterior nucleus and the dorsomedial nucleus, in the 
human and rat brain (Rubboli et al, 1994a; 1994b; Terzano et al, 1998; Wada et al, 
1989), while, 02 mRNA has low expression in the human brain, although high expression 
is shown in the rat brain, indicating that the functional nAChR formed probably contain a 
a3 nAChRs subunit but not the 02, suggesting the possibility of 04 (Table 8 & 9)
(Rubboli et al, 1994a).
The cerebellum mRNA subunit expression in human and rat brain is indicated to have 
overall moderate to high expression of the a3, a4 and 02 subunits, whereas, there is low 
to moderate expression of al nAChR subunit.  It was shown that there is a higher 
expression of a3 and 02 in the granular layer than the molecular layer, although there was 
an equal expression to al mRNA (Table 8-10).  When this was compared with 
immunohistochemistry studies done on the cerebellum, it was observed that a4 protein 
expression was greater in the molecular layer than granular layer.  For a3, al and 02, 
although there was a greater protein expression in the granular layer than in the molecular
85Brain Region a3 Distribution a4 Distribution p2 Distribution
Cerebral Cortex
- Frontal Cortex +++ + /++ +++
- Occipital Cortex
- Parietal Cortex +++ + /++
- Temporal Cortex ++ (++/+++) +
- Cingulate Cortex ± -
- Insular Cortex ± ±
Limbic Areas
- Hippocampus
- Overall +++ ++ / +++ ++ / +++
- Pyramidal layer
- CA1 +  (± / ++) (-/ + ) +  (-/+)
-CA2 +  (±/++) (±/+++) +  (±/+++)
-CA3 ± /+   (±/++) (±/+++) +  (±/+++)
-CA4 ± / +  (± / ++) (±/+++) +  (±/+++)
- Dentate granular layer ± / +
- Presubiculum ± / + (-)
- Subiculum ±/+   (+/++) (-/++)
- Entorhinal Cortex ±/+++
- Dentate gyrus +++
Basal Ganglia
- Globus Pallidus
- Putamen - + /++
- Caudate n. - + /++
Thalamus
- Overall +++ +
- Pulvinar n. + /++ ±
- Lateral dorsal n.
- Medial geniculate n.
- Lateral geniculate n.
- Anterior n.
- Lateral posterior n. ++ / +++ -
- Ventral anterior n.
- Ventral lateral n.
- Ventroposteromedial n. 1
86- Ventroposterolateral n. ++ / +++ ±
- Reticulum n. ++ -
- Centromedial n. + /++ -
- Dorsomedial n. + ±
HvDOthalamus
- PVN ++
-SON +++
- Suprachiasmatic n. ++
- Ventromedial n. ++
Substantia nigra
- Overall (+/++) +  (++)
Midbrain
- Reticular Formation + / ++
Cerebellum
- Overall ++ / +++ ++ / +++ ++ / +++
- Molecular layer ±  (±) (±/++) +++  (+ / ++)
- Granular layer + /+++  (-) (+) ++  (±)
Spinal Cord
+++ +++ +/++
Table 8.  Comparing the expression of neuronal nAChR a3, a4 and 02
subunit mRNA and protein expression in the human brain
Symbols indicate:
- = Not Detected
± = Very Weak Signal
+ = Weak Signal
++ = Moderate Signal
+++ = High Signal
() indicates protein subunit expression
87Brain Region
a3 mRNA 
Distribution
a4 mRNA 
Distribution
p2 mRNA 
Distribution
al protein 
Distribution
RhinenceDhalon
- Olfactory bulb -/ + ± -/ + - / ++
- Olfactory tubercle -/+++ + /++ + / ++ -/++
Cerebral Cortex
- Laminar I _ + ± -/ +
- Laminar II - ++ -H- -/ +
- Laminar III - ++ ± -/ +
- Laminar IV +++ + ± -/ +
- Laminar V ± ++ + /++ ++ / +++
- Laminar VI + /++ - ±/  + + /++
Limbic Areas
- Hippocampus
- Overall
- Pyramidal layer
- CA1 
-CA2
+ ++ + + /++ 
4 ~  / ++
-CA3 - + ±/++ + /+++
- Presubiculum - ±/+++ ±/++
- Subiculum ±/++ ±/++ ±/++ + /++
- Entorhinal Cortex - ±/++ ±/++ -/++
- Dentate gyrus
- Molecular layer - ± ± ±
- Granular layer - - ++ ++ / +++
- Amygdala - + ++ ++
Basal Ganglia
- Globus Pallidus _ ++ ± + /++
- Putamen - - ± -
- Caudate n. + i
88Thalamus
- Medial habenula n. +++ +++ ++ ++ /+++
- Lateral dorsal n. ++ +++ -H- + /++
- Lateral posterior n. + +++ +++ + /++
- Medial geniculate n. ++/+++ +++ +++ 4-4-
- Lateral geniculate n. ±/+++ -H-+ + /+++ ++/+++
- Anterior n. +++ +++ + /++ ++
- Ventral anterior n. +++ +++ +++ 4-4-
- Ventral lateral n. +++ +++ ++4- 4-4-
- Ventral posterior n. ++ +++ 4-4-4- ++ / +++
- Centromedial n. - + + /++ -
- Dorsal medial n. ++ / +++ + /++ 4-4- 4~f+
- Reticulum n. ± ++ + ++ / +4-4-
Hvoothalamus
- PVN _ -/ + + /++ -/ +
-SON - - ++ ++ / +++
- Suprachiasmatic n. - - + + /++
- Mammillary body -/+++ -/ + + /++ +++
- Preoptic area + ±/ + -/ +
Substantia nigra
- Pars compacta + +++ 4-H- ++/-H-+
- Ventral tegmental ++ +++ 4H -4- -/ +
area
Midbrain
- Superior colliculus ± / + ±/++ ±/++ -/++
- Inferior colliculus ±/ + + /++ + /++ ++ / +++
- Raphe + -l± + -/ +
- Reticular Formation - + + -/++
- Superior olivary ++ / +++
complex - + /++ ++
- Periaqueductal grey ++
matter - + +
- Locus coeruleus ± +++ ++ ++ / +++
- Pontine nucleus + 4 - ±
89Cerebellum
- Deep nuclei _ +++ ++ ++ / +++
- Molecular layer - - ± -
- Granular layer + ± + -/ +
Hindbrain & Medulla
- Parabrachial +++
- Inferior olivary + /++
complex
- Red nucleus +++
- Cochlear ++ / +++
Spinal Cord
+ + /++ -/+++
Table 9.  Comparing the expression of neuronal nAChR subunits a3, a4 &
02 mRNA expression in the rat brain
Symbols indicate:
- = Not Detected
± = Very Weak Signal
+ = Weak Signal
++ = Moderate Signal
+++ = High Signal
90Brain Region a7 Distribution
Cerebral Cortex
- Frontal Cortex ++/+++
- Occipital Cortex ++
- Parietal Cortex + /++
- Temporal Cortex ++/+++
- Cingulate Cortex +
- Insular Cortex ++ / +++
Limbic Areas
- Hippocampus
- Overall +++
- Pyramidal layer 
- CA1 ++ / +++  (++ / +++)
-CA2 ++ / +++  (++ / +++)
-CA3 ++ / +++  (++ / +++)
- Dentate granular layer ++
- Mol. layer of dentate gyrus ++
- Presubiculum ±
- Subiculum ±/++  (+/++)
- Entorhinal Cortex ++
- Amygdala ++
Basal Ganelia
- Globus Pallidus ±
- Putamen ±/ +
- Caudate n. -/++
Thalamus
- Overall
- Pulvinar n. + /++
- Midline n. -
- Medial geniculate n.
- Lateral geniculate n.
- Anterior n.
- Lateral posterior n.
- Ventral anterior n.
- Ventral lateral n. +
- Ventroposteromedial n.
- Ventroposterolateral n. +
91- Reticulum n. + /++
- Centromedial n. -
- Dorsomedial n. ±/ +
HvDOthalamus
- PVN +
- Mammillary bodies +
Substantia nisra
- Pars compacta -
Midbrain
- Superior colliculus -
- Inferior colliculus -
- Reticular formation +
- Pontine nucleus ++/+++
- Superior olivary complex +++
Cerebellum
- Overall + / ++  (+ / ++)
- Molecular layer +++  (+)
- Granular layer ++ / +++
Spinpl Cord
+++
White Matter ±
Table 10.  Comparing the expression of neuronal nAChR a7 subunit mRNA
and subunit protein expression in human brain.
Symbols indicate:
= Not Detected 
±  = Very Weak Signal
+  = Weak Signal
++  = Moderate Signal
+++  = High Signal
() indicates protein subunit expression
92layer, the amount of expression was greatly reduced compared with mRNA expression 
(Graham et al., 2003), but overall indicating that nAChRs are present in the cerebellum 
(Table 8-10).  This is an example that although mRNA subunits are expressed here it 
does not indicate that the protein receptors form at the same site and instead it is possible 
that they may migrate to other areas, which may account for the reduction in expression.
There is increasing evidence that nAChRs are not only found in the CNS, but also in the 
autonomic nervous system (ANS), as well as, non-neuronal cells
1.6.3.  Distribution of nAChRs in the ANS.
In order for the CNS to integrate sensory input and send the commands back to the 
organs it is required to go through the ANS.  The autonomic ganglia are the peripheral 
sites for the control of the organs and tissues by the nervous system.  Unlike nAChRs in 
the CNS, ganglionic nAChRs possess different functional and pharmacological 
characteristics due to expression of various nAChRs subunits.  However, there are 
common features found between neuronal and autonomic nAChRs; for example, 
relatively slow gating, moderate calcium permeability and significant rectification of the 
post-synaptic responses (Seguela et al., 1993).
Autonomic ganglia have high levels of mRNA for a3, and p4 subunits, as well as, 
transcripts for a4, a5, a7 and P2 nAChRs subunits (Poth et al., 1997; Xu et al, 1999a; 
1999b).  Research looking into the nAChRs involved in the neurotransmission in the 
intracardiac ganglia indicated, by in vivo and in vitro studies, that there are at least two 
nAChR subtypes present; which are the a3p4 and a7 nAChR (De et al, 2000a; Xu et al, 
1999b).  Studies found that a3 subunits in the rat combine mostly with the P4 subunit and 
that the a3p4 subunit causes an increase in heart rate upon application of nicotine (Ji et 
al, 2002).  The a7 subunits have been located in both the parasympathetic and 
sympathetic neurons that innervate the heart and upon activation cause a decrease in heart 
rate.  Studies have indicated that in the intrinsic cardiac neurons of the rat, a7 nAChRs
93may not be homomeric but instead interact with other nAChR subunits to form 
heteromeric nAChRs (Ji et al., 2002a).
Additional studies into the involvement of nAChRs in the ANS have located nAChRs in 
organ systems such as the gut and bladder.  Unfortunately, very little is known about the 
subunit composition of nAChRs in these organs (De et al., 2000b).  However by the use 
of knockout studies, it was observed that removal of the p2 and p4 subunits caused a 
disruption of gut motility (Xu et al., 1999b).  Additional studies have also shown the 
presence of a3 nAChRs in the mouse bladder, such that a3 knockout mice have 
abnormalities in the bladder which include enlarged bladder (or megabladder), bladder 
infection and dribbling urination (see Picciotto et al., 2001).  Interestingly, it was shown 
that certain nAChR subtypes may be able to mediate ganglionic transmission in the 
bladder, particularly the a3p4 nAChR.  Furthermore, bladder smooth muscle non- 
responsive to nicotine was observed in a3, p2 and p4 knockout mice (Xu et al., 1999a; 
1999b).
1.6.4.  Distribution of nAChRs in non-neuronal cells.
There are increasing studies demonstrating the presence of nAChRs, other than those 
involved in synaptic transmission in the central and peripheral nervous system which, 
upon activation, modulate certain cellular functions.  A number of non-neuronal cells 
have been observed to express functional nAChRs such as skin keratinocytes (Grando,
1997), bronchial epithelial (Maus et al., 1998), aortic endothelial cells and immune tissue 
(Table 11) (Nguyen et al., 2000; Skok et al., 2003).  Studies involving a-subunit specific 
antibodies in p-lymphocyte cell lines identified that a4 and al nAChRs were present 
(Skok et al., 2003).  In situ hybridisation studies revealed that the a9 and alO subunits are 
distributed in the lymphoid system (tonsil, thymus and spleen) (Baker et al., 2004; 
Elgoyhen et al., 2001).  The a9 subunit is expressed in sensory organs and in particular in 
outer hair cells where it modulates the encoding of auditory stimuli (Elgoyhen et al.,
2001).  The localization of nAChRs in lymphocytes is a special interest because it would
94demonstrate the participation of a7 nAChRs in the promotion of tumor cell proliferation, 
as well as in antibody production (Skok et al., 2003).
Cell type Subunit Reference
Lymphocytes al, a4, a9, and alO Skok et al., 2003
Vascular endothelial cells 
(human) a3, a5, al, p2 and p4 (Macklin et al., 1998)
Bronchial epithelium 
(human, rat) a3, a5, al, p2 and p4 Maus etal., 1998
Keratocytes a5 and a3 Grando etal., 1997
Table 11.  Distribution of nAChRs in non-neuronal cells
1.7.  Neuronal nAChR acting as auto-and heteroreceptors.
It has been discussed that neuronal nAChRs are found on post-synaptic nerve terminals 
and are involved in fast synaptic responses (see Colquhoun & Patrick, 1997; see 
McGehee & Role, 1995; see Role & Berg, 1996), however there are other areas of the 
nerve where nAChRs are also found, for example on pre-synaptic nerve teminals, 
numerous studies have investigated the role of nAChR at these locations.  Pre-synaptic 
nAChRs were first identified by [3H]-nicotine and [125I]-a-BgT binding studies which 
detected binding sites along the axons and the terminal field of the CNS (see McGehee & 
Role, 1995; see Sargent, 1993).  By the use of focal lesions and quantitative radioligand 
binding, it was shown that a  large amount of [3H]-nicotine and [125I]-a-BgT binding sites 
were found pre-synaptically (see Jones et al., 1999).  These nAChRs have been shown to 
facilitate in the release of neurotransmitters and have been termed autoreceptors and 
heteroreceptors (see Wonnacott, 1997).
Autoreceptors are receptors which facilitate the increase or reduction of its own 
neurotransmitter release by acting on receptors located axonally or terminally, for 
example, ACh acting on nACh autoreceptors to decrease or increase the release of ACh
95from nerve terminals (Balfour, 1982; see Balfour & Fagerstrom, 1996; see Chesselet, 
1984).  However, heteroreceptors are characterised as receptors that facilitate the increase 
or decrease in the release of a different neurotransmitter, for example, ACh acting on 
nACh heteroreceptors causing an increase in the release of dopamine (see Balfour & 
Fagerstrom, 1996; see Colquhoun & Patrick, 1997; see Wonnacott, 1997).  Since the 
discoveiy of autoreceptors and heteroreceptors a great amount of interest and research 
has gone in to this area and it has been documented that nAChRs modulate the release of 
nearly eveiy neurotransmitter including dopamine (DA), glutamate (Glu), gamma- 
aminobutyric acid (GABA), noradrenaline (NA), 5-hydroxytyramine (5-HT) and ACh 
(Alkondon et al., 1997; Clarke & Reuben, 1996; see Dani, 2001; Girod et al., 2000; 
Lapchak et al., 1989b; Lena et al., 1993; Mihailescu et al., 2002; see Radcliffe & Dani, 
1998; Schilstrom et al., 2003; Tani et al., 1998; Wonnacott et al., 1989).
Not only has it been noted that there are differences in the pre-synaptic receptors i.e. 
auto-and heteroreceptors but it has also been shown that the localisation of these 
receptors can vary.  Pre-synaptic receptors in the presence of tetrodotoxin (TTX), a 
sodium channel blocker, caused inhibition of some nAChRs but not all (see Dani, 2001; 
see Wonnacott, 1997).  Further studies which included looking at GABAnergic axons in 
rat interpeduncular nucleus (Lena et al., 1993) and glutamatergic axons in rat cerebellum, 
(De et al, 2001) showed that in the presence of TTX, the increase in frequency of post- 
synaptic currents caused by a nicotinic agonist was inhibited.  It has also been shown that 
neurotransmitter release can occur in the presence of TTX, for example, indicating that 
they are TTX-insensitive pre-synaptic receptors, this was shown with NA release by 
nicotine in rat hippocampal synaptosomes (Clarke & Reuben, 1996) and an increase in 
post-synaptic currents by nicotine in the medial habenula and interpeduncular nucleus 
neurons resulting in the release of glutamate (Girod et al, 2000).  Studies have suggested 
that there are different localisations for nAChR on the neuron.  The first is believed to be 
found on the axon (Figure 10) (see Dani, 2001; see Wonnacott, 1997), whereby, 
neurotransmitter release is believed to occur by the opening of nAChR ion channels, 
resulting in the influx of Na+, causing the opening of voltage-gated calcium channels and 
the influx of Ca2+, which evokes the exocytosis mechanisms and the release of 
neurotransmitter (Figure 11) (see Jones etal., 1999; see McGehee & Role, 1995;Wonnacott et al, 1989).  It has also been shown that due to the high permeability of Ca2+ 
through the ion channel of the nAChR, the influx of Na+ to open the voltage-gated ion 
channel is not always required and exocytosis of neurotransmitters can occur by the Ca2+ 
influx through the nAChR ion channel alone (see Dajas-Bailador & Wonnacott, 2004; 
Girod etal., 2000).
Unlike axonal auto-and heteroreceptors, which are believed to be found on the nerve 
bouton, terminal nAChR are believed to be found on the terminal regions of the axon but 
not in the proximity of a single synaptic bouton (Figure 10) (see Dani, 2001; see 
Wonnacott, 1997).  As previously mentioned terminal nAChR can be identified by the 
use of TTX, whereby inhibition by this sodium channel blocker indicates terminal 
nAChRs.  In contrast to axonal nAChR activation, terminal nAChR activation causes 
TTX-sensitive spikes in the terminal portion of the axons, resulting in depolarisation of 
the membrane locally, leading to activation of voltage-dependent Na+ channels that result 
in action potentials (Alkondon et al., 1997; Lena et al., 1993).  These action potentials 
presumably run down the axon, causing voltage-gated Ca2+channels to open in the pre- 
synaptic bouton and inducing the exocytosis mechanism, resulting in the release of the 
neurotransmitter (see Dajas-Bailador & Wonnacott, 2004).
1.7.1.  Neuronal nACh autoreceptors involvement in ACh 
release.
It has been clearly demonstrated that the administration of nicotine intravenously (i.v.) 
into cats resulted in an increase in the release of ACh in the brain, in particular the 
parietal cortex, although it was originally unclear how this occurred (Balfour, 1982).  Due 
to extensive research, it has been shown that nicotine and other nicotinic compounds are 
able to act on autoreceptors and cause the release of ACh from nerve terminals (Lapchak 
etal., 1989b; Tani etal., 1998).
97A particular area of interest for studying nicotinic autoreceptors is the cholinergic input 
from the medial septal nucleus to the hippocampus (Mesulam, 1995; Mesulam & Geula, 
1988).  It has been shown in vivo in free moving rats (Tani et al., 1998), as well as, in 
hippocampal synaptosomes and slices (Araujo et al., 1988; see Chesselet, 1984; Wilkie et 
al., 1996), that nicotinic agonists stimulate the release of ACh.  In the hippocampus of 
free moving rats, <*402 selective nicotinic agonist, ABT-418, enhanced the release of 
ACh, while GTS-21, a a7 selective nicotinic agonist, had no effect on ACh release (Tani 
et al., 1998), indicating that the autoreceptor present was the a4p2 receptor.  This is 
emphasized in hippocampal synaptosomes, slices and in vivo studies which demonstrated 
that ACh release by nicotinic agonists is blocked by the a4{32 antagonist, DhpE, but not 
by the al antagonists a-BgT and MLA (Araujo et al., 1988; Wilkie et al., 1996; 
Wonnacott et al., 1989).  These findings also correlate with the high levels of a4 and p2 
subunit transcripts that have been found in the cell bodies of the medial septum (Wada et 
al., 1989).  The location of the nicotinic receptor has been demonstrated to be axonal due 
to it being largely TTX-insensitive and the nicotinic-induced release of ACh is believed 
to be calcium dependent (Colquhoun & Patrick, 1997).
Other areas of the CNS that demonstrate nicotinic AChR-induced ACh release include 
the cerebellum, which is innervated by ACh containing neurons from the medullary 
tegmental nucleus.  Upon administration of nicotinic agonists into the rat cerebellum 
there is a increase in ACh release (De et al., 2005; Lapchak et al., 1989a; 1989b) which 
was blocked by the a4p2 antagonist, DhpE, but was insensitive to atropine or a-BgT 
indicating the presence of a4p2 receptors, but not al or muscarinic receptors (Lapchak et 
al., 1989b).  As with neuronal nAChRs found in the hippocampus, cerebellum 
autoreceptors are TTX-insensitive, suggesting an axonal location.
981.7.2.  Dopamine release by activation of neuronal nACh 
heteroreceptors.
Dopamine (DA) release plays an important role in mediating the reinforcement effect of 
natural rewards, as well as that of various drugs of abuse (see Jones et al., 1999; Marshall 
et al., 1997; Schilstrom et al., 1998; 2003).  One such drug of abuse is nicotine inhalation 
via cigarette smoking which has been shown to cause the release of DA which results in 
the stimulation that smokers feel (Wu et al., 2004) and the addiction (Champtiaux et al., 
2003).  Due to this effect, the release of DA by nicotine has been extensively studied to 
confirm that nicotine can induce DA release.  One technique is the use of striatal 
synaptosome preparations. The striatum has been extensively studied because it has been 
shown by lesion studies there is a high number of pre-synaptic nAChRs present.  Lesion 
studies on nigrostriatal neurons, which make up the dopaminergic projection from the 
substantia nigra to the striatum, caused a significant decrease in nicotine binding sites in 
the striatum (see Colquhoun & Patrick, 1997).  Previous studies demonstrated that the 
striatum has no detectable nicotinic genes, therefore the decrease in nicotinic binding 
sites is not due to loss of receptors on the striatal neuron, and instead it is believed that 
the decrease in nicotinic binding sites is due to the loss of presynaptic nAChRs on 
innervating nigral axons. A large number of nAChR subunits from the nigral efferent to 
the striatum have been identified, including a3, a4, a5, P2 and P3 (Wada et al., 1989).
Striatal synaptosome preparations showed that nicotinic agonists induce the release of 
DA from the perfused synaptosome preparation preloaded with radiolabelled DA (Rapier 
et al., 1988; 1990).  This release of DA by nicotinic agonists occurred at very low 
concentrations and was inhibited by the non-selective nicotinic antagonist, 
mecamylamine (Rapier etal., 1988).  More specifically, the nicotinic-mediated DA 
release was inhibited by the a4p2 selective antagonist, DhpE, although there was no 
observed inhibition by a-BgT or atropine, indicating a7 and muscarinic receptors are not 
involved (Grady et al., 1992; Rapier et al., 1990).  The release of DA is believed to be 
calcium-dependent, this is based on the finding that there is a reduction in DA release in 
the absence of Ca2+ (Grady et al., 1992; Rapier et al., 1988).  This finding, together with
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101the observation that release is TTX-insensitive, indicates that the release of DA occurs 
via direct depolarization of the axon by nicotine acting on a4f2 receptors located 
axonally.
Further studies looking into the nACh receptors involved in DA-mediated release, 
showed that in mouse striatal synaptosomes there was inhibition of nicotinic-mediated 
DA release by a-conotoxin Mil (a-Ctx Mil).  This inhibition was only partial, indicating 
that there are two classes of nACh heteroreceptors mediating DA release, which are 
termed a-Ctx Mil sensitive and a-Ctx Mil resistant, by the use of subunit deletion, the 
particularc nAChRs involved were determined (Salminen et al, 2004).  It was 
demonstrated that DhpE was more potent at inhibiting the a-Ctx Mil resistant subtype 
and MLA was more potent at inhibiting the a-Ctx Mil sensitive subtype, clearly 
indicating nAChRs with different pharmacologies.  Interestingly, knock-out of a4 and P2 
subunits caused a block of functional pre-synaptic nAChR on the dopaminergic terminal 
of the striatum.  In addition, a5 knockout studies indicated that a5 may also be involved 
in a-Ctx-MII resistant DA release.  Knockout of a7, P4 and P3 subunits were all shown to 
have no effect on DA release in a-Ctx-MII resistant subtypes.  Knockout of receptor 
subtypes for a-Ctx-MII sensitive DA release indicates that p2 and P3 are essential for DA 
release (Cui et al., 2003;Salminen et al., 2004), a4 was also observed to be important but 
again a7 was shown to have no effect on DA release.  Considering these data it could be 
concluded that the a-Ctx Mil resistant receptor subtype is most likely a4p2 and may also 
involve the a5 subunit to form the neuronal nAChR a4a5p2.  Additional studies 
determining the composition of a-Ctx-MII sensitive receptors indicated that the subunit 
composition is more complex.  Studies have shown that P3 and P2 are essential, whereas 
a6 and a4 are partially dependent; therefore the subunit composition has been suggested 
to be a4a6p3p2 and a6p3p2.  Three main heteromeric nAChR on the mouse striatum 
were identified which are a4p2, a6p2 and a4a6p2, and by knockout studies it was shown 
that the a-Ctx-MII resistant subtype was a4p2, whereas the a-Ctx-MII sensitive subtype 
was a6p2 (Champtiaux et al, 2003).  Although a3p2 is the most selective subtype for a- 
Ctx-MII (Sharpies et al., 2000) there is little evidence for the presence of a3 nAChRs in 
the striatum (Wada et al., 1989).  Additionally, in situ hybridisation only demonstrated 
very low concentrations of a3 mRNA in DA neurons (Champtiaux et al., 2003).  Using
102UB-165 (Karig et al., 2003;Sharples et al, 2000) and (±) anatoxin-a (Soliakov et al, 
1995), which are selective agonists of the a4(J2 receptor, an increase in DA release was 
observed in striatal synaptosomes and provided evidence that the a-Ctx-MII insensitive 
subtype is a4p2 (Champtiaux et al, 2003; Salminen et a l, 2004; Sharpies et al, 2000; 
Soliakov et al, 1995).  Studies suggested the nAChR-mediated DA release was calcium 
dependent and located axonally (Grady et al, 1992; Rapier et al, 1988).  However, it is 
also possible that some terminal nAChR are present since it was shown that there was 
40% inhibition in the presence of TTX (Rapier et al, 1988; Soliakov et a l, 1995). 
Interestingly, studies in vivo, demonstrated that TTX completely blocked the nicotine- 
induced DA release, suggesting that the localisation of the nAChR may be found 
terminally rather than axonally (Marshall et al, 1997).
Additional areas in the brain have been studied, including the midbrain dopaminergic 
nuclei, which apart from the substantia nigra, also include the ventral tegmental area 
(VTA).  The VTA plays an important role in mediating the effects of natural rewards 
(Klink et al, 2001; Schilstrom et al, 2003) as well as various drugs of abuse, including 
nicotine, through an increased dopaminergic transmission to the nucleus accumbens 
(Schilstrom et al, 1998; Wu et a l, 2004).  Nicotinic agonists applied to the rat VTA, 
resulted in an increase in DA release in the nucleus accumbens (Schilstrom et al., 1998). 
In later studies by Schilstrom et al (2003) nicotine increased burst firing and firing rate 
of dopaminergic neurons.  Involvement of the neuronal nACh al receptor was 
demonstrated by the use of the selective antagonist, MLA, which was observed to block 
burst firing but not firing rate, whereas, the a4p2 selective antagonist, DhpE, caused 
inhibition of firing rate but did not inhibit burst firing (Schilstrom et al., 2003).  Using the 
a4p2 selective agonist, TC-2559, it was shown that a4p2 nAChRs are present in the VTA 
and that they facilitate the release of DA (Chen et al., 2003), which was inhibited by the 
a4p2 selective antagonist, DhpE.  Studies performed by Klink et al. (2001) indicated that 
DA release by nAChRs is in fact a consequence of more diverse nAChRs such as 
a4a5(P2)2 (Klink et al, 2001).
1031.7.3.  5-HT release by activation of neuronal nACh 
heteroreceptors.
The largest serotonergic innervation of the forebrain originates from the raphe nucleus, 
with the dorsal raphe nucleus containing the largest amount of serotonergic neurons in the 
brain (see Balfour & Fagerstrom, 1996; see Chesselet, 1984; Li et al., 1998; Mihailescu 
et al., 2002).  Although it has been shown that serotonin can control its own release in 
slices such as the cortex and hypothalamus (see Balfour & Fagerstrom, 1996; see 
Chesselet, 1984), it has been shown that administration of nicotinic agonists on in vitro 
dorsal raphe neurons of the rat, caused an increase in the discharge rate of the 
serotonergic neurons and resulted in the release of 5-HT (Li et al., 1998), which was 
MLA-insensitive, suggesting that the al nAChR subtype was not involved (Li et al.,
1998).  Other studies have shown that nicotine administrated into the dorsal raphe 
nucleus of the rat midbrain also increases the release of serotonin (Mihailescu et al.,
2002).  Li et al. (1998) demonstrated that the nicotine-induced serotonin release is TTX- 
insensitive, suggesting that neuronal nACh receptors are present on the axon rather than a 
terminal location.  Neuronal nAChR subtype studies have shown a high expression of a4 
and al present in these neurons (Bitner & Nikkei, 2002), although further study is 
required to determine which neuronal nACh receptor is activated to facilitate in the 
release of serotonin.  The effects of nicotine-invoked serotonin release on other areas of 
the brain, such as the hippocampus, showed that nicotine did modulate its release but the 
dose required was very high, and therefore the effect is probably of little pharmacological 
significance (Balfour, 1982).
1.7.4.  Noradrenaline release by activation of neuronal nACh 
heteroreceptors.
Noradrenaline (NA) release has been studied in detail in many areas of the brain, the 
most extensively studied areas are the hippocampus (Colquhoun & Patrick, 1997) and
104hypothalamus (Hall & Turner, 1972), where it was shown that the application of nicotinic 
agonists evoked NA release.  Studies of rat hippocampal synaptosomes have shown that 
nicotinic agonists cause the release of NA, which can be abolished by the nicotinic 
antagonist, mecamylamine indicating the presence of neuronal nACh heteroreceptors.  It 
was observed that cytisine, a very selective agonist for a3 and p4, was as effective at 
causing NA release as nicotine (Alkondon & Albuquerque, 1993; Chavez-Noriega et al., 
1997; Colquhoun & Patrick, 1997).  Additionally, the selective antagonists DhpE and 
MLA were not as effective at inhibiting nicotinic stimulated NA release.  These results 
therefore suggest the presence of an a3 or P4 subunit (Anderson et al., 2000; Clarke & 
Reuben, 1996).  Innervation by NA-containing neurons of the hippocampus is derived 
from the locus coeruleus (see Chesselet, 1984; Lena et al., 1999; see Wonnacott, 1997), 
in situ hybridization and immunohistochemistry studies showed that the NA-containing 
neurons contained an extremely high abundance of a7 and a3 nAChR subunits (Bitner & 
Nikkei, 2002), as well as moderate levels of P4 and very little a4 subunit (Lena et al., 
1999; Seguela et al., 1993; Wada et at., 1989).  It is believed that the heteroreceptors 
present that cause the release of NA are al and a3p4, although this is not completely 
proven. The nicotine evoked NA release was unaffected by TTX therefore suggesting the 
location of these heteroreceptors are on the axon (Clarke & Reuben, 1996).  Additionally, 
it has been observed, in cell lines, that the release of NA by the activation of DMPP is 
caused by depolarization of the cell resulting in activation of L-type calcium channels
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(Vaughan et al., 1993) and the influx of Ca  enhance evoking levels of intracellular 
calcium, which would theoretically cause the exocytosis of NA from the synaptic 
terminal and release NA (see Dajas-Bailador & Wonnacott, 2004; Vaughan et al., 1993; 
Wonnacott et al., 1989).
Studies of the hypothalamus, have shown NA release upon nicotine administration both 
by i.v. and i.c.v. injection (see Hall & Turner, 1972).  In hypothalamic tissue slices, 
nicotine was demonstrated to cause an increased release of NA which is believed to be a 
calcium-dependent process (see Hall & Turner, 1972).  In hypothalamus synaptosomes 
nicotine, even at very low doses, causes the increased release of NA (Balfour, 1982).
105Additional areas of the brain have been studied to observe if neuronal nAChRs are 
causing the release of NA, and it has been shown that nicotinic agonists can cause the 
release of NA from different areas of the brain.  However, it was found that the 
concentration of agonist required to elicit a response was too great and are therefore 
unlikely to be of any physiological signficance (see Balfour, 1982) and makes it less 
plausible that it naturally occurs in these other sites of the CNS.
1.7.5.  GABA release by activation of neuronal nACh 
heteroreceptors.
The substantia nigra receives a huge GABAergic input from the caudate nucleus, 
unfortunately, not much research has gone into looking at the effects of nicotine-induced 
GABA release in this area.  One area that has been studied in great detail in terms of 
nicotine-induced GABA release is the rat hippocampus.  It has been observed in CA1 
neurons that application of nicotine results in the release of GABA from interneurons. 
These nicotinic responses were blocked by nicotinic antagonists, indicating that the 
GABA-mediated post-synaptic currents and slow decaying nicotinic currents were 
mediated by nAChRs (Alkondon et al., 1997).  The GABA-mediated post-synaptic 
currents were not blocked by either of the a7 antagonists a-BgT or MLA, whereas, the 
slow decaying nicotinic currents recorded from the intemeurons were blocked by the 
a4p2 nAChR selective antagonist DhpE (Alkondon et al., 1997).  Nicotine-induced 
release of GABA has also been observed in CA3 whereby it was suggested that nAChRs 
modulated giant depolarizing potentials (GDP) (Maggi et al., 2001).  Nicotine enhanced 
the GDP frequency and was blocked by the a4p2 antagonist, DhpE, and partially 
inhibited by the a7 antagonist, MLA.  Selective agonists for a7 also increased GDP 
frequency (Maggi et al., 2001).  It was therefore suggested that GABA release in the rat 
hippocampus is mediated by at least two nAChRs, most likely a4p2 and al, especially as 
high levels of staining for the al subunit were observed on GABAergic intemeurons 
(Kawai et al., 2002).  The CA1 was shown to be TTX-sensitive, indicating that the
106neuronal nACh heteroreceptors are found terminally (Alkondon et al, 1997; Lena et al, 
1993).
Another area of the rat brain that has a significant role in nAChR-induced GABA release 
is the IPN, due to its cholinergic innervation derived from the medial habenula and 
medio-basal forebrain through the fasciculus retroflexus (Mesulam & Geula, 1988; see 
Woolf, 1991).  This area has been shown to have radioligand binding sites for [3H]- 
nicotine and [125I]-a-BgT (Spurden et al., 1997; Whiting et al., 1991).  Nicotine applied 
to IPN neurons caused an increase in frequency of post-synaptic GABAnergic currents, 
which could be inhibited by the a4p2 antagonist, DhpE (Lena et al, 1993).  There are a 
larger number of neuronal nAChR subunits found in the IPN, with the a2 subunit gene 
having the highest expression in the CNS (Wada et al., 1989).  Other subunit genes 
expressed include a3, a4, a5, p2 and p4 (Wada et al., 1989), indicating that there could 
be a large variety of nAChR involved in GABA release (Lena et al., 1993).  Interestingly, 
the nicotinic agonist-induced GABA release was inhibited by TTX (Lena et al., 1993), as 
previously mentioned indicating that the neuronal nAChR are located on the terminal. 
Activation of these terminal nACh receptors triggers TTX sensitive spikes in the terminal 
portion of the GABAnergic axon which produces action potentials that initiate GABA 
release from multiple presynaptic terminals (Alkondon et al., 1997; Lena et al., 1993).  In 
the chick mesencephalic lateral spiriform nucleus, nicotinic agonists caused an increase 
in the frequency of spontaneous post-synaptic currents, which are inhibited by 
bicuculline, indicating GABAnergic currents (McMahon et al., 1994).  The nicotine- 
induced effects are inhibited by DhpE and the nicotinic agonist-induced post-synaptic 
currents are blocked by TTX, indicating a a4p2 nAChR located on the terminal (Lena et 
al., 1993; McMahon et al., 1994).
1071.7.6.  Glutamate release by activation of neuronal nACh 
heteroreceptors.
Glutamate has been observed to be most abundant in the hippocampus and on the medial 
habenula projection to the IPN nucleus (see Jones et al, 1999).  The medial habenula - 
IPN (MHN-EPN) synapse was observed to increase frequency of glutamatergic 
spontaneous post-synaptic currents by 57% when nicotine was applied.  Observations that 
the nAChRs were TTX-insensitive indicated that the neuronal nACh heteroreceptors 
were located on the axon (Girod et al, 2000).  Due to the high gene expression on the 
MHN and IPN with almost all the known nicotinic gene products found, it is difficult to 
determine which nAChRs are present (Wada et al, 1989), additionally it is highly 
possible that multiple receptor subtypes exist.  Studies of the MHN-IPN synapse suggests 
that a7 may be involved in glutamate release from observations of a-BgT inhibition of 
nicotine-induced effects.  Additionally, deletion of the a7 subunit diminished the 
magnitude of nicotine-elicited calcium signalling into the pre-synaptic neuron.  However, 
complete inhibition of calcium signalling did not occur.  This is likely to be due to the 
extensive expression of other receptor subunits, which would compensate for the loss of a 
specially deleted subtype by increasing their calcium signalling.  Interestingly, the 
amount of nicotine required to activate al receptors is very low compared to other al 
receptor studies which usually require a 100 fold higher nicotine concentration for 
activation.  This implies that the al may be co-assembled with other nicotinic subunits 
altering its pharmacology (Khiroug et al., 2002).  Activation of al nAChRs on the MHN 
neurons has shown that glutamate release is due to an influx of Ca 2+ into the synaptic 
bouton.  However, al receptors are able to cause this release without depolarization of 
the bouton and activation of voltage-gated calcium channels, but by Ca2+ flow directly 
through neuronal nACh heteroreceptors on the axon into the synaptic bouton (see Dajas- 
Bailador & Wonnacott, 2004; Girod et al, 2000; Seguela et al, 1993).
Nicotine-induced glutamate release has been observed in many other areas of the brain, 
including the rat cerebellum which showed an increase in post-synaptic currents and 
activation of somatic currents when ACh was applied.  This was shown to be due to
108glutamate release when the ACh-induced post-synaptic currents were completely blocked 
by glutamate antagonists.  The somatic currents were shown to be mediated by non-a7 
receptor activation, due to MLA having no effect (De et al., 2001) but were blocked by 
the a4p2 antagonist, DhpE, indicating a4p2 nACh receptors are involved, whereas 
postsynaptic currents are induced by a7 receptor activation as MLA and a-BgT both 
blocked ACh-induced glutamate release.  Similar to the MHN-IPN nucleus, the ACh- 
induced release was inhibited by TTX (TTX-sensitive) suggesting that the nicotinic 
receptors are located on the terminal (De et al., 2001; Girod et al., 2000).  In the olfactory 
bulb and amygdala, which both have large cholinergic innervation, nicotinic-induced 
glutamate release is observed, which is shown to be a-BgT sensitive indicating al 
nAChRs and are resistant to TTX localising the nAChR to the axon (see Chesslet., 1984; 
see Radcliffe & Dani., 1998).
The hippocampus, which is the centre for learning and memory, responds to nicotine by 
an increase in glutamate release which is abolished by al antagonists a-BgT and MLA 
and was shown to be inhibited by TTX indicating the a.1 receptors are found terminally 
(Aramakis & Metherate, 1998; see Radcliffe & Dani, 1998).  Similar to the MHN-IPN 
neurons and cerebellum, the nicotine-induced glutamate release was shown to be 
calcium-dependent, with nicotine directly increasing the presynaptic concentration of 
Ca2+ due to al nAChRs being highly permeable to Ca2+ (Aramakis & Metherate, 1998; 
Girod et al., 2000; see Radcliffe & Dani, 1998; Wonnacott et al., 1989).  This suggests 
that the al subtype is involved, but it is also believed that other subtypes are also 
involved due to the high expression of other subunits at these sites (Rubboli et al., 1994a; 
Seguela et al., 1993; Wada et al., 1989).
1.8.  Knockout Studies.
Research into the function of neuronal nAChRs has taken place by the use of 
electrophysiological and pharmacological studies, which have provided a vast amount of 
data on the involvement of neuronal nAChRs in a number of processes.  Unfortunately,
109there have been limitations in the research, due to the lack of sufficient selective agonists 
and antagonists.  However, due to relatively new techniques the function of neuronal 
nAChR subunits has been possible to study, with the use of knockout mice, whereby 
nACh receptor subunits are removed or “knocked out” from the mice and observations 
are made on the development of the mice.  This provides a powerful tool in 
understanding of the role of individual nAChR subunits in the CNS.
The initial work on knockout mice was completed by Thomas & Capecchi in 1987 and 
since then has helped in understanding the function of receptors.  Knockout technology 
involves embryonic stem cells grown in vitro and genetically modified by the substitution 
of a non-functional copy of a given gene.  By the use of mouse blastocysts, which are 
injected with the engineered embryonic stem cells, they are re-implanted in a host 
mother’s uterus.  Of the resulting chimeric mice, some contain the mutated embryonic 
stem cells in the germ cell layer allowing the mutation to be passed onto the next 
generation.  The resulting heterozygote mice can then be inter-bred to produce 
homozygote mutant knockout mice (see Marubio & Changeux, 2000; Wang et al., 2003; 
Xu et al., 1999b).  Below are described studies involving nAChR subtype knockout (KO) 
mice and the observed effects caused by the KO studies (Table 14).
1.8.1.  a3 Knockout studies.
The a3 subunit has been observed to be found extensively in the autonomic system and is 
expressed in all autonomic ganglia.  Expression of the a3 is also observed in the medial 
habenula; dorsal medulla and retina (Picciotto et al., 2001).  Studies have indicated that 
a3 can combine with either p2 or p4 to form a functional nAChR (Luetje & Patrick,
1991), and that a3 subunit-containing nAChRs are critical for fast-EPSP in the ANS, 
providing unique physiological and pharmacological properties (Table 14) (see Wang et 
al., 2002b).
110Knockout mice lacking the a3 subunit mostly died during the first week of life, with the 
remaining dying within the next 6-8 weeks (see Cordero-Erausquin et al., 2000; see 
Picciotto et al., 2001; see Wang et al., 2002b).  The a3 KO mice had a number of 
deformities, such as retarded growth whereby a3 KO mice had a mean weight 
approximately 40% of the wild-type (Wt) mice.  In addition to this, there were observed 
abnormalities in the bladder which included; enlarged bladder (or megabladder), bladder 
infections, dribbling urination and urinary stones.  Observations of non-responsive 
bladder strips to nicotine were also recorded in vitro (Xu et al., 1999b).  The symptoms 
caused by the knockout of a3 have been found to be similar to a human autosomal 
recessive disease called Megacytis-Microcolon-Intestinal-Hypoparistalsis Syndrome 
(MMHIS), patients suffering from this disease have a mean survival of 3.6 months (see 
Cordero-Erausquin et al., 2000).  Studies looking at these patients discovered that no a3 
mRNA was detected in the small bowel, suggesting that the a3 subunit gene mutation 
may be responsible for the disease.
In addition, KO studies of the a3 subunit caused defects in the visual system of 
mammals, suggesting that the a3 nAChR subtype may be involved in retinal development 
(Table 14).  Mutant mice have been recorded to suffer from small ocular globes, very 
widely dilated pupils with no constriction in response to light and reduction in function of 
the refinement of retinothalamic projections (which occur during early postnatal 
development).  These studies indicated that the impairments observed in a3 KO mice 
could be due to autonomic ocular innervations.(Champtiaux & Changeux, 2004; see 
Wang et al., 2002b).  Altogether, the a3 subunit has been shown to be an essential 
component for survival as it is important in the construction of nAChRs in the autonomic 
ganglia, such as the nAChRs that mediate fast synaptic transmission.
1.8.2.  a4 Knockout studies.
Upon a4 KO, there was observed no detected binding sites for [3H]-nicotine, [3H]- 
epibatidine and [ H]-cytisine in most rat brain regions suggesting that high affinity
111binding sites for nicotinic compounds represent nAChRs containing the a4 subunit (see 
Marubio & Changeux, 2000).  Interestingly mutant mice that lack the a4 subunit have 
been observed to be normal in size, fertility and home cage behaviour when compared to 
Wt mice (Table 14) (Ross et al., 2000).  It could be suggested that the involvement of 
another subunit, substituting itself for the lack of a4, may be involved and playing the 
role that a4 would be playing.  This was demonstrated when in a4 KO mice high [3H]- 
nicotine binding is still observed in certain areas of the brain including the interpeducular 
nucleus (IPN), as well as, high [3H]-epibatidine binding in substantia nigra and superior 
colliculus, suggesting the presence of another a subunit which can co-assemble with a P 
subunit and facilitate in the role that a4 should be playing (see Picciotto et al., 2001; Ross 
et al., 2000), however, there are observed difference between the a4 KO mice and Wt 
mice.
Previous studies have shown that nicotine acts like an analgesic in Wt mice for both the 
hot plate test (which tests the primary brain-mediated pain response) and the tail flick test 
(which tests the primary spinal cord mediated pain response).  Studies observing the 
nicotine-induced analgesia effect in a4 KO mice showed a decrease in nicotine-induced 
analgesia in the hot plate test and a reduced analgesic response in the tail flick test 
(Champtiaux & Changeux, 2004; see Picciotto et al., 2001).  These studies suggest that 
a4 may play a role in nicotine induced analgesia (Table 14). Further studies indicated that 
there was a decrease in [ H]-nicotine and [ H]-epibatidine binding in the thalamus and the 
raphe magnus (which both play an important role in the nicotinic antinociceptive 
pathway) in a4 KO mice, as well as a decrease in nicotine-elicited currents in the 5-HT 
neurons of the raphe magnus and neurons in the thalamus.  Altogether, it was indicated 
that the a4 subunit may be involved with the nicotinic antinociceptive pathway (see 
Cordero-Erausquin et al., 2000; see Marubio & Changeux, 2000).
In addition, it was demonstrated that a4 KO mice may be a good model for 
neurodegenerative diseases such as the dopamine neurodegeneration associated with PD. 
Studies showed that in a4 KO mice, upon acute nicotine treatment there was no 
protection against methamphetamine-induced neurodegeneration of striatal dopaminergic 
terminals, unlike in Wt mice (Champtiaux etal, 2003; Champtiaux & Changeux, 2004).
112In mice lacking the a4 subunit, the extent of the lesion caused by methamphetamine was 
similar to that observed in the Wt mice, but unlike Wt mice, it could not be prevented by 
nicotine (Table 14).  This established the a4 subunit to have a role in nAChR 
neuroprotective effects by nicotine (Champtiaux et al., 2003; Champtiaux & Changeux, 
2004; see Picciotto et al., 2001).
Interestingly, a4 KO studies have shown that a4 KO mice are prone to higher levels of 
anxiety when compared to Wt mice (Ross et al., 2000).  Studies have demonstrated that 
a4 KO mice have been observed to spend less time on the open arms of the elevated-plus 
maze, as well as making fewer open arm entries when compared with Wt mice, indicating 
that a4 may be involved in modulating the mammalian stress level (see Picciotto et al., 
2001; Ross et al., 2000).
1.8.3.  a5 Knockout studies.
Unfortunately, there has been limited study into a5 KO.  The a5 has been most 
extensively studied in the chick, whereupon it was discovered that the a5 is expressed 
most highly in deep layers of the cortex, SN and VTA, as well as in the autonomic 
ganglia (see Picciotto et al., 2001; see Wang et al., 2002b).
Studies in to the effects of a5 knockout revealed that a5 KO mice grew to normal size 
showing no obvious physical or neurological deficits. Compared to the Wt mice, the a5 
KO mice are normal in thermoregulation, pupil size and resting heart rate under 
physiological conditions (see Cordero-Erausquin et al., 2000; Wang et al., 2002a).
Studies observing if there were any abnormalities in a5 KO mice compared to Wt mice 
indicated impairment in cardiac parasympathetic ganglionic transmission during high 
frequency vagal stimulation.  It was noted that Wt mice suffer from cardiac arrest due to 
high frequency stimulation, whereas a5 KO mice were more resistant (Wang et al., 
2002a).  Furthermore, the a5 subunit may be involved in the affinity and sensitivity of 
agonists and antagonists in native receptors, due to observations that a5 KO mice had a
113significant increase in ileal contractile responses to nicotinic agonists cytisine and 
epibatidine.  Additional studies showed that in a5 KO mice had an increased sensitivity 
to low concentrations of hexamethonium, which nearly blocked the bradycardia in 
response to vagal stimulation.  This implies that a5 modulates the pharmacological 
activity of nAChRs in autonomic ganglia in vivo (Wang et al., 2002a).  In addition, 
studies suggested that a5 containing nAChRs are involved in nicotine-induced seizures as 
a5 KO mice were more resistant to nicotine-induced convulsions (Kedmi et al, 2004).
1.8.4.  a7 Knockout studies.
There is limited information about studies involving a7 KO mice.  The a7 transcripts are 
found to be abundant as early as embryonic day (E)6 in the embiyonic sympathetic 
system, and increase until E10 and then have been observed to considerably decrease 
thereafter (see Marubio & Changeux, 2000).  Interestingly, a7 nAChRs have a high 
permeability to Caz" and therefore have been suggested to be involved in embryonic 
development due to possible influences on a variety of calcium-dependent events in 
neurons, such as second messenger cascades and neuronal survival or apoptosis.  In 
addition, to high permeability to Ca2+, a7 nAChRs are believed to have a fast 
desensitisation and sensitive blockade of ACh-induced currents by a-BgT (see McGehee 
& Role, 1995; see Sargent, 1993).  Knockout studies have shown, that in comparison to 
Wt mice, a7 KO mice are found not to contain nicotine-induced fast desensitising 
currents confirming a7 nAChR are responsible for these responses (see Wang ei al, 
2002b).  Additional studies have suggested that, the high CaZ T  permeability exhibited by 
a7 nAChRs might possibly contribute to neurodegeneration.  This is suggested as in the 
developing chick embryo a-BgT infusions rescued motomeurons from naturally 
occurring cell death, although no differences were observed between a7 Wt and KO 
animals in respect to signs of neuronal injury or cell death in the hippocampus 
(Champtiaux & Changeux, 2004; see Cordero-Erausquin el al., 2000).
114Franceschini et al. (2000) investigated the role of al nAChRs in cardiac autonomic 
function by measuring baroreflex-mediated responses in al KO mice.  It was observed 
that, al KO mice, had impaired sympathetic responses to vasodilation which was 
demonstrated by sodium nitroprusside infusion, causing a 48% heart rate increase in Wt 
but only a 21% increase observed in al KO mice.  The al KO mice developed 
supersensitivity to adrenoceptor agonists while baroreflex mediated parasympathetic 
responses were normal in al KO mice.  The decreased baroreflex-mediated tachycardia 
in al mutant mice indicates that a7-containing nAChRs participate in the autonomic 
reflex that maintains blood pressure homeostasis (Franceschini et al., 2000).
Interestingly, knockout studies have suggested that al may be involved in regulation of 
inflammation (Wang et al., 2003).  Excessive inflammation is usually prevented by 
regulation of the magnitude of innate immune responses by highly conserved, 
endogenous mechanisms.  The nervous system, through the vagus nerve, can inhibit 
significantly and rapidly the release of macrophage TNF and attenuate inflammatory 
responses.  This mechanism, termed the ‘cholinergic anti-inflammatory pathway , has 
many implications in immunology and therapeutics, however the receptor that responds 
to vagus nerve signals was previously unknown (Wang et al., 2003a). Studies completed 
with al KO mice indicated that electrical stimulation of the vagus nerve inhibits 
macrophage TNF synthesis in Wt mice but failed to inhibit INF synthesis in al KO 
mice, suggesting al nACiiRs are essential for inhibiting cytokine synthesis by the 
cholinergic anti-inflammatory pathway.  Additional knockout studies have also implied 
that al nAChRs may be involved in some aspect of nicotine dependence, which was 
indicated when Wt mice showed an increase in hyperalgesia upon nicotine withdrawal, 
whereas al knockout mice did not (Grabus et al., 2005).
Including studies of al KO mice, studies have taken place whereby ‘knockin’ al subunit 
Leu24 / Thr point mutation has been generated, which involves a leucine to threonine 
mutation in the leucine ring of the M2 region of the al nAChR (see Cordero-Erausquin et 
al., 2000).  Studies with knockin al mice have shown that it dramatically effects neuronal 
survival, with homozygous mice for the a7L247T point mutation showing extensive 
apoptosis throughout the somatosensory cortex and the majority dying within 24 hours of
115birth (Champtiaux & Changeux, 2004).  Interestingly, knockin a7 nAChR contain an 
increase in nicotinic agonist affinity and a decrease in die rate of desensitisation in 
nicotine-elicited currents in hippocampal neurons.  These are surprising results as 
previously observed, al KO mice develop normally, whereas al knockin mice die within 
24 hours (Table 14).  This may be an indication that in al KO mice additional receptors 
compensate for the lost.
1.8.5.  p2 Knockout studies.
Studies observing the function of p2 subunits in the CNS (32 KO studies have suggested 
that P2 may be involved in functions such as learning and memory, the reinforcing 
properties of nicotine and nicotine-mediating antinociception (see Picciotto et al, 2001; 
Ross etal., 2000).
Nicotine administration has been shown to improve information acquisition and memory 
retention in rodents and information processing in humans (Table 14) (Levin, 1992).  The 
involvement of the p2 in memory and learning has been examined by the use of p2 KO 
studies and a test known as the passive avoidance test, which measures an animal7s 
latency to perform a highly probable response (in this case, entry from a well lit chamber 
in to an adjacent dark chamber) for which it had been previously punished during the 
training session, (see Marubio & Changeux, 2000) and the effects of p2 KO mice were 
studied compared to Wt mice.  Studies demonstrated that p2 KO mice where significantly 
different to Wt mice when tested for the retention of an avoidance response 24 hour s 
later. Administration of nicotine increased the latency of entry into the dark chamber in 
Wt rats but did not change the performance in p2 KO mice  These studies suggest that p2 
subunits are an important component in mediating the positive effect of nicotine in this 
test (see Cordero-Erausquin et al., 2000).  Observations that p2 subunit KO mice also 
exhibit an increased latency to the dark compartment suggests that the p2 subunit may 
mediate effects of endogenous ACh on learning and memory (see Picciotto et al, 2001).
116As previousiy observed with a4 subunit KO, (32 subunits may also play a role in nicotine 
reinforcement properties (or nicotine addiction).  Experiments observing the involvement 
of (32 subunits in nicotine reinforcement demonstrated that in microdialysis experiments, 
nicotine elicited a dose-dependent increase in striatal dopamine release in Wt but not in 
(32 knockout mice.  Nicotine also elicited an increase in the discharge frequency of 
dopamine-containing neurons of the SN and VTA in Wt but not in 02 KO mice 
(Champtiaux & Changeux, 2004; see Cordero-Erausquin et al., 2000). Furthermore, the 
effect of 02 KO on nicotine self administration was tested.  Wild type and KO mice both 
demonstrated cocaine self administration during the training session.  However, KO mice 
progressively ceased self administration when the cocaine was switched for nicotine 
whereas Wt mice continued.  This provides more data to the suggestion that 02 nAChR 
subtypes contribute to the reinforcing properties of nicotine.
Studies have showed that nicotine had antinociceptive effects when measuring mice on 
the hot plate test or tail-flick test.  02 KO showed that mutant mice had a greatly decrease 
nicotine-induced analgesia in the hot plate test and a low analgesic response in the tail 
flick test (Table 14) (Champtiaux & Changeux, 2004; see Picciotto et al., 2001).  Further 
studies looking into 02 involvement in the antinociceptive pathway were carried out, by 
looking at neurons in the thalamus, raphe magnus and dorsal horn of the spinal cord. 
Radioligand binding indicated that there was a loss of high affinity [3H]-nicotine binding 
sites in all these areas after 02 KO.  Consistent with these finding, patch clamp recordings 
from serotonergic neurons in the raphe magnus and neurons in the thalamus demonstrated 
a loss of nicotine-elicited currents in 02 KO mice suggesting the involvement of these 
subunits.  As previously noted, including 02, a4 is also involved in the antinociceptive 
pathway and it is suggested that the functional receptor a402 is involved in the nicotine 
pain pathway as disruption of either of these subunits results in attenuation of nicotine 
antinociceptive effects, indicating the importance of both subunits (see Cordero- 
Erausquin et al., 2000).
Observations into the cause of degenerative diseases such as PD, AD and dementias have 
demonstrated that the 02 subunit protects against the impaired cognitive performance 
associated with aging.  02 KO studies have shown that in two year old animals there is
117observed region-specific alternations in cortical structures, which include neocortical 
hypotrophy, neocortical and hippocampal gliosis, and cell loss in the CA3 hippocampal 
subfield, as well as, elevated serum corticosterone levels (Champtiaux & Changeux,
2004; see Cordero-Erausquin et al, 2000).  Furthermore, learning studies done on Wt and 
one year old p2 KO mice showed no significant difference in localizing the hidden 
platform in a water maze, however two year old p2 KO mice learned at a significantly 
slower rate.  This may be possibly due to young animals being able to compensate for the 
deficit of p2 nAChRs whereas in the adult mouse brain, the deficit reveals the effects of 
the absence of p2-nAChRs in a spatial learning task.  The P2 KO mice have anatomical 
and behavioural deficits similar to those found in pathological aging, therefore they may 
serve as a useful model for the study of dementias (Champtiaux & Changeux, 2004; see 
Marubio & Changeux, 2000).
1.8.6.  p4 Knockout studies.
Unlike p2 subunits, p4 nAChR subunits are prominently expressed in the autonomic 
ganglia (see McGehee & Role, 1995; see Sargent, 1993), with the role of P4, believed to 
be in ganglionic transmission.  The P4 KO mice behave normally, and their autonomic 
responses, i.e. tachycardia under stress, are apparently intact.  As P4 is an integral part of 
normal ganglionic nicotinic receptors, their lack, must be well compensated for (i.e. p2 
replacing p4).  However, these new receptors respond differently under some conditions 
from Wt P4 containing receptors (Wang et al., 2003) (Table 14).
Electrical stimulation of the vagus nerve results in a frequency dependent bradycardia in 
both Wt and p4 KO mice, although at high rates of stimulation a greater bradycardia was 
produced in Wt when compared with p4 KO mice (Table 14) (Wang et al, 2003). 
Additionally, when P4 KO mice were compared to Wt mice they had a significantly 
higher heart rate (Sack et al, 2005).  Further studies have demonstrated that 
supramaximal stimulation produced cardiac arrest in all W t mice but in none of the p4 
KO mice.  In addition to these studies, observations in in vitro experiments in the ileal
118contractile responses to nicotine, cytisine and DMPP indicated differences between Wt 
and P4 KO mice.  The p4 KO mice had significantly reduced ileal contractile responses to 
all of these agonists.  In addition to the ileal observations, the effects of nicotine on 
bladder strip contractions indicated reductions in p4 KO compared to Wt mice (Table 14) 
(Xu et al., 1999b).  Whole cell current studies in the superior cervical ganglion neurons 
reported profound reductions in nicotine-induced currents in p4 KO mice (see Wang et 
al., 2002b; Wang et al., 2003).  These results suggest that (34 deficit results in an 
impairment of cholinergic conductance in both sympathetic and parasympathetic ganglia. 
Therefore, it is suggested that (34 subunits are important subunits for normal ganglionic 
transmission.
Knockout studies involving the p4 subunits suggested that the p4 subunit may play a part 
in the maintenance of core body temperature.  Mice deficient in p4 subunits demonstrated 
diurnal and nocturnal baseline body temperature significantly lower than those of Wt 
mice (Table 14) (Sack et al., 2005).  In addition, p4 KO mice also demonstrated a 
reduced nicotine-induced hypothermic response and impaired desensitisation following 
repeated nicotine exposure, which is believed to be due to the reduction m receptor 
sensitivity to nicotine, due to the deficiency of the p4 subunit (Sack et al., 2005), which 
has been shown in other studies (see Wang et al., 2002b; Wang et al., 2003).
1.8.7.  P2 and P4 Knockout studies.
Studies involving the knockout of either P2 or P4 subunits have produced mice which are 
viable and develop normally.  Surprisingly, the double KO of P2 and P4 show a severe 
phenotype which is similar to the mice lacking the a3 subunits.  The p2 / p4 double KO 
mutants survive to birth but have impaired growth and increased postnatal mortality, with 
death usually occurring during the first 3 weeks of life from severe autonomic 
dysfunction.  Other dysfunctions include no papillary response to light, enlarged bladder 
with dribbling urination and the development of urinary infections and bladder stones 
(Xu et al., 1999b).  In addition bladder strips from p2/p4 KO mice did not respond to
119nicotine (Table 14) (Xu et al, 1999b).  Therefore, since mice with a single KO of P2 or 
p4 subunit do not exhibit a similar phenotype, it is suggested that p subunits play a 
compensatory role for the absence of the other P subunits (i.e. P2 replacing p4), and that a 
functional synergy between both P subunits is necessary for survival.  The similar effects 
evoked by a3 KO and p2/p4 KO suggests that a3 can be functional if co-expressed with 
either P2 or p4 but if both P subunits are lost then a3 cannot form effective ion channels 
and the a3 containing nAChR are lost (Table 14) (Wang et al, 2002b; Wang et al, 2003)
1.9.  Cardiovascular actions of nicotine.
1.9.1.  Peripheral cardiovascular actions.
The administration of nicotine intravenously (i.v.) has been performed in the rat, cat, dog 
and human.  Nicotine administered i.v. in both conscious and anaesthetised rats produces 
a large pressor response followed by either a tachycardia or bradycardia (Aubert et al, 
1987; Bisset & Fairhall, 1995; Marano et al, 1999).  A dose-dependent, short lasting 
pressor response was observed with increasing concentrations of nicotine administered 
i.v. in to conscious rats which was associated with a dose-dependent tachycardia response 
(Marano et al, 1999).  At 3 pg kg'1, nicotine (i.v.) caused a 5 mmHg increase in blood 
pressure associated with an increase of 10 beab mirf1  in heart rate.  Increasing 
concentrations of nicotine (10 and 30 gg kg'1) caused an increase in blood pressure of 15 
and 25 mmHg respectively, associated with a increase in heart rate of 25 and 65 beats 
min"1  respectively, with the highest dose of nicotine (100 pg kg1) increasing blood 
pressure by 65 mmHg and heart rate by 80 beats min1  (Marano et al, 1999).  Nicotine 
i.v. infusion for 15 min, at 20 pg min'1, in conscious rats caused a significant increase in 
blood pressure of 22 mmHg associated with a significant bradycardia.  Upon the rise in 
blood pressure by nicotine infusion, blood pressure remained stable at this height until 
nicotine infusion was ceased (Aubert et al, 1987).
120Nicotinic AChR 
subunit
Cellular / morphological basal 
phenotype
Nicotine-induced behaviour Survival
a3
ANS defects; megacystis, mydriasis and 
altered ACh-mediated responses in SCG 
neurones
ND Lethal 1-8 weeks postnatal
a4
Loss of high-affinity nic binding, loss of 
nic-mediated responses to thalamus and 
raphe magnus.
Reduced nic-elicited 
antinociception
Adult
a7
Lack of rapidly desensitising nicotinic 
currents in hippocampal neurons
ND Adult
a7 Leu247Thr Slowly desensitising nicotinic currents in 
hippocampal neurons
ND Lethal 24 hour post-natal
a9
Abnormal efferent innervation of hair 
cells in the cochlea
Suppression of cochlear 
responses
Adult
P2
Loss of high affinity nic binding; loss of 
nic-induced DA release; accelerated 
aging; loss of presynaptic receptor 
activity
Enhanced passive avoidance 
responses; loss of nic self-admin 
activity; reduced nic-elicited 
antinocoception
Adult
P3
Loss of a-conotoxin MH-senistive rec in 
striatal synaptosomes
Increased locomotor activity; 
decreased acoustic startle
Adult
P4
Reduced nic-elicited current in SCG 
neurons
ND Adult
p2 and P4
ANS defects: enlarged bladder and 
dilated ocular pupils
ND Lethal 1-3 weeks post-natal
Table 12.  Effects of nicotinic AChR subunit knockout on behaviour and pharmacology of nicotine.
Abbreviations: ACh: acetylcholine; DA: dopamine; Nic: nicotine; SCG: superior cervical ganglion; ND: not determined.
121Anaesthetised rats, administered with 100 pg kg'1  nicotine, demonstrated a significant 
rise in blood pressure of 30 mmHg.  When compared with nicotine administration in 
conscious rats, at the same dose, a pressor response was observed to increase to 65 
mmHg, indicating that the effects caused by nicotine may be reduced when the animal is 
under an anaesthetic (Bisset & Fairhall, 1995; Marano et al, 1999).The pressor response 
observed upon nicotine administration in anaesthetised rats, was not affected when pre­
treated the with homomeric neuronal nAChR antagonist a-BgT (400 ng kg'1 , i.c.v.) 
suggesting that the nicotine responses observed are not caused by the activation of central 
homomeric nicotinic receptors (Bisset & Fairhall, 1995).  Other nicotinic agonists tested 
in anaesthetised rats included cytisine, which upon i.v. administration produced a brief 
rise in blood pressure followed by a prolonged and significant depressor response (Bisset 
& Fairhall, 1995).
Experiments performed on anaesthetised cats demonstrated that blowing tobacco smoke 
into the lungs resulted in an increase in blood pressure, which matched the pressor 
response produced by nicotine administered i.v.(Armitage & Hall, 1967).  The 
experiment suggested that the nicotine intake per puff of cigarette is 1  -  2 pg kg1, as this 
correlated with an increase in blood pressure following i.v. injections of nicotine at that 
dose.  Nicotine administered i.v. in bolus injections was observed to cause a dose 
dependent increase in blood pressure, similar to experiments preformed on conscious rats, 
although the rise in blood pressure in the cat is observed to be greater than in rats (Castro 
de & Rocha E Silva, 1977).  At 5,10 and 20 pg kg'1, a pressor response of 28, 60 and 78 
mmHg respectively was observed.  Higher doses of 50 and 100 pg kg'1  produced large 
rises in blood pressure of 90 and 145 mmHg respectively, and was associated with a 
significant tachycardia (Castro de & Rocha E Silva, 1977).
Interestingly, in anaesthetised dogs, nicotine (10 pg kg'1, i.v.) caused a pressor response 
of 113 mmHg, but only after an initial depressor response of 38 mmHg.  The initial 
depressor response was also observed with other nicotinic agonists such as DMPP, which 
at 5 pg kg'1  produced a depressor response of -41 mmHg followed by a pressor response 
of 88 mmHg (Domino, 1969).  The decrease in sensitivity of nicotine i.v. in anaesthetised 
rats, compared to conscious rats (Bisset & Fairhall, 1995; Marano et al, 1999), has also
122been observed in experiments performed on dogs.  Before pentobarbital anaesthesia, 
nicotine administered i.v., at a dose of 10 pg kg1 , produced a significant depressor - 
pressor response of -38 and 113 mmHg, respectively.  After administration of an 
anaesthetising dose of pentobarbital (30 mg kg'1, i.v.), the depressor - pressor response 
caused by nicotine (i.v.) was almost abolished, producing a depressor - pressor response 
of only -10 mmHg and 20 mmHg, respectively.  The nicotinic agonist DMPP was also 
affected by pentobarbital anaesthesia, with a reduction in the depressor and pressor 
response from -40 and 88 mmHg respectively, to -15 and 22 mmHg, indicating that the 
cardiovascular responses to i.v. nicotine and DMPP were markedly reduced by 
pentobarbital anaesthesia.  The effects of anaesthesia on nicotine and DMPP responses 
were suggested to be due to decreases in sensitivity of the anesthetised animal to the 
agonists, as increasing doses of nicotine (20 and 40 pg kg"1) showed increasing 
depressor-pressor responses of -19 to 25 mmHg and -42 to 64 mmHg respectively, and 
increasing doses of DMPP (10 and 20 pg kg1 ) progressively restored the depressor- 
pressor response to levels similar to those prior to pentobarbital anaesthesia (Domino, 
1969).
The effect of nicotine i.v. has also been studied in human patients.  Two concentrations of 
nicotine were investigated in conscious humans.  At 0.25 pg kg'1  min'1  nicotine caused a 
rise in blood pressure but it was only at 0.5 pg kg'1  min1  that a significant increase in 
systolic blood pressure was observed (Newhouse et al., 1990).
The administration of nicotine i.v. has shown varied results, but it has been noted that the 
cardiovascular response to nicotine is complex.  Thus, the classic response of elevated 
blood pressure and tachycardia observed after inhalation of nicotine into cats (Armitage 
& Hall, 1967) or after i.v. administration in to the rat, cat or dog (Bisset & Fairhall, 1995; 
Castro de & Rocha E Silva, 1977; Domino, 1969) was suggested to be the result of 
several different and opposing effects of nicotine on the sympathetic and parasympathetic 
system.  As well as nicotine having opposing effects, changes in nicotine’s effects on the 
cardiovascular system were also observed by the use of different general anaesthetics, 
spinal anaesthetics and comparisons between conscious and unconscious species (Bisset 
& Fairhall, 1995; Domino, 1969; Marano et al., 1999).  Due to species variance
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was observed, upon i.v. injection of nicotine, although produced after an initial depressor 
response (Domino, 1969), which is not observed in cat or rat studies (Castro de & Rocha 
E Silva, 1977; Marano et al., 1999).  Differences have been observed in the same species, 
e.g. in the rat, nicotine (i.v.) administration was observed to cause a pressor response, 
associated with a tachycardia in conscious unrestrained rats (Marano et al, 1999), but in 
conscious restrained rats, nicotine was shown to have a pressor response associated with 
a bradycardia (Aubert et al, 1987), therefore indicating that changes in conditions, i.e. 
restrained or free moving models, can effect the cardiovascular effects produced by 
nicotine.
The pressor response of nicotine (i.v.) and its modes of action have been extensively 
researched.  Two mechanisms that are believed to cause these effects have been 
suggested; first, by nicotine-mediated vasopressin release.  Vasopressin or anti-diuretic 
hormone, as it is also known, has been shown to be synthesised in the neurons of the 
supraoptic and paraventricular nuclei (SON and PVN) and is released from the pituitary 
gland (see Holmes et al, 2003; see Howl & Wheatley, 1995; see Jard, 1998).
Vasopressin, as well as retaining water by acting on vasopressin receptors found in the 
kidney, acts on V]a vasopressin receptors found on blood vessels and upon activation by 
vasopressin results in vasoconstriction.  Nicotine is believed to cause the release of 
vasopressin, which results in vasoconstriction and the pressor responses observed. 
Intravenous injections of nicotine have been demonstrated to cause the release of 
vasopressin in cats (Castro de & Rocha E Silva, 1977) and rats (Aubert et al, 1987;
Bisset & Fairhall, 1995).  Although this is a possibility, it has been shown that when 
nicotine is in the presence of a Via vasopressin antagonist (i.v.) there was no change in 
the pressor response when compared to nicotine-alone (Aubert et al., 1987; Marano et al.,
1999).  This suggests two possibilities; one, that vasopressin release, caused by nicotine, 
is having no effect on blood pressure, or two, that nicotine-induced vasopressin release, 
could be acting via a different mechanism, i.e. vasopressin acting centrally, not 
peripherally.  Another mechanism in which nicotine may cause the pressor response is by 
sympathoexcitation.  Although it has been well documented that sympatho-adrenergic 
activation is involved in the nicotine-mediated blood pressure pressor response (Milton &
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the use of chemical sympathectomy (which destroys post ganglionic sympathetic nerve 
endings but not the adrenal medulla), and a-adrenoceptor antagonists, that nicotine i.v. 
evokes the pressor response via sympathetic nerve endings and not the adrenal medulla. It 
was observed that the nicotine-induced blood pressure rise was inhibited in the presence 
of an a-adrenoceptor antagonist, although it had no effect on the tachycardia, indicating 
that the nicotine-induced pressor response is due to a-adrenergic-mediated 
vasoconstriction and the nicotine-induced tachycardia alone is unable to raise blood 
pressure, suggesting that the tachycardia effects of nicotine are not obligatory for the 
occurrence of the blood pressure rise.  How the blood pressure rise was caused by 
nicotine-induced sympathoexcitation is not fully understood, although studies have 
indicated that central nicotinic receptors are capable of stimulating sympathetic 
cardiovascular neurons (Buccafusco & Yang, 1993; Khan et al., 1994), Therefore, 
theoretically nicotine-activated neuronal nAChRs could cause sympathetic activation, by 
stimulating the release of NA, which binds to vascular a-adrenoceptors resulting in 
vasoconstriction of blood vessels and a rise in blood pressure, causing the observed 
effects of i.v. administration of nicotine on the cardiovascular system.
1.9.2.  Central actions of nicotine.
1.9.2.1.  I.c.v., i.e. and topical administration of nicotine.
Intracerebroventricular (i.c.v.) injections through the cerebral ventricles, allows the 
injected compound to have access to many structures that form the inner and outer 
surface of the brain, therefore it is difficult to localize anatomically the compounds’ 
pharmacological actions.  However, this approach has been used extensively to establish 
the cardiovascular effect of nicotine in the CNS.
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produced a large rise in blood pressure, of over 40 mmHg which was observed to be a 
greater increase than the muscarinic receptor agonist, carbachol (Bisset & Chowdrey, 
1984).  The rise in blood pressure produced by nicotine (100 pg kg1, i.c.v.) was 
completely inhibited when in the presence of the nicotinic antagonist, hexamethonium 
(2.5 pg kg1, i.c.v.).  In conscious rats, i.c.v. injections of nicotine (10 pg kg1, i.c.v.) 
caused a small, but significant, increase in blood pressure, of up to 10 mmHg (Iitake et 
al., 1986).  Nicotine at doses 0.1,1 and 10 pg kg'1  (i.c.v.) were observed to have a 
significant decrease in heart rate, with 10 pg kg'1  shown to cause a bradycardia of up to 
40 beats  min'1  (Hoffman, 1979; Iitake et al., 1986).  Pre-treatment with the nicotinic 
antagonist, hexamethonium (10 pg kg'1, i.c.v.) was shown to block the pressor and 
bradycardia effects of nicotine (Hoffman, 1979 ;Iitake et al, 1986). 
Intracerebroventricular injection of choline, a precursor of ACh, in anaesthetised rats 
caused a dose-related increase in blood pressure.  Choline at doses 50,100 and 150 pg 
kg'1  caused an increase in blood pressure ranging from 10-20 mmHg, with the responses 
peaking within 3-4 mins after injection and returning to baseline within 15 mins (Li & 
Buccafusco, 2004).  Choline (50 and 150 pg kg'1, i.c.v.) administered in conscious rats, 
produced similar results to anaesthetised rats with 50 pg kg'1  causing an increase in blood 
pressure of 10 mmHg and 16 mmHg for 150 pg kg'1  (Savci et al., 2002).  In both 
anaesthetised and conscious rats, choline’s effects at 150 pg kg'1  were blocked by pre­
treatment with the nicotinic antagonists, mecamylamine and a-BgT, but not by the 
muscarinic antagonist, atropine, suggesting that choline is acting on the nicotinic receptor 
and not the muscarinic receptor (Li & Buccafusco, 2004; Savci et al., 2002).  Choline is 
believed to be a selective endogenous agonist for the a7 neuronal nAChR, when studied 
in the presence of the al selective antagonist, MLA, the increase in blood pressure 
produced by choline was abolished.  Observations that the a4p2 antagonist, DhpE, failed 
to significantly inhibit the pressor response produced by 150 pg kg'1  choline (Li & 
Buccafusco, 2004), suggest that choline was activating the al nAChR, rather than the 
a4p2 nAChR.
Interestingly, i.c.v. injections of nicotine (10 pg kg'1 ) in anaesthetised cats, caused a 
slight increase in blood pressure followed by a slight decrease in blood pressure.  When
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was followed by a larger depressor response than that seen at 10 pg kg'1  (Schaeppi,
1968).  Additional studies demonstrated that nicotine (0.1 & 1 mg kg"1, i.c.v.) produced a 
pressor response of around 10 mmHg for both concentrations and was followed by a 
depressor response of around 30 - 40 mmHg (Bisset et al., 1975; Bisset & Feldberg, 
1973).  Nicotine and nicotinic agonists when administered centrally by i.c.v. injections 
were observed to cause a rise in blood pressure associated with a bradycardia in both 
conscious and anaesthetised rats (Bisset & Chowdrey, 1984; Bisset & Fairhall, 1995; 
Iitake et al., 1986; Li & Buccafusco, 2004; Savci et al., 2002). These effects are 
associated with an elevation in vasopressin release suggesting that nicotine may cause 
this release of vasopressin by acting at sites reached from the ventricles, possibly the 
PVN and SON which have been shown to contain neuronal nAChR (Hatton & Yang, 
2002; Zaninetti et al., 2000).  The involvement of nAChRs in vasopressin release is 
demonstrated when the nicotine-induced release of vasopressin, as well as the increase in 
blood pressure, is inhibited by nicotinic antagonist hexamethonium (Bisset & Chowdrey, 
1984; Iitake et al., 1986).  Additional nicotinic agonist, such as cytisine, and choline, both 
caused the release of vasopressin which is inhibited by a nicotinic, but not a muscarinic, 
antagonist (Bisset & Fairhall, 1995; Li & Buccafusco, 2004; Savci et al., 2002).  This 
release of vasopressin was believed to be due to nicotine acting directly on the SON, due 
to demonstrations that the SON contains neuronal nAChRs (Hatton & Yang, 2002; 
Zaninetti et al., 2000) and direct application of nicotine causes, a increase in rate of firing 
on the supraopticohypophysial tract (Castro de & Rocha E Silva, 1977), as well as 
nicotine microinjection into the SON resulting in the increase in vasopressin release (Ota 
et al., 1992).  Bisset et al. (1975) demonstrated that although there was a increase in 
vasopressin release when nicotine was administered by i.c.v. injection, the release was 
inhibited when nicotine was prevented access to the fourth ventricle suggesting that 
nicotine may not be acting directly on the PVN and SON to cause the release of 
vasopressin (Bisset et al., 1975; Castro de & Rocha E Silva, 1977).  The mechanism of 
action of the nicotine-induced rise in blood pressure, caused by i.c.v. injection, is not 
specifically known and may involve pathways innervating the hypothalamus or other 
cholinergic pathways, although conflicting data make it difficult to interpret.
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observed to be similar to nicotine injected intracistemally in anaesthetised rats (Bisset & 
Chowdrey, 1984).  Intracistemal (i.e.) injections are injections in to the cistema magna, 
from this site injected compounds are able to move around the subarachnoid space and 
come into contact with brain areas such as the brain stem.  Nicotine (2-8 pg kg-1, i.e.) was 
observed to cause a decrease in blood pressure in anaesthetised rats, which was blocked 
by nicotinic antagonist hexamethonium, but not by the muscarinic receptor antagonist 
atropine (Bisset & Chowdrey, 1984), suggesting that the decrease in blood pressure is due 
to nicotine acting on nAChR in cardiovascular regulating areas in the brain stem.
Although intravertebrae (i.vert) injections are not directly injected into the brain like i.c.v. 
and i.e., it was observed, by the use of a dye, that injections into the vertebral artery 
results in the compound coming into contact with the brainstem especially areas in the 
lower brain stem such as the medulla and pons (Castro de & Rocha E Silva, 1977; 
Schaeppi, 1968).  Anaesthetised cats injected with increasing concentrations of nicotine 
(0.1,1,10,100 pg kg'1) into the vertebrae artery, showed similar results to nicotine given 
i.c.v in cats.  At 0.1 pg kg'1, nicotine given by i.vert injection caused a slight depressor 
response in blood pressure.  At 1 pg kg'1, nicotine caused a transient increase in blood 
pressure which then continued to become a slight decrease, this was also observed at 10 
pg kg'1, although the biphasic pattern was still a transient increase in blood pressure, it 
was followed by a substantial decrease in blood pressure, which lasted as long as 15 min. 
At 100 pg kg'1, nicotine produced a moderate increase in blood pressure followed by a 
large depressor response (Schaeppi, 1968).  Additional studies observing the increasing 
effects of nicotine (2.5,10, 20 and 50 pg kg'1, i.vert) in anaesthetised cats, had mixed 
results.  At lower doses of 2.5 and 10 pgkg1, nicotine produced a dose-dependent fall in 
blood pressure.  The onset of the decrease in blood pressure at these concentrations was 
rapid but the time needed for the blood pressure to return to normal was slow, requiring 
around 10-20 min (Castro de & Rocha E Silva, 1977).  At the higher doses of 20 and 50 
pg kg'1 , nicotine produced varying results.  Over half of the experiments showed a 
depressor response, whereas an increase in blood pressure was observed with the 
remaining animals.  Heart rate was observed to significantly decrease using nicotine 
concentrations from 10-50 pg kg'1  but these decreases were only observed to be small,
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Silva, 1977).
To determine if the depressor effects produced by nicotine injected by i.e. and i.vert 
involved the brainstem, experiments were carried out studying the effects of topical 
application of nicotine to the ventral surface of the brainstem (Bisset & Chowdrey, 1984; 
Feldberg & Guertzenstein, 1976).  These experiments involved the use of paired perspex 
rings attached to a holder.  Upon exposure of the ventral surface of the brainstem, the 
paired perspex rings are placed across the medulla each at the same distance from the 
midline and compounds are placed inside each ring.  The rings are moved along the 
ventral surface of the medulla in longitudinal and lateral directions, which allows the 
effects of applying a drug to different areas of the surface to be investigated.  In order to 
determine the areas on the ventral surface which have been covered by the nicotine 
solution placed in the paired rings, they are filled at the end of the experiment with dye 
and the stained areas on the ventral surface are measured with a divider, using as 
references the caudal border of the trapezoid and the midline.  Nicotine applied topically 
to the ventral surface of the brainstem of the cat, induced no significant change in blood 
pressure when the uppermost limit of the oval areas were just caudal to the trapezoid 
bodies (Bisset & Chowdrey, 1984; Feldberg & Guertzenstein, 1976).  As the perspex 
rings were moved away from the trapezoid bodies, a fall in blood pressure was observed. 
Depressor responses were seen when rings were placed more caudally, and the uppermost 
limits of the oval areas were about 6 mm caudal to the trapezoid bodies, in this area 
application of nicotine resulted in a depressor response of 38 mmHg (Bisset et al., 1975). 
Movement of the perspex rings by a further 0.5 mm caudal to the trapezoid bodies caused 
a further increase in depressor response, to -90 mmHg.  Application of nicotine further 
down the brainstem to a position of 8.5 and 9 mm caudal to the trapezoid bodies resulted 
in a depressor response of -74 and -40 mmHg, respectively.  Further movement of 
perspex rings away from the nicotine sensitive area (6-6.5 mm caudal to the trapezoid 
bodies), resulted in depressor responses but which were reduced in size (Bisset et al.,
1975).  Additional experiments observing the effect of topical application of nicotine to 
the ventral surface of the brainstem, by the use of perspex rings, suggested that the 
depressor response produced by the application of nicotine were most sensitive at 5-6 mmcaudal to the trapezoid bodies (Feldberg & Guertzenstein, 1976).  Unilateral application 
of nicotine to this area produced a depressor response of 15 mmHg at a concentration of 
0.33 mg ml"1  (a threshold concentration). Increasing concentrations of nicotine (0.5, 1,2 
and 4 mg ml"1) bilaterally to the perspex rings produced a dose-related decrease in blood 
pressure.  Blood pressure fell more steeply with each increase in the nicotine 
concentration, with 2 mg ml'1  causing a depressor response of -40 mmHg.  Upon 
application of nicotine at concentrations of 4 and 8 mg/ml, did not lower the blood 
pressure any further than the dose of 2 mg m l1  (Feldberg & Guertzenstein, 1976).  The 
depressor response was rapid with a fall observed 5-18 seconds after application and full 
recovery of blood pressure following 4 mg m l1  nicotine was 30 - 40 min, indicating a 
slow recovery (Feldberg & Guertzenstein, 1976).  Application of the nicotinic antagonist, 
hexamethonium, both during nicotine recovery and prior to nicotine administration 
blocked the nicotine-induced depressor response, whereas the muscarinic antagonist, 
atropine (Feldberg & Guertzenstein, 1976).  By the use of unilateral application of 2 mg 
ml"1  nicotine, using only one ring, the localization of the nicotine sensitive areas were 
determined.  Although there was variation from cat to cat and therefore some 
overlapping, it was suggested that the maximum response to nicotine was obtained from 
the region around the rootlets of the XIIth cranial nerve (Bisset et al., 1975; Feldberg & 
Guertzenstein, 1976).
The nicotine-induced fall in blood pressure, which was administered onto or near the 
brainstem, was suggested to be due to carotid sinus nerve activity; this is due to the 
similarity observed between carotid sinus nerve stimulation, which causes a decrease in 
blood pressure which is converted to a rise when given an overdose of pentobarbitone, 
and a fall in blood pressure caused by nicotine which also converted to a rise by 
pentobarbitone (Douglas et al, 1950; Katz & Thesleff, 1957a).  The rise in blood 
pressure caused by nicotine administration by i.c.v. injection could be caused by 
stimulation of the chemosensory pressor fibres in the carotid sinus and aortic nerves in 
the region of the brainstem, whereas the nicotine-induced decrease in blood pressure 
could result from stimulation of barosensory depressor fibres (Bisset et al., 1975; Katz & 
Thesleff, 1957a), therefore nicotine could be affecting sympathetic tone by indirect action 
on the vasomotor centre.  With the help of microinjections of nicotine and nicotinic
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with more accuracy.
The release of vasopressin upon nicotine administration, by i.c.v., i.e. injection and 
topically to the ventral surface of the brainstem, has been demonstrated to be caused by 
nAChR, due to inhibition by nicotinic antagonists.  It has been suggested that the 
medullary areas is the cause for nicotine-induced vasopressin release (Bisset et al., 1975; 
Castro de & Rocha E Silva, 1977) rather than the forebrain area, as vasopressin release 
induced by nicotine administered by i.c.v. can be inhibited when the nicotine is prevented 
from reaching the brainstem (Bisset et al, 1975). Including topical and i.e. administration 
of nicotine, i.vert injection of nicotine cause vasopressin release, again, with the nicotine 
observed to reach the lower brainstem especially the medulla and pons.  Observations 
that topical and i.vert nicotine administration do not go near the SON or PVN, (indicating 
by dye that i.vert injected nicotine remains in the brainstem area and topical 
administration remains in the area applied) suggests that nicotine does not act on the 
neurosecretory cell directly, but is stimulating vasopressin release by activation of some 
other pathway, i.e. upon application of nicotine to the medulla.  However, Bisset et al. 
(1975) noted that there was no correlation between the decrease in blood pressure and the 
release of vasopressin and especially since vasopressin release could still be obtained 
after the sinus and vagus nerves were cut, therefore it was suggested that nicotine- 
induced fall in blood pressure may not due to vasopressin release (Bisset et al., 1975; 
Castro de & Rocha E Silva, 1977).
1.9.2.2.  Nucleus Tractus Solitarius.
The nucleus tractus solitarius (NTS) is an elongated nucleus that extends throughout the 
dorsomedial part of the medulla oblongata from the level of the caudal edge of the facial 
motor nucleus to the cervical spinal cord.  The NTS receives baroreceptor afferents and 
plays a central role in mediating the reflexes and regulating cardiovascular responses 
(section 1.1.) (see Sun, 1995).  Areas of the NTS receiving baroreceptor and
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ventricular receptors which terminate in the NTS, have neuronal projections which 
innervate levels of the ventrolateral medulla such as the rostral and caudal ventrolateral 
medulla, evoking baroreceptor reflexes (Anand et al., 1993; see Dampney, 1994).  It is 
from the NTS that the caudal ventrolateral medulla (C VLM) neurons are innervated by 
glutamatergic pathways, which then project to the rostral ventrolateral medulla (RVLM) 
by GABAergic pathways (an inhibitory projection) (Agarwal et al., 1990; Cravo et al., 
1991; Jeske et al., 1993).  From the RVLM, neurons project on to the immediolateral cell 
column of the spinal cord, which helps in maintaining normal resting blood pressure 
(Brown & Guyenet, 1984; Ross et al., 1985).  In addition to projections to the CVLM, the 
NTS has been shown to project to the lateral hypothalamus, some forebrain nuclei, the 
dorsal motor nucleus of vagus, the ambiguus nucleus, the area postrema and 
immediolateral cell column of the spinal cord (section 1.1.2.1.) (see Dampney, 1994; see 
Sun, 1995).
The NTS has been shown to contain ChAT immunoreactive cholinergic neurons in the 
region that receives baroreceptor afferent fibres (Armstrong et al., 1988; Ruggiero et al., 
1990; Winzer-Serhan & Leslie, 1997), suggesting that ACh may have some involvement 
in the baroreflex and that the NTS may also be rich in cholinergic nerve terminals 
(Ruggiero et al., 1990).  Additional studies showed that ChAT activity in the NTS was 
decreased by removal of the nodose ganglion, which contains cholinergic cell bodies, 
thus implying that certain afferent nerve terminals have the ability to release ACh 
(Shiraki et al., 1997).  Radioligand binding studies using [3H]-nicotine and [125I]-a BgT 
have also demonstrated that nicotinic binding sites are present in the NTS of rats, cats and 
humans (Adem etal., 1989; Breese etai, 1997; Clarke et al., 1985; Maley & Seybold, 
1993; Wada et al., 1989), with binding observed in the areas of the NTS where 
cardiovascular and respiratory afferent fibres terminate (Maley & Seybold, 1993), 
although there is observed a higher binding affinity for [125I]-a-BgT in cats than [3H]- 
nicotine (Maley 8l Seybold, 1993).
Due to the importance of the NTS in cardiovascular regulation, the effects of nicotine on 
the NTS have been examined by microinjection.  Microinjections of nicotine into the
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pressure (Dhar et al., 2000; Ferreira et al., 2000; Tseng et al., 1993; 1994), with rapid 
effects observed immediately after microinjection, with the maximum effect occurring 
29-36 sec after injection and a duration from 5-8 min (Ferreira et al., 2000).  The effect 
on heart rate was similar to blood pressure, with increasing concentrations causing 
significant decreases.  Dhar et al. (2000) demonstrated that at 0.5 pM, nicotine 
microinjected in to the NTS resulted in a fall of around -45 mmHg.  However, nicotine 
microinjected into the medial NTS (mNTS) caused a greater decrease in blood pressure, 
at considerably lower doses, with 0.1 pmol kg'1  causing a 10 mmHg decrease, with 1 and 
1000 pmol kg'1  resulting in a 28 mmHg and over 40 mmHg decrease in blood pressure, 
respectively (Ferreira, Jr. et al., 2002).
Pre-treatment with homomeric nicotinic antagonist a-BgT (100 pmol kg'1) had no effect 
on nicotine-induced blood pressure changes in NTS (Ferreira et al, 2000;Tseng et al.,
1994), however, at higher concentrations of a-BgT (1 pM), nicotine was observed to 
have a small decrease (20%) in blood pressure of -21 ± 3 mmHg (Whiteaker et al., 1998). 
When the concentration of a-BgT was increased to 250 and 500 pM, there was no further 
decrease in nicotine-induced depressor responses (Dhar et al., 2000).  Pre-treatment with 
the a4(32 antagonist, Dh(3E, was shown to have no effect on the nicotine-induced 
depressor response at 1  pmol kg'1.  However, at concentrations of 10 and 100 pmol kg'1  
there was a ~30 % inhibition in the depressor response, whereas at 1000 pmol kg'1 , an 
inhibition of nearly 70 %, in the nicotine-induced decrease in blood pressure was 
recorded (Ferreira, Jr. et al., 2002).  The neuronal nAChR selective antagonist, a- 
conotoxin Iml, which is selective for the a7 nACh receptor at 1 pM, was observed to 
significantly decrease the nicotine-induced depressor response by 38% (Dhar et al.,
2000), in addition, the al selective antagonist, MLA, caused a significant inhibition of 
the depressor response (Ferreira et al., 2001).  Studies using the al antagonists, a-BgT, a- 
conotoxin Iml and MLA suggest that only a small proportion of nAChR containing al 
are involved in mediating the depressor responses induced by microinjection of nicotine 
into the mNTS, but indicated that there are also a4p2 nAChRs present (Dhar et al, 2000; 
Ferreira et al., 2000; 2001).  Neuronal nAChR selective antagonists a-conotoxin AulB 
and hexamethonium (1 pM) are selective to a3p4 nAChRs and caused significant
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decrease, which remained similar even when the concentration was increased to 100 pM, 
causing a 74% reduction.  Mecamylamine caused a reduction in the nicotine-induced 
depressor response of 69% and hexamethonium cause a 47% decrease in depressor 
response (Dhar et al, 2000).  The large inhibition of depressor response produced by 
a3p4 antagonists suggests a relatively high proportion of a3|34 nAChRs are present, 
which are involved in mediating depressor responses induced by microinjection of 
nicotine into the NTS.  Studies demonstrating that a7, a4{32 and a3p4 antagonists cause 
inhibition of the nicotine-induced affects, suggest that there are more that one type of 
nAChR present.  This was confirmed when the a7 antagonist, a-BgT, and a3p4 
antagonist, mecamylamine, were added together and caused the nicotine-induced 
depressor effect to be almost completely blocked with around 98.2 % inhibition (Dhar et 
al., 2000).  Thus it was concluded that the predominant type of nAChR in the NTS is 
a3p4, with a smaller proportions of a7 and a4p2 nAChRs present.
Studies into whether neuronal nACh heteroreceptors may cause the release of glutamate 
in the mNTS (the neurotransmitter of vagal afferent nerve terminals in the NTS is 
believed to be glutamate), resulting in the depressor response, were demonstrated by 
nicotine microinjectioned in to the NTS, pre-treated with the glutamate receptor 
antagonist kynurenic acid.  It was observed that the glutamate receptor antagonist did not 
inhibit the nicotine-induced decrease in blood pressure (Ferreira, Jr. et al, 2002; 
Mosqueda-Garcia et al, 1991), suggesting that nicotine is not acting on neuronal nACh 
heteroreceptors causing the release of glutamate, which results in the decrease in blood 
pressure.
Nicotine has been suggested to cause the depressor response in blood pressure by 
activation of nAChRs on the NTS, which evokes excitation of secondary NTS neurons 
that, in turn, excite neurons located in the CVLM.  Excitation of the CVLM neurons 
results in inhibition of neurons in the RVLM, via a GABAnergic mechanism which 
decreases the excitatory input to sympathetic preganglionic neurons located in the 
immediolateral cell column of the spinal cord (ILM) and induces a depressor response. 
This was suggested due to the nicotine-induced depressor response being unaffected by
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presumably due to inhibition of sympathetic nervous system activity.
1.9.2.3.  The Ventrolateral Medulla
Studies observing the effects of blood pressure control showed that the ventrolateral 
medulla was an essential component in blood pressure maintenance and reflex 
cardiovascular control (Feldberg & Guertzenstein, 1976; 1986; Guertzenstein & Lopes, 
1984). The ventrolateral medulla was observed to contain two distinct areas, the rostral 
ventrolateral medulla (RVLM), which was demonstrated to be responsible for 
maintaining tonic excitation of sympathetic preganglionic neurons (Calaresu & Yardley, 
1988; Guertzenstein & Silver, 1974), and the caudal ventrolateral medulla (CVLM), 
which was demonstrated to be a depressor area involved in reflex regulation of blood 
pressure (Feldberg & Guertzenstein, 1976; Guertzenstein & Lopes, 1984).
I.9.2.3.I.  The Rostral Ventrolateral Medulla.
The rostral ventrolateral medulla (RVLM) is important in the regulation of the 
cardiovascular system (see section 1.1).  This was demonstrated over a century ago when 
experiments performed in rabbits showed a profound fall in blood pressure upon bilateral 
destruction of a portion of the ventral medulla, near the level of the facial nucleus, but not 
by the destruction of a large dorsal portion of medulla oblongata (see Dampney, 1994). 
The RVLM is a pressor area and one of the sympathetic premotor neurons (Amendt et al, 
1978), which extends (in the rat) from 1 to 2.5 mm rostral to the median rootlet of the XII 
nerve and 1.5-2 mm lateral to the midline (Benarroch et al, 1986).  The RVLM 
vasomotor neurons, which are located immediately caudal to the posterior end of the 
facial motor nucleus and ventral to the nucleus ambiguus complex (see Sun, 1995), 
receive afferent input from the lateral tegmental field and the CVLM, and were shown to
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the immediolateral cell column of the spinal cord (see section 1.1).
Studies into the role of the RVLM in cardiovascular regulation demonstrated that 
electrical stimulation produced an increase in blood pressure and heart rate, whilst, 
chemical stimulation, by microinjections of glutamate, caused an increase in sympathetic 
nerve activity and blood pressure (Ross et al., 1984).  Additional studies demonstrated 
that chemical inactivation, by inhibitory amino acids, such as glycine and GABA, and 
electrolytic lesions of the RVLM, caused a decrease in blood pressure and an immediate 
decrease in sympathetic nerve activity (Anand et al, 1993; Dampney & Moon, 1980; 
Granata etal, 1983; Guertzenstein, 1973; Guertzenstein & Silver, 1974) suggesting that 
the RVLM is essential for the maintenance of the basal sympathetic vasomotor tone.
RVLM-spinal vasomotor neurons function as an essential relay, transferring signals and 
commands to the sympathetic preganglionic neurons with blockade of this transmission 
abolishing sympathetic and cardiovascular responses (see Dampney, 1994; Ross et al, 
1984).  Glutamate and glutamatergic receptors are known to be involved (Campos & 
McAllen, 1999; Dampney et al, 1982).  Studies have also demonstrated nicotine’s effects 
at sites close to the rootlet of the XIIth cranial nerve and nicotinic receptor involvement in 
glutamate release, therefore it has also been suggested that neuronal nAChRs may 
participate in the regulation of the cardiovascular system by acting at the RVLM.  Indeed, 
microinjection studies injecting nicotine into the RVLM, produced a dose-related and 
long lasting increase in blood pressure (Tseng et al, 1994), additional studies also 
demonstrated a long lasting pressor response and tachycardia (Tseng et al, 1993). The 
pressor effects of nicotine were completely inhibited by prior microinjections of 
hexamethonium, but were not affected by the muscarinic antagonist, atropine, (Tseng et 
al, 1994).  Studies also demonstrated that pre-treatment with the a and P adrenoceptor 
antagonist, labetalol, caused up to a 96% decrease in the nicotine-induced pressor 
response in Spaque Dawley (SD) rats, whilst the, ai-adrenoceptor antagonist, prazosin, 
inhibited the nicotine pressor response by 44% in SD rats (Tseng et al, 1993).  The 
inhibition of the nicotine-induced pressor response, by the use of adrenoceptor 
antagonists suggests that the pressor response may be caused by adrenergic pathways in
136the RVLM acting on the sympathetic nerves, which in turn, stimulate receptors on the 
blood vessels resulting in vasoconstriction.  Therefore, studies suggest that nicotine 
microinjections within the RVLM cause activation of neuronal nAChRs, which results in 
an increase in blood pressure and renal sympathetic nerve activity (Tseng et al., 1993). 
Interestingly, it was observed that the pressor effect of nicotine microinjected into the 
RVLM was more pronounced in spontaneously hypertensive rats (SHR) than in SD rats 
and Wistar (WKY) rats suggesting that enhanced cardiovascular responses of the RVLM 
neurons to nicotine might contribute to hypertension.  However, it has been shown that 
hypertensive animals generally show exaggerated cardiovascular responses to reflex and 
centrally evoked pressor responses (Chan et al., 1990), probably due to damaged 
integration by the control system.
I.9.2.3.2.  The Caudal Ventrolateral Medulla.
The caudal ventrolateral medulla (CVLM) is found between the nucleus ambiguus and 
lateral reticular nucleus (see Dampney, 1994; see Sun, 1995) and was first demonstrated 
to have an affect on cardiovascular function when application of nicotine to the ventral 
surface in the cat caused a decrease in blood pressure (Feldberg & Guertzenstein, 1976). 
Additional studies have shown that electrolytic lesions or chemical inactivation, by the 
GABA receptor antagonist, muscimol, in the CVLM resulted in a rise in blood pressure, 
whereas electrical stimulation and chemical stimulation, by the excitatory amino acid 
glutamate, in the CVLM produced sympathoinhibition and a fall in blood pressure (Cravo 
et al., 1991; Gordon, 1987; Jeske et al., 1993).  The Al area of the CVLM has been 
proposed to be the location of the CVLM sympathoinhibitory neurons, as lesions cause 
an increase in blood pressure, whereas electrical or chemical stimulation of the CVLM 
area causes a depressor response (Ross et al, 1985), however more precise mapping of 
the depressor sites in the CVLM of the rat has indicated that the CVLM 
sympathoinhibitory neurons are located outside the Al cell group (see Dampney, 1994). 
Interestingly, it has been observed that there is an inhibitory GABAergic synapse from 
the sympathoinhibitory pathway in the CVLM depressor neurons, to the RVLM
137sympathetic premotor neurons (Cravo et al, 1991).  It was suggested that it is by this 
pathway that activation of peripheral baroreceptors decrease or abolish the firing rate of 
RVLM sympathetic premotor neurons (Agarwal et al, 1990; Cravo et al, 1991; see 
Dampney, 1994; Gordon, 1987), therefore suggesting that CVLM elicits effects on the 
baroreflex by inhibiting neurons in the RVLM and causing sympathoinhibition and 
vasodepressor responses (see section 1.1).
Originally it was believed that the NTS was the source of the GABAnergic input but 
studies have shown that the central baroreceptor pathway consists of a pathway from the 
NTS to the CVLM, probably by a glutamatergic projection, and then from CVLM to 
RVLM by a GABAergic input (Agarwal et al, 1990).  The involvement of NMD  A 
receptors in the CVLM was demonstrated by the use of selective NMDA receptor 
antagonists, which when applied to the CVLM abolished synaptically-mediated depressor 
responses caused by aortic nerve stimulation, indicating that neural transmission of aortic 
baroreceptor information in the CVLM is mediated by activation of NMDA receptors.
The neurotransmitter released at the CVLM synapse may be an excitatory amino acid, 
possibly glutamate (Gordon, 1987).
Although the affect of application of nicotine to the CVLM has been demonstrated by 
Feldberg & Guertzenstein, (1976), the involvement of neuronal nAChRs in CVLM 
cardiovascular regulation has not been studied in great detail.  The microinjection of 
increasing concentrations of nicotine into the CVLM was shown to cause depressor 
effects in both blood pressure and heart rate.  Significant decreases of blood pressure and 
heart rate were observed at 1  mM of nicotine resulting in a decrease of 34 mmHg in 
blood pressure and 64 beats min'1  in heart rate, with increasing concentrations of nicotine 
not causing any greater effect (Aberger et al, 2001).  The effect of microinjections of 
nicotine was studied in the presence of mecamylamine (a3p4 antagonist) and a-BgT 
(homomeric selective nicotinic antagonist), these compounds were shown to block the 
depressor effect and block the decrease in heart rate (Aberger et al, 2001).  From these 
findings, Aberger et al. (2001) suggested that a304 and a7 nAChRs are present in the 
CVLM and upon activation by nicotine cause a decrease in blood pressure and 
bradycardia, unfortunately, these two antagonists were added at the same time and not
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in fact only one may be present and that inhibition of this neuronal nAChR is causing 
blockade of the pressor response.  Overall, it can be theorised that activation of neuronal 
nAChRs in the CVLM results in inhibition of neurons in the RVLM via GABAnergic 
neurons.  The inhibition of the RVLM neurons decreases excitatory inputs to sympathetic 
preganglionic neurons located in the spinal cord, which results in a depressor and 
bradycardia response (Agarwal et al., 1990; Brown & Guyenet, 1984; Cravo et al., 1991; 
see Dampney, 1994; Gordon, 1987).
1.9.2.4.  Nucleus Ambiguus & Dorsal Motor Vagal Nucleus.
Additional areas of the brain that receive afferent innervations from the NTS are the 
nucleus ambiguus (NAmb) and the dorsal vagal motor nucleus (DMVN), which also 
receive afferent input from other brain regions such as the nuclei of the hypothalamus and 
the medullary reticular formation (see section 1.1) (Hunt & Schmidt, 1978).  The NTS 
innervates the NAmb and DMVN and may mediate various vagal visceral reflexes. 
Innervations from the NTS to NAmb have been shown to project to the cardiopulmonary 
areas, whilst projections from the DMVN project to cardiac tissue.  An arc of cardiac 
preganglionic neurons extending from the ventrolateral medulla to the DMVN have also 
been shown to receive anterograde projections from the NTS.  Cardiac vagal neurons 
play a crucial role in the control of heart rate and cardiac function.  These neurons, which 
are primarily located in the NAmb and DMVN, dominate the neural control of heart rate 
under normal conditions.  Cardiac vagal neurons are intrinsically silent and therefore rely 
on synaptic inputs to control their firing.  There are three major synaptic inputs to cardiac 
vagal neurons.  One of these is cholinergic, with ACh exciting the cardiac vagal neurons 
via three mechanisms, one, activating a direct ligand-gated post-synaptic nAChR, a 
second, enhancing post-synaptic non-NMDA currents, and a third, pre-synaptically by 
facilitating transmitter release (Sahibzada et al, 2002).  The enhancement by nicotine is 
dependent upon activation of pre-and postsynaptic P-type voltage-gated calcium channels 
(Sahibzada et al., 2002).  Not much data are available concerning neuronal nAChRs and
139the NAmb, although microinjection of nicotine into the NAmb was shown to cause a 
decrease in blood pressure in dogs, although there were mixed results with heart rate, 
producing both bradycardia and tachycardia.  Studies using the nicotinic antagonist 
mecamylamine, (Shiraki et al., 1997) demonstrated the inhibition of the nicotine-induced 
depressor response suggesting that nicotinic ACh receptors are distributed in the region 
of the NAmb.
Studies using anti-ChAT staining in the DMVN revealed that every DMVN neuron 
stained for ChAT.  Using antibodies against ChAT, immunocytochemistry demonstrated 
that the DMVN contains many cholinergic neurons, as well as projections to the vagus 
nerve, which is accepted to be cholinergic in nature(Ferreira et al., 2001).  Radioligand 
binding has shown that there was an intense degree of binding of [125I]-aBgT in the 
DMVN (Eilers et al., 1997).  Additional studies also showed that DMVN neurons possess 
nicotinic not muscarinic ACh receptors (Neff et al., 1995).  Further studies demonstrated 
that a7 nAChRs are present in the DMVN neurons, shown by inhibition of ACh evoked 
currents of up to 60-75% by a7 antagonists a-BgT and MLA (Sahibzada et al., 2002), 
and by the use of anti-a7 staining in the DMVN (Ferreira et al., 2001).  DMVN neurons, 
once degenerated by unilateral cervical vagotomy, had no binding sites for a-BgT, 
therefore suggesting a-BgT binding were post-synaptic on DMVN neurons.  Although a7 
nAChRs were identified in the DMVN there were pharmacological and recovery 
differences between a7 nAChR studies in Xenopus oocytes and the studies of native a7 
on the DMVN (Ferreira et al., 2001).  It was suggested that the a7 present in the DMVN 
appear to be functionally and pharmacologically distinct from heterologously expressed 
a7 and the a7 expressed in most neural tissue. This raises the possibility that the al 
nAChR at the DMVN may exist as a heteromeric complex, comprised of the al with an, 
as of yet unknown, nicotinic receptor subunit, possibly the 02 subunit (Wang et al.,
2001).  Additional studies have shown that the nAChRs not inhibited by a-BgT were 
blocked by Dh0E, suggesting the presence of a402 in the DMVN.  Cytisine, which is 
selective for 04, was observed to evoke significant currents, which suggest the possibility 
of additional nAChR such as a304 nAChR on DMVN neurons (Sahibzada et al., 2002).
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the DMVN had no significant effect on blood pressure causing a decrease of only 7.7 
mmHg at 100 pmol kg'1  (Ferreira et al., 2000).  To observe if NTS is communicating 
with the DMVN to exert its effects on blood pressure, intemeurons and neurotransmitters 
implicated in communicating information between these nuclei where studied, including 
nitric oxide, GABAergic, glutamatergic and noradrenergic systems (Ferreira, Jr. et al.,
2002).  Additionally, the effect of specific antagonists, microinjected into the DMVN, 
was also studied.  Bicuculline, a GABAa antagonist, kynurenic acid, a glutamate 
antagonist, and yohimbine, an a2 adrenoceptor antagonist, were observed not to alter the 
decrease in the blood pressure produced by nicotine microinjected in to the NTS 
(Ferreira, Jr. et al., 2002), suggesting that the NTS is not communicating with the DMVN 
to exert its effects on blood pressure.
1.10.  Nicotine induced secretions.
The effects of nicotine and nicotinic compounds on the release of hormones has been 
observed in some detail with studies demonstrating nicotine causing the release of a 
number of hormones including anti-diuretie hormone, also known as vasopressin (Bisset 
& Chowdrey, 1984; Bisset & WALKER, 1957; Reaves, Jr. et al., 1981), oxytocin (Bisset 
& WALKER, 1957), adrenocorticotropic hormone (Cam etal., 1979; Matta etal., 1997; 
1998), prolactin and growth hormone (Andersson et al, 1983; Davis et al., 1982; Davis 
& Davis, 1980; Seyler, Jr. et al., 1986).  The nicotine-induced affects observed upon 
injection, which include changes in blood pressure and heart rate, may be due to release 
of the compounds named above.
1.10.1.  Vasopressin.
Nicotine-induced vasopressin release has been extensively studied, and because of this an 
explanation of this compound and its mechanism of action are required.  In 1953, the
141chemical structure of vasopressin was discovered as was the synthesis of this peptide (see 
Jard, 1998).  The neurophypophysial nonapeptide hormone vasopressin, is believed to be 
encoded by a gene found on chromosome 20p and contains a disulfide bridge between 2 
cysteine amino acids (see Holmes et al, 2003). Vasopressin is synthesised by neurons 
whose cells bodies are located in the paraventricular nucleus (PVN) and supraoptic 
nucleus (SON) of the hypothalamus. Axons from the neurons found in the PVN and SON 
terminate in the neurohypophysis (posterior pituitary) where, by a process of exocytotic 
secretion, vasopressin is released into the systemic circulation (see Howl & Wheatley, 
1995; see Kombian et al, 2002).
The actions of vasopressin are mediated by stimulation of tissue specific G-protein- 
coupled receptors which are classified into three major subtypes named V]a, Vib and V2 
(Cotte et al, 2000; see Howl & Wheatley, 1995).  The Vja subtype are found in high 
density on the vascular smooth muscle, V^ subtypes appears to be restricted to anterior 
pituitary corticotrophs and V2 subtypes are restricted mainly to the kidneys.  Due to the 
location of different vasopressin receptors it is indicated that the action of vasopressin can 
be varied.  Activation of Via receptors results in vasoconstriction (Harland et al, 1989; 
Unger et al, 1984; Waeber et al, 1983), believed to be caused by an increase in 
intracellular calcium via the phosphatidyl-inositol-bisphosphonate cascade (see Holmes 
et al, 2003).  Activation of V2 receptors causes the retention of water, and is how 
vasopressin received its name of anti-diuretic hormone.  Vasopressin regulates the 
excretion from the kidneys by increasing the osmotic water permeability, this is caused 
by vasopressin binding to V2 receptors, stimulating adrenylyl cyclase and elevating 
intracellular cAMP (see Jard, 1998; Macfarlane et al, 1967).  This action of vasopressin 
induces the appearance of a population of endocytic vessels containing water channels in 
vasopressin-sensitive membranes of the kidney collecting tubules. The insertion of the 
water channels into the apical membrane gives rise to the re-absorption of water and to 
the anti-diuresis observed with vasopressin (see Holmes et al, 2003; Howl & Wheatley, 
1995; Macfarlane et al, 1967).  Unfortunately, very little is known about the Vib 
receptor, due to its rarity, although it is observed to be a G-protein-coupled pituitary 
receptor.  One mechanism of action of the Vib receptor seems to be in signal transduction, 
for example, vasopressin causing the secretion of adrenocorticotropic hormone (ACTH)
142from the anterior pituitary cells in a dose-dependent manner, through activation of PKC 
(Liu et al, 1994).  Interestingly the Vib receptor is over expressed in ACTH- 
hypersecreting tumours (Thibonnier et al., 1997).
The importance of vasopressin is emphasised when it was demonstrated to act as a 
neurotransmitter/neuromodulator within the brain and sympathetic nervous system, as 
well as being shown to be distributed throughout the brain and spinal cord, which 
includes the hypothalamus, DMVN, NTS, locus coeruleus and nucleus of spinal tract of 
the trigeminal nerve (Jenkins et al., 1984).  As a consequence, vasopressin is believed to 
influence cardiovascular functions by regulating sympathetic outflow (Unger et al,
1984).  Studies have suggested that the peripheral actions of vasopressin, which are 
believed to be due to changes in systemic vasopressin concentrations, may be neurally 
evoked.  One mechanism involved is by a vasopressinergic projection to the NTS.  The 
NTS has been previously described, and is believed to be first synaptic relay in the 
brainstem for information on blood pressure levels by sinus and aortic nerve afferents. 
Depending on the change in blood pressure, the NTS excites other areas of the brainstem 
such as CVLM, RVLM, DMVN and nucleus ambiguus.  Including, projections from the 
NTS to the amygdala and cortex, the NTS was shown to project to the PVN and SON and 
cause the release of vasopressin, as well as receive monosynaptic projections from the 
PVN (Buijs et al, 1978; Nilaver et al., 1980; Sawchenko & Swanson, 1982; Sofroniew & 
Schrell, 1980) which provides a feedback control loop through which the PVN could 
modulate afferent cardiovascular inputs coming from the periphery to the NTS (see 
Michelini, 1994).  The PVN is believed to be the only source of vasopressinergic 
projection to the NTS, with the long descending projection containing as well as 
vasopressin, oxytocin, enkenphalins and somatostatin (Buijs et al, 1978; Nilaver et al, 
1980; Sofroniew & Schrell, 1980).  Therefore, the vasopressinergic projection to the NTS 
are of major importance because they constitute a pathway by which the PVN could 
directly modulate baroreceptor function (see Michelini, 1994), as well as the possibility 
that neurohormonal vasopressin could also influence the reflex control of the heart.
Due to the importance of vasopressin in cardiovascular regulation, the effects of nicotine 
and nicotinic compounds have been observed on modulating vasopressin release.
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rat (Bisset & Chowdrey, 1984; Iitake et al, 1986) and cat (Bisset et al., 1975; Castro de 
& Rocha E Silva, 1977).  Injections of nicotine into the third ventricle caused a increase 
of up to thirty fold in the concentration of vasopressin in blood collected 35-155 sec after 
injection (Bisset & Feldberg, 1973), as well as nicotine injections given into or in close 
proximity to the SON, causing an increase of vasopressin release of 175%, when 
compared to control (Milton & Paterson, 1970).  The nicotine-induced vasopressin 
release was observed to be inhibited by nicotinic antagonist hexamethonium, indicating 
the involvement of nicotinic receptors.  The effect of nicotine on the SON and PVN is 
possible due to the cholinergic cell bodies found just dorsolateral to the SON (Clarke & 
Pert, 1985), which is thought to be the source of the SON cholinergic innervations.
These may innervate neurons through other local circuit neurons, and thus, possibly 
providing the anatomical and functional basis for the cholinergic effect on neurons in the 
SON and PVN (Clarke & Pert, 1985).
Nicotine injected i.e. was more effective at inducing vasopressin release than when 
injected i.c.v in the rat.  Compounds injected i.e. cannot reach the cerebral ventricles, 
whereas drugs injected i.c.v. can readily reach the ventral surface of the brainstem, 
through the lateral foramina of the fourth ventricle.  It was suggested therefore, it is 
unlikely that nicotine induced vasopressin release by acting directly on the PVN (Bisset 
et al., 1975; Bisset & Chowdrey, 1984).  This became evident when it was demonstrated 
that nicotine injected into the cerebral ventricles after cannulation of the aqueduct, which 
prevents nicotine access to the fourth ventricle, no longer produced the vasopressin 
release (Bisset et al., 1975).  Overall, it was suggested that the dorsal and ventral surface 
of the brainstem is the site of action for nicotine-induced vasopressin release, with the 
ventral surface more likely as it is reached more readily by the i.c.v. route, which is 
consistent for both rat and cat (Bisset et al, 1975; Bisset & Chowdrey, 1984).  It was 
finally concluded when topical application to areas of the ventral surface of the brainstem 
caused the release of vasopressin (Bisset & Chowdrey, 1984;  Feldberg & Guertzenstein,
1976).
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stimulus from baro-and stretch receptors, has a nicotine sensitive synapse between the 
afferent fibres and the central projections to the neurosecretory cells, which release 
vasopressin from the PVN and SON (Bisset et al, 1975; Bisset & Chowdrey, 1984) by 
the activation of nAChRs found on the SON and PVN.  Autoradiography of the SON and 
PVN demonstrated the presence of a7 nAChR, due to [125I]-a-BgT binding sites 
(Zaninetti et al., 2000) whereas cytisine binding studies have indicated the presence of p4 
subunits (Bisset & Fairhall, 1995), as well as, strong immunoreactivity for the a4 nAChR 
subtype, suggesting the presence of the a4{32 nAChR and possibly a4f4 nAChR (Shioda 
etal., 1997b; Wada etal, 1989).
Nicotine applied to vasopressin containing-neurons in the SON, was observed to cause an 
increase in Ca2+ in the neurons, due to activation of adenylate cyclase by nAChRs 
(Shioda et al, 1997b).  The increase in Ca2+ in the rat hypothalamic vasopressin- 
containing neurons were suggested to be mediated by a cAMP-PKA signal transduction 
system, whereby nicotine acts through a cAMP-dependent mechanism, probably via a 
PKA-mediated phosphorylation of calcium channels, to trigger the influx of Ca2+ and 
facilitate vasopressin release (Shioda et al, 1997b).
1.10.2.  Oxytocin.
Oxytocin and vasopressin only differ by one amino acid (80% homology) but they have 
very different physiological actions.  Vasopressin, as previously mentioned, is essential in 
cardiovascular and water homeostasis, whereas oxytocin is important in lactation and 
sexual behaviour (see Holmes et al., 2003).  Oxytocin is also synthesised by neurons 
whose cells bodies are located in the PVN and SON of the hypothalamus with the axons 
of the neurons terminating in the neurohypophysis and, upon stimulation, release 
oxytocin in to the circulation (Acher, 1993).
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non reproductive tissues such as the heart (Gutkowska et al., 1997) and vascular 
endothelium (Thibonnier et al., 1999).  The oxytocin receptor is a GPCR coupled to Gq/n 
class binding proteins, which stimulate the activity of phospholipase C (Gimpl & 
Fahrenholz, 2001).  Phospholipase C causes the generation of inositol triphosphate, 
which triggers the release of Ca2+ from intracellular stores, and 1,2,-DAG which 
stimulates PKC to phosphorylate target proteins (Gimpl & Fahrenholz, 2001).  The 
release of Ca2+ effects many events such as stimulation of nitric oxide, which helps to 
produce cGMP and leads to vascular endothelium vasodilatation (Gimpl & Fahrenholz, 
2001;Thibonnier et al., 1999).  Calcium can also cause smooth muscle contractions and 
release in neurosecretory cells.  The concentration of oxytocin in the human brain and 
spinal cord, using specific radioimmunoassay, showed interesting results when compared 
with vasopressin concentrations.  It was shown that, in the hypothalamus, the ratio of 
vasopressin to oxytocin was approximately 3:1.  There was also observed a greater 
amount of vasopressin in the extrahypothalamic areas of the brain, such as the locus 
coeruleus and periaquaeductal grey.  In the NTS, the DMVN and nucleus of spinal tract 
of the trigeminal nerve there were observed to be higher concentrations of oxytocin than 
vasopressin, which was also the case in the spinal cord, where oxytocin predominated 
over vasopressin to an even greater extent (Jenkins et al., 1984).  Electrical stimulation of 
the PVN in lactating guinea pig and rabbit caused milk ejection without a rise in blood 
pressure suggesting release of oxytocin alone, whereas in the cat, electrical stimulation of 
the PVN increases the concentration of both hormones in the blood (Bisset et al., 1975).
Studies observing the affects of nicotine on oxytocin release have indicated that in cats, 
central administration of nicotine caused the release of vasopressin but did not cause the 
release of oxytocin (Bisset et al., 1975;Bisset & Feldberg, 1973).  This provides further 
evidence that nicotine-induced vasopressin release is not caused by direct action of 
nicotine on PVN, as stimulation of the PVN would be expected to release both hormones 
(Bisset & Chowdrey, 1984).  Administration of nicotine subcutaneously (s.c.) was 
demonstrated to cause the release of oxytocin into the blood, and was not blocked by 
hexamethonium, which is unable to cross the blood brain barrier, indicating that nicotine 
is acting centrally to cause the release of oxytocin rather than acting peripherally.
1461.10.3.  Adrenocorticotropic hormone.
Adrenocorticotropic hormone (ACTH) is a polypeptide hormone synthesised and secreted 
from corticotropes in the anterior lobe of the pituitary gland in response to the hormone 
corticotrophin-releasing factor (CRF) released by the hypothalamus (HLP.Rang et al., 
1999;Hardman J.G, 1996).  The CRT neurons are located in the parvocellular region of 
the PVN of the hypothalamus (pcPVN). ACTH has been observed to stimulate the cortex 
of the adrenal glands and boost the synthesis of corticosteroids, which are a class of 
steroid hormones and are involved in a wide range of physiological systems such as the 
stress response, immune response and regulation of inflammation (see Tortora & 
Grabowski, 2000; see Rang et al., 1999; see Hardman, 1996; Silverman et al., 2005; 
Zipser etal., 1976).
The effect of nicotine on ACTH release was observed when tobacco smoking caused an 
increase in ACTH plasma levels (Kershbaum et al., 1968;Seyler, Jr. et al., 1986).  Further 
studies on the effects of i.p. (Clarke & Pert, 1985), s.c. (Balfour et al., 1975) and i.v. 
injection (Andersson et al., 1983) of nicotine, observed the release of ACTH from the 
anterior pituitary corticotropes of adult rats.  Studies to determine the mechanism of 
action of nicotine-induced release of ACTH, were preformed and indicated that systemic 
nicotine was acting centrally to stimulate the release of ACTH from the pituitary.
Nicotine administered i.v. (2.5 -  5 pg kg'1) produced a dose-dependent increase in plasma 
levels of ACTH which was not inhibited by hexamethonium i.v. (which cannot cross the 
blood brain barrier) (Asghar & Roth, 1971), but mecamylamine, which is a centrally 
active antagonist, did block nicotine-induced ACTH release (Matta et al., 1987; 1990). 
Nicotine i.v. was observed to have no effect on corticotropes in vitro, nor did it modulate 
responses to CRF (Matta et al., 1987).  Interesting nicotine administered by i.c.v. 
injections (0.25 -  5 pg kg1 ) into the third ventricle, from which the PVN is immediately 
accessible, produced a dose-dependent elevation of plasma ACTH (Matta et al., 1987), 
which was not inhibited when mecamylamine was injected into the PVN, indicating that 
the PVN itself was not involved (Matta et al, 1987).  Matta et al. (1990) noted that 
injections of nicotine in to the fourth ventricle resulted in a dose-dependent increase in
147plasma ACTH.  Nicotine (i.v.)-induced release of ACTH was blocked by pre-treatment of 
mecamylamine at the brainstem, suggesting the involvement of brainstem structures in 
the release of ACTH.
The PVN can mediate ACTH secretion in response to central catecholamine stimulation, 
Matta et al. (1993) hypothesised that nicotine could induce ACTH secretion by activating 
catecholaminergic afferents projecting to the PVN from the brainstem.  Catecholamine 
release by nicotine has been demonstrated both in vitro (see Hall & Turner, 1972; 
Westfall, 1974) and in vivo (Andersson et al., 1983).  In situ hybridisation has identified 
specific nAChR subunit mRNA in the brainstem (Wada et al, 1989).  The NTS has 
noradrenergic (NTS - Ai and A2 regions) and adrenergic (NTS -  Ci and C2 regions) 
inputs into the PVN.  Microinjection of nicotine into these regions, indicated that the rank 
order of sensitivity of plasma ACTH responses to nicotine was A2>C2>A1 and Cl was 
insensitive (Matta et al., 1993).  Overall it was suggested that ACTH secretion can be 
stimulated by nicotine acting at multiple brainstem catecholaminergic regions, which 
show differential sensitivity to the neuroendocrine effect of nicotine (Matta et al, 1993; 
Matta etal., 1997; Seyler, Jr. etal, 1986).
1.11.  Diseases associated with neuronal nAChRs.
The role of neuronal nicotinic receptors in neurodegenerative diseases has been 
established over the last 30 years.  These include schizophrenia, Tourettes’s syndrome, 
Parkinson’s disease, Alzheimer’s disease and epilepsy.  Figure 12 shows the areas of the 
rat brain associated with these neurodegenerative diseases.
1.11.1.  Schizophrenia.
Schizophrenia is a severe mental illness that affects 0.6-1.5 % of the population 
worldwide and is characterized by disorganised thought processes, hallucinations,
148delusions, cognitive deficits and impaired learning function (see Arnold & Trojanowski, 
1996; see Salamone & Zhou, 2000).  The pathology of this disease has only just started to 
be understood in the last 30 years.
Schizophrenia was first associated with neuronal nAChRs in 1986 when Hughes et al 
reported that schizophrenic patients tended to smoke more cigarettes than the normal 
population, with a 88% prevalence of smoking in patients with schizophrenia compared 
with 33% prevalence in the local or national population (see Lohr & Flynn, 1992).  To 
determine if neuronal nAChRs had any involvement in schizophrenia the number of 
nAChRs was established in the brain of the subjects suffering from the disease.  It was 
observed that there was a significant decrease in neuronal nAChRs in certain brain areas 
such as the cingulate and orbito-frontal cortex with a loss of a4p2 nAChRs (see Court JA 
et al., 2000; Graham et al., 2002), as well as a significant decrease in a-BgT binding in 
brain areas such as in the hippocampus (Freedman et al, 1995) and a decrease in a7 
subunit protein expression in the frontal cortex (Figure 12) (Guan et al, 1999).
One of the most significant symptoms of schizophrenia is an effect on sensory gating, 
which is the failure to discriminate the P50 wave of the auditory evoked response in a 
paired stimulus conditioning testing paradigm (Adler et al, 1999).  This deficit has also 
been seen in many relatives of the patients, indicating a genetic predisposition is involved 
(Adler et al, 1992; Tsuang, 1993).  Such effects have been reproduced in animals by the 
use of the a7 antagonist, a-BgT, indicating that inhibition of this receptor could be 
involved in the schizophrenic condition (Freedman et al, 1995).  Further evidence was 
given by Alder et al (1992,1999) who demonstrated that the deficit in sensory gating 
could be reversed by nicotine administration in the form of nicotine-containing gum. 
Although the effects were only observed for an hour it showed that al nAChRs may 
control auditory sensory gating (Adler et al, 1992).  Additional studies performed 
indicated that the deficit in P50 auditory evoked potential gating has been localized and 
found to be on chromosome 15, band ql4 (Dursun & Reveley, 1997; Freedman et al,
1995), which is also the gene locus of the al nAChR (Chini et al, 1994).  Taken together 
with the decreased al gene expression observed in the hippocampus, reticular thalamic 
nucleus and superior olive complex, which are areas that receive sensory information
149(Agulhon et al., 1999) these finding suggest that a7 nicotinic receptors are involved in the 
pathophysiology of schizophrenia (Figure 12) (Agulhon et al., 1999; Freedman et al., 
1995).
In conclusion, it has been suggested that the a7 neuronal nAChR could be involved in 
certain aspects of schizophrenic and that the large number of cigarettes smoked in 
patients may help compensate for a defect in the al receptor. Unfortunately not enough 
information is known, therefore future studies will be required in order to determine the 
overall effect of nAChRs in this disease.
1.11.2.  Tourette’s syndrome.
Tourette’s syndrome is a hyperkinetic movement disorder characterized primarily by the 
expression of sudden, rapid and brief, recurrent, non-rhythmic, stereotyped motor 
movements (motor tics) or sounds (vocal tics) that are experienced as uncontrollable, but 
usually can be suppressed for varying lengths of time (Sanberg et al., 1997).  The 
incidence of Tourette’s syndrome (TS) in the population is around 0.5/1000, although this 
is believed to be an underestimate (Dursun & Reveley, 1997).  By the use of neuroleptics 
(Dopamine D2 antagonists) such as haloperidol and pimozide, the symptoms can be 
suppressed, however these drugs have side effects such as deterioration in function and 
compliance which include difficulty in concentration, drowsiness and attentional 
problems (McConville et al., 1992), therefore new drugs are required to help treat this 
disorder.
Although there is no direct evidence that nAChRs have an involvement in this disorder, it 
has been shown that the administration of nicotine causes substantial improvement of tics 
observed in TS patients.  Studies have shown that patients suffering from TS, upon 
chewing nicotine gum, exhibited a marked reduction in tics, as well as improvements in 
attention span and a reduction in hyperactivity, which allow them to do certain tasks that 
they could not do previously (Sanberg et al, 1997).  Unfortunately these therapeutic
150effects were of short duration and side effects such as bitter taste and nausea made 
patients have a low compliance.  The effects of chewing nicotine gum, when the patient is 
on haloperidol, was also studied (McConville et al., 1992).  It was shown that nicotine 
potentiated the haloperidol effects on TS patients, but the combination of haloperidol and 
nicotine gum was more effective at controlling the tic frequency and severity than 
nicotine gum alone.  Due to the side effects mentioned for chewing nicotine gum, other 
modes of administration were studied; Dursun et al. (1994) demonstrated that 
administration of nicotine by the use of transdermal nicotine patches reduced tics of non­
smoking patients with TS with no side effects for up to 4 weeks.  This study was 
important because it was carried out on TS patients whose symptoms were unable to be 
controlled by haloperidol, indicating the possibility of nicotine being used to treat TS 
(Dursun et al., 1994; Dursun & Reveley, 1997).  Interestingly, patients who have TS and 
are smokers have less severe symptoms; however, when these patients stop smoking they 
often display dramatically increase in severity.
Although neuronal nAChRs have not been directly shown to have an involvement in TS, 
the positive effect of nicotine suggests that nAChRs may play a role in symptom 
manifestation.  Although many mechanisms have been suggested for how nicotine causes 
its effects, so far none have been proven.  One suggested mechanism by which nicotine 
and neuronal nAChR may affect TS patients is due to nAChRs heteroreceptors found on 
the dopaminergic neurons modulating the release of DA from the striatum and limbic 
cortical areas (see Colquhoun & Patrick., 1997; Rapier et al., 1988; 1990).  If this is 
occurring then nicotine may be effective due to desensitization of the heteroreceptors 
nAChRs, inhibiting the release of NA.  Administration of nicotine by transdermal patch 
for 48 hours continuously, correlates with the time taken to induce receptor 
desensitization.  This indicates why the 48 hour transdermal patch is able to relieve the 
TS symptoms for up to 4 weeks, whereas, nicotine gum, which is only chewing for 30 
mins, is only able to relieve the TS symptoms for a few hours, due to the low 
desensitization of nAChRs (Dursun et al., 1994; Dursun & Reveley, 1997; Sanberg et al., 
1997).
1511.11.3. Parkinson’s disease
Parkinson’s disease was first described by James Parkinson in 1817 and is one of the 
most common neurodegenerative movement disorders affecting 1% of the population 
over 65 years of age (Bossy-Wetzel et al., 2004; Maggio et al., 1998; Meissner et al., 
2004). The disease is characterized by serious functional disturbances such as tremors at 
rest, rigidity, akinesia (or postural instability) and bradykinesia (the difficulty or failure to 
execute voluntary movement) (Femandez-Espejo, 2004; Meissner et al, 2004).  These 
functional disturbances are caused by the loss of dopaminergic neurons in the substantia 
nigra pars compacta projecting to the striatum leading to DA deficiency in the basal 
ganglia (Figure 12).  The defining neuropathological feature in Parkinson’s disease (PD) 
is the presence of cytoplasmic a-synuclein positive inclusions (Lewy bodies) in the 
substantia nigra together with nigra cell loss.  Parkinson signs appear when neuronal 
death exceeds a critical threshold of 70-80% of DA nerve terminals in the striatum 
(Femandez-Espejo, 2004; Meissner et al., 2004).
Currently, even with an extensive amount of research looking into PD, the cause of the 
disease is still unknown, although it is believed that there is a genetic component (see 
Newhouse et al, 1997).  Current treatments, such as L-DOPA, to produce DA, are only 
symptomatic and do not stop or delay the progressive loss of neurons.  Surprisingly, it 
was observed that the incidence of PD was significantly lower in smokers when 
compared to non-smokers and this lead to extensive studies observing the effects of 
nicotine and smoking (Janson et al, 1989;Morens et al, 1995;Newhouse et al., 1997), as 
well as establishing the involvement of neuronal nAChRs in PD (Burghaus et al., 2003; 
Guan et al., 2002; Martin-Ruiz et al., 2000b).
There have been extensive studies looking at the changes in nAChRs in PD. 
Autoradiography studies in rat and human brain tissues have compared healthy brains 
with patients who suffered from PD and shown that there was a significant decrease in 
nicotinic agonist binding in patients suffering from PD, the most significant loss was 
observed in the striatum showing up to 76% loss of nicotinic binding.  A decrease in
152binding in the hippocampus, cortex and temporal cortices has also been documented 
(Aubert et al., 1992; Lange et al., 1993; Newhouse et al., 1997; Perry et al., 1995; 
Schroder et al., 1995).  This loss of neuronal nACh receptors in PD are believed to be 
located pre-synaptically on degenerating cholinergic axons.  The nucleus basalis of 
Meynert has the highest concentration of nicotinic receptors in the human brain and being 
the principle nucleus of the basal forebrain, degeneration of neurons, which occurs in PD, 
will reduce pre-synaptic nAChRs which in turn will reduce the nicotine and ACh-induced 
release of ACh from the cholinergic terminals in the cortex (Figure 12) (Aubert et al., 
1992; Lange et al., 1993).  Further studies revealed that neuronal nAChR subtypes were 
decreased in additional areas of the PD brain, for example, in the striatum area, which 
includes the caudate nucleus and putamen.  Studies have shown that there is a significant 
decrease in [3H]-epibatidine radioligand binding, a3 mRNA and protein expression in the 
caudate nucleus in PD brains (Guan et al., 2002).  Degenerative changes are also 
observed in the cortices, which play an important role in cognitive deficits of Parkinson’s 
disease patients.  It has been demonstrated that there are significantly decreased amounts 
of a4 and a7 protein subunits in human cortices in PD patients (Burghaus et al., 2003).  A 
decrease in a3 and p2 mRNA and protein expression has also been observed in the 
temporal cortex in PD brains (Burghaus et al., 2003; Guan et al., 2002).  Surprisingly 
there was no change in any nicotinic subunits (a3, a4, a7, p2 and p4) expression in the 
putamen when controls (healthy brains) were compared to PD brains (Guan et al., 2002; 
Martin-Ruiz et al., 2002) suggesting that the receptors that are being reduced are in fact 
receptor subtypes not examined in this study, possibly a5, a6 and P3 nAChRs may be 
decreased and be responsible for the high-affinity nicotine binding in PD striatum. This 
would correlate with the findings that the neuronal nAChRs believed to be involved in 
the release of DA are the a6p3p2, a6p2 or a6p3 (Champtiaux et al., 2003; Cui et al.,
2003; Salminen et al., 2004).  Additional suggestions for the decrease in nicotine binding 
without any obvious change in nAChR expression, may be an increased synthesis of 
nAChR subunits in the remaining nigrostriatal neurons in PD patients, which are acting 
as some kind of compensation for the loss of nAChRs but fail to be assembled in 
degenerative terminals, so maintaining apparent subunit expression when receptor 
binding is attenuated (Guan et al, 2002; Martin-Ruiz et al., 2000b; 2002).
153All the data reported strongly support the involvement of nAChRs in this disease 
especially when it was noted that smokers were less susceptible to PD than non-smokers 
(Morens et al., 1995).  This lead to research into the effects of nicotine on PD models. 
Parkinson’s disease models were produced in rats and mice by the use of l,methyl-4- 
phenyl-1,2,3,6-tetrahydropyridine (MPTP), which is a neurotoxin and has been shown to 
induce degeneration of nigrostriatal DA neurons (Janson et al., 1992).  Other methods of 
stimulating PD include the use of partial hemitransection made at the mesodiencephalic 
junction, causing lesions in the nigrostriatal DA neuron (Janson et al., 1989; 1994; Janson 
& Moller, 1993).  Studies showed that chronic treatment with nicotine, sometimes lasting 
up to 2 weeks, caused neuroprotective effects by preventing lesion-induced upregulation 
of the high affinity agonist binding sites of the DA D2 receptor and preventing 
hypersensitivity of the D2 receptor which would normally cause rapid release of DA.
From these studies it has been suggested that nicotine acts as a neuroprotector by binding 
to nACh heteroreceptors found on DA neurons causing desensitization of nAChRs and 
decreasing burst firing of nigral DA neurons which decreases DA utilization, reducing the 
release of DA.  Studies have also shown that depolarization would reduce the release of
2+
DA by reducing the influx of Na  andCa  decreasing the energy demands to maintain 
homeostasis.  In addition a decrease in Ca2+ influx would contribute to the survival of DA 
neurons (Janson et al., 1989; Janson & Moller, 1993), as well as, reduce burst firing of 
DA neurons On the lesioned side (Janson et al., 1994).  All of the above suggest that 
nicotine would be a useful tool in the neuroprotection of PD, but unfortunately clinical 
trials of nicotine treatment have lead to controversial results with little or no improvement 
in cognitive and motor symptoms (Kelton et al, 2000).  This is not surprising when it is 
considered that there is a vast amount of nAChR present in the brain, all activated by an 
unselective agonist.  Therefore until more selective agonist and antagonist are tested for 
the treatment of PD, it is unknown if neuronal nicotinic agonists will become a useful 
tool in treating this disease.
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Figure 12.  Diagrammatic representation of the possible physiological involvement of nicotinic ACh receptor subunits
observed in the rat brain.  Modified from Jones et al., 1999.
1551.11.4. Alzheimer’s disease.
Alzheimer’s disease (AD) is the most common form of dementia in adults, with more that 
12 million individuals worldwide suffering from the disease (see Citron, 2004). 
Alzheimer’s disease is clinically characterized as a progressive and incapacitating disease 
that causes memory loss accompanied by additional cognitive and behavioral impairment 
(Mesulam, 2004).  Patients diagnosed with AD have extracellular deposits in the form of 
diffuse or neuritic plaques which contain the amyloid peptide, as well as neurofibrillary 
tangles which accumulate in neuronal perikarya and contain the protein tau (see Octave, 
1995).  Death occurs, on average, 9 years after diagnosis (see Citron, 2004).  Although 
the causes of AD are still not fully understood, it has been clearly demonstrated that there 
is a severe loss of cholinergic innervation in AD patients, especially in the cerebral cortex 
(Mesulam, 2004), with up to 80% of all cholinergic axons depleted.  Extensive research 
has gone in to looking at the effect of nAChRs in AD, with observations that there is a 
significant decrease in nicotine binding in the cerebral cortex in patients suffering from 
AD (Ferreira, Jr. etal., 2002; Whitehouse etal., 1986).  This decrease in nicotinic 
binding occurs in the temporal cortex, frontal cortex and neocortex, with a decrease in 
[3H]-nicotine binding of over 44% and 50% in temporal and frontal cortex, respectively 
(Flynn & Mash, 1986; Marutle et al., 1999; Nordberg et al., 1988; Nordberg et al., 1995; 
Nordberg & Winblad, 1986; Perry et al., 1995; Sabbagh et al., 1998; Whitehouse et al., 
1986).  Decreases in nicotine binding have also been observed in the hippocampus and 
presubiculum (Figure 12) (Marutle etal, 1999; Nordberg etal, 1995; Perry etal, 1995). 
Different nicotinic agonists have also been used, in particular [3H]-epibatidine, which is 
selective for the a3 and a4 neuronal nAChRs.  In AD patients it has been shown that 
epibatidine binding is reduced in the cerebral cortex, with a 40% decrease in the temporal 
cortex, 45% decrease in the frontal and 38% decrease in hippocampus (Marutle et al,
1999). Although this evidence is not conclusive, it goes some way to demonstrating that 
a4 and possibly a3 subunits are decreased in AD.  A great deal of research has gone in to 
examining if there is a decrease in a-BgT binding in AD, this is still inconclusive due to 
mixed results.  It has been shown that there was a decrease in a-BgT binding in the 
temporal; but not frontal cortex in AD patients (Whitehouse & Au, 1986), but this has not
156been able to be replicated with further studies showing that there is no difference between 
AD patients and controls in a-BgT binding sites in the temporal cortex (Martin-Ruiz et 
al, 2000a) and hippocampus (Whitehouse & Au, 1986).
Decreases in nicotinic AChR binding sites have also been correlated with a decrease in 
ChAT activity, with up to 60% loss in the temporal cortex and noted losses in frontal 
cortex that were about the same extent as loss of [3H]-nicotine binding sites (Nordberg & 
Winblad, 1986; Sihver et al, 1999).  This parallel reduction in nicotine binding sites and 
ChAT activity in AD suggests receptors are found pre-synaptically (Ferreira, Jr. et al., 
2002), which was also noted in neocortical slices when it was observed that nicotinic 
agonist [3H]-epibatidine binding was reduced in AD patients, as well as synaptic density. 
The loss of synaptic density, as well as nicotinic binding indicates that the loss of nAChR 
binding sites, seen in AD, results from the loss of nerve terminals bearing these receptors 
(Sabbagh et al., 1998).  This provides more evidence for the hypothesis that the nucleus 
basalis, which provides cholinergic innervation to the cortex and contains the highest 
concentration of [3H]-nicotine binding sites in the human brain, is degenerated in AD, 
resulting in a reduction in pre-synaptic receptors on the axons innervating the cortex 
(Ferreira, Jr. et al., 2002).  It is in the cerebral cortex that the substantial loss of 
cholinergic innervation occurs in AD and is shown to cause the memory loss and other 
cognitive impairment (Figure 12) (Mesulam, 2004).
Radioligand binding studies have shown that there is a reduction in nAChRs in AD 
patients, but it has only been over the last 7 years or so that studies into which specific 
nAChR subtypes are lost in AD have been performed.  Studies in the cerebral cortex have 
shown that there are significant decreases of 40% in the a4 subunit protein expression in 
AD patients when compared to age-matched controls (Wevers et al., 1999; 2000).
Further studies in the temporal cortex provided more evidence of a4 involvement in AD, 
with data showing a4 nAChR subunit protein levels decrease by 47% in AD patients 
(Martin-Ruiz et al., 1999; Perry et al., 2000; Sparks et al, 1998).  Additionally a 
reduction in a4 protein level of 35% was observed in the hippocampus (Guan et al.,
2000; Mousavi et al., 2003).  Interestingly, although there has been an observed decrease 
in the a4 nAChR subtype and radioligand [3H]-nicotine binding (which is believed to be
157most selective for the a4p2 nAChR) there has been no observed decrease in protein levels 
in the temporal cortex or hippocampus (Guan et al, 2000), indicating another receptor 
apart from the nAChR a4p2 may be involved.  Studies took place to observe if the 
protein levels of the a3 subunit were affected in AD producing some contradictory 
results, with some studies showing a reduction in the temporal cortex and hippocampus 
(Guan et al, 2000;Mousavi et al, 2003), whereas, other studies indicated that protein 
levels of a3 nAChR remain unchanged (Martin-Ruiz et al, 1999; Perry et al, 2000). 
Although there is a significant decrease in a4 and a3 protein expression, it has been 
demonstrated there is no corresponding decrease in mRNA expression for either of these 
two subunits (Mousavi etal, 2003; Terzano etal, 1998; Wevers etal, 1999; 2000).
This decrease in nAChR protein level without a change in mRNA transcription level in 
AD, supports an abnormality in the translation and/or post translational events in nAChR 
biosynthesis, whereby the neurons are failing to translate the nAChR mRNA into 
corresponding proteins and possibly causing the cholinergic deficit in AD.
Studies into the expression levels of a7 nAChR in AD patients have demonstrated a 
decrease in a7 subunit expression in the cerebral cortex (Burghaus et al, 2000; Wevers et 
al, 1999; 2000), as well as, the hippocampus (Guan et al, 2000; Mousavi et al, 2003), 
although there was no change in a7 expression in the temporal cortex (Figure 12) (Guan 
et al, 2000; Martin-Ruiz et al, 1999; Mousavi et al, 2003; Perry et al, 2000). 
Interestingly, it has been shown that there was no difference between mRNA expression 
of the a7 subunit between AD and controls in the temporal cortex (Mousavi et al, 2003) 
and cerebral cortex (Wevers et al, 1999; 2000), therefore, as with the a4 and a3 nAChR 
subunits, it appears that there is a problem in translating the mRNA of a7 into it’s 
corresponding protein.  Contradictory to this hypothesis, Martin-Ruiz et al (2000a) 
demonstrated a 65% increase in mRNA expression of a7 in the hippocampus, indicating 
that a compensation mechanism may be occurring in AD, whereby increasing 
transcription of a7 mRNA may help to maintain normal a7 subunit protein expression in 
the majority of cases.
Originally, upon discovery of AD, the belief that it was a cholinergic disease instigated 
the research and development of cholinergic agents such as anti-acetylcholinesterases
158which would prevent the breakdown of ACh and lead to symptomatic improvement 
(Mesulam, 2004), unfortunately this was not the case and they were demonstrated to only 
have modest effects.  There has been a vast amount of research into AD and one of the 
areas of research involves looking into drugs which can block the p-amyloid (A(3) 
aggregation (see Citron, 2004).  One of the characteristics of AD is the development of 
senile plaques, these are composed of a core of AP and it has been hypothesized that 
accumulation of Ap causes neurodegeneration and neuronal death (Kihara et al., 1997). 
Thus it is believed that the neurodegeneration by Ap could be inhibited by interfering 
with this sequence of events and hopefully prevent, or at least, treat AD.  Due to the 
effects of AD on nicotinic radioligand binding, the effects of nicotinic compounds were 
observed on treating the disease, especially by interfering with AP accumulation. 
Nicotinic agonist studies against Ap cytotoxicity in the cerebral cortex showed that 
nicotine exposure for 48 hours significantly reduced AP cytotoxicity in a concentration 
dependent manner (Kihara et al., 1997; 1998), the neuroprotective effects of nicotine 
were shown to be blocked by the non-selective neuronal nAChR antagonist, 
mecamylamine, which indicates that the effects of nicotine are modulated by nicotinic 
receptors (Kihara et al., 1997; 1998).  Further studies were performed using selective 
agonists and antagonists to establish if any specific nAChRs are involved.  It was shown 
that the al antagonist, a-BgT, blocked the neuroprotective effects of nicotine, as well as 
selective al agonists reducing Ap cytotoxicity significantly and protecting against Ap- 
induced neuronal death (Kihara et al., 1997).  Studies looking into a4p2 neuronal 
nAChRs by using the selective antagonist, DhpE, showed that the neuroprotective effects 
of nicotine were blocked, as well as selective a4p2 agonists causing a significant 
reduction of AP cytotoxicity (Kihara et al., 1998).  This demonstrated that both a4p2 and 
al nAChRs exert a neuroprotective effect against AP-induced cytotoxicity.  The 
neuroprotective affects have been shown in hippocampal cell cultures, with nicotine 
inhibiting the neurotoxicity of Ap in a dose-dependent manner which is inhibited by the 
nicotinic antagonist, mecamylamine, indicating that nicotine has a neuroprotective effect 
via a receptor mediated pathway (Zamani et al., 1997).  Studies have shown that the 
increasing levels of AP demonstrated in AD were correlated with the loss of a4 and 
suggested that there is an involvement of a4 subunits in the early stages of AD (Perry et 
al., 2000).
159The precise mechanism of nicotine’s neuroprotection is not clear, although one 
suggestion is that the application of nicotine causes desensitization of nACh 
heteroreceptor on glutamate neurons which may reduce the AP induced Ca  influx which 
causes the excess release of glutamate and results in cytotoxicity by glutamate toxicity 
(Kihara et al., 1998;Zamani et al., 1997).  Other nicotinic treatments have shown that 
nicotine can help improve visual attentional deficits in AD (Jones et al., 1992;Perry et al.,
2000).  Overall it has been shown that nicotine or nicotine related compounds could help 
in the loss of cortical synapses which have been shown to reduce in synaptophysin in 
correlation with nicotinic binding (Sabbagh et al., 1998) and hopefully help in the 
treatment of AD.
1.12.  Aims of the thesis.
Central administration of nicotine can evoke either an increase or decrease in blood 
pressure and sympathetic outflow.  The unselective nature of nicotine for different 
neuronal nAChR prevents identification of which nAChR mediates the different 
cardiovascular responses elicited from each central cardiovascular control region.
The aim of this study was first to determine the effects on the cardiovbascular system of 
nicotine applied to the forebrain compared to the hindbrain using intracerebroventricular 
(i.c.v.) and intracistemal (i.e.) injections respectively.  Secondly the aim was to identify 
the nAChR subtype involved in the cardiovascular responses elicted from each site of 
application and the pathways involved.  The studies were carried out in anaesthetised rats 
amd depend on the recent development of two agonists selective for a4p2 and al nAChR 
subunits.  Possible mechanisms for the cardiovascular changes such as the role of central 
and peripheral vasopressin were also employed.
160CHAPTER 2.  METHOD.
2.1.  Experimental design.
Experiments were performed on the male Sprague-Dawley normotensive rats (250-350g). 
Anaesthesia was induced by isoflurane (2.5% in oxygen) and maintained with a- 
chloralose (100 mg kg"1, i.v.).  Supplementary doses of a-chloralose (10-20 mg kg"1, 
i.v.) were given as required.  Depth of anaesthesia was assessed by the stability of 
cardiovascular and respiratory variables being recorded.  The right carotid artery was 
cannulated in order to measure blood pressure and for sampling arterial blood for analysis 
of pH and blood gases.  Blood pressure was measured using a pressure transducer (Gould 
Statham P23XL) and the heart rate was derived electronically from the blood pressure 
signal (Gould Biotach Amplifier).  The left jugular vein was cannulated for the purpose 
of drug administration and a tracheal cannula was implanted (Figure 13).  Body 
temperature was monitored by a rectal probe and maintained at 36 - 38°C with a 
homoeothermic blanket system (Harvard).  The animals were artificially ventilated (rate 
50 strokes min"1 , stroke volume 8 ml kg'1 ) with oxygen enriched room air by the use of a 
positive pressure pump (Harvard Rodent Ventilator 683) and neuromuscular blockage 
was produced with decamethonium (3 mg kg'1, i.v.).  Blood samples were taken from a 
T-piece on the carotid arterial cannula and blood gases and pH were monitored with a 
Coming pH/blood gas analyzer.  Blood gases were maintained between 90-130 mmHg 
PO2, 40-50 mmHg PCO2 and pH 7.3-7.4.  Adjustments of the respiratory pump volume 
were made as necessary to maintain blood gas and pH balance.  Once ventilated, the 
animals were infused (6 ml kg'1  h'1) via the jugular vein with a solution comprising 10 ml 
plasma substitute (gelofusine), 10 ml distilled water, 4 mg glucose, 168 mg sodium 
bicarbonate and 10 mg decamethonium.  This was to prevent the development of non- 
respiratory acidosis and to maintain blood volume and neuromuscular blockade.  During 
neuromuscular blockade, the depth of anaesthesia was assessed by monitoring the 
stability of the arterial blood pressure and heart rate and the cardiovascular responses to 
pinching the paws.
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Figure 13. Diagrammatic representation of the animal model used during the study 
illustrating a rat artificially ventilated.  Measured from the right carotid artery were 
arterial blood pressure (arterial BP) and heart rate (HR).  Blood samples were also from 
the carotid cannula to measure blood gases and pH levels.  Intra-venous (i.v.) injections 
were delivered via cannulation of the left jugular vein.  Intracerebroventricular (i.c.v.) 
injections were delivered via the cannulation of the lateral cerebral ventricles and 
intracistemal (i.e.) injections were delivered via the cannulation of the cistema magna. 
Renal nerve activity (RNA) was detected using bipolar silver hook electrodes.
1622.1.1.  Cannulation of the lateral cerebral ventricle.
The rats were placed in a sterotaxic head holder and a stainless steel guide cannula (22 
gauge) was implanted into the right lateral cerebral ventricle.  The co-ordinates used from 
the bregma were 4 mm ventral, 1.5 mm lateral and 1 mm posterior.  Drugs and vehicle 
solutions were administered through an i.c.v. injection cannula (28 gauge) attached by a 
length of polythene tubing to a 25 pi syringe (Hamilton).  At the end of the experiment, 
the cannula placement was confirmed by the administration of 5 pi of 2% pontamine sky 
blue dye.
2.1.2.  Cannulation of the cistema magna.
The rats were positioned in a sterotaxic head holder, and the atlanto-occipital membrane 
was exposed.  A stainless steel guide cannula (23 gauge) was inserted perpendicularly 
into the membrane to the depth of its bevel to just pierce the membrane.  Drugs and 
vehicle solutions were administered through an i.e. injection cannula (28 gauge) attached 
by a length of polythene tubing to a 25 pi syringe (Hamilton).  Successful cannulation 
was verified by the filling of stainless steel guide cannula with clear cerebrospinal fluid 
and at the end of the experiment, by the administration of 5 pi of 2% pontamine sky blue 
dye.
2.1.3.  Recording of renal nerve activity.
The left kidney was exposed by a retroperitoneal approach and was deflected laterally to 
reveal the renal artery and nerve.  The nerve was cleared of connective tissue and 
positioned on a bipolar silver hook electrode (Figure 13).  The renal nerve activity was 
amplified (Digitimer NL104), filtered (Digitimer NL125, frequency band width 100- 
500Hz) and quantified by integrating the signal above the background noise over 5
163seconds with a solid state integrator (Medical Electronics workshop, Royal Free Hospital 
School of Medicine) (Anderson et al., 1992).  At the end of the experiment 20 mg of 
pentobarbitone sodium (per animal) was used to validate the integrator threshold.
At the beginning of each experiment the baroreceptor reflex response was tested by 
observing whether the renal nerve activity and heart rate were reduced by a rise in blood 
pressure caused by noradrenaline (25 ng per animal, i.v.), and whether they were raised, 
by a reduction in blood pressure caused by sodium nitroprusside (0.6 fig per animal, i.v.). 
Only preparations with an intact baroreceptor reflex were used.
2.2.  Experimental protocol.
2.2.1.  Neuronal nicotinic receptor agonists (i.c.v. & i.e.).
In all the experiments recorded, the rat model preparations were performed on 
anaesthetised rats, artificially ventilated and neuromuscular blocked, by decamethonium. 
The preparation was allowed to stabilize for 20 min before the administration of 5 pi 
saline (i.c.v. or i.e.).  Ten minutes after the saline control, a single dose of test compound 
or saline control was given i.c.v. or i.e. and the response was followed for at least 20 min. 
A diagrammatic representation of this protocol is shown in Figure 14-1.  In each rat the 
cardiovascular response to a single dose of the test agonist or saline was recorded.
2.2.2.  Neuronal nicotinic receptor antagonist ligands (i.c.v. 
and i.e.).
The preparation was allowed to stabilize for 20 min before flushing the i.c.v. cannula 
with saline (5 pi).  Ten minutes after this flush injection of saline (initial saline), a
164nicotinic antagonist (dihydro-$-erythroidine, methyllycaconitine or a-bungarotoxin) was 
given i.c.v.  This was then followed 3 min later by a test drug which was given i.c.v. and 
the response followed for at least 20 min (Figure 14-2).  The control carried out for these 
experiments was an injection of saline instead of nicotinic antagonist (dihydro-P- 
erythroidine, methyllycaconitine citrate or a-bungarotoxin) i.c.v. and the response 
followed for at least 20 min.
In the case of i.e. controls, the preparation was allowed to stabilize for 20 min before 
flushing the i.e. cannula with saline (5 pi).  Ten minutes after this flush injection of saline 
(initial saline), an antagonist (a-Bungarotoxin) was given i.e.  This was then followed 3 
min later by a test drug or saline which was given i.e. and the response followed for at 
least 20 min (Figure 14-2).
2.2.3.  Pretreatment with the Vi receptor antagonist 
d(CH2)5Tyr(Me)AVP (i.v.).
The Vi receptor antagonist, d(CH2)5Tyr(Me)AVP, was administered i.v. 5 min after the 
saline flush, followed 10 min later by the administration of test drug i.c.v. or i.e.  The 
control carried out for these experiments was an injection of V) receptor antagonist 
administered i.v., 5 min after the saline flush, followed 10 min later by the administration 
of 5 pi saline i.c.v. or i.c (Figure 15-1).  These pre-treatment times were chosen to allow 
stabilization of any changes in the variables being recorded caused by the administration 
of these substances.  In each rat the cardiovascular response of a single dose of the test 
agonist and saline were recorded.
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Figure 14.  Diagrammatic representation of the experimental protocol, showing the timing of pre-treatment and drug
administration. 1) Drug or saline central administration in artificially ventilated neuromuscular blocked rats; 2) 
Pre-treatment of antagonist then drug or saline administration in artificially ventilated neuromuscular blocked 
rats.
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Diagrammatic representation of the experimental protocol, showing the timing of pre-treatment and drug 
administration. II) Vi pre-treatment (i.v.) followed by agonist or saline administration,  2) Vi pre-treatment 
administered centrally (i.c.v. & i.e.) followed by agonist or saline administration, in artificially ventilated 
neuromuscular blocked rats.
1672.2.4.  Pretreatment with the Vx  receptor antagonist
d(CH2)5Tyr(Me)AVP (i.c.v. & i.e.).
The preparation was allowed to stabilize for 20 min before flushing the i.c.v. or i.e. 
cannula with saline (5 pi).  Five minutes after this flush injection of saline, an Vj receptor 
antagonist (d(CH2)5Tyr(Me)AVP) was given i.c.v. or i.e.  This was then followed 3 min 
later by a test drug which was given i.c.v. or i.e. and the response followed for at least 20 
min (Figure 1511).  The control carried out for these experiments was an injection of 
saline instead of the test drug after the injection of Vj antagonist (i.c.v. or i.e.) and the 
response followed for at least 20 min.
2.2.5.  Nicotinic agonist infusion.
The preparation was allowed to stabilize for 20 min then given a 0.5 ml flush of saline in 
to the i.v. cannula.  Five minutes after this flush injection of saline (initial saline), 
nicotinic agonist was infused over a 3 min period through the i.v. cannula and the 
response followed for at least 20 min.  The control carried out for these experiments was 
an infusion of saline instead of the test drug for 3 min and the response followed for at 
least 20 min.
2.3.  Analysis of results.
Baseline values were taken 1  min before the addition of the drug or vehicle.  All results 
are expressed as changes from baseline values.  Nerve activity was measured as the 
average of the integrated values over 10 sec for the first 5 min and then as an average of 
the integrated values over 1  min in arbitrary units and was expressed as the percentage 
change from baseline.  Changes in mean arterial blood pressure, heart rate and renal 
nerve activity caused by the test drug were compared with time-matched vehicle controls
168using two-way analysis of variance and were subsequently analysed using the least 
significant difference test.  All values are expressed as the mean ± s.e. mean; differences 
in the mean were taken as significant when P< 0.05.
All baseline values are shown in Table 17 in the appendix.  In addition, Tables 15 and 16 
give an overview of the experiments performed and the results recorded throughout the 
thesis.
2.4.  Drugs and solutions.
Drugs were obtained from the following sources: a-chloralose; sodium nitroprusside; 
nicotine hydrogen tartrate; cytisine, decamethonium bromide; [P-Mercapto-p,p- 
Cyclopentamethylenepropionyl 1,0-Me-T  yr2,Arg8] -Vasopressin, 
(d(CH2)5Tyr(Me)AVP); dihydro-p-eiythroidine, DMPP and a-Bungarotoxin from Sigma 
Chemical Co., Poole, Dorset, U.K.; noradrenaline acid tartrate from Winthrop, Guildford, 
Surrey, U.K.; isoflurane from Abbott Labs Ltd, Queenborough, Kent; Gelofusine from 
Braun Medical Ltd, Aylesbury, Bucks; Methyllycaconitine citrate from Tocris Cookson 
Ltd., Avonmouth, Bristol, U.K. The following were gifts from Eli Lilly Co. PSAB-OFP 
((R)-(-)-5Phenylspiro[l-azabicyclo[2.2.2] octane-3,2'-(3'H)furo[2,3-b]pyridine) and TC- 
2559 ((E)-N-methyl-4-[3-(5-ethoxypyridin)yl]-3-buten-1  -amine).
Drugs given i.c.v. and i.e. were dissolved in 0.9% w/v saline.  Solutions were 
administered in dose volume of 5 pi over a 20 sec period. All drugs given i.v. were 
dissolved in saline.
169CHAPTER 3.  RESULTS.
3.1.  Effect of central administration of neuronal nAChR 
selective agonists on cardiovascular regulation.
3.1.1.  Introduction.
Although the effects on cardiovascular control of nicotine have been studied previously, 
the role of different types of nAChR in mediating these effects is unknown.  With the 
availability of selective agonists and antagonists for different neuronal nAChR subtypes 
it is now possible to determine which subtypes are involved.
Two compounds have been shown to be selective for the two most predominant neuronal 
nACh receptors in the CNS, the a4p2 and a7 receptor (Clarke et al., 1985; Wada et al., 
1988).  The first, TC-2559 (Bencherif et al., 2000) has been shown to compete with [3H]- 
nicotine (a4(32 receptors) binding but not with [I25I]-aBgT (a7 receptors).  The selectivity 
of TC-2559 was then characterised across six recombinant human nAChRs and was 
shown to selectively activate a4p2 (EC50 = 0.18 jiM), while at p4-containing nAChR 
(a2p4, a4p4 and a3p4) it was 100X weaker, having an EC50 in the range of 10-30 jiM  
and no activity at a3p2 and a7 nACh receptors (Chen et al., 2003).  TC-2559 was also 
demonstrated to be selective for a4p2 over a4p4 and a7 subtypes expressed in Xenopus 
oocytes.  The effects of TC-2559 have been studied in vitro (Bencherif et al., 2000; Chen 
et al., 2003) and in vivo (Wang et al., 2006) particularly on dopaminergic activity in the 
ventral tegmental area (VTA).  These studies have shown that TC-2559 causes an 
increase in firing of VTA neuronal dopaminergic cells in a dose-dependent manner {in 
vitro), over the same concentration range that activates a4p2 receptor in recombinant cell 
lines (Chen et al., 2003).  This effect was blocked by a4p2 selective receptor antagonist, 
dihydro-p-erythroidine (DhpE), but not by the al selective receptor antagonist, 
methyllycaconitine (MLA).  In vivo studies observing the effects of TC-2559 on
170spontaneous firing and burst properties of the dopaminergic neurons in the VTA shows 
that TC-2559 mimics nicotine-evoked excitation of VTA dopaminergic neurones.  TC- 
2559 and nicotine’s effects were blocked by DhpE, which implies a4p2 receptors are the 
dominant nAChR mediating nicotinic excitation of VTA dopaminergic neurones in vivo 
(Wang et al., 2006).  Thus TC-2559 is a useful tool for both in vivo (Wang et al., 2006) 
and in vitro (Bencherif et al, 2000) studies of the a4p2 nAChR.  At present, the effects of 
central administration of TC-2559 on the cardiovascular system are unknown.
Another novel agonist is PSAB-OFP (Astra IV) which has been shown to be selective for 
the a7 nicotinic AChR, with studies demonstrating that MLA inhibits PSAB-OFP evoked 
excitation and burst activities of dopaminergic neurons on the VTA  (Broad et al, 2002; 
Wang et al, 2006).  Currently there is limited published data about PSAB-OFP and no 
published data on the effects of central administrations of PSAB-OFP on the 
cardiovascular system.
Thus the effect of selective receptor agonists, TC-2559 and PSAB-OFP, given i.c.v. or 
i.e. were investigated on baseline arterial blood pressure, heart rate and renal sympathetic 
nerve activity in a-chloralose anaesthetised rats, to determine the role of different 
neuronal nAChRs in pathways inflencing these cardiovascular variables.
1713.1.2. Results.
3.1.2.1.  Intracerebroventricular (i.c.v.) administration of 
selective nACh receptor agonists.
Saline i.c.v. (5 jul, saline control, n=5) had little effect on mean arterial blood pressure 
(MAP), heart rate (HR) and renal nerve activity and these variables remained stable for 
the duration of the experiment (20 min).  Baseline values for MAP and HR were 137 ± 14 
mmHg and 380 ± 27 beats min'1  (see Figures 16-19).
3.1.2.1.1.  Effects of PSAB-OFP, a selective al nicotinic receptor 
agonist.
PSAB-OFP (1 pmol kg'1; n=5) had no significant effect on mean arterial blood pressure 
or heart rate, however there was a significant increase in renal nerve activity at 6 min of 
34 ± 7%, reaching a maximum of 70 ± 7% at 10 min (Figure 16).  Baseline values for 
MAP and HR were 122 ± 7 mmHg and 362 ± 44 beats min'1.  PSAB-OFP (3 pmol kg'1, 
n=5) caused a significant pressor response associated with an increase in renal nerve 
activity at 4 min of 22 ± 6 mmHg and 77 + 21%, reaching a maximum of 23 ± 6 mmHg 
and 126 ± 23% after 5 min.  There was no significant change in heart rate.  Baseline 
values for MAP and HR were 124 + 8 mmHg and 356 ± 23 beats min'1  (Figure 17 & 18). 
At the higest dose, 10 pmol kg'1  (n=5), PSAB-OFP caused a significant increase in mean 
arterial blood pressure and renal nerve activity at 4 min reaching 32 ± 9 mmHg and 290 ± 
101% at 6 min and 20 min respectively.  However a tachycardia was now observed at 6 
min reaching a maximum of 43 ± 16 beats min'1  at 20 min (Figure 19).  Baseline values 
for MAP and HR were 126 ± 22 mmHg and 350 ± 23 beats min'1.
1723.1.2.1.2.  Effects of TC-2559, a selective a4p2 nicotinic receptor 
agonist.
TC-2559 (1 jimol kg'1, n=5) had no significant effect on mean arterial blood pressure or 
heart rate, however, there was a significant increase in renal nerve activity at 3 min, 
reaching a maximum of 79 ± 21 % at 8 min (Figure 20).  Baseline values for MAP and 
HR were 120 ±17 mmHg and 368 ± 54 beats min"1.  At 3 pmol kg'1, TC-2559 (n=5) 
caused a significant increase in blood pressure at 3 min of 21 ± 6 mmHg, reaching a 
maximum of 22 ± 3 mmHg at 5 min.  There was a delayed significant increase in renal 
nerve activity at 5 min reaching a maximum of 249 ± 53% at 9 min, as well as, no 
significant change in heart rate apart from an increase at 9 min of 29 ± 9 beats min'1  
(Figure 21 & 22).  Baseline values for MAP and HR were 113 ± 16 mmHg and 366 ± 34 
beats min*1.  At the highest dose, 10 pmol kg1  (n=5), TC-2559 now caused a significant 
fall in mean arterial blood pressure and renal nerve activity, reaching a maximum of -34 
±12 mmHg and -75 ± 10% by 3 min.  The heart rate was unaffected (Figure 23). 
Baseline values for MAP and HR were 135 ± 19 mmHg and 380 ± 14 beats min'1.
173Figure 16.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by PSAB- 
OFP (1  pmol kg'1, i.c.v.) in mean arterial blood pressure (MAP), heart rate (HR) and 
renal nerve activity (RNA).  Each point represents the mean value and the vertical lines 
show s.e.mean.  Changes caused by PSAB-OFP (*) compared with saline using two-way 
analyses of variance followed by the least significant difference test to compare the 
means.  * P<0.05, ** P<0.01 and *** P<0.001.
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175Figure 17.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by PSAB- 
OFP (3 pmol kg'1 , i.c.v.) in mean arterial blood pressure (MAP), heart rate (FIR) and 
renal nerve activity (RNA).  Each point represents the mean value and the vertical lines 
show s.e.mean.  Changes caused by PSAB-OFP (*) compared with saline using two-way 
analyses of variance followed by the least significant difference test to compare the 
means.  * P<0.05, ** P<0.01 and *** PO.OOl.
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Trace showing the effect of PSAB-OFP (3 jimol kg*1, i.c.v.) on blood pressure (BP), integrative renal nerve activity (Int 
RNA) and heart rate (HR) on anaesthetised artificially ventilated and neuromuscular blocked rats.
178Figure 19.  Anaesthetised artificially Ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by PSAB- 
OFP (10 funol kg'1, i.c.v.) in mean arterial blood pressure (MAP), heart rate (HR) and 
renal nerve activity (RNA).  Each point represents the mean value and the vertical lines 
show s.e.mean.  Changes caused by PSAB-OFP (*) compared with saline using two-way 
analyses of variance followed by the least,significant difference test to compare the 
means.  * P<0.05, ** P<0.01 and *** P<0.001.
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comparison of the changes (A) from baseline values over time (min) caused by TC-2559 
(1 pmol kg'1, i.c.v.) in mean arterial blood pressure (MAP), heart rate (HR) and renal 
nerve activity (RNA).  Each point represents the mean value and the vertical lines show 
s.e.mean.  Changes caused by TC-2559 (*) compared with saline using two-way analyses 
of variance followed by the least significant difference test to compare the means.
* P<0.05 and ** P<0.01.
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182Figure 21.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by TC-2559 
(3 jimol kg'1, i.c.v.) in mean arterial blood pressure (MAP), heart rate (HR) and renal 
nerve activity (RNA).  Each point represents the mean value and the vertical lines show 
s.e.mean.  Changes caused by TC-2559 (*) compared with saline using two-way analyses 
of variance followed by the least significant difference test to compare the means. 
*P<0.05 and ** P<0.01.
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Trace showing the effect of TC-2559 (3 pmol kg’1, i.c.v.) on blood pressure (BP), integrative renal nerve activity (Int 
RNA) and heart rate (HR) on anaesthetised artificially ventilated and neuromuscular blocked rats.
185Figure 23.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by TC-2559 
(10 pmol kg'1, i.c.v.,) in mean arterial blood pressure (MAP), heart rate (HR) and renal 
nerve activity (RNA).  Each point represents die mean value and the vertical lines show 
s.e.mean.  Changes caused by TC-2559 {*) compared with saline using two-way analyses 
of variance followed by the least significant difference test to compare the means.
* P<0.05.
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receptor agonists.
Saline i.e. (5 pi, n=5) had little effect on mean arterial blood pressure, heart rate and renal 
nerve activity for the duration of the experiment.  Baseline values for MAP and HR were 
112 ± 13 mmHg and 385 ± 32 beats min'1.
3.1.2.2.1.  Effects of PSAB-OFP, a selective a7 nicotinic receptor 
agonist.
PSAB-OFP (3 pmol kg'1, n=5) caused a significant effect on mean arterial blood pressure 
resulting in a pressor response at 2 min of 36 ± 10 mmHg, reaching a maximum of 38 ± 8 
mmHg at 4 min.  The increase in renal nerve activity was delayed, appearing at 5 min and 
reaching a maximum of 130 ± 30% at 8 min.  The heart rate was unaffected for the 
duration of the experiment (Figure 24 & 25).  Baseline values for MAP and HR were 111 
± 11 mmHg and 387 ± 65 beats min'1.  PSAB-OFP i.e. compared with i.c.v. was shown 
to have no significant difference in renal nerve activity and heart rate.  However for i.e. 
administration the pressor effect was earlier in onset having a significant effect at 2 min 
compared with 4 min for i.c.v. (Figure 24 & 25).
1883.1.2.2.2.  Effects of TC-2559, a selective a4p2 nicotinic receptor 
agonist.
TC-2559 (3 fimol kg'1, n=5; i.e.) had a significant effect on mean arterial blood pressure 
resulting in a pressor response at 2 min of 13 ± 3 mmHg, reaching a maximum of 21 ± 7 
mmHg at 5 min.  The increase in renal nerve activity was delayed, with a significant 
increase at 5 min of 78 ± 34% reaching a maximum of 86 ± 28% at 10 min.  However, a 
tachycardia was now observed at 4 min of 17 ± 5 beats min1  reaching a maximum of 24 
± 4 beats min1  at 7 min (Figure 26 & 27).  Baseline values for MAP and HR were 113 ± 
14 mmHg and 392 ± 59 beats min'1.  TC-2559 administered i.e. compared with TC-2559 
i.c.v. was shown to have no significant difference in mean arterial blood pressure, renal 
nerve activity or heart rate (Figure 26 & 27).
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Figure 24.  Trace showing the effect of PSAB-OFP (3 gmol kg'1, i.e.) on blood pressure (BP), integrative renal nerve activity (Int 
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190Figure 25.  Anaesthetised artificially Ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by PSAB- 
OFP (3 pmol kg'1 , i.e.) and PSAB-OFB (3 pmol kg1, i.c.v.) and saline (5 pi. i.e.) in mean 
arterial blood pressure (MAP), heart rate (HR) and renal nerve activity (RNA).  Each 
point represents the mean value and the-vertical lines show s.e.mean.  Changes caused by 
PSAB-OFB i.c; (*) compared with saline and changes caused by PSAB-OFB i.e. (#) 
compared with PSAB-OFB i.c.v. by using two-way analyses of variance followed by the 
least significant difference test to compare the means.  *, # P<0.05 and ** P<0.01.
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2559 (3 pmol kg'1 , i.e.) and TC-2559 (3 pmol kg'1, i.c.v.) and saline (5 pi. i.e.) in 
mean arterial blood pressure (MAP), heart rate (HR) and renal nerve activity (RNA). 
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T3.1.2.3.  Effects of nicotinic ACh receptor antagonists (i.c.v.) 
on agonist responses.
In the 3 min prior to agonist administration, DhpE (a4j32 nAChR antagonist) and 
MLA (a7 nAChR antagonist) did not have any significant effect on the variables 
being recorded when compared with the saline control.
3.1.2.3.1.  Effects of TC-2559 i.c.v. (a4p2 nicotinic receptor 
agonist) in the presence of DhpE (i.c.v.).
TC-2559 (3 pmol kg'1 , n=5) in the presence of DhpE (10 pmol kg'1) failed to cause a 
significant effect on mean arterial blood pressure and heart rate when compared to 
antagonist control, apart from an increase in heart rate at 20 min.  Renal nerve activity 
was again a delay, the increase now being significant after 4 min (70 ± 16%) 
compared with 5 min for TC-2559 alone (Figure 28).  Interestingly this delayed rise 
was also significantly reduced in the presence of DhpE.  Baseline values for MAP and 
HR were 113 ± 5 mmHg and 361 ± 65 beats min'1.
3.1.2.3.2.  Effects of PSAB-OFP i.c.v. (a7 nicotinic receptor 
agonist) in the presence of DhpE (i.c.v.).
The effects of PSAB-OFP (3 pmol kg'1 , n=5) in the presence of DhpE (10 pmol kg'1) 
where overall unaffected.  Interestingly the rise in mean arterial blood pressure looked 
slightly delayed although this difference was not significant (Figure 29).  Baseline 
values for MAP and HR were 114 ± 13 mmHg and 363 ± 33 beats min'1.
1963.L2.3.3.  Effects of TC-2559 i.c.v. (a4|32 nicotinic receptor 
agonist) in the presence of MLA (i.c.v.).
TC-2559 (3 nmol kg1; n=5) in the presence of MLA (0.5 pmol kg'1) had a very 
similar effect to TC-2559 alone, causing an expected rise in mean arterial blood 
pressure and renal nerve activity at 4 min of 31 ± 8 mmHg and 67 ± 21 %, reaching a 
maximum of 42 ± 11 mmHg and 140 ± 15% after 9 min.  Interestingly, although there 
was larger rise in blood pressure associated with a smaller increase in renal nerve 
activity, when compared to TC-2559 alone these were not significantly different. 
There was no significant change in heart rate for the duration of the experiment 
(Figure 30).  Baseline values for MAP and heart rate were 114 ± 14 mmHg and 373 ± 
34 beats min'1.
3.1.2.3.4.  Effects of PSAB-OFP (a7 nicotinic agonist) in the 
presence of MLA (i.c.v.).
The effects of PSAB-OFP (3 nmol kg-1, n=5) in the presence of MLA (0.5 pmol kg'1) 
were blocked (Figure 31).  Baseline values for MAP and HR were 103 ± 9 mmHg and 
377 ± 43 beats min'1.
197Figure 28.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by TC- 
2559 (3 pmol kg"1, i.c.v.) pre-treated with DhpE (10 pmol kg"1 , i.c.v.) and TC-2559 
alone (3 pmol kg'1 , i.c.v.) and antagonist control (2 doses saline, i.c.v.) in mean 
arterial blood pressure (MAP), heart rate (HR) and renal nerve activity (RNA).  Each 
point represents the mean value and the vertical lines show s.e.mean.  Changes caused 
by TC-2559 (*) pre-treated with DhpE compared with antagonist control and changes 
caused by TC-2559 (#) pre-treated with DhpE compared with TC-2559 alone by 
using two-way analyses of variance followed by the least significant difference test to 
compare the means.  *, # P<0.05 and **, ## P<0.01.
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po  w   &Figure 29.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by PSAB- 
OFP (3 pmol kg'1, i.c.v.) pre-treated with DhpE (10 pmol kg'1, i.c.v.) and PSAB-OFP 
alone (3 pmol kg'1 , i.c.v.) and antagonist control (2 doses saline, i.c.v.) in mean 
arterial blood pressure (MAP), heart rate (HR) and renal nerve activity (RNA).  Each 
point represents the mean value and the vertical lines show s.e.mean.  Changes caused 
by PSAB-OFP (*) pre-treated with DhpE compared with antagonist control by using 
two-way analyses of variance followed by the least significant difference test to 
compare the means.  * P<0.05, ** P<0.01  and *** P<0.001.
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Time (min)Figure 30.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by TC- 
2559 (3 pmol kg'1 , i.c.v.) pre-treated with MLA (0.5 pmol k g 1, i.c.v.) and TC-2559 
alone (3 pmol k g 1 , i.c.v.) and antagonist control (2 doses saline, i.c.v.) in mean 
arterial blood pressure (MAP), heart rate (HR) and renal nerve activity (RNA).  Each 
point represents the mean value and the vertical lines show s.e.mean.  Changes caused 
by TC-2559 (*) pre-treated with MLA compared with antagonist control using two- 
way analyses of variance followed by the least significant difference test to compare 
the means.  * P<0.05, ** P<0.01 and *** P<0.001.
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203Figure 31.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by PSAB- 
OFP (3 pmol kg'1 , i.c.v.) pre-treated with MLA (0.5 pmol kg'1 , i.c.v.) and PSAB-OFP 
alone (3 pmol kg'1, i.c.v.) and antagonist control (2 doses saline, i.c.v.) in mean 
arterial blood pressure (MAP), heart rate (HR) and renal nerve activity (RNA).  Each 
point represents the mean value and the vertical lines show s.e.mean.  Changes caused 
by PSAB-OFP (*) pre-treated with MLA compared with antagonist control and 
changes caused by PSAB-OFP (#) pre-treated with MLA compared with PSAB-OFP 
alone by using two-way analyses of variance followed by the least significant 
difference test to compare the means.  *, # P<0.05 and ## P<0.01.
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205Experiments performed BP RNA HR
a7 agonist
PSAB-OFP lpmol kg1  (i.c.v.) 
PSAB-OFP 3 pmol (i.c.v.) 
PSAB-OFP lOpmol (i.c.v.)
NC BP
— BP (4 min) 
— BP (4 min)
-*t RNA (6 min) 
— R N A  (4 min) 
— R N A  (4 min)
NC HR 
NC HR
— *  T   HR (6 min)
a4f}2 agonist
NC BP
— >1 BP (3 min) 
i BP (2 min)
->t RNA (3 min) 
->T RNA (5 min) 
i  RNA (2 min)
NC HR
— HR (9 min) 
NC HR
TC-2559 lpmol kg'1  (i.c.v.) 
TC-2559 3 pmol (i.c.v.) 
TC-2559 lOpmol (i.c.v.)
a4B2 antagonist
TC-2559 (3 pmol kg'1) with 
DhpE (10 pmol kg' ) i.c.v.
PSAB-OFP (3 pmol kg'1) with 
DhpE (10 pmol kg'1) i.c.v.
NC BP 
-*t BP
-»t RNA (4 min) 
RNA (4 min)
NC HR 
NC HR
a7 antagonist
PSAB-OFP (3 pmol kg'1) with 
MLA (0.5 pmol kg'1) i.c.v.
TC-2559 (3 pmol ke'1) with 
MLA (0.5 pmol kg' ) i.c.v.
NC BP
— * T   BP (4 min)
NC RNA 
— ►  t  RNA (4min)
NC HR 
NC HR
I.e. injections
PSAB-OFP i.e. 3 pmol (i.e.) 
TC-2559 i.e. 3 pmol (i.e.)
T  BP (2 min) 
T  BP (2 min)
RNA (5 min) 
-»t RNA (5 min)
NC HR
— >f HR (4 min)
Table 13.  Overview of experiments performed and the effects induced by
the selective agonists.
NC  -  No change
T   -  Increase
I  -  Decrease
— *   -  Delay
BP  -  Blood pressure
HR  -  Heart rate
RNA  -  Renal nerve activity
2063.1.3.  Discussion.
The a7 nAChR selective agonist PSAB-OFP (Broad et al., 2002) at 1   umol kg'1  i.c.v. 
was observed to evoke a delayed increase in renal nerve activity from 6 min; however 
there was no significant change in blood pressure or heart rate.  At 3 and 10 pmol kg' 
*, PSAB-OFP caused a dose-related increase in blood pressure and renal nerve 
activity, these responses were observed to be delayed occurring after 4 min. 
Interestingly, there was observed a significant increase in heart rate at the highest dose 
of PSAB-OFP after 6 min.  Administration of PSAB-OFP (3 pmol kg1) into the 
hindbrain by i.e. injection caused a faster and larger rise in blood pressure than PSAB- 
OFP administered i.c.v. at the same dose.  Interestingly, the increase in renal nerve 
activity now did not parallel the increase in blood pressure but was still delayed, 
occurring after 5 min.  Heart rate was unaffected.  In the presence of the a7 selective 
antagonist, MLA (0.5 pmol kg'1, i.c.v.) (Ward etal., 1990), the increase in blood 
pressure and renal sympathoexcitation were now blocked.  Further actions of PSAB- 
OFP (3 pmol kg'1, i.c.v.) in the presence of a4(32 selective antagonist DhpE (10 pmol 
kg'1, i.c.v) (Bencherif et a ly  2000), at a dose known to block these receptors (see 
later), were unaffected.  These studies confirm that the effect of PSAB-OFP are due to 
the activation of a7 nAChR and do not involve directly or indirectly the a4p2 
receptors.  Thus the effect of activating central al receptors is to increase blood 
pressure.  For the i.c.v. injection this is associated with a parallel increase in renal 
sympathetic nerve activity but no change in heart rate.  However for the i.e. route the 
renal sympathoexcitation was delayed compared with the pressor response.  Thus 
overall it is difficult to conclude that the rise in blood pressure is due to an increase in 
sympathetic nerve activity assuming that RNA is representive of all sympathetic 
nerve activity.  Although it is possible that there has been an increase in sympathetic 
nerve activity to resistance vessels, it is also possible that the rise may be related to 
the central release of a pressor hormone such as vasopressin (see section 1.17.1).
The present experiments also indicate that activation of central a4p2 nACh receptors 
can increase blood pressure.  The lowest dose of the selective a4g2 agonist TC-2559 
(1  pmol kg1, i.c.v.) evoked a delayed increase in renal nerve activity occurring after 3 
min, associated with no significant change in blood pressure or heart rate.  However
207the next dose (3 nmol kg1) did cause a delayed rise in blood pressure associated with 
an increase in renal nerve activity but heart rate was unaffected.  The highest dose of 
TC-2559 (10 pmol kg'1; i.c.v.) elicited quite oppiste effects from the lower doses 
there being a delayed fall in blood pressure and renal nerve activity, associated with 
no overall change in heart rate.  However, giving TC-2559 i.e., at the intermediate 
dose, had a similar effect to i.c.v. administration although the pressor effect had a 
slightly earlier onset, the increase in renal nerve activity was still delayed but now 
there was also a delayed tachycardia.  The effect of the middle dose of i.c.v. TC-2559 
on blood pressure was blocked by i.c.v. a4J32 selective antagonist DhpE and the 
increase in renal nerve activity was attenuated, confirming that these effects are 
mainly mediated by central a4p2 receptors.  This was confirmed by studies that the 
effects of TC-2559 i.c.v. were not blocked in the presence of an effective dose (see 
above) of the a7 antagonist MLA (i.c.v.).  However, there was a larger rise in blood 
pressure which was associated with a smaller increase in renal nerve activity, 
although these effects were not significant when compared to TC-2559 i.c.v. alone. 
There were no significant changes in heart rate for the duration of the experiment. 
Again, as with the action of PSAB-OFP, the rise in blood pressure cannot be clearly 
attributed to a increase in sympathetic nerve activity to resistance vessels as it is again 
also possible that the rise may be related to the central release of a pressor hormone 
such as vasopressin (see section 1.17.1.).  However, additional possible explainations 
for these observed cardiovascular changes may involved a increase in baroreceptor 
activity due to the increase in BP, which would inhibit renal nerve activity and 
account for the delayed increase in renal nerve activity.  The activation of both 
receptor subtypes surprisingly has a similar action on the cardiovascular variables. 
Interestingly the high dose of TC-2559 had a completely opposite effect, which may 
suggest activation of another type of nAChR.  Thus activation of either a7 or a4p2 
receptors causes a rise in blood pressure associated with renal sympathoexcitation. 
When these receptors are activated via the i.c.v. route these effects are delayed 
whereas via the i.e. route the onset of the rise in blood pressure is earlier, while the 
rise in renal nerve activity was similarly delayed.  Overall the data suggests that these 
receptors are activating a common central cardiovascular regulatory pathway, 
although independently.
208Sites of Action
The location of a7 nAChR in the human and rat brain is shown in Table 9 & 10.  a7 
mRNA is found around and close to the area of the lateral 3rd ventricle, with moderate 
to high a7 mRNA expression in and around the hypothalamus (Wada et al., 1989). 
Therefore, PSAB-OFP i.c.v. may be mediating its effects at the level of the 
hypothalamus which has been shown to modulate renal sympathetic outflow, 
especially the PVN (Coote et al, 1998; Yang & Coote, 1998).  However the pressor 
response and renal sympathoexcitation evoked by PSAB-OFP i.c.v. was not a rapid 
onset and instead required at least 4 min for a significant increase in blood pressure 
and renal nerve activity to be observed.  Another possible area is the hindbrain which 
contains major areas involved in cardiovascular regulation such as the NTS and 
ventrolateral medulla, (see Dampney, 1994; see Sun, 1995).  Previous studies have 
shown a7 expression in both the NTS and RVLM of the rat (Ferreira et al., 2000; 
2002; Wada et al., 1989).  The faster onset of the effects of PSAB-OFP given i.e. and 
that they were similar in profile to that of i.c.v. injections suggests that PSAB-OFP 
has to reach the brainstem to cause its effects.  In this respect microinjection of 
nicotine into the NTS and CVLM results in a depressor response which was blocked 
by a7 nAChR antagonists MLA and a-BgT (Aberger et al., 2001; Dhar et al, 2000; 
Ferreira et al., 2000; 2002).  However, as PSAB-OFP caused a rise in blood pressure 
this is not consistent with an action at these sites.  Another area is the RVLM, which 
is the site of sympathetic premotor neurons (Amendt et al., 1978; Brown & Guyenet, 
1984; Ross et al., 1984).  Although a selective agonist has not been applied directly to 
the RVLM, studies involving microinjection of nicotine demonstrated a large pressor 
response, similar to PSAB-OFP administered i.c., as well as, a tachycardia (Tseng et 
al., 1993; 1994).  These finding suggest that PSAB-OPF could be acting on the 
RVLM inducing an increase in sympathetic tone causing vasoconstriction of blood 
vessels resulting in an increase in blood pressure, which is associated with an increase 
in renal sympathetic nerve activity.  However, although PSAB-OFP i.c. evokes a 
rapid increase in blood pressure, the onset of renal sympathoexcitation is still delayed. 
This was not significantly different from the pattern of response when PSAB-OFP 
was given i.c.v. which has suggested that the increase in blood pressure is 
independent of the renal sympathoexcitation.  These findings, as indicated above, 
suggest that an increase in sympathetic tone to resistance vessels may not be the
209mechanism for the increase in blood pressure and that the increase in renal nerve 
activity could be a separate action of the nAChR.
A possible mechanism for the PSAB-OFP-evoked pressor effect may be the release of 
vasopressin.  Several studies have indicated that a7 nAChR are found close to and 
within the PVN and SON of the hypothalamus (Wada et al, 1989; Zaninetti et al., 
2000).  Axons from the neurons found in the PVN and SON terminate in the posterior 
pituitary where vasopressin is released into the systemic circulation (see Howl & 
Wheatley, 1995; see Kombian et al, 2002).  Nicotine administered i.c.v. and i.c. 
causes a significant increase in the release of vasopressin (Bisset et al, 1975; Bisset & 
Feldberg, 1973; Bisset & Chowdrey, 1984).  It was observed that nicotine was more 
effective at inducing vasopressin release when applied to the hindbrain rather than the 
forebrain (Bisset et al., 1975).  In this respect, it has been hypothesised that a nicotinic 
cholinergic pathway from the NTS, projects to the neurosecretory cells (PVN), which 
releases vasopressin from the posterior pituitary (Bisset et al., 1975; Bisset & 
Chowdrey., 1984).  Additional pathways have also been suggested from PVN - 
secretory vasopressin cells to the RVLM which are believed to be involved in 
cardiovascular regulation (Cheng et al., 2004; Coote et al, 1998; Yang & Coote, 
1998).
Administration of vasopressin i.c.v. in conscious and anaesthetised rats was reported 
to cause a significant increase in blood pressure associated with a significant increase 
in sympathetic nerve activity (Unger et al., 1984).  Furthermore, vasopressin 
microinjected in to the NTS and RVLM caused a significant increase in blood 
pressure which was inhibited by a Via receptor antagonist (Cheng et al., 2004; Unger 
et al, 1984).  Thus it is possible that PSAB-OFP is causing the release of vasopressin 
both peripherally and/or centrally which results in the increase in blood pressure and 
renal sympathetic nerve activity.
As TC-2559 causes a similar effect to PSAB-OFP, the arguments for the site of action 
and mechanism made above for PSAB-OFP would equally apply to TC-2559.
Further, autoradiography of nAChRs has indicated the presence of a4p2 nACh 
receptors at the vasopressin releasing cells PVN and SON, as well as, in the hindbrain
210areas such as the ventrolateral medulla and NTS (Dominguez del et al, 1994; 
Swanson et al, 1987; Wada et al, 1989).
Selectivity of TC-2559
Interestingly, at the highest dose of TC-2559 (10 nmol kg'1, i.c.v.) instead of a dose- 
related increase in blood pressure, renal nerve activity and heart rate, there was a 
significant depressor response associated with a significant decrease in renal nerve 
activity suggesting a different receptor mechanism modulates this response.  In vitro 
studies of TC-2559 have shown that although TC-2559 is selective to a4p2 with an 
EC50 = 0.18 pM, the selectivity of TC-2559 changes to a2p4, a3p4, a4p2 and a4p4 at 
an EC50 = 10-30 pM (Chen et al, 2003).  Therefore the increased dose of TC-2559 
could activate these additional receptors to cause a decrease in blood pressure and 
sympathoinhibition.  Present knowledge dose not enable identification of the site 
where this action might occur.
Overall, the present interpretation of the data is that activation of a7 and a4p2 nACh 
receptors are causing a rise in blood pressure probably due to the release of 
vasopressin from the neurohypophysis by an action mediated via the lower brainstem. 
The mechanism and site for renal sympathoexcitation remains unclear.
2113.2.  The role of vasopressin in the cardiovascular action
caused by activation of central nAChRs by selective 
agonists.
3.2.1.  Introduction.
Nicotine administered by i.c.v. injections causes the release of vasopressin in rats 
(Bisset & Chowdrey, 1984; Iitake et al., 1980) and cats (Bisset et al., 1975; Castro de 
Souza & Silva, 1977), with up to a thirty fold increase in the concentration of 
vasopressin in the blood collected (Bisset & Feldberg, 1973).
Radioligand binding and immunoreactivity studies have demonstrated that there is a 
high density of a7 nAChR in the hypothalamus, especially near or on the PVN and 
SON areas (Wada et al., 1989) involved in vasopressin release. 
Intracerebroventricular injections of choline, which has been suggested to be a 
relatively selective agonist for the al nAChR(Albuquerque et al, 1997;Papke et al, 
1996), produced a dose-dependent increase in plasma vasopressin in conscious rats 
(Bisset et al., 1975).  This suggests that i.c.v. injections of nicotine are acting on a7 
nAChR on or near the PVN and SON, causing the release of vasopressin. 
Interestingly, studies have demonstrated that i.c. injections of nicotine have a greater 
effect than i.c.v. injections on releasing vasopressin in the cat. This was due to 
nicotine acting at the level of rostral ventrolateral medulla (RVLM) not, as supposed, 
at the level of the paraventricular nucleus (PVN) to cause release of vasopressin 
(Bisset et al., 1975).  This was also confirmed for the rat, with the i.c. route being 
more effective than the i.c.v. route (Bisset & Chowdrey, 1984; Souza and Silva Jr, 
1977).
Furthermore, central vasopressinergic pathways have also now been identified.  For 
instance, stimulation of the PVN has been shown to cause a five-fold increase in 
vasopressin in the NTS (Landgraf et al., 1990).  Further, vasopressin in pre-synaptic 
terminals have been shown in the NTS (Buijs & Van Heerikhuize, 1982).  In addition,
212binding sites for vasopressin have also has been located in the NTS (Dorsa et al, 
1983), as the presence of functioning V) receptors (Gao et al., 1992).  These data 
suggest that vasopressin input may influence central homoeostatic integrative 
functioning of NTS neurons.  The source of vasopressin input into the NTS has been 
shown to come from the PVN (Buijs et al., 1978; Nilaver et al, 1980; Sawchenko & 
Swanson, 1982; Sofroniew & Schrell, 1980; van der et al., 1984).  Therefore, this 
vasopressinergic projection to the NTS is of major importance because it constitutes a 
pathway by which the PVN could directly modulate baroreceptor function (Michelini, 
1994).  The NTS, as well as receiving a monosynaptic projection from the PVN, has 
been shown to send projections to the PVN and SON and cause the release of 
vasopressin (Buijs et al, 1978; Nilaver et al., 1980; Sawchenko & Swanson, 1982; 
Sofroniew & Schrell, 1980).  This provides a feedback control loop through which the 
PVN could modulate afferent cardiovascular inputs coming from the periphery to the 
NTS (see Michelini, 1994).
Attempts have been made to determine the function of vasopressin as a 
neurotransmitter in the NTS.  Microinjections of vasopressin into the NTS has shown 
to elicit a dose-related increase in blood pressure and heart rate in anaesthetised rats 
(Matsuguchi et al., 1982; Vallejo et al., 1984).  Further vasopressin administration 
into the NTS in conscious rats also had a pressor effect (King & Pang, 1987).
Evidence also exists supporting the suggestion that local vasopressin at the level of 
the NTS may act to moderate the baroreceptor reflex.  Application of a Vi receptor 
antagonist within the NTS was demonstrated to attenuate baroreflex mediated 
decreases in renal nerve sympathetic activity (RNSA) (Hegarty & Felder, 1995) and 
to impair baroreflex regulation of heart rate in response to large changes in arterial 
pressure (Michelini & Bonagamba, 1988).  Furthermore, studies also found that 
microinjection of a Vi receptor antagonist into the commissural NTS caused a small 
but significant decrease in heart rate (Lowes et al., 1993).  Additional studies have 
shown that these Vi receptors in the NTS mediate neuronal excitation (Raggenbass et 
al., 1989).  Interesting, studies have shown that around 82% of NTS neurons 
receiving baroreceptor inputs responded to vasopressin, of these neurons over 60% 
exhibited excitatory responses, supporting the view that vasopressin acting on these 
neurons is able to play significant roles in modulating the baroreceptor reflex 
(Hegarty & Felder, 1997).
213The present experiments are carried out to determine the role of vasopressin in the 
cardiovascular responses to activation of central al and a4(32 nAChRs.  This was 
done by investigating the effect of the selective vasopressin Vi antagonist ([|3- 
Mercapto-P,P-Cyclopentamethylenepropionyl 1,0-Me-Tyr2,Arg8]-Vasopressin, 
(d(CH2)5Tyr(Me)AVP)) given i.c.v., i.c. or i.v. on the responses evoked by central 
administration (i.c.v. or i.c.) of selective nACh receptor agonists TC-2559 and PSAB- 
OFP.
3.2.2.  Results.
3.2.2.1.  Effects of selective nACh receptor agonists given
i.c.v. in the presence of the V] receptor antagonist 
(i.v.).
Injection i.v. of the Vi receptor antagonist d(CH2)5Tyr(Me)AVP (30 pg kg'1; n=5) 
failed to have any effect on the baseline variables being recorded compared with 
control (see methods for full protocol).
Saline (5 pi, i.c.v.; n=5) in the presence of the V j receptor antagonist (30 pg kg'1; i.v., 
n=5) had no effect on mean arterial blood pressure, heart rate and renal nerve activity 
for the duration of the experiment.  Baseline values for MAP and HR were 106 ± 12 
mmHg and 385 ± 20 beats min'1.
2143.2.2.1.1.  Effects of PSAB-OFP i.c.v. in the presence of the Vi 
receptor antagonist (i.v.).
The expected effects evoked by PSAB-OFP (3 pmol kg1, n=5) in the presence of the 
Vi receptor antagonist (30 pg kg"1) were completely blocked, i.e. there was no 
increase in mean arterial blood pressure, renal nerve activity and heart rate when 
compared to Vi receptor antagonist control (Figure 32).  Baseline values for MAP and 
HR were 108 ± 15 mmHg and 397 ± 36 beats min'1.
3.2.2.1.2.  Effects of TC-2559 i.c.v. in the presence of the Vi 
receptor antagonist (i.v.).
The expected pressor and large delayed renal sympathoexcitation evoked by TC-2559 
(3 pmol kg'1 , n=5) in the presence of the Vi receptor antagonist (30 pg kg'1) were also 
blocked.  However, the tendency of renal nerve activity to increase between 2 and 4 
min now became significant, reaching a maximum of 30 ± 6% after 3 min (Figure 
33).  Baseline values for MAP and HR were 108 ± 10 mmHg and 378 ± 32 beats 
min'1.
3.2.2.2.  Effects of selective nACh receptor agonists given i.c. 
in the presence of the Vi receptor antagonist (i.v.).
Saline (5pl, i.e.; n=5) in the presence of Vi antagonist (30 pg kg'1; i.v.) had little or no 
effect on mean arterial blood pressure, heart rate and renal nerve activity for the 
duration of the experiment.  Baseline values for MAP and HR were 117 ± 5 mmHg 
and 403 ± 23 beats min'1.
2153.2.2.2.1.  Effects of PSAB-OFP i.c. in the presence of the V i 
receptor antagonist (i.v.).
Again the expected pressor and sympathoexcitatory response evoked by PSAB-OFP 
(3 pmol kg"1, n=5) was blocked, however there was now a small but significant fall in 
blood pressure of-13 ± 3 mmHg after 2 min (Figure 34) and a parallel non-significant 
decline in heart rate.  Baseline values for MAP and HR were 107 ± 27 mmHg and 396 
± 43 beats min"1.
3.2.2.2.2.  Effects of TC-2559 i.c. in the presence of the V! 
receptor antagonist (i.v.).
The expected effects evoked by TC-2559 (3 pmol kg'1, n=5) in the presence of the Vi 
receptor antagonists (30 pg kg"1 ) were overall similar in profile.  However the initial 
rise in mean arterial blood pressure was now very variable and did not become 
significant until after 5 min, reaching 33 ± 10 mmHg at 8 min while the increase in 
renal nerve activity again was delayed not becoming significant until 6 min reaching 
80 ± 38% at 8 min.  The expected tachycardia was unaffected (Figure 35).  Baseline 
values for MAP and FIR were 109 ± 6 mmHg and 404 ±41 beats min"1.
216Figure 32.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by PSAB- 
OFP (3 pmol kg'1 , i.c.v.) pre-treated with vasopressin Vj receptor antagonist 
d(CH2)sTyr(Me) AVP (30 pg k g 1 , i.v.) and PSAB-OFP alone (3 pmol kg'1 , i.c.v.) and 
control (Vi antagonist & saline, 5 pi, i.c.v.) in mean arterial blood pressure (MAP), 
heart rate (HR) and renal nerve activity (RNA).  Each point represents the mean value 
and the vertical lines show s.e.mean.  Changes caused by PSAB-OFP (#) pre-treated 
with Vi antagonist compared with PSAB-OFP alone by using two-way analyses of 
variance followed by the least significant difference test to compare the means.
# P<0.05, ## P<0.01  and ### P<0.001.
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218Figure 33.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by TC- 
2559 (3 pmol kg'1, i.c.v.) pre-treated with vasopressin Vi receptor antagonist 
d(CH2)5Tyr(Me) A VP (30 pg kg1 , i.v.) and TC-2559 alone (3 pmol kg'1, i.c.v.) and 
control (Vi antagonist & saline, 5 pi, i.c.v.) in mean arterial blood pressure (MAP), 
heart rate (HR) and renal nerve activity (RNA).  Each point represents the mean value 
and the vertical lines show s.e.mean.  Changes caused by TC-2559 (*) pre-treated 
with Vi antagonist compared with antagonist control and changes caused by TC-2559 
(#) pre-treated with Vi antagonist compared with TC-2559 alone by using two-way 
analyses of variance followed by the least significant difference test to compare the 
means.  *, # P<0.05 and ## P<0.01.
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220Figure 34.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by PSAB- 
OFP (3 pmol kg'1, i.c.) pre-treated with vasopressin Vi receptor antagonist 
d(CH2)5Tyr(Me) A VP (30 pg kg'1 , i.v.) and PSAB-OFP alone (3 pmol kg'1 , i.c.) and 
control (Vi antagonist & saline, 5 pi, i.c.) in mean arterial blood pressure (MAP), 
heart rate (FIR) and renal nerve activity (RNA). Each point represents the mean value 
and the vertical lines show s.e.mean.  Changes caused by PSAB-OFP (*) pre-treated 
with Vi antagonist compared with antagonist control and changes caused by PSAB- 
OFP (#) pre-treated with Vi antagonist compared with PSAB-OFP alone by using 
two-way analyses of variance followed by the least significant difference test to 
compare the means.  *, # P<0.05 and ## P<0.01.
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iFigure 35.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by TC- 
2559 (3 pmol kg'1, i.e.) pre-treated with vasopressin Vi receptor antagonist 
d(CH2)sTyr(Me) AVP (30 pg kg'1, i.v.) and TC-2559 alone (3 pmol k g 1, i.e.) and 
control (Vj antagonist & saline, 5 pi, i.e.) in mean arterial blood pressure (MAP), 
heart rate (HR) and renal nerve activity (RNA).  Each point represents the mean value 
and the vertical lines show s.e.mean.  Changes caused by TC-2559 (*) pre-treated 
with Vi antagonist compared with antagonist control and changes caused by TC-2559 
(#) pre-treated with Vi antagonist compared with TC-2559 alone by using two-way 
analyses of variance followed by the least significant difference test to compare the 
means.  *, # P<0.05, **, ## P<0.01  and *** P<0.001.
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203.2.2.3.  Effects of vasopressin i.v. in the presence of the Vi 
receptor antagonist given i.c.v.
Vasopressin alone (cumulative dose; 1,3, 10, 30 ng kg'1, i.v., n=7) was shown to 
cause a dose-related increase in mean arterial blood pressure reaching a maximum of 
43 ± 3 mmHg at 30 ng.  In the presence of Vj receptor antagonist given i.c.v (0.03 pg 
kg'1 ), the effect of i.v. vasopressin was unaffected (Figure 36).
3.2.2.4.  Effects of selective nACh receptor agonists given 
i.c.v. in the presence of the V) receptor antagonist 
given i.c.v.
Saline (i.c.v. 5pi, n=5) had little or no effect on mean arterial blood pressure, renal 
nerve activity and HR, when in the presence of Vi receptor antagonist (i.c.v.; 0.03 pg 
kg'1; Figure 37).  Baseline values for MAP and HR were 106 ± 12 mmHg and 385 ± 
20 beats  min'1.
3.2.2.4.I.  Effects of PSAB-OFP i.c.v. in the presence of the Vi
receptor antagonist (i.c.v.).
The expected delayed pressor and renal sympathoexcitation evoked by PSAB-OFP (3 
pmol kg'1 , n=5) was blocked by the Vi receptor antagonist (0.03 pg kg'1) given i.c.v. 
(Figure 37).  However, there was now observed a small but significant delayed fall in 
mean arterial blood pressure at 7 min reaching a maximum of -10 ± 2 mmHg at 20 
min.  Baseline values for MAP and HR were 113 ± 9 mmHg and 401 ± 40 beats 
min1.
2253.2.2A.2.  Effects of TC-2559 i.c.v. in the presence of the V i 
receptor antagonist (i.c.v.).
The expected pressor, sympathoexcitation and delayed tachycardia evoked by 
TC-2559 (3 pmol kg'1 , n=5) in the presence of Vi receptor antagonist (0.03 pg kg'1) 
given i.c.v. were blocked (Figure 38).  Baseline values for MAP and HR were 109 ± 
16 mmHg and 387 ± 24 beats min'1.
3.2.2.5.  Effects of vasopressin i.v. presence of the Vi 
receptor antagonist given i.e.
Vasopressin alone (cumulative dose; 1,3, 10, 30 ng kg'1 , i.v., n=7) in rats was shown 
to cause a dose-related increase in mean arterial blood pressure, reaching a maximum 
of 39 ± 7 mmHg at 30 ng.  In the presence of Vi receptor antagonist given i.c (0.03 pg 
kg'1), the effect of i.v. vasopressin was unaffected (Figure 39).
3.2.2.6.  Effects of selective nACh receptors agonists given 
i.c. in the presence of the V\ receptor antagonist 
given i.c.
Saline (i.e., 5pl, n=5) had no effect on mean arterial blood pressure, renal nerve 
activity and heart rate in the presence of Vi receptor antagonist (0.03 pg kg'1; i.c., 
Figure 40 & 41).  Baseline values for MAP and HR were 117 ± 5 mmHg and 403 ±
23 beats min'1.
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Figure 36.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) caused by vasopressin (cumulative dose;  1,3, 10 & 30 
ng kg ', i.v.) pre-treated with vasopressin Vi receptor antagonist d(CH2)sTyr(Me)
A VP (0.03 pg kg'1 , i.c.v.) and vasopressin alone (cumulative dose;  1,3, 10 & 30 ng 
kg'1 , i.v.) on mean arterial blood pressure (MAP).  Each point represents the mean 
value and the vertical lines show s.e.mean.
227Figure 37.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by PASB- 
OFP (3 pmol kg'1, i.c.v.) pre-treated with vasopressin Vi receptor antagonist 
d(CH2)5Tyr(Me) AVP (0.03 pg kg'1 , i.c.v.) and PSAB-OFP alone (3 pmol kg'1 , i.c.v.) 
and control (V) antagonist & saline, 5 pi, i.c.v.) in mean arterial blood pressure 
(MAP), heart rate (HR) and renal nerve activity (RNA). Each point represents the 
mean value and the vertical lines show s.e.mean.  Changes caused by PASB-OFP (*) 
pre-treated with Vj antagonist compared with antagonist control and changes caused 
by PASB-OFP (#) pre-treated with V) antagonist compared with PASB-OFP alone by 
using two-way analyses of variance followed by the least significant difference test to 
compare the means.  *, # P<0.05, **, ## P<0.01  and ***, ### P<0.001.
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229Figure 38.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by TC- 
2559 (3 pmol kg"1, i.c.v.) pre-treated with vasopressin Vi receptor antagonist 
d(CH2)5Tyr(Me) AVP (0.03 pg kg'1, i.c.v.) and TC-2559 alone (3 pmol kg"1 , i.c.v.) 
and control (Vi antagonist & saline, 5 pi, i.c.v.) in mean arterial blood pressure 
(MAP), heart rate (HR) and renal nerve activity (RNA).  Each point represents the 
mean value and the vertical lines show s.e.mean.  Changes caused by TC-2559 (#) 
pre-treated with V) antagonist compared with TC-2559 alone by using two-way 
analyses of variance followed by the least significant difference test to compare the 
means.  # P<0.05 and ## P<0.01.
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2313.2.2.6.1.  Effects of PSAB-OFP i.c. in the presence of the V i 
receptor antagonist (i.e.).
The expected pressor effect evoked by PSAB-OFP (3 pmol kg'1, n=5) in the presence 
of Vi receptor antagonist (0.03 pg kg'1) given i.c was reversed and a significant 
decrease in mean arterial pressure was observed after 3 min, reaching a maximum of 
-11 ± 2 mmHg at 5 min, returning to baseline by the end of the experiment (Figure 40 
& 41).  The expected maintained sympathoexcitation was blocked although a 
significant transient increase in renal nerve activity occurred after 1  min of 48 ± 18%. 
Heart rate now tended to decrease, instead of increasing over the period of the 
experiment; however the effect was not significant.  Baseline values for MAP and HR 
were 111 ± 8 mmHg and 367 ± 37 beats min1.
3.2.2.6.2.  Effects of TC-2559 i.c. in the presence of the Vj 
receptors antagonist (i.e.).
The expected pressor, delayed sympathoexcitation and tachycardia evoked by 
TC-2559 (3 pmol kg'1 , n=5) was blocked by Vi receptor antagonist (0.03 pg kg'1) 
given i.c. (Figure 42).  However, again there was an initial significant increase in 
renal nerve activity at 1   min of 32 ± 6%; this was then followed by a significant 
decrease at 9 min reaching a maximum of -46 ± 15 % at 10 min (Figure 42).  Baseline 
values for MAP and HR were 108 ± 13 mmHg and 393 ± 35 beats min'1.
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Figure 39.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) caused by vasopressin (cumulative dose; 1,3, 10 & 30 
ng kg ', i.v.) pre-treated with vasopressin Vi receptor antagonist d(CH2)5Tyr(Me)
A VP (0.03 pg kg'1 , i.c.) and vasopressin alone (cumulative dose;  1,3, 10 & 30 ng kg' 
\  i.v.) on mean arterial blood pressure.  Each point represents the mean value and the 
vertical lines show s.e.mean.
233Figure 40.
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Trace showing the effect of PSAB-OFP (3 pmol kg'1, i.c.) in the presence of V] receptor antagonist (0.03 pg kg'1, i.e.) on blood 
pressure (BP), integrative renal nerve activity (Int RNA) and heart rate (HR) on anaesthetised artificially ventilated and 
neuromuscular blocked rats.
234Figure 41.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by PSAB- 
OFP (3 pmol kg'1, i.c.) pre-treated with vasopressin Vi receptor antagonist 
d(CH2)sTyr(Me) AVP (0.03 pg kg’1, i,c.) and PSAB-OFP alone (3 pmol k g 1, i.c.) and 
control (Vi anta & saline, 5 pi, i.c.) in mean arterial blood pressure (MAP), heart rate 
(HR) and renal nerve activity (RNA).  Each point represents the mean value and the 
vertical lines show s.e.mean.  Changes caused by PSAB-OFP (*) pre-treated with Vi 
antagonist compared with antagonist control and changes caused by PSAB-OFP (#) 
pre-treated with Vi antagonist compared with PSAB-OFP alone by using two-way 
analyses of variance followed by the least significant difference test to compare the 
means.  *  # P<0.05, **, ## P<0.01  and ***, ### P<0.001A
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Time (min)Figure 42.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by TC- 
2559 (3 pmol kg'1 , i.c.) pre-treated with vasopressin Vi antagonist d(CH2)5Tyr(Me)
A VP (0.03 pg kg'1, i.c.) and TC-2559 alone (3 pmol kg'1, i.c.) and control (Vi anta & 
saline, 5 pi, i.c.) in mean arterial blood pressure (MAP), heart rate (HR) and renal 
nerve activity (RNA).  Each point represents the mean value and the vertical lines 
show s.e.mean.  Changes caused by TC-2559 (*) pre-treated with Vi antagonist 
compared with antagonist control and changes caused by TC-2559 (#) pre-treated 
with Vi antagonist compared with nicotine alone by using two-way analyses of 
variance followed by the least significant difference test to compare the means.
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238Experiments performed BP RNA HR
VI antagonist i.v.
PSAB-OFP (3 pmol kg1) i.c.v. 
with Vi antagonist (30 pg kg'1)
NC BP NC RNA NC HR
TC-2559 (3 pmol kg'1) i.c.v. with 
Vi  antagonist (30 pg kg'1)
NC BP NC RNA NC HR
PSAB-OFP (3 pmol kg'1) i.c. with 
Vi antagonist (30 pg k g ')
1 BP (2 min) NC RNA NC HR
TC-2559 (3 pmol kg1) i.c. with 
Vi  antagonist (30 pg kg1 ) -» T  BP (8 min) NCRNA NC HR
VI antagonist i.c.v.
PSAB-OFP (3 pmol kg1) i.c.v. 
with Vj antagonist (0.03 pg kg1)
->1 BP (7 min) NC RNA NC HR
TC-2559 (3 pmol kg'1) i.c.v. with 
Vi antagonist (0.03 pgkg'1)
NC BP NCRNA NC HR
VI antagonist i.c.
PSAB-OFP (3 pmol kg*1) i.c. with 
Vi antagonist (0.03 pg kg'1)
jBP (3 min)
NC RNA (apart 
T   at 1  min)
NC HR 
NC HR
TC-2559 (3 pmol kg'1) i.c. with 
Vi antagonist (0.03 pg kg'1)
NC BP
NC RNA (apart 
T   at 1  min)
Table 14.  Overview of experiments performed and the effects induced by
the selective agonists in the presence of Vi receptor antagonist.
NC  -  No change
T   -  Increase
I  -  Decrease
—>   -  Delay
BP  -  Blood pressure
HR  -  Heart rate
RNA  -  Renal nerve activity
2393.2.3.  Discussion.
Present experiments demonstrated that pre-treatment i.v. with a Vi receptor antagonist 
at doses known to block the effects of vasopressin i.v. (Anderson et al., 1992) blocked 
the expected delayed increase in blood pressure and renal nerve activity evoked by the 
a7 selective receptor agonist PSAB-OFP and the a4|32 selective agonist, TC-2559 
given i.c.v.  These observations indicate that the cardiovascular effects via the i.c.v. 
route are mediated by the release of vasopressin into the circulation.  However if these 
agonist were given by the i.c. route in the presence of the V) receptor antagonist i.v., 
although the expected effects of PSAB-OFP i.c. were blocked, PSAB-OFP now 
caused a fall in blood pressure.  While for TC-2559 the profile of the effects observed 
were similar but due to the large initial variability in the increase in blood pressure 
this now only reached significant after 5 mins.  Similarly the increase in renal nerve 
activity was delayed.  This latter observation is not consistent with view that the 
effects of i.c. TC-2559 are mediated by the release of vasopressin into the circulation, 
although the data is consistent for PSAB-OFP and in fact indicates that when the 
vasopressin released is blocked, activation of al nAChRs at the level of brainstem can 
also cause a fall in blood pressure.  Interestingly, this data suggests that the renal 
sympathoexcitation observed is also caused by the release of vasopressin into the 
circulation.
The interpretation of the above data is made under the assumption that the vasopressin 
antagonist does not enter the brain when given i.v., although it can enter areas such as 
the area postrema, found above the NTS, and subfornical organ, found above the 
pituitary, (Johnson & Gross, 1993)(Figure 43) and may be involved in the release of 
vasopressin into the circulation.  However, if the V) vasopressin antagonist is given 
centrally (i.c.v. or i.c.) in doses that do not leak out into the periphery, as indicated by 
the observation that the pressor responses to i.v. vasopressin are not blocked, then the 
pressor and renal sympathoexcitatory effects of PSAB-OFP and TC-2559 are nearly 
completely blocked.  The block of central selective agonist effects when in the 
presence of the V) receptor antagonist suggests that the selective agonists are inducing 
their effects via the central release of vasopressin.  However, the mechanism of action 
of central release of vasopressin inducing the increase in blood pressure and RNA is
240unclear although it shold be noted that vasopressin may be involved in a central 
pathway which evokes the release of vasopressin into the circulation to cause the 
increase in blood pressure, rather than causing an increase in sympathetic drive to 
resistance vessels or both.  Thus the precise mechanism behind the pressor response 
remains to be determined although it does initially, at least, involve the central release 
of vasopressin and from the published data on the central administration of nicotine 
(see section 1.16.) this would imply that these agonists are also causing the release of 
vasopressin into the peripheral.
Sites of Action.
As previously mentioned in Chapter 3.1, the delayed rise in blood pressure upon i.c.v. 
injections and the faster and higher rise in blood pressure upon i.c. injections, 
suggested that the selective agonists are not acting at the forebrain but instead evoking 
their effects by acting on areas in the hindbrain.  Therefore, if the increase in blood 
pressure is due to vasopressin release, or by the activation of a central 
vasopressinergic pathway, then this implies that the site at which the selective 
agonists, PSAB-OFP and TC-2559, act on a7 and a4p2 nAChRs is not at the level of 
PVN but at hindbrain sites such as the NTS and RVLM.  In this respect, vasopressin- 
containing terminals have been identified in these areas (Buijs & Van Heerikhuize, 
1982; Nilaver et al., 1980; Sawchenko & Swanson, 1982; Van der Kooy et al., 1984) 
as well as, Vi receptors (Cheng et al., 2004; Dogterom et al., 1978; Phillips et al., 
1988a; 1988b; Tribollet et al., 1988).  In addition nicotine can also activate neuronal 
projection from the NTS and RVLM (Cl region) to the PVN and SON (Matta et al., 
1993), thus causing vasopressin release into the circulation.  Furthermore, studies by 
Bisset et al. (1975) demonstrated that nicotine was more effective at inducing 
vasopressin release when applied to the hindbrain rather than at the forebrain.
Overall, it is suggested that selective agonists PSAB-OFP and TC-2559 are acting on 
al and a4(32 nAChR at the hindbrain aeas such as the RVLM and NTS.  Activation of 
these cardiovascular regulating areas stimulates the release of vasopressin, via a 
neuronal projection to the PVN, into the circulation.  This pathway from the hindbrain 
to the PVN is believed to involve vasopressin, possibly acting as a excitatory
241neurotransmitter between the synapse of the RVLM to the PVN, as a similar pathway 
has been observed from the PVN to the RVLM (Yang et al., 2001).
Figures 43 and 44 represent a possible mechanism of action for selective agonists 
administered in the rat brain.  Selective agonists i.c.v. do not act directly on the PVN 
to cause the release of vasopressin, or if any vasopressin is released it is not 
stimulating a noted effect.  The selective agonists pass to the hindbrain were they bind 
to a7 or a4J32 nAChRs in the NTS and/or RVLM, stimulating the pathway to the 
PVN.  This results in the release of vasopressin into the periphery inducing an 
increase in blood pressure (Figure 43).  Further, selective agonists administered i.c. 
are able to cause a faster and greater rise in blood pressure than i.c.v. injections, due 
to the selective agonists being closer to the RVLM site, therefore more of the agonist 
is able to bind to nAChRs and stimulate the neurons projecting to the PVN (Figure 
44), resulting in a greater amount of vasopressin released into the circulation.
Renal Sympathoexcitation.
The present experiments demonstrate that the renal sympathoexcitation is mediated 
also by the release of vasopressin.  However, is this due to vasopressin released into 
periphery which feeds back onto brain areas involved in cardiovascular regulation or 
due to activation of central neuronal pathways?  In this respect the renal 
sympathoexcitatory effect had a similar delay whether the selective nAChR agonists 
are given i.c. or i.c.v., that of 4 minutes favouring such an interpretation.  This 
feedback could be occurring at the level of area postrema which has been shown to 
contain Vi receptors and pathways to cardiovascular regulating areas of the brain such 
as the nucleus tractus solitarius (Shapiro & Miselis, 1985).  Another possible 
circumventricular organ site that vasopressin is able to feedback into the brain is by 
acting on the subfornical organ (SFO), possibly via Via receptors, which is located in 
the forebrain, lacks a blood brain barrier and projects to the PVN (Ferguson et al., 
1984; Li & Ferguson, 1993; Tanaka etal., 1986; Tanaka & Seto, 1988). This is quite 
an intriguing observation as it implies that vasopressin can affect the kidney directly 
by action on the collecting ducts and by the sympathetic drive to the kidney which can 
also be involved in sodium excretion as well as renin release and vasoconstriction.
242These hypothesised pathways and feedback mechanisms producing the effects 
described of the selective nAChR agonists are illustrated in Figures 43 and 44.  There 
are two possible mechanisms of action that may account for the effect of vasopressin 
on renal nerve activity.  1), Upon vasopressin release into the circulation, by the 
selective agonists, vasopressin feeds back on to the PVN through the SFO, stimulating 
the neuronal projection from the PVN to the RVLM.  The activation of this pathway 
stimulates the RVLM which results in an increase in sympathetic tone and an increase 
in renal sympathetic nerve activity.  2) Instead of the vasopressin feeding back on to 
the PVN, the site of action is the area postrema, which has a direct innervation of the 
NTS (Shapiro & Miselis, 1985), and possibly the RVLM, resulting in the increase in 
renal nerve activity.
The feedback of vasopressin onto the PVN resulting in the increase of renal nerve 
activity is the most plausible mode of action due to previous studies demonstrating 
that the PVN is able to induce sympathoexcitation in stress (Badoer, 2001; Blair et al., 
1996), as well as, stimulation of the PVN leading to an increase in blood pressure, 
heart rate and renal nerve activity (Coote et al, 1998).  The PVN causes 
sympathoexcitation both via direct projection to sympathetic pre-ganglionic neurons 
in the IML, and via collateral projections to neurons of the RVLM that sends 
excitatory input to the IML (Coote et a l,  1998; Shafton et al, 1998).  The excitatory 
input from the PVN to the RVLM may be mediated by vasopressin; acting via Vi 
receptors (see Dampney et al, 2003; Yang et al, 2001).
Cardiovascular effects not involving vasopressin.
Interestingly, both agonists when given i.c. in the presence of Vi receptor antagonist 
i.c. cause a transient sympathoexcitation after 1  min.  This is paralleled by a transient 
non-significant increase in blood pressure.  A possible site for this is the RVLM, as 
microinjections of nicotine caused pressor responses and a tachycardia (Tseng et al, 
1993; 1994).  The transient nature is also surprising unless an additional depressor 
circuit is also being activated to mask this effect and this could be claimed at least for 
PSAB-OFP where a fall in blood pressure is observed after 2 min and is paralleled by 
a non-significant decline in heart rate but no change in renal nerve activity.
243Interestingly, the delayed decline in blood pressure is also observed with PSAB-OFP 
given i.c.v. in the presence of the Vi receptor antagonist also given i.c.v., however no 
initial renal sympathoexcitation was observed.  Again the data suggests that this fall in 
blood pressure is mediated by a7 nAChRs located in the hindbrain.  In this respect, 
microinjection of nicotine into the NTS has been observed to cause a significant 
decrease in blood pressure, which was inhibited by a7 nAChR selective antagonist 
MLA and a-BgT, implying the involvement of a7 nAChR (Dhar et al, 2000; Ferreira 
etal, 2000; Ferreira, Jr. et al., 2002; Whiteaker et al., 1998).
Thus it is concluded that the major central cardiovascular effects of activating a7 and 
a4p2 nACh receptors occur at the level of brainstem and is mediated by activation of 
central pathways which leads to the release of vasopressin into the periphery.  This in 
turn can feedback and cause additional effects such as renal sympathoexcitation. 
However, there are also other actions but these are overwhelmed by the release of 
vasopressin centrally and peripherally.
244Figure 43.  Diagrammatic representation of the pathways involved upon i.c.v.
injection of a4p2 selective agonist TC-2559 and a7 selective agonist 
PSAB-OFP in the rat brain.
1)  Selective agonists are injected into the rat brain via i.c.v. injection.
2)  The selective agonists do not come into direct contact with the PVN 
and instead move through the brain until they come into contact with 
the hindbrain.
3)  The selective agonists bind with nAChR found in the RVLM and 
possibly the NTS.
4)  Stimulation of the RVLM by the selective agonists activates the PVN 
via a neuron projection.
5)  The vasopressinergic pathway stimulates the PVN to act on the 
posterior pituitary and release vasopressin;
6)  Release of vasopressin into the circulation, via the blood stream, 
results in the increase in blood pressure by acting on Vja receptors 
found on blood vessels causing vasoconstriction.
7)  Vasopressin feeds back onto areas of the brain lacking a blood brain 
barrier, i.e. circumventricular organs, particularly the subfornical organ 
and area postrema (AP).
8 & 9)  Vasopressin feedback onto the PVN stimulates the RVLM and results 
in an increase in renal nerve activity.
10)  Vasopressin may also be acting via the AP, which either stimulates the 
RVLM directly resulting in a increase in renal nerve activity, or;
11)  Via a pathway to the NTS, this relays to the RVLM, resulting in an 
increase in renal nerve activity.
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246Figure 44.  Diagrammatic representation of the pathways involved upon i.c. injection 
of a4p2 selective agonist TC-2559 and a7 selective agonist PSAB-OFP in 
the rat brain.
1)  Selective agonists are injected into the rat brain via i.c. injection.
2)  The selective agonists come into direct contact with hindbrain areas and 
acts on the RVLM, and possibly the NTS.
3)  Stimulation of the RVLM by the selective agonists activates the PVN via a 
neuronal projection.
4)  The stimulation of the PVN results in the release of vasopressin, from the 
posterior pituitary, into the circulation via the blood stream.
5)  Vasopressin release causes the increase in blood pressure by acting on VJa 
receptors, found on blood vessels, resulting in vasoconstriction.
6)  Vasopressin feeds back onto areas of the brain lacking a blood brain 
barrier, i.e. circumventricular organs, particularly the subfornical organ 
and area postrema (AP).
7 & 8)  Feedback of vasopressin onto the PVN stimulates the RVLM via a 
feedback pathway and results in an increase in renal nerve activity.
9)  Vasopressin may also be acting via the AP, which either stimulates the 
RVLM directly resulting in a increase in renal nerve activity, or;
10)  Via a neuron projectionto the NTS, this relays to the RVLM, resulting in 
an increase in renal nerve activity.
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2483.3.  Effect of central administration of nicotine and non- 
selective agonists on cardiovascular regulation.
3.3.1.  Introduction.
Intracerebroventricular (i.c.v.) injections of nicotine in anaesthetised rats caused a rise in 
blood pressure and a rise in the release of vasopressin (Bisset & Chowdrey, 1984).  In 
conscious rats, i.c.v. injections of nicotine were demonstrated to cause a pressor response 
associated with a consistent bradycardia and an increase in vasopressin release (Iitake et 
al., 1980; Hoffman, 1979).
Due to the unselective nature of nicotine on neuronal nAChRs, it is not possible to 
determine the precise nAChR subtypes involved in these effects, although studies have 
shown the pressor response to be attenuated by a non-selective nicotinic antagonist, 
hexamethonium (i.v.), in both anaesthetised (Bisset & Chowdrey, 1984) and conscious 
rats (Iitake et al., 1980; Hoffman, 1979).  These studies demonstrated that neuronal 
nAChRs mediate the cardiovascular effects of nicotine, applied to the forebrain region by 
i.c.v injection, although the non-selective nature of the antagonist provides no 
information on the neuronal nAChR involved.
The effects of nicotine on the hindbrain were shown in studies of intracistemal (i.e.) 
injections of nicotine in anaesthetised rats which resulted in a decrease in blood pressure 
(Bisset & Chowdrey, 1984; Kubo & Misu, 1981) that was attenuated by the nicotinic 
antagonist, hexamethonium.  Decreases in blood pressure were also demonstrated by 
topical application of nicotine to the brainstem of anaesthetised cats (Feldberg & 
Guertzenstein, 1976; Bisset et al., 1975).  Again, the depressor response to topical 
applications of nicotine was inhibited by hexamethonium, suggesting that neuronal 
nAChR mediate the cardiovascular effects of nicotine.
249Although there is no published information available for the central actions of selective 
neuronal nAChR agonists on cardiovascular systems, other than those in Chapters 1 and 
3, there are current studies providing some insight to neuronal nACh receptor 
involvement in cardiovascular effects.  Intracerebroventricular injections of choline, a 
precursor of neurotransmitter ACh and believed to be a relatively selective endogenous 
receptor agonist for the a7 nAChR (Albuquerque et al., 1997; Papke et al., 1996), 
produced a dose-related increase in blood pressure in both anaesthetised and conscious 
rats (Savci et al., 2002 ; Li & Buccafusco, 2004).  The pressor response produced by 
choline was inhibited by nAChR a7 selective antagonist, MLA.  In contrast, a4p2 
selective antagonist, Dh0E, and muscarinic antagonist, atropine, failed to significantly 
inhibit this choline-evoked pressor response (Li & Buccafusco, 2004).  These studies 
support the notion that choline is causing the pressor response due to activation of a7 
nAChR and not a4p2.  However, additional studies in conscious rats reported that the 
pressor response produced by choline is attenuated by mecamylamine, believed to be a 
relatively selective antagonist for the a3p4 nACh receptor (Aberger et al., 2001), again 
atropine was observed to have no affect (Savci et al., 2002).  This suggests that the a3p4 
nAChR may also be involved in the pressor response observed by i.c.v. injection of 
choline.
Currently there are a number of neuronal nACh receptor agonists, which have been 
demonstrated to be more selective to specific nAChR subtypes than nicotine.  One such 
agonist is cytisine (see Table 2, 4 & 5), the EC50 value for a4p2 is similar to that of 
nicotine, however studies have demonstrated that cytisine has a high functional potency 
at the a3p4 nAChR, with an EC50 value of 0.9 pM, which is greater than that of nicotine, 
which has an EC50 of 80 pM (Alkondon & Albuquerque, 1993; Luetje & Patrick, 1991). 
Futher studes demonstrated that cytisine had selective tendencies to a2p4, a3p4 and a4p4 
nAChRs suggesting that cytisine may be selective to neuronal nAChR subunits 
containing a p4 subunit (Alkondon & Albuquerque, 1993; Chavez-Noriega et al., 1997; 
see Colquhoun & Patrick, 1997).  Cytisine administered by i.c.v. injection has been 
reported to cause the release of vasopressin, suggesting that receptor/s containing the p4 
subunit may cause the release of vasopressin (Bisset & Fairhall, 1995).
250The present study has been carried out to determine which nAChRs are involved in the 
central cardiovascular responses to nicotine and other unselective agonists cytisine and 
DMPP.  The agonists will be tested against two neuronal nACh receptor antagonists 
DhfE, which is selective for the a402 receptor (Chavez-Noriega et al., 2000; 
Gopalakrishnan et al., 1996), and ML  A, which is selective for the al nACh receptor 
(Macallan et al., 1988; Turek et al., 1995; Ward et al., 1990).  The effective blocking 
doses for these antagonists have been determined (Chapter 3.1).  Additional experiments 
were carried out using the vasopressin V) antagonist ([f3-Mercapto-p,{3- 
Cyclopentamethylenepropionyl^O-Me-Tyr^Arg8]-Vasopressin, (d(CH2)sTyr(Me)AVP)), 
administered peripherally and centrally by i.v., i.c.v. and i.e. injections in the presence of 
nicotine, administered by i.c.v. and i.e. injection, to determine if by blocking the effects 
of vasopressin release, caused by nicotine, other central cardiovascular effects of nicotine 
can be uncovered.
2513.3.2. Results.
3.3.2.1.  Effects of i.c.v. administration of nicotine, DMPP and 
cytisine.
Saline i.c.v. (5 pi, saline control, n=5) had no effect on mean arterial blood pressure, 
heart rate and renal nerve activity for the duration of the experiment.  Baseline values for 
MAP and HR were 137 ± 14 mmHg and 380 ± 27 beats min'1  (Figures 45 - 48).
3.3.2.1.1.  Effects of Nicotine.
Nicotine (0.1 pmol kg*1, n=5) had no significant affect (P > 0.05) on mean arterial blood 
pressure, heart rate and renal nerve activity (Figure 45).  Baseline values for MAP and 
HR were 123 ± 15 mmHg and 361 ± 34 beats min1.  Nicotine (0.3 pmol kg'1, n=5) 
caused a significant increase in mean arterial blood pressure after 2 min reaching a 
maximum of 11 ±2 mmHg at 4 min, this was paralleled by a significant decrease in renal 
nerve activity at 2 min reaching a maximum of -57 ± 2% at 3 min.  Both mean arterial 
blood pressure and renal nerve activity returned to near baseline after 15 min.  There was 
no significant change in heart rate throughout the duration of the experiment (Figure 46 
& 47).  Baseline values for MAP and HR were 121 ± 12 mmHg and 388 ± 38 beats min'1. 
1  pmol kg'1  of nicotine (n=5), again caused, a significant increase in mean arterial blood 
pressure associated with a significant decrease in renal nerve activity after 1  min, 
reaching a maximum of 25 ± 9 mmHg and -76 ± 5% after 3 min (Figure 48).  Again 
returning to near baseline after 15 min.  Heart rate was unaffected for the duration of the 
experiment (Figure 48).  Baseline values for MAP and HR were 133 ± 29 mmHg and 370 
± 40 beats min'1.
252Figure 45.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by nicotine 
(0.1  pmol kg'1, i.c.v.) and saline (5 pi. i.c.v., n=5) in mean arterial blood pressure (MAP), 
heart rate (HR) and renal nerve activity (RNA).  Each point represents the mean value 
and the vertical lines show s.e.mean.  Changes caused by nicotine (*) compared with 
saline using two-way analyses of variance followed by the least significant difference test 
to compare the means.
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Figure 46.  Trace showing the effect of nicotine (0.3 nmol kg'1, i.c.v.) on blood pressure (BP), integrative renal nerve activity (Int 
RNA) and heart rate (HR) on anaesthetised artificially ventilated and neuromuscular blocked rats.
255Figure 47.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by nicotine 
(0.3 jumol kg-1, i.c.v.) and saline (5 pi. i.c.y., n=5) in mean arterial blood pressure 
(MAP), heart rate (HR) and renal nerve activity (RNA).  Each point represents the mean 
value and the vertical lines show s.e.me&n.  Changes caused by nicotine (*) compared 
with saline using two-way analyses of variance followed by the least significant 
difference test to compare the means  * P<0.05, ** P<0.01 and *** PO.OOl.
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comparison of the changes (A) from baseline values over time (min) caused by nicotine 
(1 pmol kg-1, i.c.v.) and saline (5 pi. i.c.v., n=5) in mean arterial blood pressure (MAP), 
heart rate (HR) and renal nerve activity (RNA).  Each point represents the mean value 
and the vertical lines show s.e.mean.  Changes caused by nicotine (*) compared with 
saline using two-way analyses of variance followed by the least significant difference test 
to compare the means.  * P<0.05, ** P<0.01 and *** P<0.001.
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2593.3.2.1.2.  Effects of DMPP.
DMPP (0.1 and 0.3 jimol kg'1 , n=5) had no significant effect on mean arterial blood 
pressure, heart rate and renal nerve activity (Figure 49 & 50).  DMPP at 1  pmol kg'1  
(Figure 51; n=5) caused a significant pressor response at 2 min reaching a maximum of 9 
± 1 mmHg at 4 min.  Renal nerve activity was also significantly increased by 5 min 
reaching a maximum of 50 ± 6% at 6 min.  Heart rate was unaffected for the duration of 
the experiment.  Baseline values for MAP and HR were 113 ± 5 mmHg and 381 ±30 
beats min'1.
3.3.2.1.3.  Effects of Cytisine.
Cytisine (1 pmol kg'1, n=5) failed to affect mean arterial blood pressure for the duration 
of the experiment.  However, there was a significant decrease in renal nerve activity at 1  
min of -19 ± 10%, reaching a maximum of -47 ± 9% at 4 min and a significant 
bradycardia at 15 min reaching a maximum of-18 ± 6 at 20 min (Figure 52).  Baseline 
values for MAP and HR were 121 ± 14 mmHg and 388 ± 36 beats min1.  At 3 pmol kg'1  
(n=5), cytisine caused a significant pressor response associated with a significant 
decrease in renal nerve activity at 1  min, of 20 ± 7 mmHg and -45 ± 12%, reaching a 
maximum of 34 ± 6 mmHg and -81 ± 5% after 3 min.  Heart rate was unaffected for the 
duration of the experiment (Figure 53 & 54).  Baseline values for MAP and HR were 118 
± 14 mmHg and 412 ± 73 beats min'1.
260Figure 49.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by DMPP 
(0.1  pmol kg'1 , i.c.v.) in mean arterial blood pressure (MAP), heart rate (HR) and renal 
nerve activity (RNA).  Each point represents the mean value and the vertical lines show 
s.e.mean.
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comparison of the changes (A) from baseline values over time (min) caused by DMPP 
(0.3 pmol kg1, i.c.v.) in mean arterial blood pressure (MAP), heart rate (HR) and renal 
nerve activity (RNA).  Each point represents the mean value and the vertical lines show 
s.e.mean.
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264Figure 51.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by DMPP (1 
pmol kg'1, i.c.v.) in mean arterial blood pressure (MAP), heart rate (HR) and renal nerve 
activity (RNA).  Each point represents the mean value and the vertical lines show 
s.e.mean.  Changes caused by DMPP (*) compared with saline using two-way analyses of 
variance followed by the least significant difference test to compare the means.
* P<0.05, ** P<0.01 and *** P<0.001
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266Figure 52.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by cytisine (1 
pmol kg'1 , i.c.v.) in mean arterial blood pressure (MAP), heart rate (HR) and renal nerve 
activity (RNA).  Each point represents the mean value and the vertical lines show 
s.e.mean.  Changes caused by cytisine (*) compared with saline using two-way analyses 
of variance followed by the least significant difference test to compare the means.
* P<0.05, ** PO.Ol and *** PO.OOl.
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Figure 53.  Trace showing the effect of cytisine (3 nmol kg'1, i.c.v.) on blood pressure (BP), integrative renal nerve activity (Int 
RNA) and heart rate (HR) on anaesthetised artificially ventilated and neuromuscular blocked rats.
269Figure 54.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by cytisine (3 
jimol kg-1, i.c.v.) in mean arterial blood pressure (MAP), heart rate (HR) and renal nerve 
activity (RNA).  Each point represents the mean value and the vertical lines show 
s.e.mean.  Changes caused by cytisine (*) compared with saline,using two-way analyses 
of variance followed by the least significant difference test to compare the means.
* P<0.05, ** P<0.01 and *** PO.OOl.
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2713.3.2.2.  Effects of i.e. administration of nicotine.
Saline i.e. (5 pi, n=5) had little effect on mean arterial blood pressure, heart rate and renal 
nerve activity for the duration of the experiment.  Baseline values for MAP and heart rate 
were 112 ± 13 mmHg and 385 ± 32 beats min1  (Figure 56).
3.3.2.2.1.  Effects of nicotine (i.e.).
Nicotine (0.3 pmol kg'1, n=5) in saline pre-treated rats, caused a delayed increase in mean 
arterial blood pressure with a significant increase at 4 min of 27 + 6 reaching a maximum 
of 30 ± 4 mmHg at 5 min.  However, by 1 min both renal nerve activity and heart rate 
were significantly decreased by -74 ± 12% and -46 ± 7 beats min'1  reaching a maximum 
of, -90 ± 3% and -46 ± 7 beats min'1  at 2 and 1  min respectively (Figure 55 & 56). 
Baseline values for MAP and heart rate were 116 ± 12 mmHg and 405 ± 34 beats min'1.
Nicotine i.e. had a significant difference in mean arterial blood pressure and heart rate 
when compared with nicotine administered i.c.v.  Nicotine i.e. resulted in blood pressure 
being potentiated in duration and pressure, from 4 min, when compared with nicotine 
i.c.v.  There was observed a significant difference at 2 and 3 min when heart rate was 
compared between i.e. and i.c.v. injections.
3.3.2.3.  Effects of nicotinic antagonist (i.c.v.) on nicotine.
In the 3 min prior to agonist administration, DhpE (10 pmol kg'1) and MLA (1 pmol kg'1) 
did not have any significant effect on the variables being recorded when compared with 
the saline control.
272In antagonist control experiments (n=5) where saline was given i.c.v. instead of Dh(3E or 
MLA (see methods for full protocol), nicotine had the same effects (Figure 57) on 
baseline values as described above.  Baseline values for MAP and HR were 113 ± 10 
mmHg and 393 ±51 beats min'1.
3.3.2.3.1.  Effects of nicotine i.c.v. in the presence of DhpE 
(i.c.v.).
In the presence of DhpE (10 pmol kg'2 ) the expected rise in blood pressure and renal 
sympathoinhibition evoked by nicotine (0.3 pmol kg'1 , n=5) were blocked (Figure 58). 
However there was now a significant increase in renal nerve activity after 2 min of 35 ±
11%, reaching a maximum of 44 ± 7% at 4 min.  Again heart rate was unaffected. 
Nicotine pre-treated with DhpE compared with nicotine alone, showed a significant 
difference in mean arterial blood pressure from 3 min and a significant change in renal 
nerve activity from 1  min with nicotine in the presence of DhpE causing 
sympathoexcitation, unlike nicotine alone which causes sympathoinhibition.  The heart 
rate was unaffected for the duration of the experiment (Figure 58).
3.3.2.3.2.  Effects of nicotine i.c.v. in the presence of MLA 
(i.c.v.).
In the presence of MLA (1 pmol kg1) the expected evoked rise in mean arterial blood 
pressure caused by nicotine was blocked.  Renal sympathoinhibition was still observed 
however its onset was delayed significantly, requiring 4 min to cause a decrease of -51 ± 
11% (Figure 59), compared to 1  min in the absence of MLA.  Interestingly mean arterial 
blood pressure and heart rate tended to decrease but this effect was not significant. 
Baseline values for MAP and HR were 117 ± 11 mmHg and 338 ± 83 beats min"1
273Figure 55.
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Trace showing the effect of nicotine (0.3 nmol kg'1 , i.e.) on blood pressure (BP), integrative renal nerve activity (Int 
RNA) and heart rate (HR) on anaesthetised artificially ventilated and neuromuscular blocked rats.
274Figure 56.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by nicotine 
(0.3 fimol kg'1, i.e.) and nicotine (0.3 umol kg'1 , i.c.v.) and saline (5 pi. i.e.) in mean 
arterial biood pressure (MAP), heart rate (HR) and renal nerve activity (RNA).  Each 
point represents the mean value and the vertical lines show s.e.mean.  Changes caused by 
nicotine i.e. (*) compared with saline and changes caused by nicotine i.e. (#) compared 
with nicotine i.c.v. using two-way analyses uf variance followed by the least significant 
difference test to compare the means.  *, ## P<0.05, **, ## P<0.01 and *** P<0 001.
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control (7 doses salinv,  i.c.v.) in  mean arterial blood pressure (MAP), heart rate (HR) and 
renal nerve activity (RNA).  Each point represent? the usean  value and the  veuical  hues 
show s t‘ im-mi  Cli.an.ges caused by time matched nicotine (*) compared with control by 
using two-way analyses of variance followed by  the least significant -difference test to 
tuinpdtc me  mcaiib.  * P<0.05,  **  P<0.01  and ***  PO.OOl.
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278Figure 58.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by nicotine 
(0.3 pmol kg'1, i.c.v.) pre-treated with Dh|3E (10 pmol kg'1, i.c.v.) and nicotine alone (0.3 
pmol kg'1, i.c.v.) and antagonist control (2 doses saline, i.c.v’) in mean arterial blood 
pressure (MAP), heart rate (HR) and renal nerve activity (RNA). Each point represents 
the mean value and the vertical lines show s.e.mean.  Changes caused by nicotine (*) pre­
treated with DhpE compared with antagonist control and changes caused by nicotine (#) 
pre-treated with DhpE compared with nicotine alone by using two-way analyses of 
variance followed by the least significant difference test to compare the means.
*, # P<0.05, **, M  PO.Ol and ***, ### PO.OOl.
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280Figure 59.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by nicotine 
(0.3 pmol kg'1 , i.c.v.) pre-treated with MLA (1  pmol kg*1 , i.c.v.) and nicotine alone (0.3 
pmol kg"1, i.c.v.) and antagonist control (2 doses saline, i.c.v.) in mean arterial blood 
pressure (MAP), heart rate (HR) and renal nerve activity (RNA).  Each point represents 
the mean value and the vertical lines show s.e.mean.  Changes caused by nicotine (*) pre- 
treated with MLA compared with antagonist control and changes caused by nicotine (#) 
pre-treated with MLA compared with nicotine alone using two-way analyses of variance 
followed by the least significant difference test to compare the means.  *, # P<0.05 and 
**,##P<0.01.
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2823.3.2.4.  The effects of blockade of vasopressin by a V! receptor
antagonist on the response of centrally applied nicotine. 
3.3.2.4.1.  Nicotine i.c.v. in the presence of the Vi receptor 
antagonist (i.v.).
In the presence of Vi receptor antagonist (30 pg kg'1; i.v.) the nicotine (0.3 pmol kg'1, 
n=5) evoked rises in mean arterial blood pressure and heart rate as well as the renal 
sympathoinhibition were blocked (Figure 60).  Baseline values for MAP and HR were 
113 ± 12 mmHg and 375 ± 53 beats min'1.
3.3.2.4.2.  Nicotine i.e. in the presence of the Vi receptor 
antagonist (i.v.).
In the presence of Vi receptor antagonist (30 pg kg'1; i.v.) the expected delayed evoked 
rise in mean arterial blood pressure by nicotine (0.3 pmol kg'1, n=5) was blocked and 
now a fall in mean arterial blood pressure was observed, reaching a maximum of -25 ± 2 
mmHg after 3 min and returning to baseline by 4 min.  Surprisingly the expected 
sympathoinhibition and bradycardia were unaffected reaching a maximum -67 ± 14 beats 
min'1  and -93 ± 1% after 2 mins (Figure 61).  Baseline values for MAP and HR were 103 
± 8 mmHg and 381 ± 46 beats min'1.
283Figure 60.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by nicotine 
(0.3 pmol kg'1 , i.c.v.) pre-treated with vasopressin V) receptor antagonist 
d(CH2)5Tyr(Me) AVP (30 pg kg'1 , i.v.) and nicotine alone (0.3 pmol k g 1, i.c.v.) and 
control (Vi anta & saline, 5 pi, i.c.v.) in mean arterial blood pressure (MAP), heart rate 
(HR) and renal nerve activity (RNA).  Each point represents the mean value and the 
vertical lines show s.e.mean.  Changes caused by nicotine (#) pre-treated with V) 
antagonist compared with nicotine alone by using two-way analyses of variance followed 
by the least significant difference test to compare the means.  # P<0.05, ## P<0.01  and 
###P<0.001.
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285Figure 61.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by nicotine 
(0.3 pmol kg'1 , i.e.) pre-treated with vasopressin V) antagonist d(CH2)5Tyr(Me) A VP (30 
pg k g 1 , i.v.) and nicotine alone (0.3 pmol kg'1, i.e.) and control (Vi anta & saline, 5 pi, 
i.e.) in mean arterial blood pressure (MAP), heart rate (HR) and renal nerve activity 
(RNA).  Each point represents the mean value and the vertical lines show s.e.mean. 
Changes by nicotine (*) pre-treated with Vi antagonist compared with antagonist control 
and changes caused by nicotine (#) pre-treated with Vi antagonist compared with nicotine 
alone by using two-way analyses of variance followed by the least significant difference 
test to compare the means.  *, # P<0.05, **, ## P<0.01  and *** P<0.001.
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2873.3.2.5.  Central administration of a V! receptor antagonist on 
nicotine administered centrally.
3.3.2.5.1.  Nicotine i.c.v. in the presence of the Vi receptor 
antagonist (i.c.v.).
In the presence of Vi receptor antagonist (0.03 pg kg"1 ), nicotine (0.3 pmol kg"1, n=5) still 
caused a significant increase in mean arterial blood pressure at 2 min reaching a 
maximum of 11 ± 3 mmHg at 3 min, however the associated expected renal 
sympathoinhibition was blocked (Figure 62 & 63).  Heart rate was unaffected.  Baseline 
values for MAP and HR were 106 ± 16 mmHg and 390 ±18 beats min"1
3.3.2.5.2.  Effects of nicotine i.c in the presence of the Vi receptor 
antagonist (i.e.).
In the presence of Vi receptor antagonist (0.03 pg kg'1; i.c.) nicotine’s (0.3 pmol kg'1, 
i.e.; n=5) expected evoked delayed depressor action was blocked.  The expected decline 
in renal nerve activity was still observed although this was significantly attenuated, 
declining only by -49 ± 17% after 2 min, as was the bradycardia which reached a 
maximum of-17 ± 4 beats min"1  after at 2 min returning to baseline by 5 min (Figure 64). 
Baseline values for MAP and HR were 116 ± 7 mmHg and 392 ± 37 beats min"1.
288Figure 62.
Nicotine (i.c.v.) pre-treated with Vi antagonist (i.c.v.) 
1=  500  I
(V  E  t
X  400 •  _______   T  .   .  -  .
IB  '  " T...."  1   ■   -   ‘  1   ‘      "  -
^   <*nn J
50
Trace showing the effect of nicotine (0.3 junol kg*1, i.c.v.) in the presence of Vi receptor antagonist (0.03 pg kg'1, 
i.c.v.) on blood pressure (BP), integrative renal nerve activity (Int RNA) and heart rate (HR) on anaesthetised 
artificially ventilated and neuromuscular blocked rats.
289Figure 63.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by nicotine 
(0.3 pmol kg'1, i.c.v.) pre-treated with vasopressin Vi receptor antagonist 
d(CH2)5Tyr(Me) AVP (0.03 pg kg'1, i.c.v.) and nicotine alone (0.3 pmol kg*1, i.c.v.) and 
control (Vi  anta & saline, 5 pi, i.c.v.) in mean arterial blood pressure (MAP), heart rate 
(HR) and renal nerve activity (RNA).  Each point represents the mean value and the 
vertical lines show s.e.mean.  Changes caused by nicotine (*) pre-treated with Vi 
antagonist compared with antagonist control and changes caused by nicotine (#) pre­
treated with Vi antagonist compared with nicotine alone by using two-way analyses of 
variance followed by the least significant difference test to compare the means.
*, # P<0.05, **, m P<0.01  and ***, ### PO.OOl.
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291Figure 64.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by nicotine 
(0.3 pmol kg'1, i.c.) pre-treated with vasopressin Vi receptor antagonist d(CH2)5Tyr(Me) 
AVP (0.03 pg kg'1, i.c.) and nicotine alone (0.3 pmol kg'1 , i.c.) and control (Vi anta & 
saline, 5 pi, i.c.) in mean arterial blood pressure (MAP), heart rate (HR) and renal nerve 
activity (RNA).  Each point represents the mean value and the vertical lines show 
s.e.mean.  Changes caused by nicotine (*) pre-treated with Vi antagonist compared with 
antagonist control and changes caused by nicotine (#) pre-treated with Vi antagonist 
compared with nicotine alone by using two-way analyses of variance followed by the 
least significant difference test to compare the means.  *, # P<0.05 and ## P<0.01.
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(0.03 pg kg'1,i.e., n=5)Table 15. Overview of experiments performed and the effects induced by the 
nicotine.
NC  -  No change
T   -  Increase
i   -  Decrease
— >   -  Delay
BP  -  Blood pressure
HR  -  Heart rate
RNA  -  Renal nerve activity
294Experiments performed BP RNA HR
Nicotine 0.1 nmol kg'1  (i.c.v.) 
Nicotine 0.3 nmol kg'1  (i.c.v.) 
Nicotine 1  nmol kg'  (i.c.v.)
NC BP
-> T   BP (3 min) 
-* T   BP (3 min)
NCRNA 
1  RNA (2 min) 
1  RNA (2 min)
NC HR 
NC HR 
NC HR
Cytisine 1 nmol kg'1  (i.c.v.) 
Cytisine 3 nmol kg'1  (i.c.v.)
NC BP 
T   BP (1 min)
1  RNA(1 min) 
1  RNA(1 min)
— >j HR (15 
min)
NC HR
DMPP 0.1 nmol kg'1  (i.c.v.) 
DMPP 0.3 nmol kg'1  (i.c.v.) 
DMPP 1  nmol kg'  (i.c.v.)
NC BP 
NC BP 
T   BP (2 min)
NCRNA 
NCRNA 
— R N A  (5 min)
NC HR 
NC HR 
NC HR
Nicotine 0.3 nmol kg'1  i.c. — BP (4 min) i   RNA (1 min) I   HR (2 min)
a4B2 antagonist i.c.v.
Nicotine (0.3 nmol kg'1) i.c.v. 
with DhfE (10 nmol kg'1 )
NC BP T  RNA NC HR
al antagonist i.c.v.
Nicotine (0.3 nmol kg'1) i.c.v. 
with MLA (1 nmol kg'1 )
NC BP RNA (4 min) NC HR
VI antagonist i.v.
Nicotine (0.3 nmol) i.c.v. with 
Vi antagonist (30 ng kg'1 )
Nicotine (0.3 nmol) i.c. with 
Vi antagonist (30 ng kg'1 )
NC BP 
i  BP (2 min)
NC RNA 
1 RNA (2 min)
NC HR 
I   HR (2 min)
VI antagonist i.c.v.
Nicotine (0.3 nmol) i.c.v. with 
Vi antagonist (0.03 ngkg1)
T   BP (2 min) NCRNA NC HR
VI antagonist i.c.
Nicotine (0.3 nmol) i.c. with 
Vi antagonist(0.03 ngkg'1)
NC BP
i   RNA (less 
than nic alone)
I   HR (2 min 
alone)
2953.3.3.  Discussion.
Nicotine i.c.v. caused a dose-related increase in blood pressure as previously observed by 
Bissett & Chowdry, (1984) and a decrease in renal nerve activity associated with no 
change in heart rate.  Interestingly, in conscious rats, i.c.v. injections of nicotine were 
shown to cause a pressor response associated with a consistent bradycardia (Hoffman, 
1979; Iitake et al., 1980).  Given i.e., nicotine also caused a bradycardia, interestingly; 
the onset of renal sympathoinhibition was immediate while the rise in blood pressure was 
again delayed but much larger.  This was different from that of activation of a7 and a4f2 
nACh receptors, in that there was no delayed sympathoexcitation (see Chapters 3.1). 
However, pre-treatment with the vasopressin Vj receptor antagonist (i.v., i.c.v. & i.c.) did 
attenuate / block the renal sympathoinhibition as it had done for the renal 
sympathoexcitation observed with the selective al and a4(32 nAChR agonists, although 
the Vi receptor antagonist now had inconsistent effects on nicotine-induced blood 
pressure responses.  The V) receptor antagonist given i.v. blocked the pressor response 
caused by nicotine i.c.v. and i.e., although for the i.c. there was now a fall in blood 
pressure.  However, the rise in blood pressure by nicotine i.c.v. was not blocked by i.c.v. 
Vi receptor antagonist, while for i.c. nicotine, i.c. Vi receptor antagonist pre-treatment, 
surprisingly blocked the fall in blood pressure.
Sites of Action.
The delayed increase in blood pressure induced by nicotine i.c.v. suggests that the site of 
action is located away from the forebrain and possibly in brain areas in the hindbrain. 
Interestingly, nicotine administered into the hindbrain via i.c. injections were shown to 
induce a biphasic response in blood pressure, with an initial fall followed by a increase 
which was greater than the blood pressure increase caused by nicotine i.c.v.  Studies have 
recorded that administration of nicotine at the hindbrain, either by i.c. injection or by 
application of nicotine to the ventral surface of the brainstem, results in a depressor 
response which was blocked by nicotinic antagonists, but unaffected by muscarinic
296antagonist, atropine (Bisset et al., 1975; Bisset & Chowdrey, 1984; Feldberg & 
Guertzenstein, 1976).  Additional studies have shown that nicotine microinjected into the 
NTS caused a dose-dependent decrease in blood pressure with rapid onset immediately 
after microinjection (Dhar et al., 2000; Ferreira et al., 2000), therefore it is possible that 
nicotine i.c. is acting on nAChRs found on the NTS, inducing the initial decrease in blood 
pressure, possibly via a relay to the CVLM decreasing renal nerve activity.  However, the 
initial decrease in blood pressure is not significant and instead an increase in blood 
pressure is observed suggesting that the initial decrease in blood pressure is overcome by 
a increase in blood pressure, possibly mediated by a pressor hormone such as 
vasopressin.  Further studies demonstrated that the increase in blood pressure caused by 
i.c. nicotine was due to vasopressin release, by inhibition from V) antagonist i.v. and i.c. 
When in the presence of the Vj antagonist i.v., the initial i.c. nicotine-induced decrease in 
blood pressure is potentiated, supporting the theory that the initial decrease is overcome 
by the release of vasopressin into the circulation resulting in a increase in blood pressure. 
Surprisingly, the fall in blood pressure is blocked when in the presence of the Vi 
antagonist centrally.  The mechanism of action is currently unknown; however it may be 
due to the involvement of a central vasopressin pathway.
Interestingly, nicotine i.c.v. in the presence of V) antagonist i.c.v. still caused an increase 
in blood pressure.  However, although nicotine is in the presence of a central Vj 
antagonist, there is at least 2 min until a significant increase in blood pressure is observed 
suggesting that nicotine may be acting at an additional site such as the hindbrain, causing 
a large release of vasopressin (Bisset et al., 1975) which may account for the delayed 
increase in blood pressure.  In addition, the Vi antagonist may not have completely 
blocked the Vi receptors in the hindbrain when injected i.c.v. therefore nicotine was still 
able to cause an increase in blood pressure.  However, it is possible that nicotine i.c.v. is 
causing the release of vasopressin into the circulation by acting on the PVN directly 
resulting in the increase in blood pressure, although studies have shown that the release 
of vasopressin would be low (Bisset et al., 1975), which may also explain the delayed 
increase in blood pressure.  This release of vasopressin was believed to be due to nicotine 
acting directly on the SON, due to demonstrations that the SON contains neuronal
297nAChRs (Hatton & Yang, 2002; Zaninetti et al., 2000) and direct application of nicotine 
causes an increase in the rate of firing on the supraopticohypophysial tract (Castro de & 
Rocha E Silva, 1977), as well as, nicotine microinjection into the SON resulting in the 
increase in vasopressin release (Ota et al., 1992).
Figure 65 suggests possible mechanisms of action for the i.c.v. nicotine-induced increase 
in blood pressure.  1) involves a direct effect of nicotine on the PVN; resulting in the 
release of vasopressin into the circulation evoking an increase in blood pressure; 2) 
nicotine moves from the i.c.v. injection site to sites in the hindbrain, possibly the RVLM, 
binding to nAChR, stimulating a projection to the PVN which results in the release of 
vasopressin and the increase in blood pressure.  If nicotine i.c.v. induced the release of 
vasopressin by acting on the hindbrain then it is likely that the release of vasopressin 
would be caused by a pathway from the hindbrain to the PVN (see Chapter 3.2), therefore 
the central administration of Vi antagonist would inhibit this pathway and block the 
release of vasopressin.  However, this was not observed and instead suggests that the 
release of vasopressin is caused by nicotine acting directly on the PVN.  Figure 66 shows 
a diagrammatic representation of the mechanism of action for nicotine injected i.e. 
Nicotine comes into contact with cardiovascular regulating areas such as the RVLM and 
NTS which stimulates the neuron projection to the PVN resulting in a release of 
vasopressin in to the circulation and an increase in blood pressure.  The presence of this 
pathway is indicated by inhibition by a Vi antagonist i.e. blocking the pathway to the 
PVN and preventing the release of vasopressin and increase in blood pressure.
Interestingly, the al and a4f2 selective agonists did not cause the release of vasopressin 
by acting on the PVN directly and instead acted on the hindbrain to evoke its effects (see 
Chapter 3.2).  In this respect, nicotine is not acting on the al and a4^2 nAChR in the 
PVN to induce the release of vasopressin and instead may be acting on an additional 
nACh receptor subunit found on the PVN, stimulating the release of vasopressin.
298Renal sympathinhibition.
Interestingly, due to the rapid nature of the sympathoinhibition, it is suggested that 
nicotine’s site of action is near the i.c.v. injection site.  One possible site of action is the 
hypothalamus which is positioned very closely to the i.c.v. injection site and is believed 
to contain additional nAChRs to the a4p2 and al receptors such as |34-containing 
nAChRs (Dineley-Miller & Patrick, 1992; Winzer-Serhan & Leslie, 1997).  However, 
although the sympathoinhibition caused by nicotine i.c.v. is fast, the sympathoinhibition 
response caused by nicotine i.e. is faster suggesting that the areas in the hindbrain are 
involved in nicotine-induced sympathoinhibition.  Further, it may be possible that both 
the forebrain and hindbrain sites are involved.
A possible mechanism of action is the effect of vasopressin on the area postrema (AP), 
which has been noted as being a circumventricular organ, contains Via receptors and 
shown to be innervated by cardiovascular regulating brain areas such as the NTS, 
parabrachial nucleus and PVN (see Ferguson, 1991; see Hasser et al., 2000; Hasser & 
Bishop, 1990; see Johnson & Gross, 1993).  Studies have shown that microinjection of 
vasopressin into the AP cause a decrease in renal nerve activity ( see Hasser et al., 2000; 
Hasser & Bishop, 1990).  However the decrease in renal nerve activity observed by 
central administration of nicotine is not associated with the vasopressin-induced increase 
in blood pressure evoked by nicotine; therefore suggesting the decrease in renal nerve 
activity caused by nicotine is independent of vasopressin release.  Therefore a possible 
mechanism of action is the direct affect of nicotine on the C VLM.  Previous studies have 
shown that nicotine microinjected into the CVLM caused a dose-related decrease in 
blood pressure and heart rate (Aberger et ai, 2001) which was suggested to be due to 
inhibition of the RVLM via GABAnergic neurons form the CVLM, thus resulting in a 
decrease in sympathetic nerve activity to the heart and blood vessels (Agarwal et al., 
1990; Brown & Guyenet, 1984; Cravo et al., 1991; Gordon, 1987).  This would account 
for the rapid decrease in renal sympathetic nerve activity and heart rate upon nicotine 
administered i.e., due to the i.e. injection site being located close to the CVLM and the 
delayed decrease in RSNA evoked by nicotine i.c.v.  However, the i.c.v. nicotine evoked
299renal sympathoinhibition is too fast to be leaking across the brain to evoke an effect, 
therefore it is suggested that the decrease is caused by forebrain areas such as the PVN 
innervating cardiovascular regulating hindbrain areas such as the CVLM, NTS and 
RVLM (see Dampney, 1994; see Sun, 1995).  Furthermore Yang & Coote (1998) 
demonstrated that activation of neurons at the PVN may cause a depressor response via 
inhibiting the RVLM neurons, therefore it is possible that via a pathway for the PVN to 
the RVLM nicotine is able to cause a decrease in renal sympathetic nerve activity
Interestingly the nicotine-evoked renal sympathoinhibition is inhibited and attenuated by 
central Via receptor antagonist suggesting the involvement of vasopressin centrally 
possibly acting as a neurotransmitter (Yang et al., 2001) at the synapses between 
cardiovascular regulating centres.
Nicotine in the presence of selective antagonists.
The present data using antagonists also indicate that nicotine can activate a a4p2 receptor 
which mediates sympathoinhibition, however this is not observed using the respective 
selective agonists (see Chapter 3.1).  In fact, in the presence of the antagonist DhpE, the 
renal sympathoinhibition was reversed to a sympathoexcitation associated with no 
observed changes in blood pressure and heart rate.  A possible explanation of this 
contradiction is that Dh(3E, at the concentration used, is also blocking another receptor. In 
this respect it does have a reasonable affinity for the p2 and p4 subunit (Chavez-Noriega 
et al., 1997; 2000) and receptor/s containing these subunits could mediate this renal 
sympathoinhibition.  In this respect cytisine, which has selective tendencies at neuronal 
nACh receptors containing the (34 subunit (Alkondon & Albuquerque, 1993; Chavez- 
Noriega et al., 1997; see Colquhoun & Patrick, 1997)(see section 3.3.1.), was also found 
to cause profound renal sympathoinhibition and surprisingly this was associated with no 
change in heart rate although the expected pressor response was still observed.  The 
selectivity of cytisine for nAChR subtypes has been shown in vitro to have a low efficacy 
for nAChRs containing the p2 subunits compared to other agonists such as DMPP and
300ACh, but displayed high affinity for a2p4, a3p4 and a4p4 nAChR’s (Chavez-Noriega et 
al., 1997; 2000), indicating that cytisine is selective for the p4-containing nAChR 
subtypes.  Therefore, due to the cardiovascular similarities induced by nicotine and 
cytisine, it is possible that nicotine is acting on a p4-containing nAChR subtype.
However, the receptor involved in the nicotine i.c.v. evoked renal sympathoexcitatory 
response remains to be determined.  Furthermore, in the presence of al selective 
antagonist, MLA, the nicotine-evoked renal sympathoinhibition is not blocked only 
delayed, although the blood pressure response is blocked.  The mechanism for delay is 
unclear, but presumably it is due to the balance of action of different nAChR which have 
opposing actions on renal nerve activity. However the ability of both antagonists to block 
the pressor response remains difficult to explain, although a possible mechanism could be 
that of blocking one receptor unmasking another’s effect, although in the opposite 
direction i.e. the receptors mediating the fall in pressure observed with TC-2559 at the 
highest dose.  In addition, the nicotinic receptor agonist DMPP, which has been shown to 
be selective for a2p2, a3p2 and a3p4 nAChR (Chavez-Noriega et al., 1997; Luetje & 
Patrick, 1991) evoked an increase in blood pressure and renal nerve activity, with no 
change in heart rate suggesting that a number of neuronal nicotinic receptors upon 
activation are able to cause an increase in blood pressure and renal nerve activity, most 
likely via a vasopressinergic pathway and the release of vasopressin.
In conclusion, central administration of nicotine induces an increase in blood pressure via 
the release of vasopressin in to the circulation, which involves a central pathway for 
nicotine injected into the hindbrain, and may be involved for nicotine i.c.v.  However, 
nicotine injected into the forebrain may be having a direct effect on the PVN, possibly by 
acting on (34-containing nAChRs, resulting in the release of vasopressin.  Nicotine 
evoked decrease in renal nerve activity is independent of vasopressin release, making the 
mechanism of action unknown.  Again, the similarities in cardiovascular reponses to (34 
selective agonist cytisine suggest that nicotine may be acting on p4-containing subunits 
to induce the renal sympathoinhibition.
301Figure 65.  Diagrammatic representation of the pathways involved upon i.c.v.
injection of nicotine in the rat brain.
1)  Nicotine is administered into the brain via i.c.v. injections.
2)  Nicotine comes directly into contact with the PVN and stimulates the 
release of vasopressin from the posterior pituitary.
3)  Vasopressin release causes the increase in blood pressure by acting on Via 
receptors, found on blood vessels, resulting in vasoconstriction.
4)  An additional mechanism of action involves nicotine not acting directly on 
the PVN, instead moving through the brain towards the hindbrain.
5)  Nicotine binds to nAChRs found on the RVLM and NTS.
6)  The RVLM stimulates the PVN via a neuronal projection which  results in
the release of vasopressin via points 2) and 3).
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303Figure 66.  Diagrammatic representation of the pathways involved upon i.e. injection
of nicotine in the rat brain.
1)  Nicotine is administered into the brain via i.e. injections.
2)  Nicotine comes into contact with the RVLM, and possibly the NTS.
3)  Stimulation of the RVLM by the selective agonists activates the PVN via 
aneuronal projection.
4)  The stimulation of the PVN results in the release of vasopressin, from the 
posterior pituitary, into the circulation via the blood stream.
5)  Vasopressin release causes the increase in blood pressure by acting on V)a 
receptors, found on blood vessels, resulting in vasoconstriction.
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3053.4.  Effects of i.e. administration of selective nicotinic
ACh receptor antagonists.
3.4.1.  Introduction.
During the studies to determine the selective nature of PSAB-OFP and TC-2559 i.e., 
there was observed a significant cardiovascular effect produced by the al nAChR 
selective antagonist, MLA, and a4p2 nAChR selective antagonist, DhpE, alone when 
injected i.e.  However, previously administration of these antagonists i.c.v. was found 
to have no effect on baseline values (see Chapter 3.1).  Due to these observations, the 
cardiovascular effects of these antagonists alone i.c. were recorded.  In order to 
determine if the antagonists are acting on their specific receptors to cause this effect, 
after the 20 min recording period was completed, the administration of selective 
agonists PSAB-OFP was injected i.c. and the cardiovascular effects recorded.  In 
addition to the two selective antagonists, the effect of homomeric selective (a7-a9) 
antagonist, a-bungarotoxin (a-BgT) was also observed upon i.c. injection on 
cardiovascular regulation.
3.4.2.  Results.
3.4.2.1.  Effects of DhpE, a selective a4p2 receptor
antagonist, (i.e.).
DhpE (10 pmol kg'1, i.c., n=5) caused a significant increase in mean arterial blood 
pressure and renal nerve activity at 1  min reaching a maximum of 12 ± 2 mmHg and 
105 ± 24% at 1  min.  There was no significant effect on heart rate (Figure 67 & 68). 
Baseline values for MAP and HR were 119 ± 11 mmHg and 402 ± 28 beats min'1.
3063.4.2.2.  Effects of MLA, a selective a7 receptor antagonist, 
(i.e.).
0.1 (imol kg'1  of MLA (i.e., n=5) caused a delayed depressor response with a 
significant decrease in mean arterial blood pressure at 8 min reaching a maximum 
decrease of -15 ± 4 mmHg after 10 min and returning to baseline by 20 min.  There 
was a significant decrease in renal nerve activity and heart rate after 2 min reaching a 
maximum of -58 ± 9% and -58 ± 13 beats min"1  at 15 min (Figure 69 & 70).  Baseline 
values for MAP and HR were 117 ± 17 mmHg and 413 ± 30 beats min"1.  The next 
dose (0.5 pmol kg"1, n=5) now caused a delayed, after 3 min, significant increase in 
blood pressure and renal nerve activity, reaching a maximum of 41 ± 8 mmHg and 
110 ± 43% at 5 min.  Although heart rate tended to decline, it was not significant 
(Figure 71 & 72).  Baseline values for MAP and HR were 94 ± 18 mmHg and 365 ± 
46 beats min"1.  The highest dose of MLA (1 pmol kg-1, n=5) also caused a 
significant and similar increase in blood pressure after 3 min reaching a maximum of 
37 ± 9 mmHg at 6 min.  However, although renal nerve activity increased it was much 
more variable and was not significant.  Heart rate was unaffected (Figure 73).
Baseline values for MAP and HR were 115 ± 33 mmHg and 412 ± 78 beats min"1.
3.4.2.3.  Effects of PSAB-OFP (a7 receptor agonist) i.c. pre­
treated with MLA (i.e.).
In the presence of MLA (0.5 pmol kg"1 , i.c., n=5) the expected evoked increase in 
mean arterial pressure by PSAB-OFP (3 pmol kg'1 ) was completely blocked.  The 
expected renal sympathoexcitation and tachycardia was also completely blocked 
(Figure 74 & 75).  Baseline values for MAP and HR were 85 ± 13 mmHg and 393 ±
35 beats min"1.
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Trace showing the effect of DhpE (10 jimol kg'1, i.c.) on blood pressure (BP), integrative renal nerve activity (Int RNA) and heart 
rate (HR) on anaesthetised artificially ventilated and neuromuscular blocked rats.
308Figure 68.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by DhpE 
(10 pmol kg'1 , i.c.) and saline (5 pi. i.e.) in mean arterial blood pressure (MAP), heart 
rate (HR) and renal nerve activity (RNA).  Each point represents the mean value and 
the vertical lines show s.e.mean.  Changes caused by DhpE i.c. (*) compared with 
saline using two-way analyses of variance followed by the least significant difference 
test to compare the means.  * P<0.05 and *** P<0.001.
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Figure 69.  Trace showing the effect of MLA (0.1 pmol kg'1, i.c.) on blood pressure (BP), integrative renal nerve activity (Int RNA) and heart 
rate (HR) on anaesthetised artificially ventilated and neuromuscular blocked rats.
311Figure 70.  Anaesthetised artificially Ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by MLA 
(0.1  pmol kg'1 , i.e.) and saline (5 pi  i;c.) in mean arterial blood pressure (MAP), heart 
rate (HR) and renal nerve activity (RNA),  Each point represents the mean value and 
the vertical lines show s.e.mean.  Changes caused by MLA i.c. (*) compared with 
saline using two-way analyses of variance followed by the least significant difference 
test to compare the means.  * P<0.05, ** P<0.01 and *** PO.OOl.
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Trace showing the effect of MLA (0.5 pmol kg'1, i.c.) on blood pressure (BP), integrative renal nerve activity (Int RNA) and heart 
rate (HR) on anaesthetised artificially ventilated and neuromuscular blocked rats.
314Figure 72.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by MLA 
(0.5 pmol kg'1, i.e.) and saline (5 pi. i.e.) in mean arterial blood pressure (MAP), heart 
rate (HR) and renal nerve activity (RNAX  Each point represents the mean value and 
the vertical lines show s.e.mean.  Changes caused by MLA i.e. (*) compared with 
saline using two-way analyses of variance followed by the least significant difference 
test to compare the means.  * P<0.05 and ** P<0.01.
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-100JFigure 73.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by MLA 
(1  pmol kg'1 , i.c.) and saline (5 pi.  i.c.) in mean arterial blood pressure (MAP), heart 
rate (HR) and renal nerve activity (RNA).  Each point represents the mean value and 
the vertical lines show s.e.mean.  Changes caused by MLA i.c. (*) compared with 
saline using two-way analyses of variance followed by the least significant difference 
test to compare the means.  * P<0.05 and ** P<0.01.
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Figure 74.  Trace showing the effect of PSAB-OFP (3 \imo\ kg'1, i.c.) pre-treated with MLA (0.5 pmol kg'1, i.c.) on blood pressure (BP),
integrative renal nerve activity (Int RNA) and heart rate (HR) on anaesthetised artificially ventilated and neuromuscular blocked 
rats.
319Figure 75.  Anaesthetised artificially, ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by PSAB- 
OFP (3 pmol kg'1, i.e.) pre-treated with MLA (0.5 pmol kg'1 , i.e.) and PSAB-OFP 
alone (3 pmol kg'1 , i.e.) and control (2 doses saline, i.e.) in mean arterial blood 
pressure (MAP), heart rate (HR) andrenal nerve activity (RNA).  Each point 
represents the mean value and the vertical lines show s.e.mean.  Changes caused by 
PSAB-OFP (#) pre-treated with MLA compared with PSAB-OFP alone by using two- 
way analyses of variance followed by the least significant difference test to compare 
the means.  # P<0.05 and ## P<0.01.
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3213.4.2.3.  Effects of a-BgT, a homomeric (al, 8 & 9) selective 
receptor antagonist, (i.e.).
In the a-BgT control experiments (n=5), in which saline was given i.c. instead of the 
test agonist (see methods for full protocol), there was no significant change for the 
duration of the experiment.  Baseline values for MAP and HR were 121 ± 9 mmHg 
and 398 ± 55 beats min'1.
a-BgT (0.01 pmol kg'1, n=4) had no significant effect on mean arterial blood pressure, 
renal nerve activity and heart rate over the 20 min time period (Figure 76).  Baseline 
values for MAP and HR were 111 ± 11 mmHg and 395 ± 37 beats min'1.
3.4.2.4.  Effects of PSAB-OFP (a7 receptor agonist) i.c. pre­
treated with a-BgT (i.e.).
In the presence a-BgT (0.01 pmol kg'1 , i.c. n=5) the expected evoked increase in 
mean arterial pressure by PSAB-OFP (3 pmol kg'1 , n=5) was completely blocked and 
the expected renal sympathoexcitation and tachycardia reverse to sympathoinhibition 
and a bradycardia (Figure 77 & 78).  Renal nerve activity and heart rate decreased 
after 1  min, reaching a maximum of -81 ± 5% and -57 ±15 beats min'1  after 2 min. 
Baseline values for MAP and HR were 116 ± 20 mmHg and 396 ± 35 beats min'1.
322Figure 76.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) ffom baseline values over time (min) caused by a-BgT 
(0.01  pmol kg'1, i.e.) and saline (5 pi. i.e.) in mean arterial blood pressure (MAP), 
heart rate (HR) and renal nerve activity (RNA).  Each point represents the mean value 
and the vertical lines show s.e.mean.  Changes caused by a-BgT i.e. compared with 
saline using two-way analyses of variance followed by the least significant difference 
test to compare the means.
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Trace showing the effect of PSAB-OFP (3 pmol kg'1, i.e.) pre-treated with a-BgT (0.01 pmol kg'1, i.e.) on blood pressure (BP), 
integrative renal nerve activity (Int RNA) and heart rate (HR) on anaesthetised artificially ventilated and neuromuscular blocked 
rats
325Figure 78.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by PSAB- 
OFP (3 pmol kg'1 , i.e.) pre-treated with a-BgT (0.01  pmol kg'1 , i.e.) and PSAB-OFP 
alone (3 pmol kg'1, i.e.) and control (2 doses saline, i.e.) in mean arterial blood pressure 
(MAP), heart rate (HR) and renal nerve activity (RNA).  Each point represents the mean 
value and the vertical lines show s.e.mean.  Changes caused by PSAB-OFP (*) pre- 
treated with a-BgT compared with  control and changes caused by PSAB-OFP (#) pre- 
treated with a-BgT compared with PSAB-OFP alone by using two-way analyses of 
variance followed by the least significant difference test to compare the means.
*, # P<0.05; **, ## P<0.01 and ***, ### P<0.001.
326.£  80i
»  40-
1 5   ft
d)  o-
A
" 4 0 -
< - 8 0 -
400-.
<
X 200-
<  .
-vO
*   0- 
-100-
D)  6O 1
X
£ 40-
E
Q _ 20-
< 0-
< -20-3.4.3.  Discussion
The a7 selective antagonist, MLA has been demonstrated to induce an effect on 
cardiovascular variables being recorded; with the two highest doses (0.5 and 1 pmol kg'1) 
causing similar delayed increases in blood pressure and renal nerve activity, although 
there are no changes in heart rate for the duration of the experiment.  However, at the 
lowest dose of MLA (0.1 pmol kg'1 ) there is now observed a rapid decrease in renal 
nerve activity at 2 min, with a delayed decrease in blood pressure and heart rate at 8 min 
and 4 min respectively.  To determine if the MLA is blocking a7 nAChR, at the end of 
the MLA (0.5 pmol kg'1) experiment, a7 selective receptor agonist PSAB-OFP (3 pmol 
kg'1) was injected i.e. and its effects were blocked (see Chapter 3.1).  In addition the a4p2 
selective receptor antagonist DhpE has also been shown to have an effect on these 
variables.  At 10 gmol kg'1  DhpE was demonstrated to cause a significant increase in 
blood pressure and renal nerve activity at 1  min, which returned to baseline by 2 min.
The homomeric selective receptor antagonist a-BgT (0.01 pmol kg'1 ) was shown to have 
no effect on cardiovascular variables being recorded.  Interestingly, i.e. injection of a7 
selective receptor agonist PSAB-OFP (3 pmol kg'1 ), in the presence of a-BgT (0.01  pmol 
kg'1 ), had no affect on blood pressure, however, there was a significant decrease in renal 
nerve activity and heart rate from 1 min, contrary to PSAB-OFP alone which evoked a 
increase in blood pressure and a delayed increase in renal nerve activty, with no change 
in heart rate.
These observations with selective nAChR antagonists suggest that the a7 and a4p2 
receptors located in the hindbrain are being tonically activated indicating that they are 
playing a physiological role in the control of these variables.  MLA was shown to have 
the reverse effects suggesting that these receptors can have either sympathoinhibitory 
(low dose action) or sympathoexcitatory (high dose action).  Interestingly, this 
sympathoexcitatory action does not seem to apply to the sympathetic outflow to the heart. 
The delay in this tonic sympathoexcitatory action suggests it is at a different site to that 
involved in the sympathoinhibitory action within the hindbrain.  However as it has been 
shown that MLA is able to cross the blood brain barrier upon i.v. injection (Turek et al.,
3281995), it is therefore possible that MLA is not causing these effects at the level of the 
brainstem but is acting peripherally, although if it is interfering with ganglionic 
transmission a fall blood pressure would be expected, thus this is veiy doubtful.  MLA, 
although selective for the a7 nAChRs, it is not specific for the a7 nAChRs over other 
nAChRs subtypes (Davies et al, 1999; Ward et al., 1990; Yum et al, 1996).  MLA is 
300X more selective for a7 over muscle and a4p2 nAChRs (Table 4b); however studies 
have shown that MLA is able to bind to non-a7 nAChRs in avian preparations (Yu & 
Role, 1998; Yum et al, 1996).  Therefore it is possible that MLA is acting on additional 
receptors to the a7 nAChRs causing an increase in blood pressure and renal nerve 
activity.  Due to the inhibition of al selective agonist PSAB-OFP actions, the dose used 
can be said to be an effective dose for blocking al nAChRs, however this does not prove 
that it is not acting at other receptor subtypes.
Unlike MLA, the a4p2 selective antagonist DhpE produces a rapid transient increase in 
blood pressure and renal nerve activity at 1  min, however the effects are very short 
returning to baseline by 2 min.  The speed of the DhpE-induced effect suggests that the 
site of action is close to the i.e. site of injection such as the NTS, which has been shown 
to contain a4p2 subunits (Dominguez del Toro et al, 1994; Swanson et al., 1987; Wada 
et al, 1989).  The rapid recovery may be due to an additional pathway compensating for 
the evoked changes, or that the concentration of DhpE is not high enough to keep the 
receptor blocked.
In addition to the above suggestions, a possible mechanism of action for the 
cardiovascular effects of the selective antagonists, is that the antagonists are acting on 
receptors similar to the nicotinic receptor, such as the 5-HT3 receptor.  Previous studies 
have shown that agonists and antagonists for the 5-HT3  receptor can act on the neuronal 
nicotinic receptor (Blanton et al, 2000a).  5-HT3  receptor antagonist’s tropisetron and 
ondansetron, have been shown to be able to cross over and act on nicotinic receptors, 
with tropisetron acting as a agonist on al nAChRs, whereas ondansetron was shown to 
act as a antagonist on the al receptor (Papke et al, 2004).  These two antagonists were 
also shown to act as antagonists at the a4p2 and a3p4 neuronal nAChR (Papke et al, 
2004). Therefore it may be possible that nicotinic antagonists are able to act on the 5-HT3
329receptor, especially as nicotinic antagonist d-tubocurarine has been shown to cross over 
and act as a 5-HT3  receptor antagonist (Peters et a l, 1993).  Although blockade of 5-HT3  
receptor at the level of the brainstem has no effect on resting blood pressure (see Ramage, 
2001).
Although a-BgT is a very selective antagonist at a7 nAChRs, with a binding affinity (Ki) 
of approximately 1 nM (Davis et al, 1999), it had no effect, whereas MLA did (see 
above).  It is possible that the dose of a-BgT used is not high enough to block these 
receptors, although the expected increase in blood pressure and renal nerve activity 
induced by a7 selective agonist PSAB-OFP injected i.e. was blocked.  A possible 
explanation for the lack of effect of a-BgT, is due to the very slow binding kinetics of a- 
BgT, which requires pre-incubation of around 1  hour to cause a complete block in vitro 
(Davies et al., 1999), thus allowing compensatory mechanism to take over.  However the 
data with the a7 selective agonist, PSAB-OFP does not support such an argument. 
Interestingly, in previous studies nicotine i.e. has been shown to decrease blood pressure 
and heart rate which was inhibited by a7 selective antagonist MLA, suggesting that al 
nAChRs are also involved in a depressor response.  Therefore, it is possible that a-BgT is 
unable to inhibit all the al nAChRs and these may be the ones that have greater tonic 
drive.
These data imply that central cholinergic pathways, via nAChRs at the level of brainstem, 
are involved in blood pressure regulation.  However, the lack of a dose response curve 
with MLA and the fact that these antagonists can cause a rise in mean arterial blood 
pressure as seen with the agonists makes these data difficult to interpret.
330AppendixTreatment Group n number MAP (mmHg) HR (beats min'1 )
Saline control (i.c.v.) 
Saline control (i.e.)
127 ± 14 
112 ± 13
380 ± 27 
385 ±32
T 0.1 pmol kg'  Nicotine (i.c.v.)
0.3 pmol kg'1  Nicotine (i.c.v.) 
1 pmol k^'1  Nicotine (i.c.v.)
123 ±15 
121 ±12 
123 ± 20
361 ±34 
388 ±38 
370 ± 40
1 pmol kg'1  PSAB-OFP (i.c.v.) 
3 pmol kg'1  PSAB-OFP (i.c.v.) 
10 pmol kg'1  PSAB-OFP (i.c.v.)
122 ±7 
124 ±8 
126 ±22
362 ± 44 
356 ±23 
350 ±23
1 pmol kg'  TC-2559 (i.c.v.) 
3 pmol kg'1  TC-2559 (i.c.v.) 
10 pmol kg'1  TC-2559 (i.c.v.)
120 ±17 
113 ± 16 
125 ± 19
368 ± 54 
366 ± 34 
380 ± 14
0.1 pmol kg'  DMPP (i.c.v.)
0.3 pmol kg'1  DMPP (i.c.v.) 
1  pmol kg'1  DMPP (i.c.v.)
123 ±23 
118 ± 13 
113 ± 5
350 ± 24 
265 ± 50 
381 ±30
1  pmol kg'  Cytisine (i.c.v.) 
3 pmol kg'1  Cytisine (i.c.v.)
121 ± 14 
118 ± 14
388 ±36 
412 ±73
0.3 pmol kg'  Nicotine (i.e.) 
3 pmol kg*1  PSAB-OFP (i.e.) 
3 pmol kg'1  TC-2559 (i.e.)
116 ± 12 
111 ± 11 
113 ± 14
405 ± 34 
387 ± 65 
392 ± 59
332Treatment Group n number MAP (mmHg) HR (beats min'1)
Antagonist control (2 doses saline, i.c.v.) 5 113 ±10 393 ±51
0.3 pmol kg'1  Nicotine with 2 doses of saline (i.c.v.) 5 118 ± 23 422 ± 28
0.3 pmol kg'1  Nicotine with 10 pmol kg'1  DhpE (i.c.v.) 5 114 ± 13 363 ±37
3 pmol kg'1  PSAB-OFP with 10 pmol kg'1  DhpE (i.c.v.) 5 114 ± 13 363 ±33
3 pmol kg'1  TC-2559 with 10 pmol kg'1  DhpE (i.c.v.) 5 113 ± 5 361 ±65
0.3 pmol kg'1  Nicotine with 0.5 pmol kg'1  MLA (i.c.v.) 5 117 ± 11 359± 108
3 pmol kg*1  PSAB-OFP with 0.5 pmol kg'1  MLA (i.c.v.) 
3 pmol kg'1  TC-2559 with 0.5 pmol kg'  MLA (i.c.v.)
5 103 ±9 377 ±43
5 114 ± 14 373 ±34
0.01 pmol kg'1  a-BgT (i.c.v.) 5 114 ± 7 404 ±41
3 pmol kg'1  PSAB-OFP with 0.01 pmol kg'1  a-BgT (i.c.v.) 5 120 ±9 393 ± 54
0.1 pmol kg'1  MLA (i.e.) 5 117 ± 17 413 ±30
0.5 pmol kg'1  MLA (i.e.) 5 94 ± 18 365 ± 46
1  pmol kg'1  MLA (i.e.) 5 115 ± 13 412 ±78
0.5 pmol kg'1  MLA with 3 pmol kg'1  PSAB-OFP 20 min
later (i.e.) 5 85 ±13 393 ±35
10 pmol kg'1  DhpE (i.e.) 5 119 ±11 402 ± 28
0.01 pmol kg"1  a-BgT (i.e.) 5 111 ±11 395 ±37
a-BgT control 5 121 ±9 398 ±55
3 pmol kg'1  PSAB-OFP with 0.01 pmol kg'1  a-BgT (i.e.) 5 116 ± 10 396 ± 35
333Treatment Group n number MAP (mmHg) HR (beats min'1 )
Vi antagonist control (i.v. with i.c.v. agonists) 5 106 ± 12 385 ±20
Vi antagonist control (i.v. with i.e. agonists) 5 117 ± 5 403 ± 23
Vi antagonist control (i.c.v.) 5 117 ± 14 389 ± 40
Vi antagonist control (i.e.) 5 105 ±15 381 ±40
0.3 pmol kg'1  Nicotine (i.c.v.) with Vi antagonist (i.v.) 5 113 ± 12 375 ± 53
3 pmol kg'1  PSAB-OFP (i.c.v.) with Vi antagonist (i.v.) 5 108 ± 15 397 ± 36
3 pmol kg'1  TC-2559 (i.c.v.) with Vi antagonist (i.v.) 5 108 ± 10 378 ±32
3 pmol kg'1  Cytisine (i.c.v.) with Vi antagonist (i.v.) 5 119 ± 14 419 ± 9
0.3 pmol kg'1  DMPP (i.c.v.) with Vi antagonist (i.v.) 5 102 ±8 375 ±23
0.3 pmol kg'1  Nicotine (i.e.) with Vi antagonist (i.v.) 5 103 ±8 381 ±46
3 pmol kg'1  PSAB-OFP (i.e.) with Vi antagonist (i.v.) 5 107 ±17 396 ± 43
3 pmol kg'1  TC-2559 (i.e.) with Vi antagonist (i.v.) 5 109 ±6 404 ±41
0.3 pmol kg'1  Nicotine (i.c.v.) with Vi antagonist (i.c.v.) 5 106  ±16 390  ± 18
3 pmol kg'1  PSAB-OFP (i.c.v.) with Vi antagonist (i.c.v.) 5 112  ± 17 400  ±49
3 pmol kg'1  TC-2559 (i.c.v.) with Vi antagonist (i.c.v.) 5 190  ± 16 387  ±24
0.3 pmol kg'1  Nicotine (i.e.) with Vi antagonist (i.e.) 5 116 ± 7 392 ±37
3 pmol kg'1  PSAB-OFP (i.e.) with Vi antagonist (i.e.) 5 111 ±8 376 ±28
3 pmol kg'1  TC-2559 (i.e.) with Vi antagonist (i.e.) 5 109 ±12 393 ±35
1st vasopressin 2n  vasopressin
Vi antagonist i.c.v. with vasopressin (i.v.) 7 115 ± 22 111 ± 10
Vi antagonist i.e. with vasopressin (i.v.) 7 116 ± 14 115 ± 10
334Treatment Group n number MAP (mmHg) HR (beats min*1 )
Saline infusion (i.v.) 3 102 ±7 398 ±38
0.3 pmol kg'1  Nicotine infusion (i.v.) 5 116 ± 19 407 ± 33
3 pmol kg'1  PSAB-OFP infusion (i.v.) 3 128 ±6 403 ± 30
3 pmol kg'1  TC-2559 infusion (i.v.) 3 116 ± 5 423 ± 14
Table 16. Overview of experiments performed and the baseline values for the experiments.3.5.1.  Effects of DMPP i.c.v. in the presence of the Vi 
receptor antagonist (i.v.).
In the presence of Vi receptor antagonist (30 pg kg'1; i.v.), the expected evoked rise in 
mean arterial blood pressure and the delayed renal sympathoexcitation by DMPP (1 pmol 
kg1, n=5) was completely blocked (Figure 79).  Baseline values for MAP and HR were 
102 ± 8 mmHg and 375 ± 23 beats min1.
3.5.2.  Effects of cytisine i.c.v. in the presence of the
receptor antagonist (i.v.).
In the presence of Vi receptor antagonist (100 pg kg1; i.v.), the expected evoked rise in 
mean arterial blood pressure by cytisine (3 pmol kg1) was significantly attenuated 
reaching a maximum of 17 ± 3 mmHg compared with 37 ± 14 mmHg.  Further expected 
renal sympathoinhibition was also attenuated and now transient returning to baseline after 
4 min (Figure 80).  However, again there was a delayed bradycardia with was now 
significant decrease at 9 min, reaching a maximum of -31 ±7 beats min1  at 20 min. 
Baseline values for MAP and HR were 119 ± 14 mmHg and 419 ± 9 beats min1.
336Figure 79.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by DMPP (1 
pmol kg'1 , i.c.v.) pre-treated with vasopressin Vi receptor antagonist d(CH2)5Tyr(Me) 
AVP (30 pgkg'1, i.v.) and DMPP alone (1  pmol kg'1, i.c.v.) and control (Vi anta & 
saline, 5 pi, i.c.v.) in mean arterial blood pressure (MAP), heart rate (HR) and renal nerve 
activity (RNA).  Each point represents the mean value and the vertical lines show 
s.e.mean.  Changes caused by DMPP (#) pre-treated with V) antagonist compared with 
DMPP alone by using two-way analyses of variance followed by the least significant 
difference test to compare the means.  # P<0.05 and ## P<0.01.
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338Figure 80.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by cytisine (3 
pmol kg'1 , i.c.v.) pre-treated with vasopressin V) receptor antagonist d(CH2)sTyr(Me) 
AVP (30 pgkg'1, i.v.) and cytisine alone (3 pmol kg'1 , i.c.v.) and control (Vj anta & 
saline, 5 pi, i.c.v.) in mean arterial blood pressure (MAP), heart rate (FER) and renal nerve 
activity (RNA).  Each point represents the mean value and the vertical lines show 
s.e.mean.  Changes caused by cytisine (#) pre-treated with V) antagonist compared with 
cytisine alone by using two-way analyses of variance followed by the least significant 
difference test to compare the means.  *, # P<0.05, *♦, ## P<0.01 and ***, ### P<0.001
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3403.5.3.  Infusion i.v. of nicotinic ACh receptor agonists.
This was carried out in an attempt to mimic the possible effects of these agonists leaking 
out of the brain into the circulation
3.5.3.1.  Effects of PSAB-OFP infusion.
PSAB-OFP (3 pmol kg'1, n=3) caused no significant effect on mean arterial blood 
pressure, renal nerve activity and heart rate when compared to saline control.  A 
comparison of infusion with i.c.v. administration is shown in Figure 81.  Baseline values 
for MAP and HR were 128 ± 6 mmHg and 403 ± 30 beats min1.
3.5.3.2.  Effects of TC-2559 infusion.
TC-2559 (3 pmol kg"1, n=3) caused no significant effect on mean arterial blood pressure, 
renal nerve activity and heart rate when compared to saline control.  A comparison 
infusion with i.c.v. administration is shown in Figure 82.  Baseline values for MAP and 
HR were 116 ± 5 mmHg and 423 ± 14 beats min1
3.5.3.3.  Effects of nicotine infusion.
Nicotine (0.3 pmol kg'1 , n=5) caused a significant small increase in mean arterial blood 
pressure and renal sympathoinhibition after 1  min reaching a maximum of 6 ± 2 mmHg 
and -24 ± 4% at 2 min.  There was a no significant change in heart rate when compared to 
saline control.  A comparison of this effect with i.c.v. administration is shown in Figure 
83.  Baseline values for MAP and HR were 116 ± 19 mmHg and 407 ± 33 beats min1.
341Figure 81.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by PSAB- 
OFP (3 pmol kg1 ,i.v. infusion) and PSAB-OFP alone (3 pmol kg'1, i.c.v.) and control 
(saline i.v. infusion) in mean arterial blood pressure (MAP), heart rate (HR) and renal 
nerve activity (RNA).  Each point represents the mean value and the vertical lines show 
s.e.mean.  Changes caused by PSAB-OFP infusion (*) compared with control and 
changes caused by PSAB-OFP infusion (#) compared with PSAB-OFP i.c.v. by using 
two-way analyses of variance followed by the least significant difference test to compare 
the means.
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343Figure 82.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by TC-2559 
(3 pmol kg'1 , i.v. infusion) and TC-2559 alone (3 pmol k g 1, i.c.v.) and control (saline i.v. 
infusion) in mean arterial blood pressure (MAP), heart rate (HR) and renal nerve activity 
(RNA).  Each point represents the mean value and the vertical lines show s.e.mean. 
Changes caused by TC-2559 infusion (*) compared with control and changes caused by 
TC-2559 infusion (#) compared with TC-2559 i.c.v. by using two-way analyses of 
variance followed by the least significant difference test to compare the means.
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345Figure 83.  Anaesthetised artificially ventilated and neuromuscular blocked rats: a 
comparison of the changes (A) from baseline values over time (min) caused by nicotine 
(0.3 pmol kg'1 ,i.v. infusion) and nicotine alone (0.3 pmol kg'1, i.c.v.) and control (saline
i.v. infusion) in mean arterial blood pressure (MAP), heart rate (HR) and renal nerve 
activity (RNA).  Each point represents the mean value and the vertical lines show 
s.e.mean.  Changes caused by nicotine infusion (*) compared with control and changes 
caused by nicotine infusion (#) compared with nicotine i.c.v. by using two-way analyses 
of variance followed by the least significant difference test to compare the means.
*, # P<0.05; **, ## P<0.01 and ### P<0.001.
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3473.5.5.  Discussion.
The i.v. infusion experiments at least for PSAB-OFP and TC-2559 support the view that 
the actions of these drugs when given i.c.v. and i.e. are due to a central action.  However 
nicotine does have a small effect when given by i.v. infusion implying that a small 
proportion of the raise in mean blood pressure and sympathoinhibition could be due to a 
peripheral action, although the ability of the vasopressin antagonist given i.v. to block the 
effects of nicotine i.c.v. indicates that if any nicotine leaked out of the brain it was not in 
high enough concentration to have any effect.  Furthermore, nicotine i.e. in the presence 
of Vi receptor antagonist (Chapter 3.3) demonstrated that although the antagonist did 
block the effects of i.e. nicotine, it also exposed a nicotine-evoked fall in blood pressure 
again implying that nicotine did not leak out.
Interestingly, when in the presence of V) antagonist i.v., cytisine i.c.v. was shown to still 
cause an increase in blood pressure associated with sympathoinhibition, unlike nicotine
i.c.v. which was completely blocked.  However, the increase in blood pressure and 
sympathoinhibition is significantly inhibited when compared to cytisine alone.  In 
respect, cytisine-induces the increase in blood pressure and renal sympathoinhibition via 
vasopressin release into the circulation.  Interestingly, unlike nicotine, the increase in 
blood pressure and renal nerve activity is not completely blocked by the Vi antagonist, 
even at a higher dose (100 gg kg'1 ) than given to nicotine, this suggests that cytisine may 
be stimulating the release of a larger amount of vasopressin than nicotine.  Furthermore, 
the increase in blood pressure induced by cytisine i.c.v. is faster and greater than nicotine
i.c.v., suggesting that cytisine’s site of action is close to the i.c.v. injection site, such as 
areas in and around the hypothalamus and is most selective for the p4-containing nAChR 
(Chavez-Noriega et al., 1997), which has been shown to be located in this area (Dineley- 
Miller & Patrick, 1992; Winzer-Serham & Leslie, 1997).  Therefore, cytisine may be 
acting on J34-containing nAChR on the PVN resulting in a large release of vasopressin 
into the circulation inducing a large increase in blood pressure.
348Unlike nicotine, the cytisine-induced decrease in renal nerve activity is parallel to the 
vasopressin-induced increase in blood pressure, suggesting that the decrease in renal 
nerve activity may also involve vasopressin release.  As already indicated in Chapter 3.2, 
it is possible for vasopressin to feedback and act on the brain and induce a cardiovascular 
effect.  As previously noted, an area of the brain lacking a blood brain barrier is the area 
postrema (Hasser & Bishop, 1990), which has been shown to contain Vj receptors and 
contain pathways to cardiovascular regulating areas of the brain such as the nucleus 
tractus solitarius (Shapiro & Miselis, 1985).  Infusions of vasopressin i.v. have been 
demonstrated to cause a significant increase in blood pressure associated with a reflex 
decrease in renal nerve activity (Hasser & Bishop, 1990).  In this respect, cytisine may be 
causing the release of vasopressin which is feeding back onto the area postrema resulting 
in a decrease in renal nerve activity.  However, until further studies, the mechanism of 
action for cytisine -induced sympathoinhibition is not known.
The increase in blood pressure and renal nerve activity induced by DMPP was blocked 
when in the presence of Vi antagonist i.v.  DMPP has been indicated to be selective for 
a2p2, a3p2 and a3p4 nAChR (Chavez-Noriega et al., 1997; Luetic & Patrick, 1991).
The DMPP-induced increase in blood pressure and renal nerve activity is also observed 
by a7 and a4p2 selective agonists PSAB-OFP and TC-2559 (see Chapter 3.1), similarly 
they are blocked by Vi antagonist i.v. (see Chapter 3.2).  In this respect, the DMPP- 
induced increase in blood pressure may be due to the release of vasopressin into the 
circulation; whereas the increase in renal nerve activity may be due to vasopressin 
feedback on to the brain.  However, until further studies the mechanism of action for 
DMPP-induced sympathoexcitation is not determined.
349CHAPTER 4.  GENERAL DISCUSSION
4.1.  General Discussion.
The central effects of nicotine on blood pressure has been extensively studied indicating 
that nicotine administered into the hindbrain of rats, cats and dogs causes a decrease in 
blood pressure (Bisset et al., 1975; Bisset & Chowdrey, 1984; Feldberg & Guertzenstein, 
1976; Kubo & Misu, 1981).  Interestingly, application of nicotine into the forebrain areas 
by injections into the lateral cerebral ventricle caused an increase in blood pressure in rats 
(Bisset & Chowdrey, 1984).  However, due to the unselective nature of nicotine for 
neuronal nAChRs, the particular nAChRs involved in these responses are unknown.
With the recent availability of two selective receptor agonists which have selectivity for 
the most abundant neuronal nAChRs, a4p2 and a7, and selective antagonists for different 
neuronal nAChR subtypes it is now possible to investigate the role of specific neuronal 
nAChRs in central cardiovascular regulation. This was carried out by investigating the 
effects of these selective receptor agonists, PSAB-OFP and TC-2559 given i.c.v. and i.e. 
in the presence and absence of selective antagonists, DhpE and MLA, and comparing 
these effects with that of nicotine and other unselective agonists e.g. cytisine and DMPP. 
As nicotine is well known to cause vasopressin release, the effects of these agonists were 
also studied in the presence of a vasopressin Vj receptor antagonist.
4.1.1.  Effect of selective agonists.
Neuronal nAChR al and a4p2 selective agonists PSAB-OFP and TC-2559 i.c.v. evoked 
a delayed increase in blood pressure and renal nerve activity.  PSAB-OFP produced a 
significant increase in heart rate at its highest dose, whereas TC-2559 produced an 
increase at its intermediate dose.  Administered into the hindbrain by i.e. injection caused 
a faster and greater rise in blood pressure than i.c.v. injections, however the increase in
350renal nerve activity was still observed to be delayed requiring up to 5 min.  PSAB-OFP 
evoked no significant change in heart rate, although TC-2559 caused a delayed increase.
The selectivity of PSAB-OFP and TC-2559 for its nACh receptor was demonstrated by 
the use of a7 selective antagonist, MLA, and a4p2 selective antagonist, DhpE.  In the 
presence of their corresponding antagonist the increase in blood pressure and renal nerve 
activity was blocked or significantly inhibited, whereas when in the presence of opposite 
antagonist, there was no change in blood pressure and renal nerve activity increase, 
demonstrating that the selective agonists, at the doses used, were acting on their 
individual nACh receptors.
4.1.1.1.  Sites of Action.
With studies indicating the presence of a4p2 and a7 nAChR at the hypothalamus, i.c.v. 
administration of PSAB-OFP and TC-2559 may be mediating their effects at the level of 
the hypothalamus, which has been shown to modulate renal sympathetic outflow, 
especially the PVN (Schramm et al., 1993).  However the pressor response and renal 
sympathoexcitation evoked by PSAB-OFP and TC-2559 i.c.v. was not a rapid onset and 
instead required at least 4 min for a significant increase in blood pressure and renal nerve 
activity to be observed.  In this respect, another possible area of the brain that the 
selective agonists may be mediating their effects is the hindbrain which contains major 
areas involved in cardiovascular regulation such as the NTS and ventrolateral medulla, 
(see Dampney, 1994; see Sun, 1995).  With previous studies demonstrating the presence 
of a4p2 and al nAChR at the NTS and RVLM (Ferreira et al., 2000; 2002; Swanson et 
al., 1987; Wada etal., 1989) and with the faster onset of the effects of PSAB-OFP and 
TC-2559 given i.e. with similar profiles to that of i.c.v injections, it suggests that PSAB- 
OFP and TC-2559 have to reach the brainstem to induce their effects.
Although a selective agonist has not been applied directly to the RVLM, studies 
involving microinjection of nicotine demonstrated a large pressor response, similar to the
351selective agonists administered i.e. (Tseng et al., 1993; 1994).  These findings suggest 
that the selective agonists could be acting on the RVLM inducing an increase in 
sympathetic tone causing vasoconstriction of blood vessels resulting in an increase in 
blood pressure, which is associated with an increase in renal sympathetic nerve activity. 
However, although the selective agonists i.e. evoke a rapid increase in blood pressure, the 
onset of renal sympathoexcitation is still delayed.  Upon comparison of i.e. and i.c.v. 
administration there was observed no significant difference in renal nerve activity delay 
suggesting that the increase in blood pressure is independent of the renal 
sympathoexcitation.  These finding suggest that an increase in sympathetic tone to 
resistance vessels to cause the increase in blood pressure may not be the mechanism for 
the observed increase in blood pressure and that the increase renal nerve activity could be 
independent to the increase in blood pressure.  In this respect, previous studies have 
demonstrated that nicotine administered i.c.v. and i.e. caused a significant increase in the 
release of vasopressin (Bisset et al, 1975; Bisset & Feldberg, 1973; Bisset & Chowdrey, 
1984) indicating that the rise in blood pressure by these selective agonists is probably due 
to vasopressin release.
4.1.1.2.  Vasopressin release.
When in the presence of a Vi receptor antagonist given i.v., the expected increases in 
blood pressure and renal nerve activity induced by PSAB-OFP and TC-2559 i.c.v. were 
blocked.  Thus suggesting that the selective agonists effects, via the i.c.v. route, are 
mediated by the release of vasopressin into the circulation.  Now if these agonists were 
given by the i.e. route in the presence of the V) receptor antagonist (i.v.), the expected 
effects of PSAB-OFP i.e. were blocked.  However, for TC-2559, the profile observed was 
similar due to the large initial variability in the pressor response which now only reached 
significance after 8 min.  Similarly the increase in renal nerve activity was delayed.  This 
latter observation is not consistent with the view that the effects of i.e. TC-2559 are 
mediated by the release of vasopressin into the circulation, although the data are 
consistent for PSAB-OFP.  Further these data suggested that the renal sympathoexcitation
352observed is also caused by the release of vasopressin into the circulation.  These findings 
suggest that the increase in blood pressure caused by central administration of selective 
agonist is due to the release of vasopressin into the circulation, where vasopressin binds 
to Via receptors on blood vessels causing vasoconstriction.
It is possible that the Vi receptor antagonist could have caused the above effects by 
entering the brain.  Thus a series of experiments was carried out to determine if the 
central block of Vi receptors is responsible for some of the effects observed.  The doses 
chosen to give centrally were shown not to leak into the periphery as determined by their 
failure to block the i.v. evoked pressor response to vasopressin.  In the presence of the Vi 
vasopressin antagonist given centrally (i.c.v. or i.e.), the pressor and renal 
sympathoexcitatory effects of PSAB-OFP and TC-2559 were nearly completely blocked, 
implying that these effects are in fact mediated by central release of vasopressin. 
However it should be noted that these central vasopressinergic pathways may also be 
releasing vasopressin into the circulation to cause the rise in blood pressure, rather than 
causing an increase in sympathetic drive to resistance vessels.  Thus the precise 
mechanism behind the pressor response remains to be determined although it does 
initially, at least, involve the central release of vasopressin suggesting that these agonists 
are also causing the release of vasopressin into the periphery.  Furthermore, the present 
data would indicate that this is due to activation of a central vasopressinergic pathway.
As previously noted, the selective agonists are believed to be acting on nAChRs in the 
hindbrain rather than the forebrain to induce the increase in blood pressure, therefore, if 
the increase in blood pressure is due to vasopressin release, or by the activation of a 
central vasopressinergic pathway, then this suggests that the site of action for the 
selective agonists is not at the forebrain sites such as the PVN but at hindbrain sites such 
as the NTS and RVLM.  In this respect, vasopressin-containing terminals have been 
identified in these areas (Buijs & Van Heerikhuize, 1982; Nilaver et al., 1980;
Sawchenko & Swanson, 1982; Van der Kooy et al., 1984) as well as, Vi receptors 
(Cheng et al., 2004; Dogterom et al, 1978; Philips et al., 1988; Tribollet et al.,  1988)  In 
addition, nicotine can also activate neuronal projection from the NTS and RVLM (Cl 
region) to the PVN and SON (Matta et al., 1993), thus causing vasopressin release into
353the circulation.  Furthermore, studies by Bisset et al. (1975) demonstrated that nicotine 
was more effective at inducing vasopressin release when applied to the hindbrain rather 
than the forebrain.  Overall, it is suggested that selective agonists PSAB-OFP and TC- 
2559 are acting on a7 and a4p2 nAChR at the hindbrain aeas such as the RVLM and 
NTS.  Activation of these cardiovascular regulating areas stimulates the release of 
vasopressin, via a neuronal projection to the PVN, into the circulation.  This pathway 
from the hindbrain to the PVN is believed to involve vasopressin, possibly acting as a 
excitatory neurotransmitter between the synapse of the RVLM to the PVN, as a similar 
pathway has been observed from the PVN to the RVLM (Yang et al., 2001).
Therefore as it has been suggested that central vasopressin release may be acting as a 
excitatory neurotransmitter at the synapse of the neuron projecting from the RVLM to the 
PVN, it is believed that the central administration of Vj receptor antagonist is blocking 
Vi receptors located on the PVN and SON(Ostrowski et al., 1992;Ostrowski et al., 1994), 
to which the central release of vasopressin bind and stimulate the release of vasopressin 
into the circulation.
A possible mechanism of action for the PSAB-OFP and TC-2559-induced increase in 
blood pressure is shown in Figures 47 and 48.  Selective agonists i.c.v. do not act directly 
on the PVN to cause the release of vasopressin, instead pass to the hindbrain were they 
bind to a7 or a4p2 nAChR’s in the RVLM, stimulating a neuronal pathway to the PVN. 
This results in the release of vasopressin into the circulation inducing an increase in blood 
pressure (Figure 47).  Selective agonists when administered via the i.e. route are closer to 
the NTS and RVLM, therefore they will have a quicker onset of action and the 
concentration will be larger at these sites than if administered i.c.v. (Figure 48).  Thus 
resulting in a larger amount of vasopressin being released into the circulation compared 
to the i.c.v. route.
3544.1.1.3.  Renal Sympathoexcitation.
The present experiments demonstrate that the renal sympathoexcitation is mediated also 
by the release of vasopressin.  This is believed to be due to the vasopressin released into 
the circulation feeding back and acting on the brain as renal sympathoexcitation has a 
similar delay whether the selective nAChR agonists are given i.e. or i.c.v.  It is possible 
that the feedback could be occurring at the area postrema, which has been shown to 
contain Vi receptors (Shapiro & Miselis, 1985), as well as acting on the subfornical organ 
(SFO), possibly via Via receptors, which is located in the forebrain, both lack a blood 
brain barrier and project to the PVN (Ferguson et al., 1984; Li & Ferguson, 1993; Tanaka 
et al., 1986; Tanaka & Seta, 1988).  This is quite an intriguing observation as it implies 
that vasopressin can affect the kidney directly by action on the collecting ducts and 
indirectly via the sympathetic supply which controls sodium excretion, renin release and 
local blood vessel tone.  The hypothesised pathways and feedback mechanisms producing 
the effects are illustrated for the selective nAChR receptor agonists in Figures 47 and 48. 
There are two possible mechanisms of action that may account for the effect of 
vasopressin on renal nerve activity: -1) upon the vasopressin release into the circulation 
vasopressin feeds back on to the PVN via the SFO, activating the neuronal projection 
from the PVN to the RVLM.  The activation of this pathway stimulates the RVLM which 
results in an increase in sympathetic tone and an increase in renal sympathetic nerve 
activity.  2) and/or the vasopressin feeds back via the area postrema, which has a direct 
innervation of the NTS (Shapiro & Miselis, 1985), and possibly the RVLM, resulting in 
the increase in renal nerve activity.
The feedback of vasopressin onto the PVN resulting in the increase of renal nerve activity 
is the most plausible mode of action as previous studies have demonstrated that the PVN 
is able to induce sympathoexcitation in stress (Badoer, 2001; Blair et al., 1996).  In 
addition, studies have shown that the PVN has an excitatory influence on RVLM-spinal 
vasomotor neurons resulting in increases in blood pressure, heart rate and renal nerve 
activity (Yang & Coote, 1998), and that electrical stimulation of the PVN results in a 
threefold increase in vasopressin content in the NTS (Landgraf et al., 1990).  The PVN
355causes sympathoexcitation both via direct projection to sympathetic preganglionic 
neurons in the IML and via collateral projections to neurons of the RVLM that sends 
excitatory input to the IML (Coote et al., 1998; Shafton et al., 1998).  The excitatory 
input from the PVN to the RVLM may be mediated by vasopressin; acting via V] 
receptors (see Dampney, 1994; Yang et al., 2001).
4.1.1.4.  Cardiovascular effects not involving vasopressin.
Interestingly, PSAB-OFP given i.e. in the presence of central Vi receptor antagonist no 
longer caused an increase in blood pressure, instead there was observed a depressor 
response after 2 min.  There was also observed a delayed decrease in blood pressure with 
PSAB-OFP given i.c.v. in the presence of the Vi receptor antagonist also given i.c.v. 
There was no change in renal nerve activity in response to PSAB-OFP administered at 
either of these injection sites and suggests that the decrease in blood pressure is due to 
PSAB-OFP acting at al nAChR located in the hindbrain, due to the delay in blood 
pressure decrease by PSAB-OFP i.c.v. compared to PSAB-OFP administered i.e.  In this 
respect, microinjection of nicotine into the NTS has been observed to cause a significant 
decrease in blood pressure, which was inhibited by al nAChR selective antagonist MLA 
and a-BgT, implying the involvement of al nAChR (Dhar et al., 2000; Ferreira et al., 
2000; 2002).  Interestingly upon inhibition of vasopressin release, additional affects of 
nAChR activation are observed which are not overcome by the vasopressin-induced 
increase in blood pressure.
Interestingly, both agonists when given i.e. in the presence of Vi receptor antagonist i.e. 
cause a transient sympathoexcitation after 1  min.  This is paralleled by a transient non­
significant increase in blood pressure.  A possible site for this is the RVLM, as 
microinjection of nicotine caused pressor response and a tachycardia (Tseng et al., 1993;
1994).  The transient nature is also surprising unless an additional depressor circuit is also 
being activated to mask this effect which is believed to occur for PSAB-OFP.
3564.1.2.  Effects of nicotine.
Nicotine i.c.v. caused a dose-related increase in blood pressure as previously observed by 
Bisset & Chowdry (1984) and a decrease in renal nerve activity associated with no 
change in heart rate.  Given i.e., nicotine caused a bradycardia, interestingly; the onset of 
renal sympathoinhibition was immediate while the rise in blood pressure was again 
delayed but much larger.  This was different from that observed with selective receptor 
agonists activating a7 and a4p2 nACh receptors, in that there was no observed delayed 
sympathoexcitation.
4.1.2.1.  Sites of Action.
Similar to the selective agonists there is a delayed increase in blood pressure induced by
i.c.v. injections suggesting that the site of action is located away from the forebrain and 
possibly in brain areas in the hindbrain.  Interestingly, nicotine administered into the 
hindbrain via i.e. injections was shown to induce a biphasic response in blood pressure, 
with an initial fall followed by an increase which was greater than the blood pressure 
increase caused by nicotine i.c.v.  Studies have shown that administration of nicotine into 
the hindbrain, either by i.e. injection or by application of nicotine to the ventral surface of 
the brainstem, results in a depressor response which was blocked by nicotinic antagonists, 
but unaffected by the muscarinic antagonist, atropine (Bisset et al., 1975; Bisset & 
Chowdrey, 1984; Feldberg & Guertzenstein, 1976).  In this respect, it is suggested that 
nicotine may be acting on areas of the hindbrain inducing a decrease in blood pressure; 
however nicotine is also acting on additional areas of the hindbrain overcoming the 
decrease and resulting in an increase in blood pressure.  The overall data supports the 
view that the nicotine-induced increase in blood pressure is due to the release of 
vasopressin.
3574.1.2.2. Vasopressin release.
The increase in blood pressure caused by i.c.v. and i.e. nicotine was blocked / attenuated 
when in the presence of Vi receptor antagonist i.v. consistent with the theory that nicotine 
induces vasopressin release into the circulation.  Nicotine i.e. in the presence of the Vi 
receptor antagonist given i.v. potentiated the initial decrease in blood pressure, supporting 
the theory that the initial decrease is overcome by the release of vasopressin into the 
circulation resulting in an increase in blood pressure.  Surprisingly, the fall in blood 
pressure is blocked in the presence of the Vj receptor antagonist i.e., suggesting that this 
is probably due to the involvement of a central vasopressinergic sympathoinhibitory 
pathway which is not activated by a7 and a402 nACh receptors.
Interestingly, nicotine i.c.v. in the presence of Vi receptor antagonist i.c.v. still caused an 
increase in blood pressure, suggesting that it is possible that nicotine i.c.v. is causing the 
release of vasopressin, into the circulation, by directly acting on the PVN.  Figure 69 
illustrates possible mechanisms involved in the i.c.v. nicotine-evoked increase in blood 
pressure.  1) Involves a direct effect of nicotine on the PVN; resulting in the release of 
vasopressin into the circulation. 2) Nicotine moves from the i.c.v. injection site to sites in 
the hindbrain, possibly the RVLM, activating a pathway to the PVN, which results in the 
release of vasopressin.
If nicotine i.c.v. induced the release of vasopressin by acting on the hindbrain, then the 
release of vasopressin would be caused by a neuronal projection from the hindbrain to the 
PVN (see Chapter 3.2) in which vasopressin was believed to be acting as a excitatory 
neurotransmitter at the synapse between the RVLM and PVN.  Therefore the central 
administration of a Vi receptor antagonist would inhibit the Via receptors found on the 
PVN and SON (Ostrowski et al., 1992; 1994) and block the stimulation of vasopressin 
into the circulation.  However, this was not observed and instead suggests that the release 
of vasopressin is caused by nicotine acting directly on the PVN.  Figure 70 shows a 
diagrammatic representation of the mechanism of action for nicotine injected i.e.
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cause the release of vasopressin by acting on the PVN directly and instead acted on the 
hindbrain to evoke this release (see Chapter 3.2).  In this respect, it would seem that 
nicotine is not acting on a7 and a4|32 nAChRs at the level of the PVN but different nACh 
receptors found in the PVN.
4.1.2.3.  Renal sympathoinhibition.
Pre-treatment with the vasopressin Vi receptor antagonist (i.v., i.c.v. & i.e.) attenuated / 
blocked the renal sympathoinhibition as it had done for the renal sympathoexcitation 
observed with the selective a7 and a402 nAChR agonists.  Interestingly, due to the rapid 
nature of nicotine i.c.v.-induced sympathoinhibition, it is suggested that nicotine’s site of 
action is near the i.c.v. injection site.  However, although the sympathoinhibition caused 
by nicotine i.c.v. is fast, the sympathoinhibition response caused by nicotine i.e. is faster 
suggesting that areas in the hindbrain may be involved.  Further, it may be possible that 
both the forebrain and hindbrain sites are involved.  A possible mechanism of action is 
the direct affect of nicotine on the C  VLM.  Previous studies have shown that nicotine 
microinjected into the CVLM caused a dose-related decrease in blood pressure and heart 
rate (Aberger et al, 2001) which was suggested to be due to inhibition of the RVLM via 
GABAnergic neurons form the CVLM, thus resulting in a decrease in sympathetic nerve 
activity to the heart and blood vessels (Agarwal et al., 1990; Brown & Guyenet, 1984; 
Cravo et al, 1991; Gordon, 1987).  This would account for the rapid decrease in renal 
sympathetic nerve activity and heart rate upon nicotine administered i.e., due to the i.e. 
injection site being located close to the CVLM and the delayed decrease in RSNA evoked 
by nicotine i.c.v.  However, the i.c.v. nicotine evoked renal sympathoinhibition is too fast 
to be leaking across the brain to evoke an effect, therefore it is suggested that the decrease 
is caused by forebrain areas such as the PVN innervating cardiovascular regulating 
hindbrain areas such as the CVLM, NTS and RVLM (see Dampney, 1994; see Sun,
1995).  Furthermore Yang & Coote (1998) demonstrated that activation of neurons at the 
PVN may cause a depressor response via inhibiting the RVLM neurons, therefore it is
359possible that via a pathway for the PVN to the RVLM nicotine is able to cause a decrease 
in renal sympathetic nerve activity
Interestingly the nicotine-evoked renal sympathoinhibition is inhibited and attenuated by 
central Via receptor antagonist suggesting the involvement of vasopressin centrally 
possibly acting as a neurotransmitter (Yang et al., 2001) at the synapses between 
cardiovascular regulating centres.
4.1.2.4.  Nicotine in the presence of selective nAChR 
antagonists.
To determine which nAChRs are activated by nicotine, the effects of nicotine were 
studied in the absence and presence of a7 selective receptor antagonist MLA and a4p2 
selective antagonist DhpE.  The present data indicates that nicotine can activate a a4p2 
nACh receptor, which mediates sympathoinhibition, which was not observed using the 
respective selective receptor agonists (see Chapter 3.1).  In fact, in the presence of the 
receptor antagonist DhpE, the renal sympathoinhibition was reversed to 
sympathoexcitation and associated with no changes in blood pressure and heart rate.  A 
possible explanation of this contradiction is that DhpE at the concentration used is also 
blocking another receptor. In this respect, DhpE does have reasonable affinity for the p2 
and p4 subunits (Chavez-Noriega et al, 1997; 2000) and receptor/s containing these 
subunits could mediate this renal sympathoinhibition.  Furthermore, cytisine which has a 
good affinity at receptors containing the p4 subunit (see Introduction) was also found to 
cause profound renal sympathoinhibition and surprisingly this was associated with no 
change in heart rate although the expected pressor response was still observed.  The 
selectivity of cytisine for nAChR subtypes has been shown in vitro to have a low affinity 
for nAChRs containing the p2 subunits compared to other agonists such as DMPP and 
ACh, but displayed high affinity for a2p4, a3p4 and a4p4 nAChR’s (Chavez-Noriega et 
al., 1997; 2000), indicating that cytisine is selective for the p4-containing nAChR 
subtypes.  Therefore, due to the cardiovascular similarities induced by nicotine and
360cytisine, it is possible that nicotine is acting on a p4-containing nAChR subtype.
However further experiments are required to clarify this issue.  Furthermore, in the 
presence of a7 selective receptor antagonist, MLA the nicotinic-evoked renal 
sympathoinhibition was not blocked only delayed, although the blood pressure response 
was blocked.  The mechanism for the delay is unclear, but maybe due to the balance of 
action of different nAChRs which have opposing actions on renal nerve activity. 
However, the ability of both receptor antagonists to block the pressor response remains 
difficult to explain, although a possible mechanism could be in one case that of the 
physiological antagonist again by blocking one receptor unmasking another effect, 
although in the opposite direction i.e. the receptors mediating the fall in blood pressure 
observed with TC-2559 at the high dose.
4.1.3.  Conclusion.
It is concluded that the major central cardiovascular effects of activating al and a4p2 
receptors occurs at the level of brainstem by activation of a neuronal projection to the 
PVN, leading to the release of vasopressin into the circulation.  This in turn can feedback 
and cause additional effects such as renal sympathoexcitation.  However, there are also 
other actions but these are masked by the release of vasopressin centrally and 
peripherally.
Nicotine (i.c.v. & i.e.) caused the increase in blood pressure by the release of vasopressin 
into the circulation.  It is possible that nicotine i.c.v. differs from the selective receptor 
agonists in that it is acting on the PVN directly to cause vasopressin release, although the 
release of vasopressin is low and may account for the delayed increase in blood pressure. 
However, nicotine is also acting on the hindbrain, causing a greater increase in blood 
pressure compared to nicotine i.c.v.  Nicotine administered into the hindbrain has been 
shown to release more vasopressin than nicotine i.c.v. therefore, accounting for the larger 
increase in blood pressure and a faster decrease in renal nerve activity for nicotine i.e. 
(Figure 69 & 70).  Interestingly, the renal sympathoinhibition is independent of the
361vasopressin-induced increase in blood pressure, therefore the nicotine evoked decrease in 
renal nerve activity is independent of vasopressin release, making the mechanism of 
action possibly involving the inhibition of the RVLM by nicotine acting on nAChR found 
on the CVLM (Aberger et al., 2001; Agarwal et al, 1990; Brown & Guyenet, 1984).
4.1.4.  Future experiments.
In order to clarify and take the data in this thesis further, a number of additional 
experiments are required.
Firstly, it needs to be determined if the dose of Vi receptor antagonist given i.v. in these 
studies is able to get into the brain and act centrally.  This will be carried out by studying 
the effects of i.c.v. and i.e. vasopressin in the presence of the Vi receptor antagonist given 
i.v.  To determine exclusively if the increase in blood pressure caused by selective 
receptor agonists and nicotine is induced by the release of vasopressin into the 
circulation, additional studies could also be preformed.  Experiments would involve the 
central injection of the selective receptor agonists, and nicotine, and at the peak pressor 
response an injection i.v. of the Vi receptor antagonist is given.  If the increase in blood 
pressure falls rapidly to baseline then this would indicate that the increase in blood 
pressure is caused by the release of vasopressin.
Additional experiments would also be preformed to investigate if selective receptor 
agonists and nicotine are acting on a central angiotensinergic pathway and/or a central 5- 
HT pathway to cause vasopressin release, as both these pathways are known to be 
involved (see Ramage, 2001).
Studies have shown that angiotensin II (AT) administered centrally caused an increase in 
blood pressure by releasing vasopressin (Keil et al., 1975), therefore studies should 
investigate the effects of these selective receptor agonists and nicotine in the presence of 
a ATi and AT2 receptor antagonist, administered centrally, to determine if the release of
362vasopressin is due to direct action of nAChR activation or activation of central 
angiotensinergic pathways.  Interestingly, circulating angiotensin II could be involved as 
it has been shown to activate neurons in the subfornical organ to stimulate the PVN.  The 
activation of the PVN can lead to an increase in vasopressin release by acting on 
magnocellular vasopressin neurons (Ferguson & Wall, 1992), as well as, causing an 
increase in renal nerve activity due to the pathway from the PVN to the RVLM (Pyner & 
Coote, 1999; Yang & Coote, 1998).
In addition, due to the similar structure of the neuronal nAChRs and the 5-HT3 receptors 
it may be possible that the selective agonists, and especially nicotine, induce then- 
cardiovascular changes by activation of 5-HT3  receptors.  The 5-HT3 receptor has 
significant homology to the al nAChR, even in the ligand-binding domain (Gurley & 
Lanthom, 1998), with previous studies showing that 5-HT is a potent non-competitive 
antagonist of the neuronal nAChR (Nakazawa et al., 1995).  Additional studies of 
tropisetron and ordansetron indicated that these were shown to not only be an antagonist 
at the 5-HT3  receptor but have a crossover effect on nAChR (Mair et al., 1998; Peters et 
al., 1993).  In addition, studies have shown that PSAB-OFP is also a potent agonist for 
the 5-HT3  receptor (Broad et al., 2002).  Therefore, it may be possible that nicotine and 
the selective agonists are acting on the 5-HT3 receptors and inducing some of the 
cardiovascular effects, therefore the effects of this nicotinic receptor agonist should be 
observed in the presence of a 5-HT3  receptor antagonist.  However, it has been shown 
that the 5-HT3  receptor antagonist have an effect on the nAChR, therefore the results may 
be variable.  It may be interesting to compare the effects of selective 5-HT3 receptor 
agonists, on the central cardiovascular effects by administration i.c.v. and i.e. injection, 
with the effects of selective agonist and nicotine to observe if there are any similarities 
and possible cross over.
Finally, concerning the effects of nicotine on the cardiovascular system, unlike the 
activation of the a402 and al which caused an increase in blood pressure and renal nerve 
activity, nicotine caused an increase in blood pressure associated with a decrease in renal 
nerve activity.  A possibility is that nicotine is acting on a different receptor to the a4p2 
and al selective agonists.  Due to nicotine’s cardiovascular effects being similar to that of
363cytisine, which is selective for p4-containing receptors, it suggests that nicotine may be 
acting on the p4-containing receptor.  As the presence of the (34 mRNA has been shown 
around the forebrain areas such as the hypothalamus (Winzer-Serhan & Leslie, 1997; 
Dineley-Miller & Patrick, 1992), these receptors may be having a direct effect on 
nicotine-induced cardiovascular effects.  Therefore a future experiment would involve the 
observation of a p4 selective agonist administered centrally, by i.c.v. and i.e. injection, on 
central cardiovascular regulation and demonstrate whether these effects were similar to 
the effects produced by nicotine.
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